,Title,Structure Details,Source Organism,Taxonomy ID,Abstract,Method,Resolution,Original Number of Models,Original Number of Chains,Selected Chain,Canonical Sequence Coverage,Identity Percentage,Number of Atoms,Number of Residues,Number of Hetero Residues,Number of Ligands in Chain,Ligands in Chain,RCSB Ligand Codes,RCSB Ligands,Read Activity Status,Number of Waters,Number of GLY,Number of ALA,Number of MET,Number of SER,Number of THR,Number of GLU,Number of TYR,Number of LYS,Number of LEU,Number of VAL,Number of ILE,Number of GLN,Number of ASN,Number of HIS,Number of PHE,Number of ASP,Number of PRO,Number of ARG,Number of CYS,Number of TRP
1A2B,HUMAN RHOA COMPLEXED WITH GTP ANALOGUE,,Homo sapiens,9606,"The 2.4-A resolution crystal structure of a dominantly active form of the small guanosine triphosphatase (GTPase) RhoA, RhoAV14, complexed with the nonhydrolyzable GTP analogue, guanosine 5'-3-O-(thio)triphosphate (GTPgammaS), reveals a fold similar to RhoA-GDP, which has been recently reported (Wei, Y., Zhang, Y., Derewenda, U., Liu, X., Minor, W., Nakamoto, R. K., Somlyo, A. V., Somlyo, A. P., and Derewenda, Z. S. (1997) Nat. Struct. Biol. 4, 699-703), but shows large conformational differences localized in switch I and switch II. These changes produce hydrophobic patches on the molecular surface of switch I, which has been suggested to be involved in its effector binding. Compared with H-Ras and other GTPases bound to GTP or GTP analogues, the significant conformational differences are located in regions involving switches I and II and part of the antiparallel beta-sheet between switches I and II. Key residues that produce these conformational differences were identified. In addition to these differences, RhoA contains four insertion or deletion sites with an extra helical subdomain that seems to be characteristic of members of the Rho family, including Rac1, but with several variations in details. These sites also display large displacements from those of H-Ras. The ADP-ribosylation residue, Asn41, by C3-like exoenzymes stacks on the indole ring of Trp58 with a hydrogen bond to the main chain of Glu40. The recognition of the guanosine moiety of GTPgammaS by the GTPase contains water-mediated hydrogen bonds, which seem to be common in the Rho family. These structural differences provide an insight into specific interaction sites with the effectors, as well as with modulators such as guanine nucleotide exchange factor (GEF) and guanine nucleotide dissociation inhibitor (GDI).",x-ray diffraction,2.4,1,1,A,94.17989417989418%,31.818181818181817%,1488,218,2,2,"['MG', 'GSP']","MG, GSP","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,38,9,12,5,6,8,16,5,14,13,17,10,5,6,2,7,15,11,10,5,2
1AA9,"HUMAN C-HA-RAS(1-171)(DOT)GDP, NMR, MINIMIZED AVERAGE STRUCTURE",,Homo sapiens,9606,"The backbone 1H, 13C, and 15N resonances of the c-Ha-Ras protein [a truncated version consisting of residues 1-171, Ras(1-171)] bound with GMPPNP (a slowly hydrolyzable analogue of GTP) were assigned and compared with those of the GDP-bound Ras(1-171). The backbone amide resonances of amino acid residues 10-13, 21, 31-39, 57-64, and 71 of Ras(1-171).GMPPNP, but not those of Ras(1-171).GDP, were extremely broadened, whereas other residues of Ras(1-171).GMPPNP exhibited amide resonances nearly as sharp as those of Ras(1-171). GDP. The residues exhibiting the extreme broadening, except for residues 21 and 71, are localized in three functional loop regions [loops L1, L2 (switch I), and L4 (switch II)], which are involved in hydrolysis of GTP and interactions with other proteins. From the temperature and magnetic field strength dependencies of the backbone amide resonance intensities, the extreme broadening was ascribed to the exchange at an intermediate rate on the NMR time scale. It was shown that the Ras(1-171) protein bound with GTP or GTPgammaS (another slowly hydrolyzable analogue of GTP) exhibits the same type of broadening. Therefore, it is a characteristic feature of the GTP-bound form of Ras that the L1, L2, and L4 loop regions, but not other regions, are in a rather slow interconversion between two or more stable conformers. This phenomenon, termed a ""regional polysterism"", of these loop regions may be related with their multifunctionality: the GTP-dependent interactions with several downstream target groups such as the Raf and RalGDS families and also with the GTPase activating protein (GAP) family. In fact, the binding of Ras(1-171).GMPPNP with the Ras-binding domain (residues 51-131) of c-Raf-1 was shown to eliminate the regional polysterism nearly completely. It was indicated, therefore, that each target/regulator selects its appropriate conformer among those presented by the ""polysteric"" binding interface of Ras. As the downstream target groups exhibit no apparent sequence homology to each other, it is possible that one target group prefers a conformer different from that preferred by another group. The involvement of loop L1 in the regional polysterism might suggest that the negative regulators, GAPs, bind to the polysteric binding interface (loops L2 and L4) of Ras and cooperatively select a conformer suitable for transition of the GTPase catalytic center, involving loops L1 and L4, into the highly active state.",solution nmr,,1,1,A,90.47619047619048%,100.0%,2766,173,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,0,11,11,4,8,11,13,9,10,13,15,11,11,4,3,5,14,3,12,3,
1AGP,THREE-DIMENSIONAL STRUCTURES AND PROPERTIES OF A TRANSFORMING AND A NONTRANSFORMING GLY-12 MUTANT OF P21-H-RAS,"C-H-RAS P21 PROTEIN MUTANT WITH GLY 12 REPLACED BY ASP (G12D) COMPLEXED WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE",Homo sapiens,9606,"The three-dimensional structures and biochemical properties of two mutants of the G-domain (residues 1-166) of p21H-ras, p21 (G12D) and p21 (G12P), have been determined in the triphosphate-bound form using guanosine 5'-(beta,gamma-imido)triphosphate (GppNHp). They correspond to the most frequent oncogenic and the only nononcogenic mutation of Gly-12, respectively. The G12D mutation is the only mutant analyzed so far that crystallizes in a space group different from wild type, and the atomic model of the protein shows the most drastic changes of structure around the active site as compared to wild-type p21. This is due to the interactions of the aspartic acid side chain with Tyr-32, Gln-61, and the gamma-phosphate, which result in reduced mobility of these structural elements. The interaction between the carboxylate group of Asp-12 and the gamma-phosphate is mediated by a shared proton, which we show by 31P NMR measurements to exist in solution as well. The structure of p21 (G12P) is remarkably similar to that of wild-type p21 in the active site, including the position of the nucleophilic water. The pyrrolidine ring of Pro-12 points outward and seems to be responsible for the weaker affinity toward GAP (GTPase-activating protein) and the failure of GAP to stimulate GTP hydrolysis.",x-ray diffraction,2.3,1,1,A,87.83068783068782%,99.3975903614458%,1797,207,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,39,10,11,4,8,11,13,9,8,11,15,11,11,4,3,5,15,3,11,3,
1AM4,COMPLEX BETWEEN CDC42HS.GMPPNP AND P50 RHOGAP (H. SAPIENS),,Homo sapiens,9606,"Small G proteins transduce signals from plasma-membrane receptors to control a wide range of cellular functions. These proteins are clustered into distinct families but all act as molecular switches, active in their GTP-bound form but inactive when GDP-bound. The Rho family of G proteins, which includes Cdc42Hs, activate effectors involved in the regulation of cytoskeleton formation, cell proliferation and the JNK signalling pathway. G proteins generally have a low intrinsic GTPase hydrolytic activity but there are family-specific groups of GTPase-activating proteins (GAPs) that enhance the rate of GTP hydrolysis by up to 10(5) times. We report here the crystal structure of Cdc42Hs, with the non-hydrolysable GTP analogue GMPPNP, in complex with the GAP domain of p50rhoGAP at 2.7A resolution. In the complex Cdc42Hs interacts, mainly through its switch I and II regions, with a shallow pocket on rhoGAP which is lined with conserved residues. Arg 85 of rhoGAP interacts with the P-loop of Cdc42Hs, but from biochemical data and by analogy with the G-protein subunit G(i alpha1), we propose that it adopts a different conformation during the catalytic cycle which enables it to stabilize the transition state of the GTP-hydrolysis reaction.",x-ray diffraction,2.7,1,6,D,77.24867724867724%,33.532934131736525%,1406,212,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,36,9,11,1,8,16,10,7,14,17,18,8,6,5,2,8,11,12,5,5,1
1AN0,CDC42HS-GDP COMPLEX,,Homo sapiens,9606,No DOI found,x-ray diffraction,2.8,1,2,A,76.19047619047619%,32.1608040201005%,1547,232,4,4,"['MG', 'MSE', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,41,9,11,,10,16,13,7,17,17,19,8,6,5,2,8,11,15,6,6,1
1C1Y,CRYSTAL STRUCTURE OF RAP.GMPPNP IN COMPLEX WITH THE RAS-BINDING-DOMAIN OF C-RAF1 KINASE (RAFRBD).,RAP.,Homo sapiens,9606,"The X-ray crystal structure of the complex between the Ras-related protein Rap1A in the GTP-analogue (GppNHp) form and the Ras-binding domain (RBD) of the Ras effector molecule c-Raf1, a Ser/Thr-specific protein kinase, has been solved to a resolution of 2.2 A. It shows that RBD has the ubiquitin superfold and that the structure of Rap1A is very similar to that of Ras. The interaction between the two proteins is mediated by an apparent central antiparallel beta-sheet formed by strands B1-B2 from RBD and strands beta 2-beta 3 from Rap1A. Complex formation is mediated by main-chain and side-chain interactions of the so-called effector residues in the switch I region of Rap1A.",x-ray diffraction,1.9,1,2,A,88.35978835978835%,57.57575757575758%,1412,216,2,2,"['GTP', 'MG']","MG, GTP, CA","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE, CALCIUM ION",active,47,11,8,5,8,8,13,6,10,15,16,9,14,8,,7,12,2,9,5,1
1CC0,CRYSTAL STRUCTURE OF THE RHOA.GDP-RHOGDI COMPLEX,transforming protein rhoA/rho GDP dissociation inhibitor alpha Complex,Homo sapiens,9606,"Like all Rho (Ras homology) GTPases, RhoA functions as a molecular switch in cell signaling, alternating between GTP- and GDP-bound states, with its biologically inactive GDP-bound form maintained as a cytosolic complex with RhoGDI (guanine nucleotide-exchange inhibitor). The crystal structures of RhoA-GDP and of the C-terminal immunoglobulin-like domain of RhoGDI (residues 67-203) are known, but the mechanism by which the two proteins interact is not known. The functional human RhoA-RhoGDI complex has been expressed in yeast and crystallized (P6(5)22, unit-cell parameters a = b = 139, c = 253 A, two complexes in the asymmetric unit). Although diffraction from these crystals extends to 3.5 A and is highly anisotropic, the experimentally phased (MAD plus MIR) electron-density map was adequate to reveal the mutual disposition of the two molecules. The result was validated by molecular-replacement calculations when data were corrected for anisotropy. Furthermore, the N-terminus of RhoGDI (the region involved in inhibition of nucleotide exchange) can be identified in the electron-density map: it is bound to the switch I and switch II regions of RhoA, occluding an epitope which binds Dbl-like nucleotide-exchange factors. The entrance of the hydrophobic pocket of RhoGDI is 25 A from the last residue in the RhoA model, with its C-terminus oriented to accommodate the geranylgeranyl group without conformational change in RhoA.",x-ray diffraction,5.0,1,4,A,93.65079365079364%,32.02247191011236%,1444,189,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,0,12,12,5,7,8,16,5,17,13,16,10,5,7,2,6,15,11,12,6,2
1DPF,CRYSTAL STRUCTURE OF A MG-FREE FORM OF RHOA COMPLEXED WITH GDP,CRYSTAL STRUCTURE OF A MG-FREE FORM OF RHOA COMPLEXED WITH GDP,Homo sapiens,9606,"Mg(2+) ions are essential for guanosine triphosphatase (GTPase) activity and play key roles in guanine nucleotide binding and preserving the structural integrity of GTP-binding proteins. We determined the crystal structure of a small GTPase RHOA complexed with GDP in the absence of Mg(2+) at 2.0-A resolution. Elimination of a Mg(2+) ion induces significant conformational changes in the switch I region that opens up the nucleotide-binding site. Similar structural changes have been observed in the switch regions of Ha-Ras bound to its guanine nucleotide exchange factor, Sos. This RHOA-GDP structure reveals an important regulatory role for Mg(2+) and suggests that guanine nucleotide exchange factor may utilize this feature of switch I to produce an open conformation in GDP/GTP exchange.",x-ray diffraction,2.0,1,1,A,94.17989417989418%,32.95454545454545%,1614,366,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,187,9,16,5,6,8,14,5,14,12,17,10,5,6,2,7,15,11,9,5,2
1DS6,CRYSTAL STRUCTURE OF A RAC-RHOGDI COMPLEX,,Homo sapiens,9606,"Rho family-specific guanine nucleotide dissociation inhibitors (RhoGDIs) decrease the rate of nucleotide dissociation and release Rho proteins such as RhoA, Rac and Cdc42 from membranes, forming tight complexes that shuttle between cytosol and membrane compartments. We have solved the crystal structure of a complex between the RhoGDI homolog LyGDI and GDP-bound Rac2, which are abundant in leukocytes, representing the cytosolic, resting pool of Rho species to be activated by extracellular signals. The N-terminal domain of LyGDI (LyN), which has been reported to be flexible in isolated RhoGDIs, becomes ordered upon complex formation and contributes more than 60% to the interface area. The structure is consistent with the C-terminus of Rac2 binding to a hydrophobic cavity previously proposed as isoprenyl binding site. An inner segment of LyN forms a helical hairpin that contacts mainly the switch regions of Rac2. The architecture of the complex interface suggests a mechanism for the inhibition of guanine nucleotide dissociation that is based on the stabilization of the magnesium (Mg2+) ion in the nucleotide binding pocket.",x-ray diffraction,2.35,1,2,A,95.76719576719577%,31.46067415730337%,1514,255,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,72,9,13,2,10,12,9,8,13,19,16,10,6,5,2,6,13,13,7,6,2
1E96,Structure of the Rac/p67phox complex,"RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1, NEUTROPHIL CYTOSOL FACTOR 2 (NCF-2) TPR DOMAIN, RESIDUES 1-203",Homo sapiens,9606,No abstract found,x-ray diffraction,2.4,1,2,A,94.17989417989418%,31.03448275862069%,1465,225,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,45,11,13,2,7,13,9,8,13,19,16,10,4,6,2,6,12,12,7,6,2
1FTN,CRYSTAL STRUCTURE OF THE HUMAN RHOA/GDP COMPLEX,,Homo sapiens,9606,"RhoA, a ubiquitous intracellular GTPase, mediates cytoskeletal responses to extracellular signals. A 2.1 A resolution crystal structure of the human RhoA-GDP complex shows unique stereochemistry in the switch I region, which results in a novel mode of Mg2+ binding.",x-ray diffraction,2.1,1,1,A,93.65079365079364%,32.02247191011236%,1653,398,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,219,10,11,5,6,8,16,5,14,13,16,10,5,7,2,6,15,11,10,5,2
1G17,"CRYSTAL STRUCTURE OF SEC4-GUANOSINE-5'-(BETA,GAMMA)-IMIDOTRIPHOSPHATE",RAS-RELATED PROTEIN SEC4,Saccharomyces cerevisiae,4932,"We have determined crystal structures of Sec4, a member of the Rab family in the G protein superfamily, in two states: bound to GDP, and to a non-hydrolyzable GTP analog, guanosine-5'-(beta, gamma)-imidotriphosphate (GppNHp). This represents the first structure of a Rab protein bound to GDP. Sec4 in both states grossly resembles other G proteins bound to GDP and GppNHp. In Sec4-GppNHp, structural features common to active Rab proteins are observed. In Sec4-GDP, the switch I region is highly disordered and displaced relative to the switch I region of Ras-GDP. In two of the four molecules of Sec4-GDP in the asymmetric unit of the Sec4-GDP crystals, the switch II region adopts a conformation similar to that seen in the structure of the small G protein Ran bound to GDP. This allows residues threonine 76, glutamate 80, and arginine 81 of Sec4 to make contacts with other conserved residues and water molecules important for nucleotide binding. In the other two molecules in the asymmetric unit, these interactions do not take place. This structural variability in both the switch I and switch II regions of GDP-bound Sec4 provides a possible explanation for the high off-rate of GDP bound to Sec4, and suggests a mechanism for regulation of the GTPase cycle of Rab proteins by GDI proteins.",x-ray diffraction,2.0,1,2,A,88.88888888888889%,34.5679012345679%,1420,226,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,56,11,10,3,8,14,11,3,15,13,11,19,6,9,1,10,13,2,6,1,2
1G4U,CRYSTAL STRUCTURE OF THE SALMONELLA TYROSINE PHOSPHATASE AND GTPASE ACTIVATING PROTEIN SPTP BOUND TO RAC1,,Salmonella enterica subsp. enterica serovar Typhimurium,90371,No abstract found,x-ray diffraction,2.3,1,2,R,95.23809523809523%,31.843575418994412%,1560,312,3,3,"['MG', 'AF3', 'GDP']","MG, GDP, AF3","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, ALUMINUM FLUORIDE",inactive,129,11,13,3,8,13,9,8,13,18,16,10,5,6,2,5,12,13,7,6,2
1GUA,"HUMAN RAP1A, RESIDUES 1-167, DOUBLE MUTANT (E30D,K31E) COMPLEXED WITH GPPNHP AND THE RAS-BINDING-DOMAIN OF HUMAN C-RAF1, RESIDUES 51-131",,Homo sapiens,9606,"Members of the Ras subfamily of small GTP-binding proteins have been shown to be promiscuous towards a variety of putative effector molecules such as the protein kinase c-Raf and the Ral-specific guanine nucleotide exchange factor (Ral-GEF). To address the question of specificity of interactions we have introduced the mutations E30D and K31E into Rap and show biochemically, by X-ray structure analysis and by transfection in vivo that the identical core effector region of Ras and Rap (residues 32-40) is responsible for molecular recognition, but that residues outside this region are responsible for the specificity of the interaction. The major determinant for the switch in specificity is the opposite charge of residue 31--Lys in Rap, Glu in Ras--which creates a favourable complementary interface for the Ras-Raf interaction.",x-ray diffraction,2.0,1,2,A,88.35978835978835%,58.78787878787879%,1415,220,2,2,"['MG', 'GNP']","MG, GNP, CA","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, CALCIUM ION",active,51,11,8,5,8,8,13,6,9,15,16,9,14,8,,7,13,2,9,5,1
1HE1,Crystal structure of the complex between the GAP domain of the Pseudomonas aeruginosa ExoS toxin and human Rac,"EXOENZYME S, RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1",Pseudomonas aeruginosa,287,"Pseudomonas aeruginosa is an opportunistic bacterial pathogen. One of its major toxins, ExoS, is translocated into eukaryotic cells by a type III secretion pathway. ExoS is a dual function enzyme that affects two different Ras-related GTP binding proteins. The C-terminus inactivates Ras through ADP ribosylation, while the N-terminus inactivates Rho proteins through its GTPase activating protein (GAP) activity. Here we have determined the three-dimensional structure of a complex between Rac and the GAP domain of ExoS in the presence of GDP and AlF3. Composed of approximately 130 residues, this ExoS domain is the smallest GAP hitherto described. The GAP domain of ExoS is an all-helical protein with no obvious structural homology, and thus no recognizable evolutionary relationship, with the eukaryotic RhoGAP or RasGAP fold. Similar to other GAPs, ExoS downregulates Rac using an arginine finger to stabilize the transition state of the GTPase reaction, but the details of the ExoS-Rac interaction are unique. Considering the intrinsic resistance of P. aeruginosa to antibiotics, this might open up a new avenue towards blocking its pathogenicity.",x-ray diffraction,2.0,1,4,C,93.12169312169311%,31.60919540229885%,1637,409,5,5,"['MG', 'AF3', 'NI', 'GDP']","NI, GDP, AF3, MG","NICKEL (II) ION, GUANOSINE-5'-DIPHOSPHATE, ALUMINUM FLUORIDE, MAGNESIUM ION",inactive,228,11,13,2,7,13,9,8,13,17,16,10,5,6,2,6,12,12,7,5,2
1HE8,Ras G12V - PI 3-kinase gamma complex,"PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT, GAMMA ISOFORM (E.C.2.7.1.137), TRANSFORMING PROTEIN P21/H-RAS-1",Homo sapiens,9606,No abstract found,x-ray diffraction,3.0,1,2,B,87.83068783068782%,99.3975903614458%,1364,173,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,5,10,11,4,8,11,13,9,8,11,16,11,11,4,3,5,14,3,11,3,
1HH4,Rac1-RhoGDI complex involved in NADPH oxidase activation,"RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1, RHO GDP-DISSOCIATION INHIBITOR 1",Homo sapiens,9606,"A heterodimer of prenylated Rac1 and Rho GDP dissociation inhibitor was purified and found to be competent in NADPH oxidase activation. Small angle neutron scattering experiments confirmed a 1:1 stoichiometry. The crystal structure of the Rac1-RhoGDI complex was determined at 2.7 A resolution. In this complex in which Rac1 is bound to GDP, the switch I region of Rac1 is in the GDP conformation whereas the switch II region resembles that of a GTP-bound GTPase. Two types of interaction between RhoGTPases and RhoGDI were investigated. The lipid-protein interaction between the geranylgeranyl moiety of Rac1 and RhoGDI resulted in numerous structural changes in the core of RhoGDI. The interactions between Rac1 and RhoGDI occur through hydrogen bonds which involve a number of residues of Rac1, namely, Tyr64(Rac), Arg66(Rac), His103(Rac), and His104(Rac), conserved within the Rho family and localized in the switch II region or in its close neighborhood. Moreover, in the switch II region of Rac1, hydrophobic interactions involving Leu67(Rac) and Leu70(Rac) contribute to the stability of the Rac1-RhoGDI complex. Inhibition of the GDP-GTP exchange in Rac1 upon binding to RhoGDI partly results from interaction of Thr35(Rac) with Asp45(GDI). In the Rac1-RhoGDI complex, the accessibility of the effector loops of Rac1 probably accounts for the ability of the Rac1-RhoGDI complex to activate the NADPH oxidase.",x-ray diffraction,2.7,1,4,A,100.0%,33.14285714285714%,1489,203,2,2,"['MG', 'GDP']","GDP, MG, GER","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, GERAN-8-YL GERAN",inactive,12,11,13,2,8,13,9,8,17,18,17,10,5,6,2,5,12,15,9,7,2
1HUQ,1.8A CRYSTAL STRUCTURE OF THE MONOMERIC GTPASE RAB5C (MOUSE),,Mus musculus,10090,No DOI found,x-ray diffraction,1.8,1,1,A,86.77248677248677%,33.12883435582822%,1471,319,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,153,7,23,4,9,11,10,6,11,14,12,9,10,7,2,9,8,2,6,2,2
1I4D,CRYSTAL STRUCTURE ANALYSIS OF RAC1-GDP COMPLEXED WITH ARFAPTIN (P21),"ARFAPTIN 2, RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 1",Homo sapiens,9606,"Small G proteins are GTP-dependent molecular switches that regulate numerous cellular functions. They can be classified into homologous subfamilies that are broadly associated with specific biological processes. Cross-talk between small G-protein families has an important role in signalling, but the mechanism by which it occurs is poorly understood. The coordinated action of Arf and Rho family GTPases is required to regulate many cellular processes including lipid signalling, cell motility and Golgi function. Arfaptin is a ubiquitously expressed protein implicated in mediating cross-talk between Rac (a member of the Rho family) and Arf small GTPases. Here we show that Arfaptin binds specifically to GTP-bound Arf1 and Arf6, but binds to Rac.GTP and Rac.GDP with similar affinities. The X-ray structure of Arfaptin reveals an elongated, crescent-shaped dimer of three-helix coiled-coils. Structures of Arfaptin with Rac bound to either GDP or the slowly hydrolysable analogue GMPPNP show that the switch regions adopt similar conformations in both complexes. Our data highlight fundamental differences between the molecular mechanisms of Rho and Ras family signalling, and suggest a model of Arfaptin-mediated synergy between the Arf and Rho family signalling pathways.",x-ray diffraction,2.5,1,3,D,93.65079365079364%,32.58426966292135%,1455,224,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,45,11,13,2,7,13,9,8,13,18,16,10,5,6,2,6,12,11,7,6,2
1I4T,CRYSTAL STRUCTURE ANALYSIS OF RAC1-GMPPNP IN COMPLEX WITH ARFAPTIN,,Homo sapiens,9606,"Small G proteins are GTP-dependent molecular switches that regulate numerous cellular functions. They can be classified into homologous subfamilies that are broadly associated with specific biological processes. Cross-talk between small G-protein families has an important role in signalling, but the mechanism by which it occurs is poorly understood. The coordinated action of Arf and Rho family GTPases is required to regulate many cellular processes including lipid signalling, cell motility and Golgi function. Arfaptin is a ubiquitously expressed protein implicated in mediating cross-talk between Rac (a member of the Rho family) and Arf small GTPases. Here we show that Arfaptin binds specifically to GTP-bound Arf1 and Arf6, but binds to Rac.GTP and Rac.GDP with similar affinities. The X-ray structure of Arfaptin reveals an elongated, crescent-shaped dimer of three-helix coiled-coils. Structures of Arfaptin with Rac bound to either GDP or the slowly hydrolysable analogue GMPPNP show that the switch regions adopt similar conformations in both complexes. Our data highlight fundamental differences between the molecular mechanisms of Rho and Ras family signalling, and suggest a model of Arfaptin-mediated synergy between the Arf and Rho family signalling pathways.",x-ray diffraction,2.6,1,3,D,93.65079365079364%,30.89887640449438%,1443,209,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,30,11,13,2,7,13,9,8,13,19,16,10,4,6,2,6,12,11,7,6,2
1KAO,CRYSTAL STRUCTURE OF THE SMALL G PROTEIN RAP2A WITH GDP,"RAP2A, GUANOSINE-5'-DIPHOSPHATE",Homo sapiens,9606,"The small G protein Rap2A has been crystallized in complex with GDP, GTP and GTPgammaS. The Rap2A-GTP complex is the first structure of a small G protein with its natural ligand GTP. It shows that the hydroxyl group of Tyr32 forms a hydrogen bond with the gamma-phosphate of GTP and with Gly13. This interaction does not exist in the Rap2A-GTPgammaS complex. Tyr32 is conserved in many small G proteins, which probably also form this hydrogen bond with GTP. In addition, Tyr32 is structurally equivalent to a conserved arginine that binds GTP in trimeric G proteins. The actual participation of Tyr32 in GTP hydrolysis is not yet clear, but several possible roles are discussed. The conformational changes between the GDP and GTP complexes are located essentially in the switch I and II regions as described for the related oncoprotein H-Ras. However, the mobile segments vary in length and in the amplitude of movement. This suggests that even though similar regions might be involved in the GDP-GTP cycle of small G proteins, the details of the changes will be different for each G protein and will ensure the specificity of its interaction with a given set of cellular proteins.",x-ray diffraction,1.7,1,1,A,88.35978835978835%,49.390243902439025%,1429,240,3,3,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,70,11,8,6,14,8,17,7,11,11,18,11,8,4,,8,9,5,9,1,1
1KMQ,Crystal Structure of a Constitutively Activated RhoA Mutant (Q63L),,Homo sapiens,9606,"Mutants of the small G protein RhoA that are deficient in GTPase activity and thereby exhibit constitutive molecular signaling activity are commonly used to discover its cellular functions. In particular, two such mutants, Gly14-->Val (G14V) and Gln63-->Leu (Q63L), are often used interchangeably for such studies. However, while their in vitro rates of GTP hydrolysis are very similar, differences are observed in their other functional properties. The structure of G14V-RhoA is known; in order to assess whether structural variations are responsible for functional differences, the crystal structure of a Q63L-RhoA bound to the GTP-analog 5'-guanylylimidodiphosphate (GMPPNP) was determined at 1.5 A resolution. Overall, the structure is very similar to that of G14V-RhoA, but the significantly higher resolution data permit an improved basis for structural analysis and comparison. The data support the notion that differences observed between the mutants in vivo are likely to arise from altered affinities for RhoGDI and not from direct structural differences.",x-ray diffraction,1.55,1,1,A,93.65079365079364%,31.818181818181817%,1642,392,5,5,"['MG', 'GNP', 'DIO']","MG, GNP, DIO","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, 1,4-DIETHYLENE DIOXIDE",active,210,10,11,5,6,8,16,5,14,14,16,10,4,7,2,6,15,11,10,5,2
1KY2,GPPNHP-BOUND YPT7P AT 1.6 A RESOLUTION,GTP-BINDING PROTEIN YPT7P,Saccharomyces cerevisiae,4932,No abstract found,x-ray diffraction,1.6,1,1,A,95.23809523809523%,31.76470588235294%,1667,422,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,240,10,17,2,15,10,11,5,15,13,16,11,9,10,2,9,12,3,6,2,2
1LF0,Crystal Structure of RasA59G in the GTP-bound form,,Homo sapiens,9606,"The conformational changes in Ras that accompany the hydrolysis of GTP are critical to its function as a molecular switch in signaling pathways. Understanding how GTP is hydrolyzed by revealing the sequence of intermediary structures in the reaction is essential for understanding Ras signaling. Until now, no structure of an intermediate in GTP hydrolysis has been experimentally determined for Ras alone. We have solved the crystal structure of the Ala-59 to Gly mutant of Ras, (RasA59G), bound to guanosine 5'-imidotriphosphate or GDP to 1.7-A resolution. In the guanosine 5'-imidotriphosphate-bound form, this mutant adopts a conformation that is intermediate between the GTP- and GDP-bound forms of wild-type Ras and that is similar to what has been predicted by molecular dynamics simulation [Ma, J. P. & Karplus, M. (1997) Proc. Natl. Acad. Sci. USA 94, 11905-11910]. This conformation is stabilized by direct and water-mediated interactions between the switch 1 and switch 2 regions and is characterized by an increase in the binding affinity for GTP. We propose that the structural changes promoted by the Ala-59 to Gly mutation exhibit a discrete conformational state assumed by wild-type Ras during GTP hydrolysis.",x-ray diffraction,1.7,1,1,A,87.83068783068782%,99.3975903614458%,1475,288,4,4,"['CA', 'MG', 'GNP']","MG, CA, GNP","MAGNESIUM ION, CALCIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,118,12,10,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
1LFD,CRYSTAL STRUCTURE OF THE ACTIVE RAS PROTEIN COMPLEXED WITH THE RAS-INTERACTING DOMAIN OF RALGDS,,Rattus norvegicus,10116,"The Ras protein signals to a number of distinct pathways by interacting with diverse downstream effectors. Among the effectors of Ras are the Raf kinase and RalGDS, a guanine nucleotide dissociation stimulator specific for Ral. Despite the absence of significant sequence similarities, both effectors bind directly to Ras, but with different specificities. We report here the 2.1 A crystal structure of the complex between Ras and the Ras-interacting domain (RID) of RalGDS. This structure reveals that the beta-sheet of the RID joins the switch I region of Ras to form an extended beta-sheet with a topology similar to that found in the Rap-Raf complex. However, the side chain interactions at the joining junctions of the two interacting systems and the relative orientation of the two binding domains are distinctly different. Furthermore, in the case of the Ras-RID complex a second RID molecule also interacts with a different part of the Ras molecule, the switch II region. These findings account for the cross-talk between the Ras and Ral pathways and the specificity with which Ras distinguishes the two effectors.",x-ray diffraction,2.1,1,4,B,88.35978835978835%,99.40119760479041%,1467,272,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,103,11,11,4,8,11,12,9,10,11,15,11,11,4,3,5,14,3,11,3,
1MH1,SMALL G-PROTEIN,,Homo sapiens,9606,"The crystal structure of human rac1, a member of the rho family of small G-proteins, complexed with the non-hydrolysable GTP analogue, guanosine-5'-(beta gamma-imino)triphosphate (GMPPNP), has been determined by X-ray analysis at a resolution of 1.38 A. Comparison with the structure of H-ras indicates that rac1 has an extra alpha-helical domain that is characteristic of the rho G proteins, and may be involved in the signalling pathway of this family.",x-ray diffraction,1.38,1,1,A,96.82539682539682%,32.0%,1667,441,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,256,12,13,2,9,13,9,8,13,18,16,10,5,6,2,5,12,15,7,6,2
1N6H,Crystal Structure of Human Rab5a,Ras-related protein Rab-5A,Homo sapiens,9606,"GTPase domain crystal structures of Rab5a wild type and five variants with mutations in the phosphate-binding loop are reported here at resolutions up to 1.5 A. Of particular interest, the A30P mutant was crystallized in complexes with GDP, GDP+AlF(3), and authentic GTP, respectively. The other variant crystals were obtained in complexes with a non-hydrolyzable GTP analog, GppNHp. All structures were solved in the same crystal form, providing an unusual opportunity to compare structures of small GTPases with different catalytic rates. The A30P mutant exhibits dramatically reduced GTPase activity and forms a GTP-bound complex stable enough for crystallographic analysis. Importantly, the A30P structure with bound GDP plus AlF(3) has been solved in the absence of a GTPase-activating protein, and it may resemble that of a transition state intermediate. Conformational changes are observed between the GTP-bound form and the transition state intermediate, mainly in the switch II region containing the catalytic Gln(79) residue and independent of A30P mutation-induced local alterations in the P-loop. The structures suggest an important catalytic role for a P-loop backbone amide group, which is eliminated in the A30P mutant, and support the notion that the transition state of GTPase-mediated GTP hydrolysis is of considerable dissociative character.",x-ray diffraction,1.51,1,1,A,88.35978835978835%,32.515337423312886%,1610,433,3,3,"['MG', 'BME', 'GNP']","MG, GNP, BME","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, BETA-MERCAPTOETHANOL",active,263,8,20,4,12,9,11,5,12,14,12,9,10,9,2,10,8,2,6,2,2
1N6I,Crystal Structure of Human Rab5a A30P mutant Complex with GDP,,Homo sapiens,9606,"GTPase domain crystal structures of Rab5a wild type and five variants with mutations in the phosphate-binding loop are reported here at resolutions up to 1.5 A. Of particular interest, the A30P mutant was crystallized in complexes with GDP, GDP+AlF(3), and authentic GTP, respectively. The other variant crystals were obtained in complexes with a non-hydrolyzable GTP analog, GppNHp. All structures were solved in the same crystal form, providing an unusual opportunity to compare structures of small GTPases with different catalytic rates. The A30P mutant exhibits dramatically reduced GTPase activity and forms a GTP-bound complex stable enough for crystallographic analysis. Importantly, the A30P structure with bound GDP plus AlF(3) has been solved in the absence of a GTPase-activating protein, and it may resemble that of a transition state intermediate. Conformational changes are observed between the GTP-bound form and the transition state intermediate, mainly in the switch II region containing the catalytic Gln(79) residue and independent of A30P mutation-induced local alterations in the P-loop. The structures suggest an important catalytic role for a P-loop backbone amide group, which is eliminated in the A30P mutant, and support the notion that the transition state of GTPase-mediated GTP hydrolysis is of considerable dissociative character.",x-ray diffraction,1.6,1,1,A,88.35978835978835%,31.92771084337349%,1581,406,3,3,"['MG', 'BME', 'GDP']","MG, GDP, BME","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, BETA-MERCAPTOETHANOL",inactive,236,8,19,4,12,9,11,5,12,14,12,9,10,9,2,10,8,3,6,2,2
1N6N,Crystal Structure of Human Rab5a A30R mutant complex with GppNHp,,Homo sapiens,9606,"GTPase domain crystal structures of Rab5a wild type and five variants with mutations in the phosphate-binding loop are reported here at resolutions up to 1.5 A. Of particular interest, the A30P mutant was crystallized in complexes with GDP, GDP+AlF(3), and authentic GTP, respectively. The other variant crystals were obtained in complexes with a non-hydrolyzable GTP analog, GppNHp. All structures were solved in the same crystal form, providing an unusual opportunity to compare structures of small GTPases with different catalytic rates. The A30P mutant exhibits dramatically reduced GTPase activity and forms a GTP-bound complex stable enough for crystallographic analysis. Importantly, the A30P structure with bound GDP plus AlF(3) has been solved in the absence of a GTPase-activating protein, and it may resemble that of a transition state intermediate. Conformational changes are observed between the GTP-bound form and the transition state intermediate, mainly in the switch II region containing the catalytic Gln(79) residue and independent of A30P mutation-induced local alterations in the P-loop. The structures suggest an important catalytic role for a P-loop backbone amide group, which is eliminated in the A30P mutant, and support the notion that the transition state of GTPase-mediated GTP hydrolysis is of considerable dissociative character.",x-ray diffraction,1.6,1,1,A,88.35978835978835%,32.515337423312886%,1598,415,3,3,"['MG', 'BME', 'GNP']","MG, GNP, BME","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, BETA-MERCAPTOETHANOL",active,245,8,19,4,12,9,11,5,12,14,12,9,10,9,2,10,8,2,7,2,2
1N6O,Crystal Structure of Human Rab5a A30K mutant complex with GppNHp,,Homo sapiens,9606,"GTPase domain crystal structures of Rab5a wild type and five variants with mutations in the phosphate-binding loop are reported here at resolutions up to 1.5 A. Of particular interest, the A30P mutant was crystallized in complexes with GDP, GDP+AlF(3), and authentic GTP, respectively. The other variant crystals were obtained in complexes with a non-hydrolyzable GTP analog, GppNHp. All structures were solved in the same crystal form, providing an unusual opportunity to compare structures of small GTPases with different catalytic rates. The A30P mutant exhibits dramatically reduced GTPase activity and forms a GTP-bound complex stable enough for crystallographic analysis. Importantly, the A30P structure with bound GDP plus AlF(3) has been solved in the absence of a GTPase-activating protein, and it may resemble that of a transition state intermediate. Conformational changes are observed between the GTP-bound form and the transition state intermediate, mainly in the switch II region containing the catalytic Gln(79) residue and independent of A30P mutation-induced local alterations in the P-loop. The structures suggest an important catalytic role for a P-loop backbone amide group, which is eliminated in the A30P mutant, and support the notion that the transition state of GTPase-mediated GTP hydrolysis is of considerable dissociative character.",x-ray diffraction,1.8,1,1,A,89.94708994708994%,32.515337423312886%,1579,376,3,3,"['MG', 'BME', 'GNP']","MG, GNP, BME","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, BETA-MERCAPTOETHANOL",active,203,8,19,4,12,9,11,5,14,14,12,9,10,10,2,10,8,3,6,2,2
1N6P,Crystal Structure of Human Rab5a A30E mutant complex with GppNHp,,Homo sapiens,9606,"GTPase domain crystal structures of Rab5a wild type and five variants with mutations in the phosphate-binding loop are reported here at resolutions up to 1.5 A. Of particular interest, the A30P mutant was crystallized in complexes with GDP, GDP+AlF(3), and authentic GTP, respectively. The other variant crystals were obtained in complexes with a non-hydrolyzable GTP analog, GppNHp. All structures were solved in the same crystal form, providing an unusual opportunity to compare structures of small GTPases with different catalytic rates. The A30P mutant exhibits dramatically reduced GTPase activity and forms a GTP-bound complex stable enough for crystallographic analysis. Importantly, the A30P structure with bound GDP plus AlF(3) has been solved in the absence of a GTPase-activating protein, and it may resemble that of a transition state intermediate. Conformational changes are observed between the GTP-bound form and the transition state intermediate, mainly in the switch II region containing the catalytic Gln(79) residue and independent of A30P mutation-induced local alterations in the P-loop. The structures suggest an important catalytic role for a P-loop backbone amide group, which is eliminated in the A30P mutant, and support the notion that the transition state of GTPase-mediated GTP hydrolysis is of considerable dissociative character.",x-ray diffraction,1.54,1,1,A,86.77248677248677%,32.515337423312886%,1568,408,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,242,7,19,4,12,9,12,5,11,14,12,9,10,8,2,10,8,2,6,2,2
1N6R,Crystal Structure of Human Rab5a A30L mutant complex with GppNHp,,Homo sapiens,9606,"GTPase domain crystal structures of Rab5a wild type and five variants with mutations in the phosphate-binding loop are reported here at resolutions up to 1.5 A. Of particular interest, the A30P mutant was crystallized in complexes with GDP, GDP+AlF(3), and authentic GTP, respectively. The other variant crystals were obtained in complexes with a non-hydrolyzable GTP analog, GppNHp. All structures were solved in the same crystal form, providing an unusual opportunity to compare structures of small GTPases with different catalytic rates. The A30P mutant exhibits dramatically reduced GTPase activity and forms a GTP-bound complex stable enough for crystallographic analysis. Importantly, the A30P structure with bound GDP plus AlF(3) has been solved in the absence of a GTPase-activating protein, and it may resemble that of a transition state intermediate. Conformational changes are observed between the GTP-bound form and the transition state intermediate, mainly in the switch II region containing the catalytic Gln(79) residue and independent of A30P mutation-induced local alterations in the P-loop. The structures suggest an important catalytic role for a P-loop backbone amide group, which is eliminated in the A30P mutant, and support the notion that the transition state of GTPase-mediated GTP hydrolysis is of considerable dissociative character.",x-ray diffraction,1.55,1,1,A,88.35978835978835%,32.515337423312886%,1582,402,3,3,"['MG', 'BME', 'GNP']","MG, GNP, BME","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, BETA-MERCAPTOETHANOL",active,232,8,19,4,12,9,11,5,12,15,12,9,10,9,2,10,8,2,6,2,2
1NVV,Structural evidence for feedback activation by RasGTP of the Ras-specific nucleotide exchange factor SOS,,Homo sapiens,9606,No abstract found,x-ray diffraction,2.18,1,3,Q,87.83068783068782%,99.3975903614458%,1392,207,3,3,"['MG', 'GNP', 'PO4']","MG, PO4, GNP","MAGNESIUM ION, PHOSPHATE ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,38,11,12,4,8,11,13,8,8,11,15,11,11,4,3,5,14,3,11,3,
1OIV,X-ray structure of the small G protein Rab11a in complex with GDP,RAS-RELATED PROTEIN RAB-11A,Homo sapiens,9606,"The small GTP-binding protein Rab11 is an essential regulator of the dynamics of recycling endosomes. Here we report the crystallographic analysis of the GDP/GTP cycle of human Rab11a, and a structure-based mutagenesis study that identifies a novel mutant phenotype. The crystal structures show that the nucleotide-sensitive switch 1 and 2 regions differ from those of other Rab proteins. In Rab11-GDP, they contribute to a close packed symmetrical dimer, which may associate to membranes in the cell and allow Rab11 to undergo GDP/GTP cycles without recycling to the cytosol. The structure of active Rab11 delineates a three-dimensional site that includes switch 1 and is separate from the site defined by the Rab3/Rabphilin interface. It is proposed to form a novel interface for a Rab11 partner compatible with the simultaneous binding of another partner at the Rabphilin interface. Mutation of Ser(29) to Phe in this epitope resulted in morphological modifications of the recycling compartment that are distinct from those induced by the classical dominant-negative and constitutively active Rab11 mutants. Recycling endosomes condensed in the perinuclear region where they retained recycling transferrin, and they clustered Rab11- and EEA1-positive membranes. Altogether, our study suggests that this mutation impairs a specific subset of Rab11 interactions, possibly those involved in cytoskeleton-based movements driving the slow recycling pathway.",x-ray diffraction,1.98,1,2,A,88.88888888888889%,37.65432098765432%,1452,254,2,2,"['SO4', 'GDP']","GDP, SO4, EDO","GUANOSINE-5'-DIPHOSPHATE, SULFATE ION, 1,2-ETHANEDIOL",inactive,84,10,16,1,12,12,13,8,9,16,12,12,4,8,3,7,11,1,11,,2
1OIW,X-ray structure of the small G protein Rab11a in complex with GTPgammaS,RAS-RELATED PROTEIN RAB-11A,Homo sapiens,9606,"The small GTP-binding protein Rab11 is an essential regulator of the dynamics of recycling endosomes. Here we report the crystallographic analysis of the GDP/GTP cycle of human Rab11a, and a structure-based mutagenesis study that identifies a novel mutant phenotype. The crystal structures show that the nucleotide-sensitive switch 1 and 2 regions differ from those of other Rab proteins. In Rab11-GDP, they contribute to a close packed symmetrical dimer, which may associate to membranes in the cell and allow Rab11 to undergo GDP/GTP cycles without recycling to the cytosol. The structure of active Rab11 delineates a three-dimensional site that includes switch 1 and is separate from the site defined by the Rab3/Rabphilin interface. It is proposed to form a novel interface for a Rab11 partner compatible with the simultaneous binding of another partner at the Rabphilin interface. Mutation of Ser(29) to Phe in this epitope resulted in morphological modifications of the recycling compartment that are distinct from those induced by the classical dominant-negative and constitutively active Rab11 mutants. Recycling endosomes condensed in the perinuclear region where they retained recycling transferrin, and they clustered Rab11- and EEA1-positive membranes. Altogether, our study suggests that this mutation impairs a specific subset of Rab11 interactions, possibly those involved in cytoskeleton-based movements driving the slow recycling pathway.",x-ray diffraction,2.05,1,1,A,87.83068783068782%,37.03703703703704%,1424,247,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,79,10,16,1,12,12,12,8,9,17,12,12,3,8,3,7,10,1,11,,2
1S1C,Crystal structure of the complex between the human RhoA and Rho-binding domain of human ROCKI,"Transforming protein RhoA, Rho-associated, coiled-coil containing protein kinase 1",Homo sapiens,9606,"The Rho-ROCK pathway modulates the phosphorylation level of a variety of important signaling proteins and is thereby involved in miscellaneous cellular processes including cell migration, neurite outgrowth, and smooth muscle contraction. The observation of the involvement of the Rho-ROCK pathway in tumor invasion and in diseases such as hypertension and bronchial asthma makes it an interesting target for drug development. We herein present the crystal structure of the complex between active RhoA and the Rho-binding domain of ROCKI. The Rho-binding domain structure forms a parallel alpha-helical coiled-coil dimer and, in contrast to the published Rho-protein kinase N structure, binds exclusively to the switch I and II regions of the guanosine 5'-(beta,gamma-imido)triphosphate-bound RhoA. The switch regions of two different RhoA molecules form a predominantly hydrophobic patch, which is complementarily bound by two identical short helices of 13 residues (amino acids 998-1010). The identified ROCK-binding site of RhoA strikingly supports the assumption of a common consensus-binding site for effector recognition.",x-ray diffraction,2.6,1,4,A,94.70899470899471%,32.38636363636363%,1472,210,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,29,10,13,5,6,8,16,5,14,13,16,10,5,6,2,7,15,11,10,5,2
1T91,crystal structure of human small GTPase Rab7(GTP),,Homo sapiens,9606,"Rab7 regulates vesicle traffic from early to late endosomes, and from late endosomes to lysosomes. The crystal structure of Rab7-GTP in complex with the Rab7 binding domain of RILP reveals that Rab7 interacts with RILP specifically via two distinct areas, with the first one involving the switch and interswitch regions and the second one consisting of RabSF1 and RabSF4. Disruption of these interactions by mutations abrogates late endosomal/lysosomal targeting of Rab7 and RILP. The Rab7 binding domain of RILP forms a coiled-coil homodimer with two symmetric surfaces to interact with two separate Rab7-GTP molecules, forming a dyad configuration of Rab7-RILP(2)-Rab7. Mutations that disrupt RILP dimerization also abolish its interactions with Rab7-GTP and late endosomal/lysosomal targeting, suggesting that the dimeric form of RILP is a functional unit. Structural comparison suggests that the combined use of RabSF1 and RabSF4 with the switch regions may be a general mode of action for most Rab proteins in regulating membrane trafficking.",x-ray diffraction,1.9,1,4,A,93.12169312169311%,30.303030303030305%,1559,300,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,122,8,15,3,8,12,11,5,12,15,16,9,10,11,,11,11,5,8,3,3
1TU3,Crystal Structure of Rab5 complex with Rabaptin5 C-terminal Domain,"Ras-related protein Rab-5A, Rab GTPase binding effector protein 1",Homo sapiens,9606,"Rab5 is a small GTPase that regulates early endosome fusion. We present here the crystal structure of the Rab5 GTPase domain in complex with a GTP analog and the C-terminal domain of effector Rabaptin5. The proteins form a dyad-symmetric Rab5-Rabaptin5(2)-Rab5 ternary complex with a parallel coiled-coil Rabaptin5 homodimer in the middle. Two Rab5 molecules bind independently to the Rabaptin5 dimer using their switch and interswitch regions. The binding does not involve the Rab complementarity-determining regions. We also present the crystal structures of two distinct forms of GDP-Rab5 complexes, both of which are incompatible with Rabaptin5 binding. One has a dislocated and disordered switch I but a virtually intact switch II, whereas the other has its beta-sheet and both switch regions reorganized. Biochemical and functional analyses show that the crystallographically observed Rab5-Rabaptin5 complex also exists in solution, and disruption of this complex by mutation abrogates endosome fusion.",x-ray diffraction,2.31,1,10,A,87.3015873015873%,32.515337423312886%,1391,229,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,62,7,20,4,12,9,11,5,11,14,12,9,10,8,2,10,8,3,6,2,2
1TX4,RHO/RHOGAP/GDP(DOT)ALF4 COMPLEX,,Homo sapiens,9606,"Small G proteins of the Rho family, which includes Rho, Rac and Cdc42Hs, regulate phosphorylation pathways that control a range of biological functions including cytoskeleton formation and cell proliferation. They operate as molecular switches, cycling between the biologically active GTP-bound form and the inactive GDP-bound state. Their rate of hydrolysis of GTP to GDP by virtue of their intrinsic GTPase activity is slow, but can be accelerated by up to 10(5)-fold through interaction with rhoGAP, a GTPase-activating protein that stimulates Rho-family proteins. As such, rhoGAP plays a crucial role in regulating Rho-mediated signalling pathways. Here we report the crystal structure of RhoA and rhoGAP complexed with the transition-state analogue GDP.AlF4- at 1.65 A resolution. There is a rotation of 20 degrees between the Rho and rhoGAP proteins in this complex when compared with the ground-state complex Cdc42Hs.GMPPNP/rhoGAP, in which Cdc42Hs is bound to the non-hydrolysable GTP analogue GMPPNP. Consequently, in the transition state complex but not in the ground state, the rhoGAP domain contributes a residue, Arg85(GAP) directly into the active site of the G protein. We propose that this residue acts to stabilize the transition state of the GTPase reaction. RhoGAP also appears to function by stabilizing several regions of RhoA that are important in signalling the hydrolysis of GTP.",x-ray diffraction,1.65,1,2,B,77.24867724867724%,32.55813953488372%,1636,401,3,3,"['MG', 'ALF', 'GDP']","MG, ALF, GDP","MAGNESIUM ION, TETRAFLUOROALUMINATE ION, GUANOSINE-5'-DIPHOSPHATE",inactive,224,10,12,5,6,8,15,5,14,13,15,10,4,7,2,6,15,10,10,5,2
1UAD,Crystal structure of the RalA-GppNHp-Sec5 Ral-binding domain complex,Ras-related protein Ral-A/Exocyst complex component Sec5,Homo sapiens,9606,"The sec6/8 complex or exocyst is an octameric protein complex that functions during cell polarization by regulating the site of exocytic vesicle docking to the plasma membrane, in concert with small GTP-binding proteins. The Sec5 subunit of the mammalian sec6/8 complex binds Ral in a GTP-dependent manner. Here we report the crystal structure of the complex between the Ral-binding domain of Sec5 and RalA bound to a non-hydrolyzable GTP analog (GppNHp) at 2.1 A resolution, providing the first structural insights into the mechanism and specificity of sec6/8 regulation. The Sec5 Ral-binding domain folds into an immunoglobulin-like beta-sandwich structure, which represents a novel fold for an effector of a GTP-binding protein. The interface between the two proteins involves a continuous antiparallel beta-sheet, similar to that found in other effector/G-protein complexes, such as Ras and Rap1A. Specific interactions unique to the RalA.Sec5 complex include Sec5 Thr11 and Arg27, and RalA Glu38, which we show are required for complex formation by isothermal titration calorimetry. Comparison of the structures of GppNHp- and GDP-bound RalA suggests a nucleotide-dependent switch mechanism for Sec5 binding.",x-ray diffraction,2.1,1,4,A,91.53439153439153%,54.21686746987952%,1500,253,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,78,9,14,5,11,7,19,6,12,12,17,7,6,7,1,10,15,2,11,1,1
1VG0,The crystal structures of the REP-1 protein in complex with monoprenylated Rab7 protein,,Rattus norvegicus,10116,"Members of the RabGDI/REP family serve as multifunctional regulators of the Rab family of GTP binding proteins. Mutations in members of this family, such as REP-1, lead to abnormalities, including progressive retinal degradation (choroideremia) in humans. The crystal structures of the REP-1 protein in complex with monoprenylated or C-terminally truncated Rab7 proteins revealed that Rab7 interacts with the Rab binding platform of REP-1 via an extended interface involving the Switch 1 and 2 regions. The C terminus of the REP-1 molecule functions as a mobile lid covering a conserved hydrophobic patch on the surface of REP-1 that in the complex coordinates the C terminus of Rab proteins. Using semisynthetic fluorescent Rab27A, we demonstrate that although Rab27A can be prenylated by REP-2, this reaction can be effectively inhibited by other Rab proteins, providing a possible explanation for the accumulation of unprenylated Rab27A in choroideremia.",x-ray diffraction,2.2,1,2,B,80.42328042328042%,30.303030303030305%,1586,276,3,3,"['PG4', 'MG', 'GDP']","CL, GER, MG, GDP, PG4","CHLORIDE ION, GERAN-8-YL GERAN, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, TETRAETHYLENE GLYCOL",inactive,91,8,14,3,8,11,13,5,13,15,16,10,10,12,,12,11,7,8,3,3
1VG1,GDP-Bound Rab7,Ras-related protein Rab-7,Rattus norvegicus,10116,"Members of the RabGDI/REP family serve as multifunctional regulators of the Rab family of GTP binding proteins. Mutations in members of this family, such as REP-1, lead to abnormalities, including progressive retinal degradation (choroideremia) in humans. The crystal structures of the REP-1 protein in complex with monoprenylated or C-terminally truncated Rab7 proteins revealed that Rab7 interacts with the Rab binding platform of REP-1 via an extended interface involving the Switch 1 and 2 regions. The C terminus of the REP-1 molecule functions as a mobile lid covering a conserved hydrophobic patch on the surface of REP-1 that in the complex coordinates the C terminus of Rab proteins. Using semisynthetic fluorescent Rab27A, we demonstrate that although Rab27A can be prenylated by REP-2, this reaction can be effectively inhibited by other Rab proteins, providing a possible explanation for the accumulation of unprenylated Rab27A in choroideremia.",x-ray diffraction,1.9,1,1,A,60.317460317460316%,33.95061728395062%,1506,312,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,144,6,13,3,8,11,11,5,13,14,16,8,8,11,,10,11,5,7,3,3
1WMS,High resolution crystal structure of human Rab9 GTPase: a novel antiviral drug target,Ras-related protein Rab-9A,Homo sapiens,9606,"Rab GTPases and their effectors facilitate vesicular transport by tethering donor vesicles to their respective target membranes. Rab9 mediates late endosome to trans-Golgi transport and has recently been found to be a key cellular component for human immunodeficiency virus-1, Ebola, Marburg, and measles virus replication, suggesting that it may be a novel target in the development of broad spectrum antiviral drugs. As part of our structure-based drug design program, we have determined the crystal structure of a C-terminally truncated human Rab9 (residues 1-177) to 1.25-A resolution. The overall structure shows a characteristic nucleotide binding fold consisting of a six-stranded beta-sheet surrounded by five alpha-helices with a tightly bound GDP molecule in the active site. Structure-based sequence alignment of Rab9 with other Rab proteins reveals that its active site consists of residues highly conserved in the Rab GTPase family, implying a common catalytic mechanism. However, Rab9 contains seven regions that are significantly different in conformation from other Rab proteins. Some of those regions coincide with putative effector-binding sites and switch I and switch II regions identified by structure/sequence alignments. The Rab9 structure at near atomic resolution provides an excellent model for structure-based antiviral drug design.",x-ray diffraction,1.25,1,2,A,72.4867724867725%,33.33333333333333%,1629,416,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,245,11,12,2,14,11,12,6,10,12,13,7,6,8,1,13,13,4,9,3,3
1X1R,Crystal structure of M-Ras in complex with GDP,Ras-related protein M-Ras,Mus musculus,10090,"Although some members of Ras family small GTPases, including M-Ras, share the primary structure of their effector regions with Ras, they exhibit vastly different binding properties to Ras effectors such as c-Raf-1. We have solved the crystal structure of M-Ras in the GDP-bound and guanosine 5'-(beta,gamma-imido)triphosphate (Gpp(NH)p)-bound forms. The overall structure of M-Ras resembles those of H-Ras and Rap2A, except that M-Ras-Gpp(NH)p exhibits a distinctive switch I conformation, which is caused by impaired intramolecular interactions between Thr-45 (corresponding to Thr-35 of H-Ras) of the effector region and the gamma-phosphate of Gpp(NH)p. Previous 31P NMR studies showed that H-Ras-Gpp(NH)p exists in two interconverting conformations, states 1 and 2. Whereas state 2 is a predominant form of H-Ras and corresponds to the ""on"" conformation found in the complex with effectors, state 1 is thought to represent the ""off"" conformation, whose tertiary structure remains unknown. 31P NMR analysis shows that free M-Ras-Gpp(NH)p predominantly assumes the state 1 conformation, which undergoes conformational transition to state 2 upon association with c-Raf-1. These results indicate that the solved structure of M-Ras-Gp-p(NH)p corresponds to the state 1 conformation. The predominance of state 1 in M-Ras is likely to account for its weak binding ability to the Ras effectors, suggesting the importance of the tertiary structure factor in small GTPase-effector interaction. Further, the first determination of the state 1 structure provides a molecular basis for developing novel anti-cancer drugs as compounds that hold Ras in the state 1 ""off"" conformation.",x-ray diffraction,1.3,1,1,A,89.41798941798942%,56.886227544910184%,1644,409,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,238,8,8,5,7,11,9,7,12,14,16,11,9,5,5,9,16,7,9,,1
1XTQ,Structure of small GTPase human Rheb in complex with GDP,GTP-binding protein Rheb,Homo sapiens,9606,"The small GTPase Rheb displays unique biological and biochemical properties different from other small GTPases and functions as an important mediator between the tumor suppressor proteins TSC1 and TSC2 and the mammalian target of rapamycin to stimulate cell growth. We report here the three-dimensional structures of human Rheb in complexes with GDP, GTP, and GppNHp (5'-(beta,gamma-imide)triphosphate), which reveal novel structural features of Rheb and provide a molecular basis for its distinct properties. During GTP/GDP cycling, switch I of Rheb undergoes conformational change while switch II maintains a stable, unusually extended conformation, which is substantially different from the alpha-helical conformation seen in other small GTPases. The unique switch II conformation results in a displacement of Gln64 (equivalent to the catalytic Gln61 of Ras), making it incapable of participating in GTP hydrolysis and thus accounting for the low intrinsic GTPase activity of Rheb. This rearrangement also creates space to accommodate the side chain of Arg15, avoiding its steric hindrance with the catalytic residue and explaining its noninvolvement in GTP hydrolysis. Unlike Ras, the phosphate moiety of GTP in Rheb is shielded by the conserved Tyr35 of switch I, leading to the closure of the GTP-binding site, which appears to prohibit the insertion of a potential arginine finger from its GTPase-activating protein. Taking the genetic, biochemical, biological, and structural data together, we propose that Rheb forms a new group of the Ras/Rap subfamily and uses a novel GTP hydrolysis mechanism that utilizes Asn1643 of the tuberous sclerosis complex 2 GTPase-activating protein domain instead of Gln64 of Rheb as the catalytic residue.",x-ray diffraction,2.0,1,1,A,89.41798941798942%,36.477987421383645%,1537,335,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,164,10,9,3,15,9,14,8,13,14,15,17,9,6,3,7,8,3,5,,1
1YU9,GppNHp-Bound Rab4A,GTP-binding protein,Homo sapiens,9606,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.07,1,1,A,92.5925925925926%,32.71604938271605%,1664,416,4,4,"['MG', 'GNP', 'SO4']","MG, SO4, GNP","MAGNESIUM ION, SULFATE ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,237,14,14,2,10,12,13,6,12,18,10,11,6,9,2,11,10,1,9,3,2
1YVD,GppNHp-Bound Rab22 GTPase,Ras-related protein Rab-22A,Mus musculus,10090,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,1.93,1,1,A,87.83068783068782%,30.909090909090907%,1593,416,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,248,8,14,3,11,10,12,5,9,11,12,16,4,8,3,8,10,6,11,2,3
1YZK,GppNHp bound Rab11 GTPase,Ras-related protein Rab-11A,Homo sapiens,9606,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.0,1,1,A,88.88888888888889%,37.65432098765432%,1561,389,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,219,10,16,1,12,12,12,8,9,16,12,13,4,8,3,7,10,1,12,,2
1YZL,GppNHp-Bound Rab9 GTPase,Ras-related protein Rab-9A,Mus musculus,10090,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,1.85,1,1,A,91.005291005291%,33.33333333333333%,1655,427,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,253,10,10,2,15,11,12,6,12,13,11,8,7,8,2,14,13,4,8,3,3
1YZN,GppNHp-Bound Ypt1p GTPase,GTP-binding protein YPT1,Saccharomyces cerevisiae,4932,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.06,1,1,A,94.17989417989418%,37.19512195121951%,1577,333,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,153,12,8,3,14,14,10,9,14,18,14,11,5,6,2,8,16,2,8,2,2
1YZQ,GppNHp-Bound Rab6 GTPase,small GTP binding protein RAB6 isoform,Homo sapiens,9606,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,1.78,1,1,A,86.77248677248677%,32.278481012658226%,1516,361,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,195,9,12,5,11,13,9,6,10,13,13,12,8,6,,9,12,2,12,,2
1YZU,GppNHp-Bound Rab21 GTPase at 2.50 A Resolution,Ras-related protein Rab-21,Homo sapiens,9606,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.5,1,2,A,87.3015873015873%,32.098765432098766%,1385,270,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,103,12,10,2,9,7,13,7,17,17,11,12,5,9,5,6,8,1,7,5,2
1Z06,GppNHp-Bound Rab33 GTPase,Ras-related protein Rab-33B,Mus musculus,10090,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,1.81,1,1,A,87.3015873015873%,35.50295857988166%,1413,278,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,111,7,14,5,7,10,8,4,8,10,12,13,6,8,6,10,13,6,12,4,2
1Z07,GppNHp-Bound Rab5c G55Q mutant GTPase,,Mus musculus,10090,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,1.81,1,1,A,87.3015873015873%,33.12883435582822%,1550,410,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,243,6,23,4,10,11,10,6,11,14,12,9,11,7,2,9,8,2,6,2,2
1Z0A,GDP-Bound Rab2A GTPase,Ras-related protein Rab-2A,Homo sapiens,9606,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.12,1,4,A,71.42857142857143%,35.80246913580247%,1509,340,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,172,12,14,4,10,13,14,7,11,13,6,15,6,6,3,9,9,,11,1,2
1Z0D,GDP-Bound Rab5c GTPase,,Mus musculus,10090,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.2,1,2,A,87.3015873015873%,32.515337423312886%,1551,408,3,3,"['MG', 'GDP', 'PO4']","PO4, MG, GDP","PHOSPHATE ION, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,240,7,23,4,9,11,10,6,11,15,12,9,9,7,2,9,8,3,6,2,2
1Z0F,GDP-Bound Rab14 GTPase,"RAB14, member RAS oncogene family",Homo sapiens,9606,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.15,1,1,A,88.35978835978835%,32.121212121212125%,1363,257,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,88,12,16,3,8,12,13,9,11,13,8,14,6,8,3,8,8,2,9,2,2
1Z0J,Structure of GTP-Bound Rab22Q64L GTPase in complex with the minimal Rab binding domain of Rabenosyn-5,,Mus musculus,10090,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,1.32,1,2,A,89.41798941798942%,30.303030303030305%,1628,414,4,4,"['GTP', 'MG', 'TRS', 'GOL']","MG, GTP, TRS, GOL","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, GLYCEROL",active,241,9,15,4,12,10,12,5,9,12,11,16,3,8,3,8,10,6,11,2,3
1Z0K,Structure of GTP-Bound Rab4Q67L GTPase in complex with the central Rab binding domain of Rabenosyn-5,,Homo sapiens,9606,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,1.92,1,4,A,89.41798941798942%,32.098765432098766%,1511,334,2,2,"['GTP', 'MG']","MG, GTP, MES","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID",active,163,12,14,2,9,12,12,6,12,18,10,11,5,9,2,11,10,,9,3,2
1Z22,GDP-Bound Rab23 GTPase crystallized in C222(1) space group,Ras-related protein Rab-23,Mus musculus,10090,"Rab GTPases regulate all stages of membrane trafficking, including vesicle budding, cargo sorting, transport, tethering and fusion. In the inactive (GDP-bound) conformation, accessory factors facilitate the targeting of Rab GTPases to intracellular compartments. After nucleotide exchange to the active (GTP-bound) conformation, Rab GTPases interact with functionally diverse effectors including lipid kinases, motor proteins and tethering complexes. How effectors distinguish between homologous Rab GTPases represents an unresolved problem with respect to the specificity of vesicular trafficking. Using a structural proteomic approach, we have determined the specificity and structural basis underlying the interaction of the multivalent effector rabenosyn-5 with the Rab family. The results demonstrate that even the structurally similar effector domains in rabenosyn-5 can achieve highly selective recognition of distinct subsets of Rab GTPases exclusively through interactions with the switch and interswitch regions. The observed specificity is determined at a family-wide level by structural diversity in the active conformation, which governs the spatial disposition of critical conserved recognition determinants, and by a small number of both positive and negative sequence determinants that allow further discrimination between Rab GTPases with similar switch conformations.",x-ray diffraction,2.06,1,1,A,86.77248677248677%,34.394904458598724%,1468,371,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,205,9,13,3,9,8,14,6,15,13,17,10,7,5,1,7,12,1,9,3,2
1Z2C,Crystal structure of mDIA1 GBD-FH3 in complex with RhoC-GMPPNP,,Homo sapiens,9606,"Formins are involved in a variety of cellular processes that require the remodelling of the cytoskeleton. They contain formin homology domains FH1 and FH2, which initiate actin assembly. The Diaphanous-related formins form a subgroup that is characterized by an amino-terminal Rho GTPase-binding domain (GBD) and an FH3 domain, which bind somehow to the carboxy-terminal Diaphanous autoregulatory domain (DAD) to keep the protein in an inactive conformation. Upon binding of activated Rho proteins, the DAD is released and the ability of the formin to nucleate and elongate unbranched actin filaments is induced. Here we present the crystal structure of RhoC in complex with the regulatory N terminus of mammalian Diaphanous 1 (mDia1) containing the GBD/FH3 region, an all-helical structure with armadillo repeats. Rho uses its 'switch' regions for interacting with two subdomains of GBD/FH3. We show that the FH3 domain of mDia1 forms a stable dimer and we also identify the DAD-binding site. Although binding of Rho and DAD on the N-terminal fragment of mDia1 are mutually exclusive, their binding sites are only partially overlapping. On the basis of our results, we propose a structural model for the regulation of mDia1 by Rho and DAD.",x-ray diffraction,3.0,1,4,A,94.70899470899471%,32.62032085561498%,1452,181,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,0,10,12,5,8,8,17,5,13,14,15,11,5,6,2,6,14,10,11,5,2
1ZC3,Crystal structure of the Ral-binding domain of Exo84 in complex with the active RalA,,Homo sapiens,9606,"The Sec6/8 complex, also known as the exocyst complex, is an octameric protein complex that has been implicated in tethering of secretory vesicles to specific regions on the plasma membrane. Two subunits of the Sec6/8 complex, Exo84 and Sec5, have recently been shown to be effector targets for active Ral GTPases. However, the mechanism by which Ral proteins regulate the Sec6/8 activities remains unclear. Here, we present the crystal structure of the Ral-binding domain of Exo84 in complex with active RalA. The structure reveals that the Exo84 Ral-binding domain adopts a pleckstrin homology domain fold, and that RalA interacts with Exo84 via an extended interface that includes both switch regions. Key residues of Exo84 and RalA were found that determine the specificity of the complex interactions; these interactions were confirmed by mutagenesis binding studies. Structural and biochemical data show that Exo84 and Sec5 competitively bind to active RalA. Taken together, these results further strengthen the proposed role of RalA-regulated assembly of the Sec6/8 complex.",x-ray diffraction,2.0,1,4,A,91.53439153439153%,53.6144578313253%,1541,295,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,120,9,14,5,11,7,19,6,12,13,17,7,5,7,1,10,15,2,11,1,1
1ZVQ,Structure of the Q61G mutant of Ras in the GDP-bound form,,Homo sapiens,9606,"The flexibility of the conserved 57DTAGQ61 motif is essential for Ras proper cycling in response to growth factors. Here, we increase the flexibility of the 57DTAGQ61 motif by mutating Gln61 to Gly. The crystal structure of the RasQ61G mutant reveals a new conformation of switch 2 that bears remarkable structural homology to an intermediate for GTP hydrolysis revealed by targeted molecular dynamics simulations. The mutation increased retention of GTP and inhibited Ras binding to the catalytic site, but not to the distal site of Sos. Most importantly, the thermodynamics of RafRBD binding to Ras are altered even though the structure of switch 1 is not affected by the mutation. Our results suggest that interplay and transmission of structural information between the switch regions are important factors for Ras function. They propose that initiation of GTP hydrolysis sets off the separation of the Ras/effector complex even before the GDP conformation is reached.",x-ray diffraction,2.0,1,1,A,87.83068783068782%,99.3975903614458%,1426,248,3,3,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,79,12,11,4,8,11,13,9,8,11,15,11,10,4,3,5,14,3,11,3,
1ZW6,Crystal Structure of the GTP-bound form of RasQ61G,,Homo sapiens,9606,"The flexibility of the conserved 57DTAGQ61 motif is essential for Ras proper cycling in response to growth factors. Here, we increase the flexibility of the 57DTAGQ61 motif by mutating Gln61 to Gly. The crystal structure of the RasQ61G mutant reveals a new conformation of switch 2 that bears remarkable structural homology to an intermediate for GTP hydrolysis revealed by targeted molecular dynamics simulations. The mutation increased retention of GTP and inhibited Ras binding to the catalytic site, but not to the distal site of Sos. Most importantly, the thermodynamics of RafRBD binding to Ras are altered even though the structure of switch 1 is not affected by the mutation. Our results suggest that interplay and transmission of structural information between the switch regions are important factors for Ras function. They propose that initiation of GTP hydrolysis sets off the separation of the Ras/effector complex even before the GDP conformation is reached.",x-ray diffraction,1.5,1,1,A,60.84656084656085%,98.79518072289156%,1522,339,7,7,"['CA', 'MG', 'CSO', 'GNP']","MG, CA, GNP","MAGNESIUM ION, CALCIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,167,12,11,4,8,11,13,9,8,11,15,11,10,4,3,5,14,3,11,2,
221P,THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES,"H-RAS P21 PROTEIN MUTANT WITH ASP 38 REPLACED BY GLU (D38E) COMPLEX WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE",Homo sapiens,9606,No abstract found,x-ray diffraction,2.3,1,1,A,87.83068783068782%,99.3975903614458%,1566,378,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,210,11,11,4,8,11,14,9,8,11,15,11,11,4,3,5,13,3,11,3,
2A5J,Crystal Structure of Human RAB2B,Ras-related protein Rab-2B,Homo sapiens,9606,No DOI found,x-ray diffraction,1.5,1,1,A,73.01587301587301%,35.80246913580247%,1717,452,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,273,15,12,4,14,10,13,6,10,14,8,15,8,6,4,10,8,2,14,2,2
2A78,Crystal structure of the C3bot-RalA complex reveals a novel type of action of a bacterial exoenzyme,"Ras-related protein Ral-A, Mono-ADP-ribosyltransferase C3 (E.C.2.4.2.-)",Homo sapiens,9606,"C3 exoenzymes from bacterial pathogens ADP-ribosylate and inactivate low-molecular-mass GTPases of the Rho subfamily. Ral, a Ras subfamily GTPase, binds the C3 exoenzymes from Clostridium botulinum and C. limosum with high affinity without being a substrate for ADP ribosylation. In the complex, the ADP-ribosyltransferase activity of C3 is blocked, while binding of NAD and NAD-glycohydrolase activity remain. Here we report the crystal structure of C3 from C. botulinum in a complex with GDP-bound RalA at 1.8 A resolution. C3 binds RalA with a helix-loop-helix motif that is adjacent to the active site. A quaternary complex with NAD suggests a mode for ADP-ribosyltransferase inhibition. Interaction of C3 with RalA occurs at a unique interface formed by the switch-II region, helix alpha3 and the P loop of the GTPase. C3-binding stabilizes the GDP-bound conformation of RalA and blocks nucleotide release. Our data indicate that C. botulinum exoenzyme C3 is a single-domain toxin with bifunctional properties targeting Rho GTPases by ADP ribosylation and Ral by a guanine nucleotide dissociation inhibitor-like effect, which blocks nucleotide exchange.",x-ray diffraction,1.81,1,2,A,89.94708994708994%,54.21686746987952%,1557,332,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,160,9,14,5,9,7,19,6,12,11,17,7,6,7,1,10,15,2,11,1,1
2ATV,The crystal structure of human RERG in the GDP bound state,RAS-like estrogen-regulated growth inhibitor,Homo sapiens,9606,No DOI found,x-ray diffraction,1.9,1,1,A,88.88888888888889%,40.476190476190474%,1430,263,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,93,12,11,3,7,12,20,5,9,15,13,11,4,4,3,7,10,3,13,4,2
2ATX,Crystal Structure of the TC10 GppNHp complex,small GTP binding protein TC10 (E.C.3.6.5.2),Homo sapiens,9606,"The specific and rapid formation of protein complexes is essential for diverse cellular processes such as remodeling of actin filaments in response to the interaction between Rho GTPases and the Wiskott-Aldrich syndrome proteins (WASp and N-WASp). Although Cdc42, TC10, and other members of the Rho family have been implicated in binding to and activating the WAS proteins, the exact nature of such a protein-protein recognition process has remained obscure. Here, we describe a mechanism that ensures rapid and selective long-range Cdc42-WASp recognition. The crystal structure of TC10, together with mutational and bioinformatic analyses, proved that the basic region of WASp and two unique glutamates in Cdc42 generate favorable electrostatic steering forces that control the accelerated WASp-Cdc42 association reaction. This process is a prerequisite for WASp activation and a critical step in temporal regulation and integration of WASp-mediated cellular responses.",x-ray diffraction,2.65,1,2,A,98.4126984126984%,32.93413173652694%,1469,196,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,8,13,15,5,7,10,12,9,12,20,18,8,7,5,2,7,12,12,4,7,1
2BMD,high resolution structure of GDP-bound human Rab4a,RAS-RELATED PROTEIN RAB4A (E.C.3.6.5.2),Homo sapiens,9606,"The Ras-related human GTPase Rab4a is involved in the regulation of endocytosis through the sorting and recycling of early endosomes. Towards further insight, we have determined the three-dimensional crystal structure of human Rab4a in its GppNHp-bound state to 1.6 Angstroms resolution and in its GDP-bound state to 1.8 Angstroms resolution, respectively. Despite the similarity of the overall structure with other Rab proteins, Rab4a displays significant differences. The structures are discussed with respect to the recently determined structure of human Rab5a and its complex with the Rab5-binding domain of the bivalent effector Rabaptin-5. The Rab4 specific residue His39 modulates the nucleotide binding pocket giving rise to a reduced rate for nucleotide hydrolysis and exchange. In comparison to Rab5, Rab4a has a different GDP-bound conformation within switch 1 region and displays shifts in position and orientation of the hydrophobic triad. The observed differences at the S2-L3-S3 region represent a new example of structural plasticity among Rab proteins and may provide a structural basis to understand the differential binding of similar effector proteins.",x-ray diffraction,1.8,1,1,A,74.60317460317461%,32.71604938271605%,1615,384,3,3,"['GOL', 'GDP']","GDP, GOL","GUANOSINE-5'-DIPHOSPHATE, GLYCEROL",inactive,208,13,14,3,9,11,16,6,12,18,9,11,6,9,1,11,8,1,10,3,2
2BOV,Molecular recognition of an ADP-ribosylating Clostridium botulinum C3 exoenzyme by RalA GTPase,"RAS-RELATED PROTEIN RAL-A, MONO-ADP-RIBOSYLTRANSFERASE C3 (E.C.2.4.2.-)",Homo sapiens,9606,"C3 exoenzymes (members of the ADP-ribosyltranferase family) are produced by Clostridium botulinum (C3bot1 and -2), Clostridium limosum (C3lim), Bacillus cereus (C3cer), and Staphylococcus aureus (C3stau1-3). These exoenzymes lack a translocation domain but are known to specifically inactivate Rho GTPases in host target cells. Here, we report the crystal structure of C3bot1 in complex with RalA (a GTPase of the Ras subfamily) and GDP at a resolution of 2.66 A. RalA is not ADP-ribosylated by C3 exoenzymes but inhibits ADP-ribosylation of RhoA by C3bot1, C3lim, and C3cer to different extents. The structure provides an insight into the molecular interactions between C3bot1 and RalA involving the catalytic ADP-ribosylating turn-turn (ARTT) loop from C3bot1 and helix alpha4 and strand beta6 (which are not part of the GDP-binding pocket) from RalA. The structure also suggests a molecular explanation for the different levels of C3-exoenzyme inhibition by RalA and why RhoA does not bind C3bot1 in this manner.",x-ray diffraction,2.66,1,2,A,92.06349206349206%,54.21686746987952%,1549,307,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,131,9,14,5,11,7,19,6,13,12,17,7,6,7,1,10,15,2,11,1,1
2C2H,CRYSTAL STRUCTURE OF THE HUMAN RAC3 IN COMPLEX WITH GDP,RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 3,Homo sapiens,9606,No DOI found,x-ray diffraction,1.85,1,2,A,74.07407407407408%,32.02247191011236%,1532,289,16,16,"['CA', 'SO4', 'MG', 'GDP']","GDP, CA, SO4, MG","GUANOSINE-5'-DIPHOSPHATE, CALCIUM ION, SULFATE ION, MAGNESIUM ION",inactive,105,11,13,2,8,11,7,7,10,19,15,8,4,5,3,5,13,10,10,5,2
2C5L,Structure of PLC epsilon Ras association domain with hRas,"GTPASE HRAS (E.C.3.6.5.2), PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C PLC-EPSILON (E.C.3.1.4.11)",Homo sapiens,9606,"Ras proteins signal to a number of distinct pathways by interacting with diverse effectors. Studies of ras/effector interactions have focused on three classes, Raf kinases, ral guanylnucleotide-exchange factors, and phosphatidylinositol-3-kinases. Here we describe ras interactions with another effector, the recently identified phospholipase C epsilon (PLCepsilon). We solved structures of PLCepsilon RA domains (RA1 and RA2) by NMR and the structure of the RA2/ras complex by X-ray crystallography. Although the similarity between ubiquitin-like folds of RA1 and RA2 proves that they are homologs, only RA2 can bind ras. Some of the features of the RA2/ras interface are unique to PLCepsilon, while the ability to make contacts with both switch I and II regions of ras is shared only with phosphatidylinositol-3-kinase. Studies of PLCepsilon regulation suggest that, in a cellular context, the RA2 domain, in a mode specific to PLCepsilon, has a role in membrane targeting with further regulatory impact on PLC activity.",x-ray diffraction,1.9,1,4,A,87.83068783068782%,99.3975903614458%,1545,344,4,4,"['GTP', 'MG', 'GOL']","GTP, MG, GOL","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, GLYCEROL",active,174,10,11,4,8,11,13,9,8,11,16,11,11,4,3,5,14,3,11,3,
2E9S,human neuronal Rab6B in three intermediate forms,Ras-related protein Rab-6B,Homo sapiens,9606,No DOI found,x-ray diffraction,1.78,1,3,A,86.77248677248677%,32.69230769230769%,1514,319,3,3,"['MG', 'NO3', 'GDP']","NO3, MG, GDP","NITRATE ION, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,152,8,8,4,13,15,10,6,10,15,13,12,9,5,,9,12,1,12,,2
2EFC,Ara7-GDP/AtVps9a,"Similarity to vacuolar protein sorting-associated protein VPS9, Small GTP-binding protein-like",Arabidopsis thaliana,3702,"Many GTPases regulate intracellular transport and signaling in eukaryotes. Guanine nucleotide exchange factors (GEFs) activate GTPases by catalyzing the exchange of their GDP for GTP. Here we present crystallographic and biochemical studies of a GEF reaction with four crystal structures of Arabidopsis thaliana ARA7, a plant homolog of Rab5 GTPase, in complex with its GEF, VPS9a, in the nucleotide-free and GDP-bound forms, as well as a complex with aminophosphonic acid-guanylate ester and ARA7VPS9a(D185N) with GDP. Upon complex formation with ARA7, VPS9 wedges into the interswitch region of ARA7, inhibiting the coordination of Mg(2+) and decreasing the stability of GDP binding. The aspartate finger of VPS9a recognizes GDP -phosphate directly and pulls the P-loop lysine of ARA7 away from GDP -phosphate toward switch II to further destabilize GDP for its release during the transition from the GDP-bound to nucleotide-free intermediates in the nucleotide exchange reaction.",x-ray diffraction,2.09,1,4,B,87.3015873015873%,34.161490683229815%,1385,236,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,70,9,24,4,9,10,11,5,10,13,13,7,10,8,1,11,8,3,7,,2
2ERY,The crystal structure of the Ras related protein RRas2 (RRAS2) in the GDP bound state,Ras-related protein R-Ras2,Homo sapiens,9606,No DOI found,x-ray diffraction,1.7,1,2,A,56.08465608465608%,60.24096385542169%,1535,332,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,163,11,10,6,7,9,12,7,9,12,14,11,15,2,2,10,13,2,14,1,
2EW1,Crystal Structure of Rab30 in complex with a GTP analogue,Ras-related protein Rab-30,Homo sapiens,9606,No DOI found,x-ray diffraction,2.0,1,1,A,90.47619047619048%,35.08771929824561%,1517,279,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,106,10,12,2,10,10,17,7,9,16,11,13,9,6,,9,9,3,12,4,2
2F7S,The crystal structure of human Rab27b bound to GDP,Ras-related protein Rab-27B,Homo sapiens,9606,No DOI found,x-ray diffraction,2.7,1,2,A,67.72486772486772%,35.11904761904761%,1488,186,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,5,10,14,5,6,12,11,8,11,19,11,7,10,10,1,12,13,4,11,2,2
2F9L,3D structure of inactive human Rab11b GTPase,"RAB11B, member RAS oncogene family",Homo sapiens,9606,"Rab GTPases constitute the largest family of small monomeric GTPases, including over 60 members in humans. These GTPases share conserved residues related to nucleotide binding and hydrolysis, and main sequence divergences lie in the carboxyl termini. They cycle between inactive (GDP-bound) and active (GTP-bound) forms and the active site regions, termed Switch I and II, undergo the larger conformational changes between the two states. The Rab11 subfamily members, comprising Rab11a, Rab11b, and Rab25, act in recycling of proteins from the endosomes to the plasma membrane, in transport of molecules from the trans-Golgi network to the plasma membrane and in phagocytosis. In this work, we describe Rab11b-GDP and Rab11b-GppNHp crystal structures solved to 1.55 and 1.95 angstroms resolution, respectively. Although Rab11b shares 90% amino acid identity to Rab11a, its crystal structure shows critical differences relative to previously reported Rab11a structures. Inactive Rab11a formed dimers with unusually ordered Switch regions and missing the magnesium ion at the nucleotide binding site. In this work, inactive Rab11b crystallized as a monomer showing a flexible Switch I and a magnesium ion which is coordinated by four water molecules, the phosphate beta of GDP (beta-P) and the invariant S25. S20 from the P-loop and S42 from the Switch I are associated to GTP hydrolysis rate. In the active structures, S20 interacts with the gamma-P oxygen in Rab11b-GppNHp but does not in Rab11a-GppNHp and the Q70 side chain is found in different positions. In the Rab11a-GTPgammaS structure, S40 is closer to S25 and S42 does not interact with the gamma-P oxygen. These differences indicate that the Rab11 isoforms may possess different GTP hydrolysis rates. In addition, the Switch II of inactive Rab11b presents a 3(10)-helix (residues 69-73) that disappears upon activation. This 3(10)-helix is not found in the Rab11a-GDP structure, which possesses a longer alpha2 helix, spanning from residue 73 to 82 alpha-helix 5.",x-ray diffraction,1.55,1,1,A,74.60317460317461%,35.80246913580247%,1555,360,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,185,9,15,2,12,11,12,8,10,16,13,14,5,10,3,7,10,1,13,,2
2FG5,Crystal structure of human RAB31 in complex with a GTP analogue,Ras-related protein Rab-31,Homo sapiens,9606,No DOI found,x-ray diffraction,2.8,1,1,A,87.3015873015873%,33.12883435582822%,1306,175,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,8,11,13,3,11,8,12,5,13,11,12,16,5,6,5,7,9,6,6,4,2
2FJU,Activated Rac1 bound to its effector phospholipase C beta 2,"Ras-related C3 botulinum toxin substrate 1/1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta 2 (E.C.3.1.4.11)",Homo sapiens,9606,"Although diverse signaling cascades require the coordinated regulation of heterotrimeric G proteins and small GTPases, these connections remain poorly understood. We present the crystal structure of the GTPase Rac1 bound to phospholipase C-beta2 (PLC-beta2), a classic effector of heterotrimeric G proteins. Rac1 engages the pleckstrin-homology (PH) domain of PLC-beta2 to optimize its orientation for substrate membranes. Gbetagamma also engages the PH domain to activate PLC-beta2, and these two activation events are compatible, leading to additive stimulation of phospholipase activity. In contrast to PLC-delta, the PH domain of PLC-beta2 cannot bind phosphoinositides, eliminating this mode of regulation. The structure of the Rac1-PLC-beta2 complex reveals determinants that dictate selectivity of PLC-beta isozymes for Rac GTPases over other Rho-family GTPases, and substitutions within PLC-beta2 abrogate its stimulation by Rac1 but not by Gbetagamma, allowing for functional dissection of this integral signaling node.",x-ray diffraction,2.2,1,2,A,93.65079365079364%,32.58426966292135%,1488,251,2,2,"['MG', 'GSP']","MG, GSP, CA","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, CALCIUM ION",inactive,72,11,13,3,7,13,9,8,13,18,16,10,5,6,2,6,12,11,7,5,2
2FN4,"The crystal structure of human Ras-related protein, RRAS, in the GDP-bound state",Ras-related protein R-Ras,Homo sapiens,9606,No DOI found,x-ray diffraction,1.65,1,1,A,91.53439153439153%,57.30994152046783%,1467,269,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,94,13,15,2,12,6,12,6,8,13,17,8,11,4,4,11,12,7,11,1,
2FV8,The crystal structure of RhoB in the GDP-bound state,Rho-related GTP-binding protein RhoB,Homo sapiens,9606,No DOI found,x-ray diffraction,1.9,1,1,A,77.77777777777779%,32.417582417582416%,1527,293,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,112,8,13,4,9,8,15,7,13,14,18,8,6,4,2,7,16,9,12,5,2
2G0N,The Crystal Structure of the Human RAC3 in complex with GDP and Chloride,Ras-related C3 botulinum toxin substrate 3,Homo sapiens,9606,No DOI found,x-ray diffraction,1.9,1,2,A,94.70899470899471%,32.02247191011236%,1552,332,4,4,"['MG', 'CL', 'GDP']","MG, CL, GDP","MAGNESIUM ION, CHLORIDE ION, GUANOSINE-5'-DIPHOSPHATE",inactive,149,12,13,3,9,12,8,8,10,19,16,9,5,5,3,6,13,11,10,5,2
2G3Y,Crystal structure of the human small GTPase GEM,GTP-binding protein GEM,Homo sapiens,9606,No DOI found,x-ray diffraction,2.4,1,1,A,71.95767195767195%,33.72781065088758%,1369,205,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,35,11,11,4,11,8,15,5,6,14,17,12,6,6,4,5,13,1,14,4,2
2GCN,Crystal structure of the human RhoC-GDP complex,Rho-related GTP-binding protein RhoC,Homo sapiens,9606,"RhoC is a member of the Rho family of Ras-related (small) GTPases and shares significant sequence similarity with the founding member of the family, RhoA. However, despite their similarity, RhoA and RhoC exhibit different binding preferences for effector proteins and give rise to distinct cellular outcomes, with RhoC being directly implicated in the invasiveness of cancer cells and the development of metastasis. While the structural analyses of the signaling-active and -inactive states of RhoA have been performed, thus far, the work on RhoC has been limited to an X-ray structure for its complex with the effector protein, mDia1 (for mammalian Diaphanous 1). Therefore, in order to gain insights into the molecular basis for RhoC activation, as well as clues regarding how it mediates distinct cellular responses relative to those induced by RhoA, we have undertaken a structural comparison of RhoC in its GDP-bound (signaling-inactive) state versus its GTP-bound (signaling-active) state as induced by the nonhydrolyzable GTP analogues, guanosine 5'-(beta,gamma-iminotriphosphate) (GppNHp) and guanosine 5'-(3-O-thiotriphosphate) (GTPgammaS). Interestingly, we find that GppNHp-bound RhoC only shows differences in its switch II domain, relative to GDP-bound RhoC, whereas GTPgammaS-bound RhoC exhibits differences in both its switch I and switch II domains. Given that each of the nonhydrolyzable GTP analogues is able to promote the binding of RhoC to effector proteins, these results suggest that RhoC can undergo at least two conformational transitions during its conversion from a signaling-inactive to a signaling-active state, similar to what has recently been proposed for the H-Ras and M-Ras proteins. In contrast, the available X-ray structures for RhoA suggest that it undergoes only a single conformational transition to a signaling-active state. These and other differences regarding the changes in the switch domains accompanying the activation of RhoA and RhoC provide plausible explanations for the functional specificity exhibited by the two GTPases.",x-ray diffraction,1.85,1,1,A,93.65079365079364%,33.13953488372093%,1675,401,7,7,"['MG', 'EDO', 'GDP']","MG, GDP, EDO","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1,2-ETHANEDIOL",inactive,217,10,11,4,8,8,17,5,13,14,15,11,5,5,2,7,14,10,11,5,2
2GF0,The crystal structure of the human DiRas1 GTPase in the inactive GDP bound state,GTP-binding protein Di-Ras1,Homo sapiens,9606,No DOI found,x-ray diffraction,1.9,1,4,A,91.53439153439153%,39.62264150943396%,1538,333,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,158,10,8,5,14,14,12,5,11,14,17,10,11,6,2,8,8,4,9,4,1
2GF9,Crystal structure of human RAB3D in complex with GDP,Ras-related protein Rab-3D,Homo sapiens,9606,No DOI found,x-ray diffraction,1.53,1,1,A,93.12169312169311%,32.70440251572327%,1631,363,4,4,"['MG', 'UNX', 'GDP']","MG, UNX, GDP","MAGNESIUM ION, UNKNOWN ATOM OR ION, GUANOSINE-5'-DIPHOSPHATE",inactive,183,10,14,4,9,10,11,8,11,13,15,10,7,7,1,12,15,3,11,2,3
2GIL,Structure of the extremely slow GTPase Rab6A in the GTP bound form at 1.8 resolution,Ras-related protein Rab-6A,Homo sapiens,9606,"Rab/Ypt GTPases represent a>60 member large family of membrane traffic regulators in eukaryotic cells. Members of this group display intrinsic GTPase activity varying over two orders of magnitude. Here, we show that Rab6A represents the RabGTPase with the slowest spontaneous GTPase activity yet measured (5x10(-6)s(-1)). Due to the very low intrinsic hydrolysis rate we were able to crystallise and solve the structure of the Rab6A:GTP complex to 1.82A resolution. Analysis of the structure suggests that low catalytic activity of the Rab6A might be due to high flexibility of the Switch II region and a low degree of constraint of critically important for catalysis Gln 72.",x-ray diffraction,1.82,1,4,A,85.18518518518519%,32.69230769230769%,1513,342,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,179,8,10,4,11,14,9,6,10,13,15,11,8,6,,9,12,1,12,,2
2H7V,Co-crystal structure of YpkA-Rac1,,Homo sapiens,9606,"Yersinia spp. cause gastroenteritis and the plague, representing historically devastating pathogens that are currently an important biodefense and antibiotic resistance concern. A critical virulence determinant is the Yersinia protein kinase A, or YpkA, a multidomain protein that disrupts the eukaryotic actin cytoskeleton. Here we solve the crystal structure of a YpkA-Rac1 complex and find that YpkA possesses a Rac1 binding domain that mimics host guanidine nucleotide dissociation inhibitors (GDIs) of the Rho GTPases. YpkA inhibits nucleotide exchange in Rac1 and RhoA, and mutations that disrupt the YpkA-GTPase interface abolish this activity in vitro and impair in vivo YpkA-induced cytoskeletal disruption. In cell culture experiments, the kinase and the GDI domains of YpkA act synergistically to promote cytoskeletal disruption, and a Y. pseudotuberculosis mutant lacking YpkA GDI activity shows attenuated virulence in a mouse infection assay. We conclude that virulence in Yersinia depends strongly upon mimicry of host GDI proteins by YpkA.",x-ray diffraction,2.6,1,4,A,96.29629629629629%,31.843575418994412%,1449,193,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,9,12,13,3,9,13,9,8,14,19,16,10,5,6,2,5,12,11,7,6,2
2HEI,Crystal structure of human RAB5B in complex with GDP,Crystal structure of human RAB5B in complex with GDP,Homo sapiens,9606,No DOI found,x-ray diffraction,1.55,1,2,A,61.37566137566137%,33.146067415730336%,1373,229,2,2,"['D1D', 'GDP']","GDP, D1D","GUANOSINE-5'-DIPHOSPHATE, (4S,5S)-1,2-DITHIANE-4,5-DIOL",inactive,64,7,22,4,10,9,11,7,12,16,12,8,10,6,2,8,6,3,6,2,2
2HT6,Crystal structure of Human Gem G-domain bound to GDP,GTP-binding protein GEM,Homo sapiens,9606,"Gem, a member of the Rad,Gem/Kir subfamily of small G-proteins, has unique sequence features. We report here the crystallographic structure determination of the Gem G-domain in complex with nucleotide to 2.4 A resolution. Although the basic Ras protein fold is maintained, the Gem switch regions emphatically differ from the Ras paradigm. Our ensuing biochemical characterization indicates that Gem G-domain markedly prefers GDP over GTP. Two known functions of Gem are distinctly affected by spatially separated clusters of mutations.",x-ray diffraction,2.4,1,2,A,55.55555555555556%,33.72781065088758%,1392,215,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,47,11,11,3,10,8,15,5,6,14,18,12,6,6,3,5,11,1,14,5,2
2HUP,Crystal structure of human RAB43 in complex with GDP,Crystal structure of human RAB43 in complex with GDP,Homo sapiens,9606,No DOI found,x-ray diffraction,2.05,1,2,A,70.37037037037037%,34.96932515337423%,1309,204,4,4,"['MG', 'UNX', 'GDP']","MG, GDP, UNX","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, UNKNOWN ATOM OR ION",inactive,38,10,14,2,14,10,11,6,10,16,12,11,7,4,3,8,9,1,10,2,2
2HV8,Crystal structure of GTP-bound Rab11 in complex with FIP3,,Homo sapiens,9606,"The Rab11 GTPase regulates recycling of internalized plasma membrane receptors and is essential for completion of cytokinesis. A family of Rab11 interacting proteins (FIPs) that conserve a C-terminal Rab-binding domain (RBD) selectively recognize the active form of Rab11. Normal completion of cytokinesis requires a complex between Rab11 and FIP3. Here, we report the crystal structure and mutational analysis of a heterotetrameric complex between constitutively active Rab11 and a FIP3 construct that includes the RBD. Two Rab11 molecules bind to dyad symmetric sites at the C terminus of FIP3, which forms a non-canonical coiled-coiled dimer with a flared C terminus and hook region. The RBD overlaps with the coiled coil and extends through the C-terminal hook. Although FIP3 engages the switch and interswitch regions of Rab11, the mode of interaction differs significantly from that of other Rab-effector complexes. In particular, the switch II region undergoes a large structural rearrangement from an ordered but non-complementary active conformation to a remodeled conformation that facilitates the interaction with FIP3. Finally, we provide evidence that FIP3 can form homo-oligomers in cells, and that a critical determinant of Rab11 binding in vitro is necessary for FIP3 recruitment to recycling endosomes during cytokinesis.",x-ray diffraction,1.86,1,6,A,89.41798941798942%,37.03703703703704%,1619,429,3,3,"['GTP', 'MG', 'SO4']","MG, SO4, GTP, 2ME, MES","MAGNESIUM ION, SULFATE ION, GUANOSINE-5'-TRIPHOSPHATE, METHOXYETHANE, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID",active,257,10,16,1,12,12,13,8,9,17,12,13,3,8,3,7,10,1,12,,2
2IEZ,Crystal Structure of mouse Rab27b bound to GDP in monoclinic space group,Ras-related protein Rab-27B (E.C.3.6.5.2),Mus musculus,10090,"Members of the Rab family of small GTPases regulate membrane traffic within the cell by recruiting their specific effectors in a nucleotide-dependent manner. The Rab27 subfamily consists of Rab27a and Rab27b, which share 70% sequence identity. By interacting with a large set of effector proteins such as melanophilin and granuphilin, both Rab27a and Rab27b regulate the exocytosis of secretory lysosomes. Here, the crystal structures of mouse Rab27b in complex with GDP have been determined in three distinct crystal lattices. Surprisingly, Rab27b-GDP exists in an open conformation with protruding switch and interswitch regions, which are stabilized through dimerization by means of domain-swapping in the crystals. In contrast, small-angle X-ray scattering measurements showed an extended monomer form of Rab27b in solution. The observed dimer formation of Rab27b-GDP in the crystals would restrain the highly flexible switch regions. Possible biological implications of this atypical structure of Rab27b and its plausible influence in effector interaction are discussed.",x-ray diffraction,2.8,1,4,A,68.25396825396825%,33.50785340314136%,1491,194,2,2,"['CA', 'GDP']","CA, GDP","CALCIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,14,10,12,5,8,12,12,8,12,20,11,7,8,9,1,12,12,4,11,2,2
2IF0,Crystal Structure of mouse Rab27b bound to GDP in monoclinic space group,Ras-related protein Rab-27B (E.C.3.6.5.2),Mus musculus,10090,"Members of the Rab family of small GTPases regulate membrane traffic within the cell by recruiting their specific effectors in a nucleotide-dependent manner. The Rab27 subfamily consists of Rab27a and Rab27b, which share 70% sequence identity. By interacting with a large set of effector proteins such as melanophilin and granuphilin, both Rab27a and Rab27b regulate the exocytosis of secretory lysosomes. Here, the crystal structures of mouse Rab27b in complex with GDP have been determined in three distinct crystal lattices. Surprisingly, Rab27b-GDP exists in an open conformation with protruding switch and interswitch regions, which are stabilized through dimerization by means of domain-swapping in the crystals. In contrast, small-angle X-ray scattering measurements showed an extended monomer form of Rab27b in solution. The observed dimer formation of Rab27b-GDP in the crystals would restrain the highly flexible switch regions. Possible biological implications of this atypical structure of Rab27b and its plausible influence in effector interaction are discussed.",x-ray diffraction,2.8,1,2,A,66.13756613756614%,33.92857142857143%,1459,186,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,10,9,12,5,7,12,11,8,11,20,11,7,8,9,1,12,12,4,11,2,2
2J0V,The crystal structure of Arabidopsis thaliana RAC7-ROP9: the first RAS superfamily GTPase from the plant kingdom,RAC-LIKE GTP-BINDING PROTEIN ARAC7,Arabidopsis thaliana,3702,"Arabidopsis thaliana RAC/ROP GTPases constitute a plant specific Rho GTPase family in the RAS superfamily, which has been implicated in numerous pivotal signalling cascades in plants. Research has shown that plants in some cases have evolved different modes of regulating Rho GTPase activity as compared to the equivalent systems in animals and yeast. In order to gain structural insight into plant signaling at the molecular level, we have determined the first crystal structure of a RAC-like GTPase belonging to the RAS superfamily from the plant kingdom. The structure of AtRAC7/ROP9 bound to GDP was solved at a resolution of 1.78 A. We have found that the structure of plant Rho GTPases is based upon a conserved G-domain architecture, but structural differences were found concerning the insert region and switch II region of the protein.",x-ray diffraction,1.78,1,4,A,56.613756613756614%,33.88888888888889%,1472,254,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,74,11,14,3,13,12,6,7,13,14,18,11,7,8,2,8,12,7,6,4,2
2NTY,Rop4-GDP-PRONE8,Rop4-GDP-PRONE8,Arabidopsis thaliana,3702,"Rho of plants (Rop) proteins belong to the superfamily of small GTP-binding (G) proteins and are vital regulators of signal transduction in plants. In order to become activated, Rop proteins need to exchange GDP for GTP, an intrinsically slow process catalyzed by guanine nucleotide exchange factors (GEFs). RopGEFs show no homology to animal RhoGEFs, and the catalytic mechanism remains elusive. GEF-catalysed nucleotide exchange proceeds via transient ternary and stable binary complexes. While a number of structural studies have analyzed binary nucleotide-free G protein-GEF complexes, very little is known about the ternary complexes. Here we report the X-ray structure of the catalytic PRONE domain of RopGEF8 from Arabidopsis thaliana, both alone and in a ternary complex with Rop4 and GDP. The features of the latter complex, a transient intermediate of the exchange reaction never directly observed before, suggest a common mechanism of catalyzed nucleotide exchange applicable to small G proteins in general.",x-ray diffraction,3.1,1,4,C,75.66137566137566%,33.33333333333333%,1338,174,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,0,12,12,1,11,12,6,6,12,14,17,13,6,9,2,9,11,9,6,3,2
2O52,Crystal structure of human RAB4B in complex with GDP,Crystal structure of human RAB4B in complex with GDP,Homo sapiens,9606,No DOI found,x-ray diffraction,2.2,1,2,A,74.60317460317461%,33.95061728395062%,1356,209,4,4,"['MG', 'UNX', 'BME', 'GDP']","MG, GDP, BME, UNX","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, BETA-MERCAPTOETHANOL, UNKNOWN ATOM OR ION",inactive,38,12,14,2,12,12,15,4,8,19,12,8,4,7,1,10,8,3,11,3,2
2OCB,Crystal structure of human RAB9B in complex with a GTP analogue,Crystal structure of human RAB9B in complex with a GTP,Homo sapiens,9606,No DOI found,x-ray diffraction,2.2,1,1,A,91.53439153439153%,34.146341463414636%,1435,219,9,9,"['MG', 'UNX', 'GNP']","MG, GNP, UNX","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, UNKNOWN ATOM OR ION",active,37,12,9,2,8,12,13,6,10,16,17,4,8,8,2,12,15,4,9,3,3
2OIL,Crystal structure of human RAB25 in complex with GDP,Ras-related protein Rab-25,Homo sapiens,9606,No DOI found,x-ray diffraction,2.3,1,1,A,92.06349206349206%,33.33333333333333%,1384,195,3,3,"['MG', 'UNX', 'GDP']","MG, GDP, UNX","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, UNKNOWN ATOM OR ION",inactive,18,10,17,3,11,16,16,6,9,18,18,6,4,7,3,10,7,1,10,,2
2Q21,CRYSTAL STRUCTURES AT 2.2 ANGSTROMS RESOLUTION OF THE CATALYTIC DOMAINS OF NORMAL RAS PROTEIN AND AN ONCOGENIC MUTANT COMPLEXED WITH GSP,C-H-RAS P21 PROTEIN CATALYTIC DOMAIN (MUTANT WITH GLY 12 REPLACED BY VAL) (G12V) COMPLEX WITH GDP,Homo sapiens,9606,No abstract found,x-ray diffraction,2.2,1,1,A,90.47619047619048%,99.41520467836257%,1440,213,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,40,10,11,4,8,11,13,9,10,13,16,11,11,4,3,5,14,3,12,3,
2QUZ,"Crystal Structure of the activating H-RasK117R mutant in Costello Syndrome, bound to Mg-GDP",,Homo sapiens,9606,"Costello syndrome is a mental retardation syndrome characterized by high birth weight, postnatal growth retardation, coarse face, loose skin, cardiovascular problems, and tumor predisposition. De novo heterozygous missense mutations in HRAS codon 12 and 13 disturbing the intrinsic GTP hydrolysis cause Costello syndrome. We report a patient with typical Costello syndrome and a novel heterozygous missense mutation in codon 117 (c.350A>G, p.Lys117Arg) of the HRAS gene, resulting in constitutive activation of the RAS/MAPK pathway similar to the typical p.Gly12Ser and p.Gly12Ala mutations. Recombinant HRAS p.Lys117Arg demonstrates normal intrinsic GTP hydrolysis and responsiveness to GTPase-activating proteins, but the nucleotide dissociation rate is increased 80-fold. Consistent with the biochemical data, the crystal structure of the p.Lys117Arg mutant indicates an altered interaction pattern of the side chain that is associated with unfavorable nucleotide binding properties. Together, these data show that a RAS mutation that only perturbs guanine nucleotide binding has similar functional consequences as mutations that impair GTP hydrolysis and causes human disease.",x-ray diffraction,1.49,1,1,A,87.83068783068782%,99.3975903614458%,1464,279,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,111,11,11,4,8,11,13,9,7,11,15,11,11,4,3,5,14,3,12,3,
2RGA,Crystal structure of H-RasQ61I-GppNHp,,Homo sapiens,9606,"Transformation efficiencies of Ras mutants at residue 61 range over three orders of magnitude, but the in vitro GTPase activity decreases 10-fold for all mutants. We show that Raf impairs the GTPase activity of RasQ61L, suggesting that the Ras/Raf complex differentially modulates transformation. Our crystal structures show that, in transforming mutants, switch II takes part in a network of hydrophobic interactions burying the nucleotide and precatalytic water molecule. Our results suggest that Y32 and a water molecule bridging it to the gamma-phosphate in the wild-type structure play a role in GTP hydrolysis in lieu of the Arg finger in the absence of GAP. The bridging water molecule is absent in the transforming mutants, contributing to the burying of the nucleotide. We propose a mechanism for intrinsic hydrolysis in Raf-bound Ras and elucidate structural features in the Q61 mutants that correlate with their potency to transform cells.",x-ray diffraction,1.9,1,1,A,87.83068783068782%,99.3975903614458%,1492,313,4,4,"['CA', 'MG', 'GNP']","CA, MG, GNP","CALCIUM ION, MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,143,11,11,4,8,11,13,9,8,11,15,12,10,4,3,5,14,3,11,3,
2RGB,Crystal structure of H-RasQ61K-GppNHp,,Homo sapiens,9606,"Transformation efficiencies of Ras mutants at residue 61 range over three orders of magnitude, but the in vitro GTPase activity decreases 10-fold for all mutants. We show that Raf impairs the GTPase activity of RasQ61L, suggesting that the Ras/Raf complex differentially modulates transformation. Our crystal structures show that, in transforming mutants, switch II takes part in a network of hydrophobic interactions burying the nucleotide and precatalytic water molecule. Our results suggest that Y32 and a water molecule bridging it to the gamma-phosphate in the wild-type structure play a role in GTP hydrolysis in lieu of the Arg finger in the absence of GAP. The bridging water molecule is absent in the transforming mutants, contributing to the burying of the nucleotide. We propose a mechanism for intrinsic hydrolysis in Raf-bound Ras and elucidate structural features in the Q61 mutants that correlate with their potency to transform cells.",x-ray diffraction,1.35,1,1,A,87.83068783068782%,99.3975903614458%,1546,366,4,4,"['CA', 'MG', 'GNP']","CA, MG, GNP","CALCIUM ION, MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,196,11,11,4,8,11,13,9,9,11,15,11,10,4,3,5,14,3,11,3,
2RGC,Crystal structure of H-RasQ61V-GppNHp,,Homo sapiens,9606,"Transformation efficiencies of Ras mutants at residue 61 range over three orders of magnitude, but the in vitro GTPase activity decreases 10-fold for all mutants. We show that Raf impairs the GTPase activity of RasQ61L, suggesting that the Ras/Raf complex differentially modulates transformation. Our crystal structures show that, in transforming mutants, switch II takes part in a network of hydrophobic interactions burying the nucleotide and precatalytic water molecule. Our results suggest that Y32 and a water molecule bridging it to the gamma-phosphate in the wild-type structure play a role in GTP hydrolysis in lieu of the Arg finger in the absence of GAP. The bridging water molecule is absent in the transforming mutants, contributing to the burying of the nucleotide. We propose a mechanism for intrinsic hydrolysis in Raf-bound Ras and elucidate structural features in the Q61 mutants that correlate with their potency to transform cells.",x-ray diffraction,1.6,1,1,A,87.83068783068782%,99.3975903614458%,1499,321,4,4,"['CA', 'MG', 'GNP']","MG, CA, GNP","MAGNESIUM ION, CALCIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,151,11,11,4,8,11,13,9,8,11,16,11,10,4,3,5,14,3,11,3,
2RGD,Crystal structure of H-RasQ61L-GppNHp,,Homo sapiens,9606,"Transformation efficiencies of Ras mutants at residue 61 range over three orders of magnitude, but the in vitro GTPase activity decreases 10-fold for all mutants. We show that Raf impairs the GTPase activity of RasQ61L, suggesting that the Ras/Raf complex differentially modulates transformation. Our crystal structures show that, in transforming mutants, switch II takes part in a network of hydrophobic interactions burying the nucleotide and precatalytic water molecule. Our results suggest that Y32 and a water molecule bridging it to the gamma-phosphate in the wild-type structure play a role in GTP hydrolysis in lieu of the Arg finger in the absence of GAP. The bridging water molecule is absent in the transforming mutants, contributing to the burying of the nucleotide. We propose a mechanism for intrinsic hydrolysis in Raf-bound Ras and elucidate structural features in the Q61 mutants that correlate with their potency to transform cells.",x-ray diffraction,2.0,1,1,A,87.83068783068782%,99.3975903614458%,1507,329,4,4,"['CA', 'MG', 'GNP']","CA, MG, GNP","CALCIUM ION, MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,159,11,11,4,8,11,13,9,8,12,15,11,10,4,3,5,14,3,11,3,
2W2T,Rac2 (G12V) in complex with GDP,RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 2,Homo sapiens,9606,"Rho family GTPases are important cellular switches and control a number of physiological functions. Understanding the molecular basis of interaction of these GTPases with their effectors is crucial in understanding their functions in the cell. Here we present the crystal structure of the complex of Rac2 bound to the split pleckstrin homology (spPH) domain of phospholipase C-gamma(2) (PLCgamma(2)). Based on this structure, we illustrate distinct requirements for PLCgamma(2) activation by Rac and EGF and generate Rac effector mutants that specifically block activation of PLCgamma(2), but not the related PLCbeta(2) isoform. Furthermore, in addition to the complex, we report the crystal structures of free spPH and Rac2 bound to GDP and GTPgammaS. These structures illustrate a mechanism of conformational switches that accompany formation of signaling active complexes and highlight the role of effector binding as a common feature of Rac and Cdc42 interactions with a variety of effectors.",x-ray diffraction,1.95,1,1,A,94.17989417989418%,31.03448275862069%,1502,317,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,137,8,13,1,10,12,9,8,13,19,17,10,5,5,2,6,13,12,7,6,2
2W2V,Rac2 (G12V) in complex with GTPgS,RAS-RELATED C3 BOTULINUM TOXIN SUBSTRATE 2,Homo sapiens,9606,"Rho family GTPases are important cellular switches and control a number of physiological functions. Understanding the molecular basis of interaction of these GTPases with their effectors is crucial in understanding their functions in the cell. Here we present the crystal structure of the complex of Rac2 bound to the split pleckstrin homology (spPH) domain of phospholipase C-gamma(2) (PLCgamma(2)). Based on this structure, we illustrate distinct requirements for PLCgamma(2) activation by Rac and EGF and generate Rac effector mutants that specifically block activation of PLCgamma(2), but not the related PLCbeta(2) isoform. Furthermore, in addition to the complex, we report the crystal structures of free spPH and Rac2 bound to GDP and GTPgammaS. These structures illustrate a mechanism of conformational switches that accompany formation of signaling active complexes and highlight the role of effector binding as a common feature of Rac and Cdc42 interactions with a variety of effectors.",x-ray diffraction,2.0,1,4,A,67.72486772486772%,30.89887640449438%,1504,333,1,1,['GTP'],GTP,GUANOSINE-5'-TRIPHOSPHATE,active,161,7,13,2,9,12,8,7,12,19,17,10,5,5,2,6,12,11,7,5,2
2Y8E,Crystal structure of D. melanogaster Rab6 GTPase bound to GMPPNP,RAB-PROTEIN 6,Drosophila melanogaster,7227,"Rab6 is a small GTPase that belongs to the p21 Ras superfamily. It is involved in vesicle trafficking between the Golgi apparatus and endosomes/ER in eukaryotes. The GDP-bound inactive protein undergoes conformational changes when the nucleotide is exchanged to GTP, allowing Rab6 to interact with a variety of different effector proteins. To further understand how these changes affect downstream protein binding, the crystal structure of Rab6 from Drosophila melanogaster has been solved to 1.4 resolution, the highest resolution for a Rab6 structure to date. The crystals belonged to space group C2, with unit-cell parameters a=116.5, b=42.71, c=86.86, =90, =133.12, =90. The model was refined to an R factor of 14.5% and an Rfree of 17.3%.",x-ray diffraction,1.39,1,2,A,87.3015873015873%,32.278481012658226%,1493,288,3,3,"['SO4', 'MG', 'GNP']","SO4, GNP, MG","SULFATE ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,120,8,9,4,13,15,9,6,11,14,14,10,7,6,1,9,12,2,13,,2
3A58,Crystal structure of Sec3p - Rho1p complex from Saccharomyces cerevisiae,,Saccharomyces cerevisiae,4932,"The exocyst complex is a hetero-octameric protein complex that functions during cell polarization by tethering the secretory vesicle to the target membrane. The yeast exocyst subunit Sec3 binds to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P(2)) and the small GTPases Rho1 and Cdc42 via its N-terminal domain (Sec3-N), and these interactions target Sec3 to the plasma membrane. Here we report the crystal structure of the Sec3-N in complex with Rho1 at 2.6-A resolution. Sec3-N adopts a pleckstrin homology (PH) fold, despite having no detectable sequence homology with other PH domains of known structure. Clusters of conserved basic residues constitute a positively charged cleft, which was identified as a binding site for PtdIns(4,5)P(2). Residues Phe77, Ile115 and Leu131 of Sec3 bind to an extended hydrophobic surface formed around switch regions I and II of Rho1. To our knowledge, these are the first structural insights into how an exocyst subunit might interact with both protein and phospholipid factors on the target membrane.",x-ray diffraction,2.6,1,6,B,94.17989417989418%,32.748538011695906%,1425,187,2,2,"['MG', 'GNP']","PO4, GNP, MG","PHOSPHATE ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,7,14,11,1,10,8,14,7,6,15,21,10,12,5,1,5,12,8,10,6,2
3BBP,Rab6-GTP:GCC185 Rab binding domain complex,,Homo sapiens,9606,"GCC185 is a large coiled-coil protein at the trans Golgi network that is required for receipt of transport vesicles inbound from late endosomes and for anchoring noncentrosomal microtubules that emanate from the Golgi. Here, we demonstrate that recruitment of GCC185 to the Golgi is mediated by two Golgi-localized small GTPases of the Rab and Arl families. GCC185 binds Rab6, and mutation of residues needed for Rab binding abolishes Golgi localization. The crystal structure of Rab6 bound to the GCC185 Rab-binding domain reveals that Rab6 recognizes a two-fold symmetric surface on a coiled coil immediately adjacent to a C-terminal GRIP domain. Unexpectedly, Rab6 binding promotes association of Arl1 with the GRIP domain. We present a structure-derived model for dual GTPase membrane attachment that highlights the potential ability of Rab GTPases to reach binding partners at a significant distance from the membrane via their unstructured and membrane-anchored, hypervariable domains.",x-ray diffraction,3.0,1,6,A,85.18518518518519%,31.645569620253166%,1332,163,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,0,8,10,4,11,14,9,6,10,14,15,11,7,6,,9,12,1,12,,2
3BFK,Crystal structure of Plasmodium falciparum Rab11a in complex with GDP,Small GTPase Rab11 (E.C.3.6.5.2),Plasmodium falciparum 3D7,36329,No DOI found,x-ray diffraction,1.8,1,5,A,53.96825396825397%,35.294117647058826%,1389,249,1,1,['GDP'],"GDP, GOL","GUANOSINE-5'-DIPHOSPHATE, GLYCEROL",inactive,89,7,13,,9,8,10,8,14,19,10,14,5,14,2,7,11,,6,,2
3BRW,Structure of the Rap-RapGAP complex,,Homo sapiens,9606,"The GTP-binding protein Rap1 regulates integrin-mediated and other cell adhesion processes. Unlike most other Ras-related proteins, it contains a threonine in switch II instead of a glutamine (Gln61 in Ras), a residue crucial for the GTPase reaction of most G proteins. Furthermore, unlike most other GTPase-activating proteins (GAPs) for small G proteins, which supply a catalytically important Arg-finger, no arginine residue of RapGAP makes a significant contribution to the GTPase reaction of Rap1. For a detailed understanding of the reaction mechanism, we have solved the structure of Rap1 in complex with Rap1GAP. It shows that the Thr61 of Rap is away from the active site and that an invariant asparagine of RapGAPs, the Asn-thumb, takes over the role of the cis-glutamine of Ras, Rho or Ran. The structure and biochemical data allow to further explain the mechanism and to define the important role of a conserved tyrosine. The structure and biochemical data furthermore show that the RapGAP homologous region of the tumour suppressor Tuberin is sufficient for catalysis on Rheb.",x-ray diffraction,3.4,1,4,D,88.35978835978835%,58.18181818181818%,1369,174,3,3,"['MG', 'GDP', 'BEF']","MG, BEF, GDP","MAGNESIUM ION, BERYLLIUM TRIFLUORIDE ION, GUANOSINE-5'-DIPHOSPHATE",inactive,4,11,9,5,8,8,12,6,10,15,16,9,14,9,,7,13,2,9,3,1
3C5C,"Crystal structure of human Ras-like, family 12 protein in complex with GDP",RAS-like protein 12,Homo sapiens,9606,No DOI found,x-ray diffraction,1.85,1,4,A,55.55555555555556%,31.736526946107784%,1371,227,4,4,"['MG', 'UNX', 'GDP']","MG, GDP, UNX","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, UNKNOWN ATOM OR ION",inactive,59,7,16,2,13,7,13,6,6,20,14,3,6,5,7,9,9,4,13,3,1
3CBQ,Crystal structure of the human REM2 GTPase with bound GDP,GTP-binding protein REM 2,Homo sapiens,9606,No DOI found,x-ray diffraction,1.82,1,1,A,89.41798941798942%,32.16374269005848%,1417,244,5,5,"['MG', 'EDO', 'UNX', 'GDP']","MG, GDP, EDO, UNX","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1,2-ETHANEDIOL, UNKNOWN ATOM OR ION",inactive,70,17,10,2,11,10,15,2,6,19,14,7,4,3,8,6,10,5,16,2,2
3CPH,Crystal structure of Sec4 in complex with Rab-GDI,"Rab GDP-dissociation inhibitor, Ras-related protein SEC4",Saccharomyces cerevisiae,4932,"Rab GDP dissociation inhibitors (GDI)-facilitated extraction of prenylated Rab proteins from membranes plays an important role in vesicular membrane trafficking. The investigated thermodynamic properties of yeast Rab.GDI and Rab.MRS6 complexes demonstrated differences in the Rab binding properties of the closely related Rab GDI and MRS6 proteins, consistent with their functional diversity. The importance of the Rab C terminus and its prenylation for GDI/MRS6 binding was demonstrated using both biochemical and structural data. The presented structures of the apo-form yeast Rab GDI and its two complexes with unprenylated Rab proteins, together with the earlier published structures of the prenylated Ypt1.GDI, provide evidence of allosteric regulation of the GDI lipid binding site opening, which plays a key role in the proposed mechanism of GDI-mediated Rab extraction. We suggest a model for the interaction of GDI with prenylated Rab proteins that incorporates a stepwise increase in affinity as the three different partial interactions are successively formed.",x-ray diffraction,2.9,1,3,A,92.5925925925926%,33.33333333333333%,1437,206,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,29,13,10,3,7,14,11,3,16,15,14,17,6,11,1,10,13,2,6,1,2
3CWZ,Structure of RAB6(GTP)-R6IP1 complex,,Homo sapiens,9606,"Small GTPase Rab6 regulates vesicle trafficking at the level of Golgi via recruitment of numerous and unrelated effectors. The crystal structure of Rab6a(GTP) in complex with a 378-residue internal fragment of the effector Rab6IP1 was solved at 3.2 angstroms resolution. This Rab6IP1 region encompasses an all alpha-helical RUN domain followed in tandem by a PLAT domain that adopts a beta sandwich fold. The structure reveals that the first and last alpha helices of the RUN domain mediate binding to switch I, switch II, and the interswitch region of Rab6. It represents the largest Rab-effector complex determined to date. Comparisons with the recent structure of Rab6 in complex with an unrelated effector, human golgin GCC185, reveals significant conformational changes in the conserved hydrophobic triad of Rab6. Flexibility in the switch and interswitch regions of Rab6 mediates recognition of compositionally distinct alpha-helical coiled coils, thereby contributing to Rab6 promiscuity in effector recruitment.",x-ray diffraction,3.2,1,2,A,87.83068783068782%,31.645569620253166%,1360,176,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,8,9,10,5,11,14,9,6,11,14,15,11,7,6,,9,12,2,13,,2
3DDC,Crystal Structure of NORE1A in Complex with RAS,"GTPase HRas (E.C.3.6.5.2), Ras association domain-containing family protein 5",Homo sapiens,9606,"A class of putative Ras effectors called Ras association domain family (RASSF) represents non-enzymatic adaptors that were shown to be important in tumour suppression. RASSF5, a member of this family, exists in two splice variants known as NORE1A and RAPL. Both of them are involved in distinct cellular pathways triggered by Ras and Rap, respectively. Here we describe the crystal structure of Ras in complex with the Ras binding domain (RBD) of NORE1A/RAPL. All Ras effectors share a common topology in their RBD creating an interface with the switch I region of Ras, whereas NORE1A/RAPL RBD reveals additional structural elements forming a unique Ras switch II binding site. Consequently, the contact area of NORE1A is extended as compared with other Ras effectors. We demonstrate that the enlarged interface provides a rationale for an exceptionally long lifetime of the complex. This is a specific attribute characterizing the effector function of NORE1A/RAPL as adaptors, in contrast to classical enzymatic effectors such as Raf, RalGDS or PI3K, which are known to form highly dynamic short-lived complexes with Ras.",x-ray diffraction,1.8,1,2,A,87.83068783068782%,98.79518072289156%,1421,233,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,65,11,11,4,8,11,13,9,9,11,15,11,11,4,3,5,13,3,11,3,
3DZ8,Crystal structure of human Rab3B GTPase bound with GDP,Crystal structure of human Rab3B GTPase bound with GDP,Homo sapiens,9606,No DOI found,x-ray diffraction,1.9,1,1,A,94.17989417989418%,33.33333333333333%,1454,215,7,7,"['UNX', 'GDP']","GDP, UNX","GUANOSINE-5'-DIPHOSPHATE, UNKNOWN ATOM OR ION",inactive,30,10,13,5,8,13,13,9,11,11,13,11,9,8,1,14,12,2,10,2,3
3EG5,Crystal structure of MDIA1-TSH GBD-FH3 in complex with CDC42-GMPPNP,,Mus musculus,10090,"Formins are key regulators of actin nucleation and polymerization. They contain formin homology 1 (FH1) and 2 (FH2) domains as the catalytic machinery for the formation of linear actin cables. A subclass of formins constitutes the Diaphanous-related formins, members of which are regulated by the binding of a small GTP-binding protein of the Rho subfamily. Binding of these molecular switch proteins to the regulatory N-terminal mDia(N), including the GTPase-binding domain, leads to the release of auto-inhibition. From the three mDia isoforms, mDia1 is activated only by Rho (RhoA, -B, and -C), in contrast to mDia2 and -3, which is also activated by Rac and Cdc42. Little is known about the determinants of specificity. Here we report on the interactions of RhoA, Rac1, and Cdc42 with mDia1 and an mDia1 mutant (mDia(N)-Thr-Ser-His (TSH)), which based on structural information should mimic mDia2 and -3. Specificity is analyzed by biochemical studies and a structural analysis of a complex between Cdc42.Gpp(NH)p and mDia(N)-TSH. A triple NNN motif in mDia1 (amino acids 164-166), corresponding to the TSH motif in mDia2/3 (amino acids 183-185 and 190-192), and the epitope interacting with the Rho insert helix are essential for high affinity binding. The triple N motif of mDia1 allows tight interaction with Rho because of the presence of Phe-106, whereas the corresponding His-104 in Rac and Cdc42 forms a complementary interface with the TSH motif in mDia2/3. We also show that the F106H and H104F mutations drastically alter the affinities and thermodynamics of mDia interactions.",x-ray diffraction,2.7,1,4,A,94.17989417989418%,33.33333333333333%,1439,195,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,15,9,11,2,9,16,12,7,14,17,18,8,6,5,2,8,11,12,5,5,1
3GFT,Human K-Ras (Q61H) in complex with a GTP analogue,GTPase KRas,Homo sapiens,9606,No DOI found,x-ray diffraction,2.27,1,6,A,88.35978835978835%,93.41317365269461%,1399,207,3,3,"['MG', 'UNX', 'GNP']","MG, GNP, UNX, CIT","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, UNKNOWN ATOM OR ION, CITRIC ACID",active,37,11,9,4,8,12,12,8,11,11,15,11,8,4,5,6,15,4,10,3,
3I3S,Crystal Structure of H-Ras with Thr50 replaced by Isoleucine,,Homo sapiens,9606,"Noonan syndrome, a developmental disorder characterized by congenital heart defects, reduced growth, facial dysmorphism and variable cognitive deficits, is caused by constitutional dysregulation of the RAS-MAPK signaling pathway. Here we report that germline NRAS mutations conferring enhanced stimulus-dependent MAPK activation account for some cases of this disorder. These findings provide evidence for an obligate dependency on proper NRAS function in human development and growth.",x-ray diffraction,1.36,1,1,R,87.83068783068782%,99.3975903614458%,1458,273,5,5,"['CA', 'MG', 'GNP']","GNP, MG, CA","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, CALCIUM ION",active,102,11,11,4,8,10,13,9,8,11,15,12,11,4,3,5,14,3,11,3,
3KKO,Crystal structure of M-Ras P40D/D41E/L51R in complex with GppNHp,Ras-related protein M-Ras,Mus musculus,10090,"Ras family small GTPases assume two interconverting conformations, ""inactive"" state 1 and ""active"" state 2, in their GTP-bound forms. Here, to clarify the mechanism of state transition, we have carried out x-ray crystal structure analyses of a series of mutant H-Ras and M-Ras in complex with guanosine 5'-(beta,gamma-imido)triphosphate (GppNHp), representing various intermediate states of the transition. Crystallization of H-RasT35S-GppNHp enables us to solve the first complete tertiary structure of H-Ras state 1 possessing two surface pockets unseen in the state 2 or H-Ras-GDP structure. Moreover, determination of the two distinct crystal structures of H-RasT35S-GppNHp, showing prominent polysterism in the switch I and switch II regions, reveals a pivotal role of the guanine nucleotide-mediated interaction between the two switch regions and its rearrangement by a nucleotide positional change in the state 2 to state 1 transition. Furthermore, the (31)P NMR spectra and crystal structures of the GppNHp-bound forms of M-Ras mutants, carrying various H-Ras-type amino acid substitutions, also reveal the existence of a surface pocket in state 1 and support a similar mechanism based on the nucleotide-mediated interaction and its rearrangement in the state 1 to state 2 transition. Intriguingly, the conformational changes accompanying the state transition mimic those that occurred upon GDP/GTP exchange, indicating a common mechanistic basis inherent in the high flexibility of the switch regions. Collectively, these results clarify the structural features distinguishing the two states and provide new insights into the molecular basis for the state transition of Ras protein.",x-ray diffraction,1.9,1,3,A,89.41798941798942%,58.68263473053892%,1587,339,3,3,"['MG', 'GNP', 'SO4']","GNP, MG, SO4","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, SULFATE ION",active,167,8,8,5,7,11,10,7,12,13,16,11,9,5,5,9,16,6,10,,1
3KKP,Crystal structure of M-Ras P40D in complex with GppNHp,Ras-related protein M-Ras,Mus musculus,10090,"Ras family small GTPases assume two interconverting conformations, ""inactive"" state 1 and ""active"" state 2, in their GTP-bound forms. Here, to clarify the mechanism of state transition, we have carried out x-ray crystal structure analyses of a series of mutant H-Ras and M-Ras in complex with guanosine 5'-(beta,gamma-imido)triphosphate (GppNHp), representing various intermediate states of the transition. Crystallization of H-RasT35S-GppNHp enables us to solve the first complete tertiary structure of H-Ras state 1 possessing two surface pockets unseen in the state 2 or H-Ras-GDP structure. Moreover, determination of the two distinct crystal structures of H-RasT35S-GppNHp, showing prominent polysterism in the switch I and switch II regions, reveals a pivotal role of the guanine nucleotide-mediated interaction between the two switch regions and its rearrangement by a nucleotide positional change in the state 2 to state 1 transition. Furthermore, the (31)P NMR spectra and crystal structures of the GppNHp-bound forms of M-Ras mutants, carrying various H-Ras-type amino acid substitutions, also reveal the existence of a surface pocket in state 1 and support a similar mechanism based on the nucleotide-mediated interaction and its rearrangement in the state 1 to state 2 transition. Intriguingly, the conformational changes accompanying the state transition mimic those that occurred upon GDP/GTP exchange, indicating a common mechanistic basis inherent in the high flexibility of the switch regions. Collectively, these results clarify the structural features distinguishing the two states and provide new insights into the molecular basis for the state transition of Ras protein.",x-ray diffraction,1.35,1,1,A,88.88888888888889%,57.48502994011976%,1581,348,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,178,8,8,5,7,11,9,7,12,14,16,11,9,4,5,9,17,6,9,,1
3KZ1,Crystal Structure of the Complex of PDZ-RhoGEF DH/PH domains with GTP-gamma-S Activated RhoA,"Rho guanine nucleotide exchange factor 11, Transforming protein RhoA",Homo sapiens,9606,"Guanine nucleotide exchange factors (GEFs) catalyze exchange of GDP for GTP by stabilizing the nucleotide-free state of the small GTPases through their Dbl homology/pleckstrin homology (DH.PH) domains. Unconventionally, PDZ-RhoGEF (PRG), a member of the RGS-RhoGEFs, binds tightly to both nucleotide-free and activated RhoA (RhoA.GTP). We have characterized the interaction between PRG and activated RhoA and determined the structure of the PRG-DH.PH-RhoA.GTPgammaS (guanosine 5'-O-[gamma-thio]triphosphate) complex. The interface bears striking similarity to a GTPase-effector interface and involves the switch regions in RhoA and a hydrophobic patch in PRG-PH that is conserved among all Lbc RhoGEFs. The two surfaces that bind activated and nucleotide-free RhoA on PRG-DH.PH do not overlap, and a ternary complex of PRG-DH.PH bound to both forms of RhoA can be isolated by size-exclusion chromatography. This novel interaction between activated RhoA and PH could play a key role in regulation of RhoGEF activity in vivo.",x-ray diffraction,2.7,1,4,E,94.70899470899471%,32.38636363636363%,1464,193,2,2,"['MG', 'GSP']","MG, GSP","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,12,10,13,5,6,8,16,5,14,13,16,10,5,6,2,7,15,11,10,5,2
3LAW,Structure of GTP-bound L129F mutant Rab7,,Homo sapiens,9606,"Rab GTPases are molecular switches that orchestrate vesicular trafficking, maturation and fusion by cycling between an active, GTP-bound form, and an inactive, GDP-bound form. The activity cycle is coupled to GTP hydrolysis and is tightly controlled by regulatory proteins. Missense mutations of the GTPase Rab7 cause a dominantly inherited axonal degeneration known as Charcot-Marie-Tooth type 2B through an unknown mechanism. We present the 2.8 A crystal structure of GTP-bound L129F mutant Rab7 which reveals normal conformations of the effector binding regions and catalytic site, but an alteration to the nucleotide binding pocket that is predicted to alter GTP binding. Through extensive biochemical analysis, we demonstrate that disease-associated mutations in Rab7 do not lead to an intrinsic GTPase defect, but permit unregulated nucleotide exchange leading to both excessive activation and hydrolysis-independent inactivation. Consistent with augmented activity, mutant Rab7 shows significantly enhanced interaction with a subset of effector proteins. In addition, dynamic imaging demonstrates that mutant Rab7 is abnormally retained on target membranes. However, we show that the increased activation of mutant Rab7 is counterbalanced by unregulated, GTP hydrolysis-independent membrane cycling. Notably, disease mutations are able to rescue the membrane cycling of a GTPase-deficient mutant. Thus, we demonstrate that disease mutations uncouple Rab7 from the spatial and temporal control normally imposed by regulatory proteins and cause disease not by a gain of novel toxic function, but by misregulation of native Rab7 activity.",x-ray diffraction,2.8,1,5,A,93.65079365079364%,30.303030303030305%,1460,189,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,10,8,15,3,8,12,11,5,13,13,16,9,11,11,,12,11,5,8,3,3
3LW8,"Shigella IpgB2 in complex with human RhoA, GDP and Mg2+ (complex A)","Transforming protein RhoA, IpgB2",Homo sapiens,9606,"A common theme in bacterial pathogenesis is the manipulation of eukaryotic cells by targeting the cytoskeleton. This is in most cases achieved either by modifying actin, or indirectly via activation of key regulators controlling actin dynamics such as Rho-GTPases. A novel group of bacterial virulence factors termed the WXXXE family has emerged as guanine nucleotide exchange factors (GEFs) for these GTPases. The precise mechanism of nucleotide exchange, however, has remained unclear. Here we report the structure of the WXXXE-protein IpgB2 from Shigella flexneri and its complex with human RhoA. We unambiguously identify IpgB2 as a bacterial RhoA-GEF and dissect the molecular mechanism of GDP release, an essential prerequisite for GTP binding. Our observations uncover that IpgB2 induces conformational changes on RhoA mimicking DbI- but not DOCK family GEFs. We also show that dissociation of the GDP.Mg(2+) complex is preceded by the displacement of the metal ion to the alpha-phosphate of the nucleotide, diminishing its affinity to the GTPase. These data refine our understanding of the mode of action not only of WXXXE GEFs but also of mammalian GEFs of the DH/PH family.",x-ray diffraction,1.85,1,8,A,97.88359788359789%,32.38636363636363%,1734,440,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,253,12,14,5,7,8,16,5,14,14,16,10,5,6,2,7,15,12,10,5,2
3MJH,Crystal Structure of Human Rab5A in complex with the C2H2 Zinc Finger of EEA1,,Homo sapiens,9606,"Regulation of endosomal trafficking by Rab GTPases depends on selective interactions with multivalent effectors, including EEA1 and Rabenosyn-5, which facilitate endosome tethering, sorting, and fusion. Both EEA1 and Rabenosyn-5 contain a distinctive N-terminal C(2)H(2) zinc finger that binds Rab5. How these C(2)H(2) zinc fingers recognize Rab GTPases remains unknown. Here, we report the crystal structure of Rab5A in complex with the EEA1 C(2)H(2) zinc finger. The binding interface involves all elements of the zinc finger as well as a short N-terminal extension but is restricted to the switch and interswitch regions of Rab5. High selectivity for Rab5 and, to a lesser extent Rab22, is observed in quantitative profiles of binding to Rab family GTPases. Although critical determinants are identified in both switch regions, Rab4-to-Rab5 conversion-of-specificity mutants reveal an essential requirement for additional substitutions in the proximal protein core that are predicted to indirectly influence recognition through affects on the structure and conformational stability of the switch regions.",x-ray diffraction,2.03,1,4,A,88.88888888888889%,31.901840490797547%,1495,311,2,2,"['GTP', 'MG']","GTP, MG, ZN","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, ZINC ION",active,141,7,20,4,12,9,11,5,13,15,12,9,9,9,2,10,8,3,6,2,2
3MSX,Crystal structure of RhoA.GDP.MgF3 in complex with GAP domain of ArhGAP20,,Homo sapiens,9606,No DOI found,x-ray diffraction,1.65,1,2,A,93.65079365079364%,32.38636363636363%,1565,307,3,3,"['MG', 'MGF', 'GDP']","GDP, MG, MGF","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, TRIFLUOROMAGNESATE",inactive,127,10,11,5,6,8,16,5,14,13,16,10,5,7,2,6,15,11,10,5,2
3PIR,Crystal structure of M-RasD41E in complex with GppNHp (type 1),Ras-related protein M-Ras,Mus musculus,10090,No DOI found,x-ray diffraction,2.75,1,1,A,88.88888888888889%,57.48502994011976%,1422,189,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,19,8,8,5,7,11,10,7,12,14,16,11,9,4,5,9,15,7,9,,1
3QBT,Crystal structure of OCRL1 540-678 in complex with Rab8a:GppNHp,"Ras-related protein Rab-8A, Inositol polyphosphate 5-phosphatase OCRL-1 (E.C.3.1.3.36)",Homo sapiens,9606,"The oculocerebrorenal syndrome of Lowe (OCRL), also called Lowe syndrome, is characterized by defects of the nervous system, the eye and the kidney. Lowe syndrome is a monogenetic X-linked disease caused by mutations of the inositol-5-phosphatase OCRL1. OCRL1 is a membrane-bound protein recruited to membranes via interaction with a variety of Rab proteins. The structural and kinetic basis of OCRL1 for the recognition of several Rab proteins is unknown. In this study, we report the crystal structure of the Rab-binding domain (RBD) of OCRL1 in complex with Rab8a and the kinetic binding analysis of OCRL1 with several Rab GTPases (Rab1b, Rab5a, Rab6a and Rab8a). In contrast to other effectors that bind their respective Rab predominantly via -helical structure elements, the Rab-binding interface of OCRL1 consists mainly of the IgG-like -strand structure of the ASPM-SPD-2-Hydin domain as well as one -helix. Our results give a deeper structural understanding of disease-causing mutations of OCRL1 affecting Rab binding.",x-ray diffraction,2.0,1,8,A,89.94708994708994%,36.19631901840491%,1445,211,2,2,"['MG', 'GNP']","MG, GNP, SO4","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, SULFATE ION",active,39,11,12,5,8,11,11,5,17,12,7,18,3,10,1,11,13,,11,2,2
3QBV,Structure of designed orthogonal interaction between CDC42 and nucleotide exchange domains of intersectin,"Cell division control protein 42 homolog, Intersectin-1",Homo sapiens,9606,"Signaling pathways depend on regulatory protein-protein interactions; controlling these interactions in cells has important applications for reengineering biological functions. As many regulatory proteins are modular, considerable progress in engineering signaling circuits has been made by recombining commonly occurring domains. Our ability to predictably engineer cellular functions, however, is constrained by complex crosstalk observed in naturally occurring domains. Here we demonstrate a strategy for improving and simplifying protein network engineering: using computational design to create orthogonal (non-crossreacting) protein-protein interfaces. We validated the design of the interface between a key signaling protein, the GTPase Cdc42, and its activator, Intersectin, biochemically and by solving the crystal structure of the engineered complex. The designed GTPase (orthoCdc42) is activated exclusively by its engineered cognate partner (orthoIntersectin), but maintains the ability to interface with other GTPase signaling circuit components in vitro. In mammalian cells, orthoCdc42 activity can be regulated by orthoIntersectin, but not wild-type Intersectin, showing that the designed interaction can trigger complex processes. Computational design of protein interfaces thus promises to provide specific components that facilitate the predictable engineering of cellular functions.",x-ray diffraction,2.65,1,4,A,78.3068783068783%,33.33333333333333%,1337,199,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,21,9,11,2,8,16,12,7,15,17,18,8,6,5,2,7,11,12,5,5,1
3RAB,GPPNHP-BOUND RAB3A AT 2.0 A RESOLUTION,RAB3A,Rattus norvegicus,10116,No abstract found,x-ray diffraction,2.0,1,1,A,89.41798941798942%,31.446540880503143%,1520,294,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,123,9,10,4,11,12,10,8,11,9,12,13,7,9,1,13,14,1,10,2,3
3REF,Crystal structure of EhRho1 bound to GDP and Magnesium,Rho-like small GTPase,Entamoeba histolytica,5759,"The single-celled human parasite Entamoeba histolytica possesses a dynamic actin cytoskeleton vital for its intestinal and systemic pathogenicity. The E. histolytica genome encodes several Rho family GTPases known to regulate cytoskeletal dynamics. EhRho1, the first family member identified, was reported to be insensitive to the Rho GTPase-specific Clostridium botulinum C3 exoenzyme, raising the possibility that it may be a misclassified Ras family member. Here, we report the crystal structures of EhRho1 in both active and inactive states. EhRho1 is activated by a conserved switch mechanism, but diverges from mammalian Rho GTPases in lacking a signature Rho insert helix. EhRho1 engages a homolog of mDia, EhFormin1, suggesting a role in mediating serum-stimulated actin reorganization and microtubule formation during mitosis. EhRho1, but not a constitutively active mutant, interacts with a newly identified EhRhoGDI in a prenylation-dependent manner. Furthermore, constitutively active EhRho1 induces actin stress fiber formation in mammalian fibroblasts, thereby identifying it as a functional Rho family GTPase. EhRho1 exhibits a fast rate of nucleotide exchange relative to mammalian Rho GTPases due to a distinctive switch one isoleucine residue reminiscent of the constitutively active F28L mutation in human Cdc42, which for the latter protein, is sufficient for cellular transformation. Nonconserved, nucleotide-interacting residues within EhRho1, revealed by the crystal structure models, were observed to contribute a moderating influence on fast spontaneous nucleotide exchange. Collectively, these observations indicate that EhRho1 is a bona fide member of the Rho GTPase family, albeit with unique structural and functional aspects compared with mammalian Rho GTPases.",x-ray diffraction,1.95,1,2,A,91.53439153439153%,32.73809523809524%,1489,274,4,4,"['MG', 'SO4', 'GDP']","GDP, MG, SO4","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, SULFATE ION",inactive,97,12,11,1,10,9,13,6,17,16,18,10,3,7,3,8,14,4,4,5,2
3RWM,Crystal Structure of Ypt32 in Complex with GppNHp,GTP-binding protein YPT32/YPT11,Saccharomyces cerevisiae S288C,559292,"Rab GTPases localize to distinct sub-cellular compartments and regulate vesicle trafficking in eukaryotic cells. Yeast Rabs Ypt31/32 and Sec4 have 68% homology and bind to common interactors, yet play distinct roles in the transport of exocytic vesicles. The structures of Ypt31/32 have not previously been reported in the uncomplexed state. We describe the crystal structures of GTP and GDP forms of Ypt32 to understand the molecular basis for Rab function. The structure of Ypt32(GTP) reveals that the switch II conformation is distinct from Sec4(GTP) in spite of a highly conserved amino acid sequence. Also, Ypt32(GDP) reveals a remarkable change in conformation of the switch II helix induced by binding to GDI, which has not been described previously.",x-ray diffraction,2.0,1,1,B,94.70899470899471%,32.31707317073171%,1672,374,3,3,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,192,10,16,4,14,11,13,8,11,14,13,13,4,12,3,8,13,1,8,1,2
3RYT,The Plexin A1 intracellular region in complex with Rac1,"Plexin-A1, Ras-related C3 botulinum toxin substrate 1",Mus musculus,10090,"Plexins are cell surface receptors that bind to semaphorins and transduce signals that regulate neuronal development, immune responses, and other processes. Signaling through plexins has been proposed to rely on specific guanosine triphosphatase (GTPase)-activating protein (GAP) activity for R-Ras and M-Ras. Activation of this GAP activity of plexins appears to require simultaneous binding of semaphorin to the plexin extracellular domain and of the Rho GTPases Rac1 or Rnd1 to the cytoplasmic region. However, GAP activity of plexins has eluded detection in several recent studies. We show that the purified cytoplasmic region of plexin uses a noncanonical catalytic mechanism to act as a GAP for Rap, but not for R-Ras or M-Ras. The RapGAP activity of plexins was autoinhibited and was activated by induced dimerization. Biochemical and crystallographic analyses demonstrated that binding of Rho GTPases did not directly contribute to activation of plexin RapGAP activity. Semaphorin stimulated the RapGAP activity of full-length plexin in cells, which was required for plexin-mediated neuronal growth cone collapse. Together, these findings define a pathway for plexin signaling and provide insights into the mechanism for semaphorin-induced activation of plexins.",x-ray diffraction,3.58,1,3,C,60.84656084656085%,30.89887640449438%,1306,176,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,0,11,13,2,7,13,9,8,13,17,16,10,4,6,2,6,12,11,7,5,2
3SBD,Crystal structure of RAC1 P29S mutant,Ras-related C3 botulinum toxin substrate 1,Homo sapiens,9606,"We characterized the mutational landscape of melanoma, the form of skin cancer with the highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed melanomas had markedly more ultraviolet (UV)-like C>T somatic mutations compared to sun-shielded acral, mucosal and uveal melanomas. Among the newly identified cancer genes was PPP6C, encoding a serine/threonine phosphatase, which harbored mutations that clustered in the active site in 12% of sun-exposed melanomas, exclusively in tumors with mutations in BRAF or NRAS. Notably, we identified a recurrent UV-signature, an activating mutation in RAC1 in 9.2% of sun-exposed melanomas. This activating mutation, the third most frequent in our cohort of sun-exposed melanoma after those of BRAF and NRAS, changes Pro29 to serine (RAC1(P29S)) in the highly conserved switch I domain. Crystal structures, and biochemical and functional studies of RAC1(P29S) showed that the alteration releases the conformational restraint conferred by the conserved proline, causes an increased binding of the protein to downstream effectors, and promotes melanocyte proliferation and migration. These findings raise the possibility that pharmacological inhibition of downstream effectors of RAC1 signaling could be of therapeutic benefit.",x-ray diffraction,2.1,1,2,A,93.65079365079364%,31.60919540229885%,1481,249,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,70,12,13,2,8,13,9,8,13,18,16,10,5,6,2,6,12,10,7,5,2
3SFV,Crystal structure of the GDP-bound Rab1a S25N mutant in complex with the coiled-coil domain of LidA from Legionella pneumophila,"Ras-related protein Rab-1A, LidA protein, substrate of the Dot/Icm system",Homo sapiens,9606,"The intracellular pathogen Legionella pneumophila hijacks the endoplasmic reticulum (ER)-derived vesicles to create an organelle designated Legionella-containing vacuole (LCV) required for bacterial replication. Maturation of the LCV involved acquisition of Rab1, which is mediated by the bacterial effector protein SidM/DrrA. SidM/DrrA is a bifunctional enzyme having the activity of both Rab1-specific GDP dissociation inhibitor (GDI) displacement factor (GDF) and guanine nucleotide exchange factor (GEF). LidA, another Rab1-interacting bacterial effector protein, was reported to promote SidM/DrrA-mediated recruitment of Rab1 to the LCV as well. Here we report the crystal structures of LidA complexes with GDP- and GTP-bound Rab1 respectively. Structural comparison revealed that GDP-Rab1 bound by LidA exhibits an active and nearly identical conformation with that of GTP-Rab1, suggesting that LidA can disrupt the switch function of Rab1 and render it persistently active. As with GTP, LidA maintains GDP-Rab1 in the active conformation through interaction with its two conserved switch regions. Consistent with the structural observations, biochemical assays showed that LidA binds to GDP- and GTP-Rab1 equally well with an affinity approximately 7.5 nM. We propose that the tight interaction with Rab1 allows LidA to facilitate SidM/DrrA-catalyzed release of Rab1 from GDIs. Taken together, our results support a unique mechanism by which a bacterial effector protein regulates Rab1 recycling.",x-ray diffraction,1.73,1,2,A,94.70899470899471%,35.75757575757576%,1595,321,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,141,11,10,5,13,16,11,9,14,16,11,13,6,9,1,8,13,2,7,2,2
3SU8,Crystal structure of a truncated intracellular domain of Plexin-B1 in complex with Rac1,"Ras-related C3 botulinum toxin substrate 1, Plexin-B1",Homo sapiens,9606,"Plexins are cell surface receptors for the semaphorin family of cell guidance cues. The cytoplasmic region comprises a Ras GTPase-activating protein (GAP) domain and a RhoGTPase binding domain. Concomitant binding of extracellular semaphorin and intracellular RhoGTPase triggers GAP activity and signal transduction. The mechanism of this intricate regulation remains elusive. We present two crystal structures of the human Plexin-B1 cytoplasmic region in complex with a constitutively active RhoGTPase, Rac1. The structure of truncated Plexin-B1-Rac1 complex provides no mechanism for coupling RhoGTPase and Ras binding sites. On inclusion of the juxtamembrane helix, a trimeric structure of Plexin-B1-Rac1 complexes is stabilised by a second, novel, RhoGTPase binding site adjacent to the Ras site. Site-directed mutagenesis combined with cellular and biophysical assays demonstrate that this new binding site is essential for signalling. Our findings are consistent with a model in which extracellular and intracellular plexin clustering events combine into a single signalling output.",x-ray diffraction,3.2,1,2,A,94.17989417989418%,31.46067415730337%,1425,180,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,0,11,13,3,7,13,9,8,14,18,16,10,5,6,2,6,12,11,7,5,2
3TH5,Crystal structure of wild-type RAC1,Ras-related C3 botulinum toxin substrate 1,Homo sapiens,9606,"We characterized the mutational landscape of melanoma, the form of skin cancer with the highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed melanomas had markedly more ultraviolet (UV)-like C>T somatic mutations compared to sun-shielded acral, mucosal and uveal melanomas. Among the newly identified cancer genes was PPP6C, encoding a serine/threonine phosphatase, which harbored mutations that clustered in the active site in 12% of sun-exposed melanomas, exclusively in tumors with mutations in BRAF or NRAS. Notably, we identified a recurrent UV-signature, an activating mutation in RAC1 in 9.2% of sun-exposed melanomas. This activating mutation, the third most frequent in our cohort of sun-exposed melanoma after those of BRAF and NRAS, changes Pro29 to serine (RAC1(P29S)) in the highly conserved switch I domain. Crystal structures, and biochemical and functional studies of RAC1(P29S) showed that the alteration releases the conformational restraint conferred by the conserved proline, causes an increased binding of the protein to downstream effectors, and promotes melanocyte proliferation and migration. These findings raise the possibility that pharmacological inhibition of downstream effectors of RAC1 signaling could be of therapeutic benefit.",x-ray diffraction,2.3,1,2,A,93.12169312169311%,31.60919540229885%,1419,189,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,11,11,13,2,7,13,9,8,13,18,16,10,5,6,2,6,12,11,7,5,2
3TKL,Crystal structure of the GTP-bound Rab1a in complex with the coiled-coil domain of LidA from Legionella pneumophila,"Ras-related protein Rab-1A, LidA protein, substrate of the Dot/Icm system",Homo sapiens,9606,"The intracellular pathogen Legionella pneumophila hijacks the endoplasmic reticulum (ER)-derived vesicles to create an organelle designated Legionella-containing vacuole (LCV) required for bacterial replication. Maturation of the LCV involved acquisition of Rab1, which is mediated by the bacterial effector protein SidM/DrrA. SidM/DrrA is a bifunctional enzyme having the activity of both Rab1-specific GDP dissociation inhibitor (GDI) displacement factor (GDF) and guanine nucleotide exchange factor (GEF). LidA, another Rab1-interacting bacterial effector protein, was reported to promote SidM/DrrA-mediated recruitment of Rab1 to the LCV as well. Here we report the crystal structures of LidA complexes with GDP- and GTP-bound Rab1 respectively. Structural comparison revealed that GDP-Rab1 bound by LidA exhibits an active and nearly identical conformation with that of GTP-Rab1, suggesting that LidA can disrupt the switch function of Rab1 and render it persistently active. As with GTP, LidA maintains GDP-Rab1 in the active conformation through interaction with its two conserved switch regions. Consistent with the structural observations, biochemical assays showed that LidA binds to GDP- and GTP-Rab1 equally well with an affinity approximately 7.5 nM. We propose that the tight interaction with Rab1 allows LidA to facilitate SidM/DrrA-catalyzed release of Rab1 from GDIs. Taken together, our results support a unique mechanism by which a bacterial effector protein regulates Rab1 recycling.",x-ray diffraction,2.18,1,2,A,90.47619047619048%,35.02824858757062%,1460,231,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,58,10,10,3,11,16,11,9,14,15,11,13,6,7,1,8,13,2,7,2,2
3TSO,Structure of the cancer associated Rab25 protein in complex with FIP2,"Ras-related protein Rab-25, Rab11 family-interacting protein 2",Homo sapiens,9606,No DOI found,x-ray diffraction,1.8,1,4,A,89.41798941798942%,33.33333333333333%,1476,263,7,7,"['MG', 'PO4', 'GNP', 'GOL']","MG, GNP, GOL, PO4","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, GLYCEROL, PHOSPHATE ION",active,87,10,17,3,11,16,15,5,8,18,18,6,3,7,3,10,6,1,10,,2
3TVD,Crystal Structure of Mouse RhoA-GTP complex,Transforming protein RhoA,Rattus norvegicus,10116,"RhoA, a member of the Rho sub-family of small GTPases, plays a significant signaling role in cell morphogenesis, migration, neuronal development, cell division and adhesion. So far, 4 structures of RhoA:GDP/GTP analogs and 14 structures of RhoA in complex with other proteins have been reported. All RhoA:GDP/GTP analog complexes have been crystallized in primitive lattices and RhoA is monomeric. This is the first time a RhoA:GTP analog complex has been crystallized as a dimer in a centered lattice. The present structure reveals structural differences in the switch-I (residues 28-42) and switch-II (residues 61-66) regions, which play important roles in interactions with downstream targets to transduce signals, when compared to the previously reported structures.",x-ray diffraction,2.99,1,2,A,95.23809523809523%,32.02247191011236%,1472,198,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,16,10,14,5,6,8,16,5,14,13,16,10,5,6,2,7,15,11,10,5,2
3V4F,"H-Ras PEG 400/CaCl2, ordered off",GTPase HRas,Rattus norvegicus,10116,"Ras GTPase cycles between its active GTP-bound form promoted by GEFs and its inactive GDP-bound form promoted by GAPs to affect the control of various cellular functions. It is becoming increasingly apparent that subtle regulation of the GTP-bound active state may occur through promotion of substates mediated by an allosteric switch mechanism that induces a disorder to order transition in switch II upon ligand binding at an allosteric site. We show with high-resolution structures that calcium acetate and either dithioerythritol (DTE) or dithiothreitol (DTT) soaked into H-Ras-GppNHp crystals in the presence of a moderate amount of poly(ethylene glycol) (PEG) can selectively shift the equilibrium to the ""on"" state, where the active site appears to be poised for catalysis (calcium acetate), or to what we call the ""ordered off"" state, which is associated with an anticatalytic conformation (DTE or DTT). We also show that the equilibrium is reversible in our crystals and dependent on the nature of the small molecule present. Calcium acetate binding in the allosteric site stabilizes the conformation observed in the H-Ras-GppNHp/NOR1A complex, and PEG, DTE, and DTT stabilize the anticatalytic conformation observed in the complex between the Ras homologue Ran and Importin-. The small molecules are therefore selecting biologically relevant conformations in the crystal that are sampled by the disordered switch II in the uncomplexed GTP-bound form of H-Ras. In the presence of a large amount of PEG, the ordered off conformation predominates, whereas in solution, in the absence of PEG, switch regions appear to remain disordered in what we call the off state, unable to bind DTE.",x-ray diffraction,1.39,1,1,A,87.83068783068782%,99.3975903614458%,1526,345,6,6,"['CA', 'MG', 'DTU', 'GNP']","CA, MG, DTU, GNP","CALCIUM ION, MAGNESIUM ION, (2R,3S)-1,4-DIMERCAPTOBUTANE-2,3-DIOL, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,173,11,11,4,8,11,14,9,8,11,15,11,10,4,3,5,14,3,11,3,
3X1W,Ras-related protein Rap1B with GDP,Ras-related protein Rap-1b,Rattus norvegicus,10116,"Rap1B is a small GTPase involved in the regulation of numerous cellular processes including synaptic plasticity, one of the bases of memory. Like other members of the Ras family, the active GTP-bound form of Rap1B can bind to a large number of effector proteins and so transmit signals to downstream components of the signaling pathways. The structure of Rap1B bound only to a nucleotide has yet to be solved, but might help reveal an inactive conformation that can be stabilized by a small molecule drug. Unlike other Ras family proteins such as H-Ras and Rap2A, Rap1B crystallizes in an intermediate state when bound to a non-hydrolyzable GTP analog. Comparison with H-Ras and Rap2A reveals conservative mutations relative to Rap1B, distant from the bound nucleotide, which control how readily the protein may adopt the fully activated form in the presence of GTP. High resolution crystallographic structures of mutant proteins show how these changes may influence the hydrogen bonding patterns of the key switch residues.",x-ray diffraction,1.2,1,1,A,88.35978835978835%,58.18181818181818%,1432,242,3,3,"['MG', 'CD', 'GDP']","GDP, MG, CD","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, CADMIUM ION",inactive,72,11,9,5,9,8,12,6,10,15,16,9,14,8,,7,13,2,9,3,1
3X1Y,Ras-related protein Rap1B(L9V) with GppNHp,Ras-related protein Rap-1b,Rattus norvegicus,10116,"Rap1B is a small GTPase involved in the regulation of numerous cellular processes including synaptic plasticity, one of the bases of memory. Like other members of the Ras family, the active GTP-bound form of Rap1B can bind to a large number of effector proteins and so transmit signals to downstream components of the signaling pathways. The structure of Rap1B bound only to a nucleotide has yet to be solved, but might help reveal an inactive conformation that can be stabilized by a small molecule drug. Unlike other Ras family proteins such as H-Ras and Rap2A, Rap1B crystallizes in an intermediate state when bound to a non-hydrolyzable GTP analog. Comparison with H-Ras and Rap2A reveals conservative mutations relative to Rap1B, distant from the bound nucleotide, which control how readily the protein may adopt the fully activated form in the presence of GTP. High resolution crystallographic structures of mutant proteins show how these changes may influence the hydrogen bonding patterns of the key switch residues.",x-ray diffraction,1.17,1,1,A,87.83068783068782%,58.78787878787879%,1550,363,4,4,"['MG', 'GNP', 'CD', 'GOL']","GNP, MG, GOL, CD","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL, CADMIUM ION",active,193,11,9,5,9,8,12,6,10,14,17,9,14,8,,7,13,2,8,3,1
3X1Z,Ras-related protein Rap1B(T65A) with GppNHp,Ras-related protein Rap-1b,Rattus norvegicus,10116,"Rap1B is a small GTPase involved in the regulation of numerous cellular processes including synaptic plasticity, one of the bases of memory. Like other members of the Ras family, the active GTP-bound form of Rap1B can bind to a large number of effector proteins and so transmit signals to downstream components of the signaling pathways. The structure of Rap1B bound only to a nucleotide has yet to be solved, but might help reveal an inactive conformation that can be stabilized by a small molecule drug. Unlike other Ras family proteins such as H-Ras and Rap2A, Rap1B crystallizes in an intermediate state when bound to a non-hydrolyzable GTP analog. Comparison with H-Ras and Rap2A reveals conservative mutations relative to Rap1B, distant from the bound nucleotide, which control how readily the protein may adopt the fully activated form in the presence of GTP. High resolution crystallographic structures of mutant proteins show how these changes may influence the hydrogen bonding patterns of the key switch residues.",x-ray diffraction,1.25,1,2,A,88.35978835978835%,58.18181818181818%,1575,378,3,3,"['MG', 'GNP', 'GOL']","GNP, MG, GOL","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL",active,208,11,10,5,9,7,12,6,10,15,16,9,14,8,,7,13,2,9,3,1
421P,THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES,"H-RAS P21 PROTEIN MUTANT WITH GLY 12 REPLACED BY ARG (G12R) COMPLEX WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE",Homo sapiens,9606,No abstract found,x-ray diffraction,2.2,1,1,A,87.83068783068782%,99.3975903614458%,1564,370,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,202,10,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,12,3,
4C4P,Crystal Structure of Wild-Type Rab11 Complexed to FIP2,"RAS-RELATED PROTEIN RAB-11A, RAB11 FAMILY-INTERACTING PROTEIN 2",Homo sapiens,9606,"Rab small GTPases are the master regulators of intracellular trafficking in eukaryotes. They mediate spatial and temporal recruitment of effector proteins to distinct cellular compartments through GTP-induced changes in their conformation. Despite numerous structural studies, the molecular basis for Rab/effector specificity and subsequent biological activity remains poorly understood. Rab25, also known as Rab11c, which is epithelial-specific, has been heavily implicated in ovarian cancer development and independently appears to act as a tumour suppressor in the context of a distinct subset of carcinomas. Here, we show that Rab25 associates with FIP2 and can recruit this effector protein to endosomal membranes. We report the crystal structure of Rab25 in complex with the C-terminal region of FIP2, which consists of a central dimeric FIP2 coiled-coil that mediates a heterotetrameric Rab25-(FIP2)2-Rab25 complex. Thermodynamic analyses show that, despite a relatively conserved interface, FIP2 binds to Rab25 with an approximate 3-fold weaker affinity than to Rab11a. Reduced affinity is mainly associated with lower enthalpic gains for Rab25:FIP2 complex formation, and can be attributed to subtle differences in the conformations of switch 1 and switch 2. These cellular, structural and thermodynamic studies provide insight into the Rab11/Rab25 subfamily of small GTPases that regulate endosomal trafficking pathways in eukaryotes.",x-ray diffraction,2.0,1,2,A,88.35978835978835%,37.65432098765432%,2821,300,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,131,10,16,1,12,12,13,8,9,16,12,12,4,8,3,7,10,1,11,,2
4D0G,Structure of Rab14 in complex with Rab-Coupling Protein (RCP),"RAS-RELATED PROTEIN RAB-14, RAB11 FAMILY-INTERACTING PROTEIN 1",Homo sapiens,9606,"Rab GTPases recruit effector proteins, via their GTP-dependent switch regions, to distinct subcellular compartments. Rab11 and Rab25 are closely related small GTPases that bind to common effectors termed the Rab11 family of interacting proteins (FIPs). The FIPs are organized into two subclasses (class I and class II) based on sequence and domain organization, and both subclasses contain a highly conserved Rab-binding domain at their C termini. Yeast two-hybrid and biochemical studies have revealed that the more distantly related Rab14 also interacts with class I FIPs. Here, we perform detailed structural, thermodynamic, and cellular analyses of the interactions between Rab14 and one of the class I FIPs, the Rab-coupling protein (RCP), to clarify the molecular aspects of the interaction. We find that Rab14 indeed binds to RCP, albeit with reduced affinity relative to conventional Rab11-FIP and Rab25-FIP complexes. However, in vivo, Rab11 recruits RCP onto biological membranes. Furthermore, biophysical analyses reveal a noncanonical 1:2 stoichiometry between Rab14-RCP in dilute solutions, in contrast to Rab11/25 complexes. The structure of Rab14-RCP reveals that Rab14 interacts with the canonical Rab-binding domain and also provides insight into the unusual properties of the complex. Finally, we show that both the Rab coupling protein and Rab14 function in neuritogenesis.",x-ray diffraction,2.5,1,2,A,88.35978835978835%,31.515151515151512%,1338,186,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,17,12,16,3,8,12,13,9,11,14,8,14,6,7,3,8,8,2,9,2,2
4D0L,Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS,"PHOSPHATIDYLINOSITOL 4-KINASE BETA (E.C.2.7.1.67), RAS-RELATED PROTEIN RAB-11A (E.C.3.6.5.2)",Homo sapiens,9606,"Phosphatidylinositol 4-kinases (PI4Ks) and small guanosine triphosphatases (GTPases) are essential for processes that require expansion and remodeling of phosphatidylinositol 4-phosphate (PI4P)-containing membranes, including cytokinesis, intracellular development of malarial pathogens, and replication of a wide range of RNA viruses. However, the structural basis for coordination of PI4K, GTPases, and their effectors is unknown. Here, we describe structures of PI4K (PI4KIII) bound to the small GTPase Rab11a without and with the Rab11 effector protein FIP3. The Rab11-PI4KIII interface is distinct compared with known structures of Rab complexes and does not involve switch regions used by GTPase effectors. Our data provide a mechanism for how PI4KIII coordinates Rab11 and its effectors on PI4P-enriched membranes and also provide strategies for the design of specific inhibitors that could potentially target plasmodial PI4KIII to combat malaria.",x-ray diffraction,2.94,1,6,B,91.53439153439153%,37.03703703703704%,1412,177,2,2,"['MG', 'GSP']","093, GSP, MG","N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,2,10,16,1,13,12,13,8,9,17,13,13,4,8,3,7,11,1,12,,2
4D0N,AKAP13 (AKAP-Lbc) RhoGEF domain in complex with RhoA,"TRANSFORMING PROTEIN RHOA (E.C.3.6.5.2), A-KINASE ANCHOR PROTEIN 13",Homo sapiens,9606,"The RhoGEF (Rho GTPase guanine-nucleotide-exchange factor) domain of AKAP-Lbc (A-kinase-anchoring protein-Lbc, also known as AKAP13) catalyses nucleotide exchange on RhoA and is involved in the development of cardiac hypertrophy. The RhoGEF activity of AKAP-Lbc has also been implicated in cancer. We have determined the X-ray crystal structure of the complex between RhoA-GDP and the AKAP-Lbc RhoGEF [DH (Dbl-homologous)-PH (pleckstrin homology)] domain to 2.1  (1  = 0.1 nm) resolution. The structure reveals important differences compared with related RhoGEF proteins such as leukaemia-associated RhoGEF. Nucleotide-exchange assays comparing the activity of the DH-PH domain to the DH domain alone showed no role for the PH domain in nucleotide exchange, which is explained by the RhoA-AKAP-Lbc structure. Comparison with a structure of the isolated AKAP-Lbc DH domain revealed a change in conformation of the N-terminal 'GEF switch' region upon binding to RhoA. Isothermal titration calorimetry showed that AKAP-Lbc has only micromolar affinity for RhoA, which combined with the presence of potential binding pockets for small molecules on AKAP-Lbc, raises the possibility of targeting AKAP-Lbc with GEF inhibitors.",x-ray diffraction,2.1,1,2,A,94.70899470899471%,32.02247191011236%,1516,259,3,3,"['SO4', 'EDO', 'GDP']","GDP, SO4, EDO","GUANOSINE-5'-DIPHOSPHATE, SULFATE ION, 1,2-ETHANEDIOL",inactive,77,10,13,5,6,8,16,5,14,13,16,10,5,6,2,7,15,11,10,5,2
4DID,Crystal structure of Salmonella effector N-terminal domain SopB in complex with Cdc42,"Cell division control protein 42 homolog, Inositol phosphate phosphatase sopB (E.C.3.1.3.-)",Homo sapiens,9606,"SopB is a type III secreted Salmonella effector protein with phosphoinositide phosphatase activity and a distinct GTPase binding domain. The latter interacts with host Cdc42, an essential Rho GTPase that regulates critical events in eukaryotic cytoskeleton organization and membrane trafficking. Structural and biochemical analysis of the SopB GTPase binding domain in complex with Cdc42 shows for the first time that SopB structurally and functionally mimics a host guanine nucleotide dissociation inhibitor (GDI) by contacting key residues in the regulatory switch regions of Cdc42 and slowing Cdc42 nucleotide exchange.",x-ray diffraction,2.35,1,2,A,94.70899470899471%,32.10526315789474%,1467,224,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,43,9,11,2,9,16,12,7,15,17,18,8,6,5,2,8,11,13,4,5,1
4DRZ,Crystal structure of human RAB14,Ras-related protein Rab-14,Homo sapiens,9606,No DOI found,x-ray diffraction,2.3,1,1,A,53.43915343915344%,31.515151515151512%,1309,203,2,2,"['CA', 'GDP']","GDP, CA","GUANOSINE-5'-DIPHOSPHATE, CALCIUM ION",inactive,41,11,15,2,8,12,12,10,11,13,8,14,6,9,3,6,7,2,7,2,2
4DVG,Crystal structure of E. histolytica Formin1 bound to EhRho1-GTPgammaS,"Rho-like small GTPase (E.C.3.6.5.2), Diaphanous protein",Entamoeba histolytica,5759,"Entamoeba histolytica requires a dynamic actin cytoskeleton for intestinal and systemic pathogenicity. Diaphanous-related formins represent an important family of actin regulators that are activated by Rho GTPases. The E. histolytica genome encodes a large family of Rho GTPases and three diaphanous-related formins, of which EhFormin1 is known to regulate mitosis and cytokinesis in trophozoites. We demonstrate that EhFormin1 modulates actin polymerization through its formin homology 2 domain. Despite a highly divergent diaphanous autoinhibitory domain, EhFormin1 is autoinhibited by an N- and C-terminal intramolecular interaction but activated upon binding of EhRho1 to the N-terminal domain tandem. A crystal structure of the EhRho1GTPS-EhFormin1 complex illustrates an EhFormin1 conformation that diverges from mammalian mDia1 and lacks a secondary interaction with a Rho insert helix. The structural model also highlights residues required for specific recognition of the EhRho1 GTPase and suggests that the molecular mechanisms of EhFormin1 autoinhibition and activation differ from those of mammalian homologues.",x-ray diffraction,2.6,1,2,A,86.77248677248677%,33.12101910828025%,1323,168,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,2,10,10,1,10,9,12,6,14,16,18,9,3,6,3,8,14,4,4,5,2
4DXA,Co-crystal structure of Rap1 in complex with KRIT1,"Ras-related protein Rap-1b (E.C.3.6.5.2), Krev interaction trapped protein 1",Homo sapiens,9606,"Cerebral cavernous malformations (CCMs) affect 0.1-0.5% of the population resulting in leaky vasculature and severe neurological defects. KRIT1 (Krev interaction trapped-1) mutations associate with 40% of familial CCMs. KRIT1 is an effector of Ras-related protein 1 (Rap1) GTPase. Rap1 relocalizes KRIT1 from microtubules to cell membranes to impact integrin activation, potentially important for CCM pathology. We report the 1.95  co-crystal structure of KRIT1 FERM domain in complex with Rap1. Rap1-KRIT1 interaction encompasses an extended surface, including Rap1 Switch I and II and KRIT1 FERM F1 and F2 lobes. Rap1 binds KRIT1-F1 lobe using a GTPase-ubiquitin-like fold interaction but binds KRIT1-F2 lobe by a novel interaction. Point mutagenesis confirms the interaction. High similarity between KRIT1-F2/F3 and talin is revealed. Additionally, the mechanism for FERM domains acting as GTPase effectors is suggested. Finally, structure-based alignment of each lobe suggests classification of FERM domains as ERM-like and TMFK-like (talin-myosin-FAK-KRIT-like) and that FERM lobes resemble domain ""modules.""",x-ray diffraction,1.95,1,2,A,88.88888888888889%,57.57575757575758%,1480,277,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,107,10,9,5,9,8,12,6,10,15,17,9,14,9,,7,13,2,9,3,1
4EFL,Crystal structure of H-Ras WT in complex with GppNHp (state 1),GTPase HRas,Homo sapiens,9606,"GTP-bound Ras adopts two interconverting conformations, ""inactive"" state 1 and ""active"" state 2. However, the tertiary structure of wild-type (WT) state 1 remains unsolved. Here we solve the state 1 crystal structures of H-Ras WT together with its oncogenic G12V and Q61L mutants. They assume open structures characterized by impaired interactions of both Thr-35 in switch I and Gly-60 in switch II with the -phosphate of GTP and possess two surface pockets of mutually different shapes unseen in state 2, a potential target for selective inhibitor development. Furthermore, they provide a structural basis for the low GTPase activity of state 1.",x-ray diffraction,1.9,1,1,A,87.83068783068782%,100.0%,1446,258,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,90,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
4EFM,Crystal structure of H-Ras G12V in complex with GppNHp (state 1),GTPase HRas,Homo sapiens,9606,"GTP-bound Ras adopts two interconverting conformations, ""inactive"" state 1 and ""active"" state 2. However, the tertiary structure of wild-type (WT) state 1 remains unsolved. Here we solve the state 1 crystal structures of H-Ras WT together with its oncogenic G12V and Q61L mutants. They assume open structures characterized by impaired interactions of both Thr-35 in switch I and Gly-60 in switch II with the -phosphate of GTP and possess two surface pockets of mutually different shapes unseen in state 2, a potential target for selective inhibitor development. Furthermore, they provide a structural basis for the low GTPase activity of state 1.",x-ray diffraction,1.9,1,1,A,87.83068783068782%,99.3975903614458%,1438,247,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,79,10,11,4,8,11,13,9,8,11,16,11,11,4,3,5,14,3,11,3,
4EFN,Crystal structure of H-Ras Q61L in complex with GppNHp (state 1),GTPase HRas,Homo sapiens,9606,"GTP-bound Ras adopts two interconverting conformations, ""inactive"" state 1 and ""active"" state 2. However, the tertiary structure of wild-type (WT) state 1 remains unsolved. Here we solve the state 1 crystal structures of H-Ras WT together with its oncogenic G12V and Q61L mutants. They assume open structures characterized by impaired interactions of both Thr-35 in switch I and Gly-60 in switch II with the -phosphate of GTP and possess two surface pockets of mutually different shapes unseen in state 2, a potential target for selective inhibitor development. Furthermore, they provide a structural basis for the low GTPase activity of state 1.",x-ray diffraction,2.3,1,1,A,87.83068783068782%,99.3975903614458%,1422,235,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,67,11,11,4,8,11,13,9,8,12,15,11,10,4,3,5,14,3,11,3,
4EPR,Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation.,GTPase KRas (E.C.3.6.5.2),Homo sapiens,9606,,x-ray diffraction,2.0,1,1,A,87.83068783068782%,92.81437125748504%,1488,300,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,132,10,9,4,9,12,12,8,10,11,15,11,9,4,4,6,16,4,10,2,
4EPT,Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation,GTPase KRas (E.C.3.6.5.2),Homo sapiens,9606,,x-ray diffraction,2.0,1,1,A,87.83068783068782%,93.41317365269461%,1482,285,3,3,"['MG', '0QW', 'GDP']","GDP, MG, 0QW","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, (2-hydroxyphenyl)(pyrrolidin-1-yl)methanethione",inactive,116,11,9,4,9,12,12,8,10,11,15,11,9,4,4,6,15,4,10,2,
4EPX,Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-mediated Activation,GTPase KRas (E.C.3.6.5.2),Homo sapiens,9606,,x-ray diffraction,1.76,1,1,A,89.94708994708994%,92.81437125748504%,1604,372,3,3,"['0QR', 'MG', 'GDP']","GDP, MG, 0QR","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, N-(6-aminopyridin-2-yl)-4-fluorobenzenesulfonamide",inactive,199,11,9,4,9,12,13,8,12,11,16,11,9,4,4,6,15,4,10,2,
4FMB,VirA-Rab1 complex structure,"Cysteine protease-like virA (E.C.3.4.22.-), Ras-related protein Rab-1A",Shigella flexneri,623,"Rab GTPases are frequent targets of vacuole-living bacterial pathogens for appropriate trafficking of the vacuole. Here we discover that bacterial effectors including VirA from nonvacuole Shigella flexneri and EspG from extracellular Enteropathogenic Escherichia coli (EPEC) harbor TBC-like dual-finger motifs and exhibits potent RabGAP activities. Specific inactivation of Rab1 by VirA/EspG disrupts ER-to-Golgi trafficking. S. flexneri intracellular persistence requires VirA TBC-like GAP activity that mediates bacterial escape from autophagy-mediated host defense. Rab1 inactivation by EspG severely blocks host secretory pathway, resulting in inhibited interleukin-8 secretion from infected cells. Crystal structures of VirA/EspG-Rab1-GDP-aluminum fluoride complexes highlight TBC-like catalytic role for the arginine and glutamine finger residues and reveal a 3D architecture distinct from that of the TBC domain. Structure of Arf6-EspG-Rab1 ternary complex illustrates a pathogenic signaling complex that rewires host Arf signaling to Rab1 inactivation. Structural distinctions of VirA/EspG further predict a possible extensive presence of TBC-like RabGAP effectors in counteracting various host defenses.",x-ray diffraction,3.2,1,6,B,90.47619047619048%,36.36363636363637%,1398,177,3,3,"['MG', 'AF3', 'GDP']","AF3, GDP, MG","ALUMINUM FLUORIDE, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,3,10,11,3,11,16,11,8,14,15,11,13,6,7,1,8,13,2,7,2,2
4FMD,EspG-Rab1 complex structure at 3.05 A,"EspG protein, Ras-related protein Rab-1A",Escherichia coli,562,"Rab GTPases are frequent targets of vacuole-living bacterial pathogens for appropriate trafficking of the vacuole. Here we discover that bacterial effectors including VirA from nonvacuole Shigella flexneri and EspG from extracellular Enteropathogenic Escherichia coli (EPEC) harbor TBC-like dual-finger motifs and exhibits potent RabGAP activities. Specific inactivation of Rab1 by VirA/EspG disrupts ER-to-Golgi trafficking. S. flexneri intracellular persistence requires VirA TBC-like GAP activity that mediates bacterial escape from autophagy-mediated host defense. Rab1 inactivation by EspG severely blocks host secretory pathway, resulting in inhibited interleukin-8 secretion from infected cells. Crystal structures of VirA/EspG-Rab1-GDP-aluminum fluoride complexes highlight TBC-like catalytic role for the arginine and glutamine finger residues and reveal a 3D architecture distinct from that of the TBC domain. Structure of Arf6-EspG-Rab1 ternary complex illustrates a pathogenic signaling complex that rewires host Arf signaling to Rab1 inactivation. Structural distinctions of VirA/EspG further predict a possible extensive presence of TBC-like RabGAP effectors in counteracting various host defenses.",x-ray diffraction,3.05,1,6,F,59.78835978835979%,36.58536585365854%,1165,153,3,3,"['MG', 'AF3', 'GDP']","AF3, GDP, MG, PGE, PEG","ALUMINUM FLUORIDE, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, TRIETHYLENE GLYCOL, DI(HYDROXYETHYL)ETHER",inactive,1,9,10,3,10,14,8,6,12,12,11,11,5,7,1,7,11,1,7,2,2
4GZL,Crystal structure of RAC1 Q61L mutant,Ras-related C3 botulinum toxin substrate 1 (E.C.3.6.5.2),Homo sapiens,9606,"RAC1 is a small, Ras-related GTPase that was recently reported to harbor a recurrent UV-induced signature mutation in melanoma, resulting in substitution of P29 to serine (RAC1(P29S)), ranking this the third most frequently occurring gain-of-function mutation in melanoma. Although the Ras family GTPases are mutated in about 30% of all cancers, mutations in the Rho family GTPases have rarely been observed. In this study, we demonstrate that unlike oncogenic Ras proteins, which are primarily activated by mutations that eliminate GTPase activity, the activated melanoma RAC1(P29S) protein maintains intrinsic GTP hydrolysis and is spontaneously activated by substantially increased inherent GDP/GTP nucleotide exchange. Determination and comparison of crystal structures for activated RAC1 GTPases suggest that RAC1(F28L)--a known spontaneously activated RAC1 mutant--and RAC1(P29S) are self-activated in distinct fashions. Moreover, the mechanism of RAC1(P29S) and RAC1(F28L) activation differs from the common oncogenic mutations found in Ras-like GTPases that abrogate GTP hydrolysis. The melanoma RAC1(P29S) gain-of-function point mutation therefore represents a previously undescribed class of cancer-related GTPase activity.",x-ray diffraction,2.0,1,2,A,68.25396825396825%,31.03448275862069%,1469,256,3,3,"['IPA', 'MG', 'GNP']","GNP, MG, IPA","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, ISOPROPYL ALCOHOL",active,80,10,13,2,7,13,8,8,13,19,16,10,3,6,2,6,12,11,7,5,2
4GZM,Crystal structure of RAC1 F28L mutant,Ras-related C3 botulinum toxin substrate 1 (E.C.3.6.5.2),Homo sapiens,9606,"RAC1 is a small, Ras-related GTPase that was recently reported to harbor a recurrent UV-induced signature mutation in melanoma, resulting in substitution of P29 to serine (RAC1(P29S)), ranking this the third most frequently occurring gain-of-function mutation in melanoma. Although the Ras family GTPases are mutated in about 30% of all cancers, mutations in the Rho family GTPases have rarely been observed. In this study, we demonstrate that unlike oncogenic Ras proteins, which are primarily activated by mutations that eliminate GTPase activity, the activated melanoma RAC1(P29S) protein maintains intrinsic GTP hydrolysis and is spontaneously activated by substantially increased inherent GDP/GTP nucleotide exchange. Determination and comparison of crystal structures for activated RAC1 GTPases suggest that RAC1(F28L)--a known spontaneously activated RAC1 mutant--and RAC1(P29S) are self-activated in distinct fashions. Moreover, the mechanism of RAC1(P29S) and RAC1(F28L) activation differs from the common oncogenic mutations found in Ras-like GTPases that abrogate GTP hydrolysis. The melanoma RAC1(P29S) gain-of-function point mutation therefore represents a previously undescribed class of cancer-related GTPase activity.",x-ray diffraction,2.8,1,2,A,92.06349206349206%,31.03448275862069%,1391,176,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,0,11,12,2,7,13,9,8,13,19,16,10,4,6,2,5,12,11,7,5,2
4I1O,Crystal structure of the Legionella pneumophila GAP domain of LepB in complex with Rab1b bound to GDP and BeF3,"Ras-related protein Rab-1B, LepB",Homo sapiens,9606,"Legionella pneumophila is an intracellularly surviving pathogen that releases about 270 different proteins into the host cell during infection. A set of secreted proteins takes control of the vesicular trafficking regulator Rab1. Legionella LepB inactivates Rab1 by acting as a GTPase-activating protein (GAP). We present the crystal structure of the Rab1b:LepB complex together with a thorough biochemical analysis and show that the GAP domain of LepB consists of an unusual fold. LepB acts by an atypical RabGAP mechanism that is reminiscent of classical GAPs and therefore sets the protein apart from mammalian TBC-like GAPs. Surprisingly, LepB can function as a GAP for Rab3, Rab8, Rab13 and Rab35, too, suggesting that it has a broader cellular role than previously thought.",x-ray diffraction,2.7,1,8,A,93.65079365079364%,35.97560975609756%,1426,197,4,4,"['BEF', 'MG', 'PEG', 'GDP']","MG, GDP, BEF, PEG","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, BERYLLIUM TRIFLUORIDE ION, DI(HYDROXYETHYL)ETHER",inactive,16,11,12,3,11,16,12,9,14,17,12,13,7,7,1,8,13,1,7,1,2
4JS0,Complex of Cdc42 with the CRIB-PR domain of IRSp53,"Cell division control protein 42 homolog, Brain-specific angiogenesis inhibitor 1-associated protein 2",Homo sapiens,9606,"The Rho family GTPase effector IRSp53 has essential roles in filopodia formation and neuronal development, but its regulatory mechanism is poorly understood. IRSp53 contains a membrane-binding BAR domain followed by an unconventional CRIB motif that overlaps with a proline-rich region (CRIB-PR) and an SH3 domain that recruits actin cytoskeleton effectors. Using a fluorescence reporter assay, we show that human IRSp53 adopts a closed inactive conformation that opens synergistically with the binding of human Cdc42 to the CRIB-PR and effector proteins, such as the tumor-promoting factor Eps8, to the SH3 domain. The crystal structure of Cdc42 bound to the CRIB-PR reveals a new mode of effector binding to Rho family GTPases. Structure-inspired mutations disrupt autoinhibition and Cdc42 binding in vitro and decouple Cdc42- and IRSp53-dependent filopodia formation in cells. The data support a combinatorial mechanism of IRSp53 activation.",x-ray diffraction,1.9,1,2,A,94.17989417989418%,32.748538011695906%,3002,315,6,6,"['MG', 'GNP', 'PE4']","GNP, MG, PE4","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL",active,131,8,11,2,9,16,12,7,15,17,19,8,6,5,2,8,11,12,4,5,1
4JVS,Crystal structure of LepB GAP domain from Legionella drancourtii in complex with Rab1-GDP and AlF3,"Putative uncharacterized protein, Ras-related protein Rab-1A",Legionella drancourtii LLAP12,658187,"Rab GTPases are emerging targets of diverse bacterial pathogens. Here, we perform biochemical and structural analyses of LepB, a Rab GTPase-activating protein (GAP) effector from Legionella pneumophila. We map LepB GAP domain to residues 313-618 and show that the GAP domain is Rab1 specific with a catalytic activity higher than the canonical eukaryotic TBC GAP and the newly identified VirA/EspG family of bacterial RabGAP effectors. Exhaustive mutation analyses identify Arg444 as the arginine finger, but no catalytically essential glutamine residues. Crystal structures of LepB313-618 alone and the GAP domain of Legionella drancourtii LepB in complex with Rab1-GDP-AlF3 support the catalytic role of Arg444, and also further reveal a 3D architecture and a GTPase-binding mode distinct from all known GAPs. Glu449, structurally equivalent to TBC RabGAP glutamine finger in apo-LepB, undergoes a drastic movement upon Rab1 binding, which induces Rab1 Gln70 side-chain flipping towards GDP-AlF3 through a strong ionic interaction. This conformationally rearranged Gln70 acts as the catalytic cis-glutamine, therefore uncovering an unexpected RasGAP-like catalytic mechanism for LepB. Our studies highlight an extraordinary structural and catalytic diversity of RabGAPs, particularly those from bacterial pathogens.",x-ray diffraction,2.78,1,2,B,89.94708994708994%,36.36363636363637%,1398,176,3,3,"['MG', 'AF3', 'GDP']","ACY, GDP, AF3, MG","ACETIC ACID, GUANOSINE-5'-DIPHOSPHATE, ALUMINUM FLUORIDE, MAGNESIUM ION",inactive,3,10,10,3,11,16,11,9,14,15,11,13,6,7,1,8,13,1,7,2,2
4K81,Crystal structure of the Grb14 RA and PH domains in complex with GTP-loaded H-Ras,"Growth factor receptor-bound protein 14, GTPase HRas",Homo sapiens,9606,"Grb14, a member of the Grb7-10-14 family of cytoplasmic adaptor proteins, is a tissue-specific negative regulator of insulin signaling. Grb7-10-14 contain several signaling modules, including a Ras-associating (RA) domain, a pleckstrin-homology (PH) domain, a family-specific BPS (between PH and SH2) region, and a C-terminal Src-homology-2 (SH2) domain. We showed previously that the RA and PH domains, along with the BPS region and SH2 domain, are necessary for downregulation of insulin signaling. Here, we report the crystal structure at 2.4- resolution of the Grb14 RA and PH domains in complex with GTP-loaded H-Ras (G12V). The structure reveals that the Grb14 RA and PH domains form an integrated structural unit capable of binding simultaneously to small GTPases and phosphoinositide lipids. The overall mode of binding of the Grb14 RA domain to activated H-Ras is similar to that of the RA domains of RalGDS and Raf1 but with important distinctions. The integrated RA-PH structural unit in Grb7-10-14 is also found in a second adaptor family that includes Rap1-interacting adaptor molecule (RIAM) and lamellipodin, proteins involved in actin-cytoskeleton rearrangement. The structure of Grb14 RA-PH in complex with H-Ras represents the first detailed molecular characterization of tandem RA-PH domains bound to a small GTPase and provides insights into the molecular basis for specificity.",x-ray diffraction,2.4,1,8,B,90.47619047619048%,99.3975903614458%,1415,198,3,3,"['GTP', 'MG', 'GOL']","GOL, GTP, MG","GLYCEROL, GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,24,12,12,5,9,11,13,9,8,11,16,11,11,4,3,5,14,3,11,3,
4KVG,Crystal structure of RIAM RA-PH domains in complex with GTP bound Rap1,"Ras-related protein Rap-1A, Amyloid beta A4 precursor protein-binding family B member 1-interacting protein",Homo sapiens,9606,"The small GTPase Rap1 induces integrin activation via an inside-out signaling pathway mediated by the Rap1-interacting adaptor molecule (RIAM). Blocking this pathway may suppress tumor metastasis and other diseases that are related to hyperactive integrins. However, the molecular basis for the specific recognition of RIAM by Rap1 remains largely unknown. Herein we present the crystal structure of an active, GTP-bound GTPase domain of Rap1 in complex with the Ras association (RA)-pleckstrin homology (PH) structural module of RIAM at 1.65 . The structure reveals that the recognition of RIAM by Rap1 is governed by side-chain interactions. Several side chains are critical in determining specificity of this recognition, particularly the Lys31 residue in Rap1 that is oppositely charged compared with the Glu31/Asp31 residue in other Ras GTPases. Lys31 forms a salt bridge with RIAM residue Glu212, making it the key specificity determinant of the interaction. We also show that disruption of these interactions results in reduction of Rap1:RIAM association, leading to a loss of co-clustering and cell adhesion. Our findings elucidate the molecular mechanism by which RIAM mediates Rap1-induced integrin activation. The crystal structure also offers new insight into the structural basis for the specific recruitment of RA-PH module-containing effector proteins by their small GTPase partners.",x-ray diffraction,1.65,1,4,A,54.4973544973545%,56.886227544910184%,1462,280,2,2,"['GTP', 'MG']","GTP, MG, EDO","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, 1,2-ETHANEDIOL",active,113,10,8,5,8,8,12,6,10,15,17,9,13,8,1,6,12,2,9,5,1
4KYI,Crystal structure of the phospholipase VipD from Legionella pneumophila in complex with the human GTPase Rab5,"VipD, Ras-related protein Rab-5C",Legionella pneumophila subsp. pneumophila str. Philadelphia 1,272624,"A challenge for microbial pathogens is to assure that their translocated effector proteins target only the correct host cell compartment during infection. The Legionella pneumophila effector vacuolar protein sorting inhibitor protein D (VipD) localizes to early endosomal membranes and alters their lipid and protein composition, thereby protecting the pathogen from endosomal fusion. This process requires the phospholipase A1 (PLA1) activity of VipD that is triggered specifically on VipD binding to the host cell GTPase Rab5, a key regulator of endosomes. Here, we present the crystal structure of VipD in complex with constitutively active Rab5 and reveal the molecular mechanism underlying PLA1 activation. An active site-obstructing loop that originates from the C-terminal domain of VipD is repositioned on Rab5 binding, thereby exposing the catalytic pocket within the N-terminal PLA1 domain. Substitution of amino acid residues located within the VipD-Rab5 interface prevented Rab5 binding and PLA1 activation and caused a failure of VipD mutant proteins to target to Rab5-enriched endosomal structures within cells. Experimental and computational analyses confirmed an extended VipD-binding interface on Rab5, explaining why this L. pneumophila effector can compete with cellular ligands for Rab5 binding. Together, our data explain how the catalytic activity of a microbial effector can be precisely linked to its subcellular localization.",x-ray diffraction,3.08,1,8,B,86.77248677248677%,32.515337423312886%,1324,168,4,4,"['MG', 'EDO', 'GNP']","EDO, GOL, GNP, MG","1,2-ETHANEDIOL, GLYCEROL, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,0,7,23,4,9,11,10,6,11,15,12,9,9,7,2,9,8,2,6,2,2
4LHV,Crystal structure of Rab8 in its inactive GDP-bound form,Ras-related protein Rab-8A,Homo sapiens,9606,"Small G-proteins of the Ras superfamily control the temporal and spatial coordination of intracellular signaling networks by acting as molecular on/off switches. Guanine nucleotide exchange factors (GEFs) regulate the activation of these G-proteins through catalytic replacement of GDP by GTP. During nucleotide exchange, three distinct substrateenzyme complexes occur: a ternary complex with GDP at the start of the reaction (G-proteinGEFGDP), an intermediary nucleotide-free binary complex (G-proteinGEF), and a ternary GTP complex after productive G-protein activation (G-proteinGEFGTP). Here, we show structural snapshots of the full nucleotide exchange reaction sequence together with the G-protein substrates and products using Rabin8/GRAB (GEF) and Rab8 (G-protein) as a model system. Together with a thorough enzymatic characterization, our data provide a detailed view into the mechanism of Rabin8/GRAB-mediated nucleotide exchange.",x-ray diffraction,1.95,1,5,A,54.4973544973545%,36.19631901840491%,1472,301,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,134,11,11,5,9,10,10,5,17,12,7,17,2,10,2,10,14,,9,2,2
4M8N,Crystal Structure of PlexinC1/Rap1B Complex,"PlexinC1 Intracellular Region, Ras-related protein Rap-1b",Danio rerio,7955,"Plexins are cell surface receptors that bind semaphorins and transduce signals for regulating neuronal axon guidance and other processes. Plexin signaling depends on their cytoplasmic GTPase activating protein (GAP) domain, which specifically inactivates the Ras homolog Rap through an ill-defined non-canonical catalytic mechanism. The plexin GAP is activated by semaphorin-induced dimerization, the structural basis for which remained unknown. Here we present the crystal structures of the active dimer of zebrafish PlexinC1 cytoplasmic region in the apo state and in complex with Rap. The structures show that the dimerization induces a large-scale conformational change in plexin, which opens the GAP active site to allow Rap binding. Plexin stabilizes the switch II region of Rap in an unprecedented conformation, bringing Gln63 in Rap into the active site for catalyzing GTP hydrolysis. The structures also explain the unique Rap-specificity of plexins. Mutational analyses support that these mechanisms underlie plexin activation and signaling. DOI:http://dx.doi.org/10.7554/eLife.01279.001.",x-ray diffraction,3.29,1,8,E,88.88888888888889%,58.18181818181818%,1310,171,3,3,"['MG', 'AF3', 'GDP']","MG, GDP, AF3","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, ALUMINUM FLUORIDE",inactive,0,12,9,5,9,8,12,6,10,15,16,9,14,9,,7,13,2,8,3,1
4NYI,Approach for Targeting Ras with Small Molecules that Activate SOS-Mediated Nucleotide Exchange,"GTPase HRas, Son of sevenless homolog 1",Homo sapiens,9606,"Aberrant activation of the small GTPase Ras by oncogenic mutation or constitutively active upstream receptor tyrosine kinases results in the deregulation of cellular signals governing growth and survival in 30% of all human cancers. However, the discovery of potent inhibitors of Ras has been difficult to achieve. Here, we report the identification of small molecules that bind to a unique pocket on the Ras:Son of Sevenless (SOS):Ras complex, increase the rate of SOS-catalyzed nucleotide exchange in vitro, and modulate Ras signaling pathways in cells. X-ray crystallography of Ras:SOS:Ras in complex with these molecules reveals that the compounds bind in a hydrophobic pocket in the CDC25 domain of SOS adjacent to the Switch II region of Ras. The structure-activity relationships exhibited by these compounds can be rationalized on the basis of multiple X-ray cocrystal structures. Mutational analyses confirmed the functional relevance of this binding site and showed it to be essential for compound activity. These molecules increase Ras-GTP levels and disrupt MAPK and PI3K signaling in cells at low micromolar concentrations. These small molecules represent tools to study the acute activation of Ras and highlight a pocket on SOS that may be exploited to modulate Ras signaling.",x-ray diffraction,2.96,1,3,Q,88.35978835978835%,99.3975903614458%,1377,193,2,2,"['MG', 'GNP']","MG, GNP, 2PX","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, N-{1-[(5-methyl-1H-indol-3-yl)methyl]piperidin-4-yl}-L-tryptophanamide",active,24,12,12,4,8,11,13,8,8,11,15,11,11,4,3,5,14,3,11,3,
4O25,Structure of Wild Type Mus musculus Rheb bound to GTP,GTP-binding protein Rheb,Mus musculus,10090,"Constitutively activated variants of small GTPases, which provide valuable functional probes of their role in cellular signaling pathways, can often be generated by mutating the canonical catalytic residue (e.g. Ras Q61L) to impair GTP hydrolysis. However, this general approach is ineffective for a substantial fraction of the small GTPase family in which this residue is not conserved (e.g. Rap) or not catalytic (e.g. Rheb). Using a novel engineering approach, we have manipulated nucleotide binding through structure-guided substitutions of an ultraconserved glycine residue in the G3-box motif (DXXG). Substitution of Rheb Gly-63 with alanine impaired both intrinsic and TSC2 GTPase-activating protein (GAP)-mediated GTP hydrolysis by displacing the hydrolytic water molecule, whereas introduction of a bulkier valine side chain selectively blocked GTP binding by steric occlusion of the -phosphate. Rheb G63A stimulated phosphorylation of the mTORC1 substrate p70S6 kinase more strongly than wild-type, thus offering a new tool for mammalian target of rapamycin (mTOR) signaling.",x-ray diffraction,2.2,1,2,A,88.35978835978835%,36.477987421383645%,1437,248,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,79,10,9,3,15,9,13,8,14,13,15,17,9,6,3,7,8,3,4,,1
4O2L,Structure of Mus musculus Rheb G63A mutant bound to GTP,GTP-binding protein Rheb,Mus musculus,10090,"Constitutively activated variants of small GTPases, which provide valuable functional probes of their role in cellular signaling pathways, can often be generated by mutating the canonical catalytic residue (e.g. Ras Q61L) to impair GTP hydrolysis. However, this general approach is ineffective for a substantial fraction of the small GTPase family in which this residue is not conserved (e.g. Rap) or not catalytic (e.g. Rheb). Using a novel engineering approach, we have manipulated nucleotide binding through structure-guided substitutions of an ultraconserved glycine residue in the G3-box motif (DXXG). Substitution of Rheb Gly-63 with alanine impaired both intrinsic and TSC2 GTPase-activating protein (GAP)-mediated GTP hydrolysis by displacing the hydrolytic water molecule, whereas introduction of a bulkier valine side chain selectively blocked GTP binding by steric occlusion of the -phosphate. Rheb G63A stimulated phosphorylation of the mTORC1 substrate p70S6 kinase more strongly than wild-type, thus offering a new tool for mammalian target of rapamycin (mTOR) signaling.",x-ray diffraction,2.4,1,2,A,88.35978835978835%,35.84905660377358%,1420,230,2,2,"['GTP', 'MG']","GTP, MG, TRS, ACT","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, ACETATE ION",active,61,9,10,3,15,9,13,8,14,13,15,17,9,6,3,7,8,3,4,,1
4O2R,Structure of Mus musculus Rheb G63V mutant bound to GDP,GTP-binding protein Rheb,Mus musculus,10090,"Constitutively activated variants of small GTPases, which provide valuable functional probes of their role in cellular signaling pathways, can often be generated by mutating the canonical catalytic residue (e.g. Ras Q61L) to impair GTP hydrolysis. However, this general approach is ineffective for a substantial fraction of the small GTPase family in which this residue is not conserved (e.g. Rap) or not catalytic (e.g. Rheb). Using a novel engineering approach, we have manipulated nucleotide binding through structure-guided substitutions of an ultraconserved glycine residue in the G3-box motif (DXXG). Substitution of Rheb Gly-63 with alanine impaired both intrinsic and TSC2 GTPase-activating protein (GAP)-mediated GTP hydrolysis by displacing the hydrolytic water molecule, whereas introduction of a bulkier valine side chain selectively blocked GTP binding by steric occlusion of the -phosphate. Rheb G63A stimulated phosphorylation of the mTORC1 substrate p70S6 kinase more strongly than wild-type, thus offering a new tool for mammalian target of rapamycin (mTOR) signaling.",x-ray diffraction,2.25,1,2,A,88.35978835978835%,35.84905660377358%,1443,255,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,86,9,9,3,15,9,13,8,14,13,16,17,9,6,3,7,8,3,4,,1
4OJK,Structure of the cGMP Dependent Protein Kinase II and Rab11b Complex,"Ras-related protein Rab-11B (E.C.3.6.5.2), cGMP-dependent protein kinase 2 (E.C.2.7.11.12)",Homo sapiens,9606,"cGMP-dependent protein kinase (PKG)-interacting proteins (GKIPs) mediate cellular targeting of PKG isoforms by interacting with their leucine zipper (LZ) domains. These interactions prevent aberrant signaling cross-talk between different PKG isotypes. To gain detailed insight into isotype-specific GKIP recognition by PKG, we analyzed the type II PKG leucine zipper domain and found that residues 40-83 dimerized and specifically interacted with Rab11b. Next, we determined a crystal structure of the PKG II LZ-Rab11b complex. The PKG II LZ domain presents a mostly nonpolar surface onto which Rab11b docks, through van der Waals interactions. Contact surfaces in Rab11b are found in switch I and II, interswitch, and the 1/N-terminal regions. This binding surface dramatically differs from that seen in the Rab11 family of interacting protein complex structures. Structural comparison with PKG I and I LZs combined with mutagenic analysis reveals that GKIP recognition is mediated through surface charge interactions.",x-ray diffraction,2.66,1,4,A,92.06349206349206%,35.51912568306011%,1409,192,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,17,10,15,1,14,11,13,8,11,16,13,13,4,10,3,7,10,1,12,,2
4PZY,Second-site screening of K-Ras in the presence of covalently attached first-site ligands,K-Ras (E.C.3.6.5.2),Homo sapiens,9606,"K-Ras is a well-validated cancer target but is considered to be ""undruggable"" due to the lack of suitable binding pockets. We previously discovered small molecules that bind weakly to K-Ras but wanted to improve their binding affinities by identifying ligands that bind near our initial hits that we could link together. Here we describe an approach for identifying second site ligands that uses a cysteine residue to covalently attach a compound for tight binding to the first site pocket followed by a fragment screen for binding to a second site. This approach could be very useful for targeting Ras and other challenging drug targets.",x-ray diffraction,1.88,1,2,A,89.94708994708994%,92.21556886227546%,1572,360,2,2,"['MG', 'GDP']","GDP, MG, 2XR","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 2-chloro-1-(1H-indol-3-yl)ethanone",inactive,188,11,9,4,9,12,13,8,12,11,16,11,8,4,4,6,15,4,10,3,
4PZZ,Second-site screening of K-Ras in the presence of covalently attached first-site ligands,K-Ras (E.C.3.6.5.2),Homo sapiens,9606,"K-Ras is a well-validated cancer target but is considered to be ""undruggable"" due to the lack of suitable binding pockets. We previously discovered small molecules that bind weakly to K-Ras but wanted to improve their binding affinities by identifying ligands that bind near our initial hits that we could link together. Here we describe an approach for identifying second site ligands that uses a cysteine residue to covalently attach a compound for tight binding to the first site pocket followed by a fragment screen for binding to a second site. This approach could be very useful for targeting Ras and other challenging drug targets.",x-ray diffraction,1.4,1,1,A,89.94708994708994%,92.21556886227546%,3054,477,3,3,"['MG', '2XO', 'GDP']","GDP, MG, 2XO","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 1H-benzimidazol-2-ylmethanethiol",inactive,304,11,9,4,8,12,13,8,12,11,16,11,9,4,4,6,15,4,10,3,
4Q01,Second-site screening of K-Ras in the presence of covalently attached first-site ligands,K-Ras (E.C.3.6.5.2),Homo sapiens,9606,"K-Ras is a well-validated cancer target but is considered to be ""undruggable"" due to the lack of suitable binding pockets. We previously discovered small molecules that bind weakly to K-Ras but wanted to improve their binding affinities by identifying ligands that bind near our initial hits that we could link together. Here we describe an approach for identifying second site ligands that uses a cysteine residue to covalently attach a compound for tight binding to the first site pocket followed by a fragment screen for binding to a second site. This approach could be very useful for targeting Ras and other challenging drug targets.",x-ray diffraction,1.29,1,2,A,87.83068783068782%,92.21556886227546%,2863,360,3,3,"['MG', '2XH', 'GDP']","GDP, MG, 2XH","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, naphthalene-1-thiol",inactive,191,10,9,4,8,12,12,8,10,11,16,11,9,4,4,6,15,4,10,3,
4Q21,MOLECULAR SWITCH FOR SIGNAL TRANSDUCTION: STRUCTURAL DIFFERENCES BETWEEN ACTIVE AND INACTIVE FORMS OF PROTOONCOGENIC RAS PROTEINS,C-H-RAS P21 PROTEIN CATALYTIC DOMAIN COMPLEX WITH GDP,Homo sapiens,9606,No DOI found,x-ray diffraction,2.0,1,1,A,89.41798941798942%,100.0%,1447,249,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,78,11,11,4,8,11,13,9,9,12,15,11,11,4,3,5,14,3,12,3,
4QL3,Crystal Structure of a GDP-bound G12R Oncogenic Mutant of Human GTPase KRas,GTPase KRas (E.C.3.6.5.2),Homo sapiens,9606,"KRAS mutations are the most common genetic abnormalities in cancer, but the distribution of specific mutations across cancers and the differential responses of patients with specific KRAS mutations in therapeutic clinical trials suggest that different KRAS mutations have unique biochemical behaviors. To further explain these high-level clinical differences and to explore potential therapeutic strategies for specific KRAS isoforms, we characterized the most common KRAS mutants biochemically for substrate binding kinetics, intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activities, and interactions with the RAS effector, RAF kinase. Of note, KRAS G13D shows rapid nucleotide exchange kinetics compared with other mutants analyzed. This property can be explained by changes in the electrostatic charge distribution of the active site induced by the G13D mutation as shown by X-ray crystallography. High-resolution X-ray structures are also provided for the GDP-bound forms of KRAS G12V, G12R, and Q61L and reveal additional insight. Overall, the structural data and measurements, obtained herein, indicate that measurable biochemical properties provide clues for identifying KRAS-driven tumors that preferentially signal through RAF.Biochemical profiling and subclassification of KRAS-driven cancers will enable the rational selection of therapies targeting specific KRAS isoforms or specific RAS effectors.",x-ray diffraction,1.04,1,1,A,89.94708994708994%,93.41317365269461%,2986,413,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,241,11,9,4,8,12,13,8,12,11,15,11,9,4,4,6,15,4,11,3,
4QXA,Crystal structure of the Rab9A-RUTBC2 RBD complex,"Ras-related protein Rab-9A, Small G protein signaling modulator 1",Mus musculus,10090,"Rab9 plays a vital role in regulating the transport of mannose 6-phosphate receptors from late endosomes to the trans-Golgi network through interactions with various effectors. Here, we report the crystal structure of GTP-bound Rab9A in complex with the Rab-binding domain (RBD) of the effector RUTBC2. RUTBC2 RBD assumes a pleckstrin homology domain fold that uses a binding site consisting of mainly 1 and the 1 insertion to interact with the switch and interswitch regions of Rab9A. The C-terminal hypervariable region of Rab9A is disordered and thus not required for RUTBC2 binding. The conformational plasticity of the switch and interswitch regions of Rab9A primarily determines the specificity for RUTBC2. Our biochemical and biological data confirm these findings and further show that Rab9B can bind to RUTBC2 probably in a similar manner as Rab9A. These results together reveal the molecular basis for the binding specificity of Rab9A with RUTBC2.",x-ray diffraction,2.3,1,2,A,91.005291005291%,32.72727272727273%,1495,248,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,74,10,10,2,14,11,13,6,11,14,11,8,6,8,2,14,14,4,8,3,3
4RKE,Drosophila melanogaster Rab2 bound to GMPPNP,GH01619p,Drosophila melanogaster,7227,"Rab GTPases belong to the large family of Ras proteins. They act as key regulators of membrane organization and intracellular trafficking. Functionally, they act as switches. In the active GTP-bound form they can bind to effector proteins to facilitate the delivery of transport vesicles. Upon stimulation, the GTP is hydrolyzed and the Rab proteins undergo conformational changes in their switch regions. This study focuses on Rab2 and Rab3 from Drosophila melanogaster. Whereas Rab2 is involved in vesicle transport between the Golgi and the endoplasmatic reticulum, Rab3 is a key player in exocytosis, and in the synapse it is involved in the assembly of the presynaptic active zone. Here, high-resolution crystal structures of Rab2 and Rab3 in complex with GMPPNP and Mg2+ are presented. In the structure of Rab3 a modified cysteine residue is observed with an enigmatic electron density attached to its thiol function.",x-ray diffraction,2.0,1,1,A,93.12169312169311%,34.5679012345679%,1567,293,4,4,"['MG', '1PE', 'GNP']","GNP, MG, 1PE","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, PENTAETHYLENE GLYCOL",active,113,14,16,6,9,13,14,7,10,14,8,15,6,6,4,9,9,1,12,1,2
4RKF,Drosophila melanogaster Rab3 bound to GMPPNP,Ras-related protein Rab-3,Drosophila melanogaster,7227,"Rab GTPases belong to the large family of Ras proteins. They act as key regulators of membrane organization and intracellular trafficking. Functionally, they act as switches. In the active GTP-bound form they can bind to effector proteins to facilitate the delivery of transport vesicles. Upon stimulation, the GTP is hydrolyzed and the Rab proteins undergo conformational changes in their switch regions. This study focuses on Rab2 and Rab3 from Drosophila melanogaster. Whereas Rab2 is involved in vesicle transport between the Golgi and the endoplasmatic reticulum, Rab3 is a key player in exocytosis, and in the synapse it is involved in the assembly of the presynaptic active zone. Here, high-resolution crystal structures of Rab2 and Rab3 in complex with GMPPNP and Mg2+ are presented. In the structure of Rab3 a modified cysteine residue is observed with an enigmatic electron density attached to its thiol function.",x-ray diffraction,1.5,1,2,A,90.47619047619048%,30.81761006289308%,1645,367,4,4,"['MG', '1PE', 'GNP']","GNP, MG, 1PE","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, PENTAETHYLENE GLYCOL",active,192,9,9,5,11,12,8,7,11,10,17,11,8,8,1,14,15,,10,2,3
4TQ9,Crystal Structure of a GDP-bound G12V Oncogenic Mutant of Human GTPase KRas,GTPase KRas,Homo sapiens,9606,"KRAS mutations are the most common genetic abnormalities in cancer, but the distribution of specific mutations across cancers and the differential responses of patients with specific KRAS mutations in therapeutic clinical trials suggest that different KRAS mutations have unique biochemical behaviors. To further explain these high-level clinical differences and to explore potential therapeutic strategies for specific KRAS isoforms, we characterized the most common KRAS mutants biochemically for substrate binding kinetics, intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activities, and interactions with the RAS effector, RAF kinase. Of note, KRAS G13D shows rapid nucleotide exchange kinetics compared with other mutants analyzed. This property can be explained by changes in the electrostatic charge distribution of the active site induced by the G13D mutation as shown by X-ray crystallography. High-resolution X-ray structures are also provided for the GDP-bound forms of KRAS G12V, G12R, and Q61L and reveal additional insight. Overall, the structural data and measurements, obtained herein, indicate that measurable biochemical properties provide clues for identifying KRAS-driven tumors that preferentially signal through RAF.Biochemical profiling and subclassification of KRAS-driven cancers will enable the rational selection of therapies targeting specific KRAS isoforms or specific RAS effectors.",x-ray diffraction,1.49,1,2,A,89.41798941798942%,93.41317365269461%,2888,352,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,181,11,9,4,8,12,13,8,11,11,16,11,9,4,4,6,15,4,10,3,
4TQA,Crystal Structure of a GDP-bound G13D Oncogenic Mutant of Human GTPase KRas,GTPase KRas,Homo sapiens,9606,"KRAS mutations are the most common genetic abnormalities in cancer, but the distribution of specific mutations across cancers and the differential responses of patients with specific KRAS mutations in therapeutic clinical trials suggest that different KRAS mutations have unique biochemical behaviors. To further explain these high-level clinical differences and to explore potential therapeutic strategies for specific KRAS isoforms, we characterized the most common KRAS mutants biochemically for substrate binding kinetics, intrinsic and GTPase-activating protein (GAP)-stimulated GTPase activities, and interactions with the RAS effector, RAF kinase. Of note, KRAS G13D shows rapid nucleotide exchange kinetics compared with other mutants analyzed. This property can be explained by changes in the electrostatic charge distribution of the active site induced by the G13D mutation as shown by X-ray crystallography. High-resolution X-ray structures are also provided for the GDP-bound forms of KRAS G12V, G12R, and Q61L and reveal additional insight. Overall, the structural data and measurements, obtained herein, indicate that measurable biochemical properties provide clues for identifying KRAS-driven tumors that preferentially signal through RAF.Biochemical profiling and subclassification of KRAS-driven cancers will enable the rational selection of therapies targeting specific KRAS isoforms or specific RAS effectors.",x-ray diffraction,1.13,1,2,A,89.41798941798942%,93.41317365269461%,2902,372,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,201,11,9,4,8,12,13,8,11,11,15,11,9,4,4,6,16,4,10,3,
4U5X,Structure of plant small GTPase OsRac1 complexed with the non-hydrolyzable GTP analog GMPPNP,OsRac1,Oryza sativa Japonica Group,39947,"Rac/Rop proteins are Rho-type small GTPases that act as molecular switches in plants. Recent studies have identified these proteins as key components in many major plant signaling pathways, such as innate immunity, pollen tube growth, and root hair formation. In rice, the Rac/Rop protein OsRac1 plays an important role in regulating the production of reactive oxygen species (ROS) by the NADPH oxidase OsRbohB during innate immunity. However, the molecular mechanism by which OsRac1 regulates OsRbohB remains unknown. Here, we report the crystal structure of OsRac1 complexed with the non-hydrolyzable GTP analog guanosine 5'-(,-imido)triphosphate at 1.9  resolution; this represents the first active-form structure of a plant small GTPase. To elucidate the ROS production in rice cells, structural information was used to design OsRac1 mutants that displayed reduced binding to OsRbohB. Only mutations in the OsRac1 Switch I region showed attenuated interactions with OsRbohB in vitro. In particular, Tyr(39) and Asp(45) substitutions suppressed ROS production in rice cells, indicating that these residues are critical for interaction with and activation of OsRbohB. Structural comparison of active-form OsRac1 with AtRop9 in its GDP-bound inactive form showed a large conformational difference in the vicinity of these residues. Our results provide new insights into the molecular mechanism of the immune response through OsRac1 and the various cellular responses associated with plant Rac/Rop proteins.",x-ray diffraction,1.9,1,1,A,94.17989417989418%,31.60919540229885%,1525,273,5,5,"['MG', 'GNP', 'GOL']","GNP, MG, GOL","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL",active,90,12,13,2,15,12,8,7,10,16,18,11,4,6,1,8,11,7,11,4,2
4UJ3,Crystal structure of human Rab11-Rabin8-FIP3,"RAS-RELATED PROTEIN RAB-11A, RAB-3A-INTERACTING PROTEIN, RAB11 FAMILY-INTERACTING PROTEIN 3",Homo sapiens,9606,"The small GTPase Rab11 and its effectors FIP3 and Rabin8 are essential to membrane-trafficking pathways required for cytokinesis and ciliogenesis. Although effector binding is generally assumed to be sequential and mutually exclusive, we show that Rab11 can simultaneously bind FIP3 and Rabin8. We determined crystal structures of human Rab11-GMPPNP-Rabin8 and Rab11-GMPPNP-FIP3-Rabin8. The structures reveal that the C-terminal domain of Rabin8 adopts a previously undescribed fold that interacts with Rab11 at an unusual effector-binding site neighboring the canonical FIP3-binding site. We show that Rab11-GMPPNP-FIP3-Rabin8 is more stable than Rab11-GMPPNP-Rabin8, owing to direct interaction between Rabin8 and FIP3 within the dual effector-bound complex. The data allow us to propose a model for how membrane-targeting complexes assemble at the trans-Golgi network and recycling endosomes, through multiple weak interactions that create high-avidity complexes.",x-ray diffraction,3.0,1,24,A,93.12169312169311%,37.03703703703704%,1411,191,2,2,"['MG', 'GNP']","GNP, MG, SO4, PG4","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, SULFATE ION, TETRAETHYLENE GLYCOL",active,13,10,16,1,13,12,13,8,10,17,13,13,4,8,3,7,12,1,13,,2
4UJ4,Crystal structure of human Rab11-Rabin8-FIP3,"RAS-RELATED PROTEIN RAB-11A, RAB-3A-INTERACTING PROTEIN, RAB11 FAMILY-INTERACTING PROTEIN 3",Homo sapiens,9606,"The small GTPase Rab11 and its effectors FIP3 and Rabin8 are essential to membrane-trafficking pathways required for cytokinesis and ciliogenesis. Although effector binding is generally assumed to be sequential and mutually exclusive, we show that Rab11 can simultaneously bind FIP3 and Rabin8. We determined crystal structures of human Rab11-GMPPNP-Rabin8 and Rab11-GMPPNP-FIP3-Rabin8. The structures reveal that the C-terminal domain of Rabin8 adopts a previously undescribed fold that interacts with Rab11 at an unusual effector-binding site neighboring the canonical FIP3-binding site. We show that Rab11-GMPPNP-FIP3-Rabin8 is more stable than Rab11-GMPPNP-Rabin8, owing to direct interaction between Rabin8 and FIP3 within the dual effector-bound complex. The data allow us to propose a model for how membrane-targeting complexes assemble at the trans-Golgi network and recycling endosomes, through multiple weak interactions that create high-avidity complexes.",x-ray diffraction,4.2,1,12,A,93.12169312169311%,37.03703703703704%,1398,178,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,0,10,16,1,13,12,13,8,10,17,13,13,4,8,3,7,12,1,13,,2
4UJ5,Crystal structure of human Rab11-Rabin8-FIP3,"RAS-RELATED PROTEIN RAB-11A, RAB-3A-INTERACTING PROTEIN",Homo sapiens,9606,"The small GTPase Rab11 and its effectors FIP3 and Rabin8 are essential to membrane-trafficking pathways required for cytokinesis and ciliogenesis. Although effector binding is generally assumed to be sequential and mutually exclusive, we show that Rab11 can simultaneously bind FIP3 and Rabin8. We determined crystal structures of human Rab11-GMPPNP-Rabin8 and Rab11-GMPPNP-FIP3-Rabin8. The structures reveal that the C-terminal domain of Rabin8 adopts a previously undescribed fold that interacts with Rab11 at an unusual effector-binding site neighboring the canonical FIP3-binding site. We show that Rab11-GMPPNP-FIP3-Rabin8 is more stable than Rab11-GMPPNP-Rabin8, owing to direct interaction between Rabin8 and FIP3 within the dual effector-bound complex. The data allow us to propose a model for how membrane-targeting complexes assemble at the trans-Golgi network and recycling endosomes, through multiple weak interactions that create high-avidity complexes.",x-ray diffraction,2.6,1,4,A,56.08465608465608%,37.03703703703704%,1367,213,3,3,"['MG', 'GNP', 'SO4']","GNP, MG, SO4","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, SULFATE ION",active,37,10,17,1,14,12,12,7,10,17,13,13,4,8,3,7,11,1,11,,2
4XOI,Structure of hsAnillin bound with RhoA(Q63L) at 2.1 Angstroms resolution,,Homo sapiens,9606,"Anillins and Mid1 are scaffold proteins that play key roles in anchorage of the contractile ring at the cell equator during cytokinesis in animals and fungi, respectively. Here, we report crystal structures and functional analysis of human anillin and S.pombe Mid1. The combined data show anillin contains acryptic C2 domain and a Rho-binding domain. Together with the tethering PH domain, three membrane-associating elements synergistically bind to RhoA and phospholipids to anchor anillin at the cleavage furrow. Surprisingly, Mid1 also binds to the membrane through a cryptic C2 domain. Dimerization of Mid1 leads to high affinity and preference for PI(4,5)P2, which stably anchors Mid1 at the division plane, bypassing the requirement for Rho GTPase. These findings uncover the unexpected general machinery and the divergent regulatory logics for the anchorage of the contractile ring through the anillin/Mid1 family proteins from yeast to humans.",x-ray diffraction,2.09,1,4,A,93.65079365079364%,31.818181818181817%,1495,237,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,58,10,11,5,6,8,16,5,14,14,16,10,4,7,2,6,15,11,10,5,2
4XSG,The complex structure of C3cer exoenzyme and GTP bound RhoA (NADH-free state),"Transforming protein RhoA, ADP-ribosyltransferase",Homo sapiens,9606,"C3 exoenzyme is a mono-ADP-ribosyltransferase (ART) that catalyzes transfer of an ADP-ribose moiety from NAD(+) to Rho GTPases. C3 has long been used to study the diverse regulatory functions of Rho GTPases. How C3 recognizes its substrate and how ADP-ribosylation proceeds are still poorly understood. Crystal structures of C3-RhoA complex reveal that C3 recognizes RhoA via the switch I, switch II, and interswitch regions. In C3-RhoA(GTP) and C3-RhoA(GDP), switch I and II adopt the GDP and GTP conformations, respectively, which explains why C3 can ADP-ribosylate both nucleotide forms. Based on structural information, we successfully changed Cdc42 to an active substrate with combined mutations in the C3-Rho GTPase interface. Moreover, the structure reflects the close relationship among Gln-183 in the QXE motif (C3), a modified Asn-41 residue (RhoA) and NC1 of NAD(H), which suggests that C3 is the prototype ART. These structures show directly for the first time that the ARTT loop is the key to target protein recognition, and they also serve to bridge the gaps among independent studies of Rho GTPases and C3.",x-ray diffraction,1.8,1,2,A,93.12169312169311%,32.55813953488372%,1579,328,2,2,"['MG', 'GSP']","GSP, MG, EDO","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION, 1,2-ETHANEDIOL",inactive,150,10,11,5,6,8,16,5,14,13,16,10,4,7,2,6,15,11,10,5,2
4XVQ,H-Ras Y137E,H-Ras (E.C.3.6.5.2),Homo sapiens,9606,"RAS proteins are signal transduction gatekeepers that mediate cell growth, survival, and differentiation through interactions with multiple effector proteins. The RAS effector RAS- and RAB-interacting protein 1 (RIN1) activates its own downstream effectors, the small GTPase RAB5 and the tyrosine kinase Abelson tyrosine-protein kinase (ABL), to modulate endocytosis and cytoskeleton remodeling. To identify ABL substrates downstream of RAS-to-RIN1 signaling, we examined human HEK293T cells overexpressing components of this pathway. Proteomic analysis revealed several novel phosphotyrosine peptides, including Harvey rat sarcoma oncogene (HRAS)-pTyr(137). Here we report that ABL phosphorylates tyrosine 137 of H-, K-, and NRAS. Increased RIN1 levels enhanced HRAS-Tyr(137) phosphorylation by nearly 5-fold, suggesting that RAS-stimulated RIN1 can drive ABL-mediated RAS modification in a feedback circuit. Tyr(137) is well conserved among RAS orthologs and is part of a transprotein H-bond network. Crystal structures of HRAS(Y137F) and HRAS(Y137E) revealed conformation changes radiating from the mutated residue. Although consistent with Tyr(137) participation in allosteric control of HRAS function, the mutations did not alter intrinsic GTP hydrolysis rates in vitro. HRAS-Tyr(137) phosphorylation enhanced HRAS signaling capacity in cells, however, as reflected by a 4-fold increase in the association of phosphorylated HRAS(G12V) with its effector protein RAF proto-oncogene serine/threonine protein kinase 1 (RAF1). These data suggest that RAS phosphorylation at Tyr(137) allosterically alters protein conformation and effector binding, providing a mechanism for effector-initiated modulation of RAS signaling.",x-ray diffraction,1.89,1,1,A,54.4973544973545%,99.3975903614458%,1389,250,4,4,"['MG', 'GNP', 'GOL']","MG, GNP, GOL","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, GLYCEROL",active,82,11,11,4,8,11,12,8,8,11,15,11,11,4,3,5,14,3,11,3,
4YC7,Crystal structure of human FMNL2 GBD-FH3 Domains bound to Cdc42-GppNHp,"FMNL2, Cdc42",Homo sapiens,9606,"Formins are actin polymerization factors that elongate unbranched actin filaments at the barbed end. Rho family GTPases activate Diaphanous-related formins through the relief of an autoregulatory interaction. The crystal structures of the N-terminal domains of human FMNL1 and FMNL2 in complex with active Cdc42 show that Cdc42 mediates contacts with all five armadillo repeats of the formin with specific interactions formed by the Rho-GTPase insert helix. Mutation of three residues within Rac1 results in a gain-of-function mutation for FMNL2 binding and reconstitution of the Cdc42 phenotype in vivo. Dimerization of FMNL1 through a parallel coiled coil segment leads to formation of an umbrella-shaped structure thattogether with Cdc42spans more than 15nm in diameter. The two interacting FMNL-Cdc42 heterodimers expose six membrane interaction motifs on a convex protein surface, the assembly of which may facilitate actin filament elongation at the leading edge of lamellipodia and filopodia.",x-ray diffraction,2.5,1,2,A,94.70899470899471%,33.33333333333333%,1457,210,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,29,9,12,2,9,16,12,7,14,17,18,8,6,5,2,8,11,12,5,5,1
4Z8Y,Crystal structure of Rab GTPase Sec4p mutant - S29V,Ras-related protein SEC4,Saccharomyces cerevisiae S288C,559292,"<h4>Background</h4>Sec4p is a small monomeric Ras-related GTP-binding protein (23kDa) that regulates polarized exocytosis in S. cerevisiae. In this study we examine the structural effects of a conserved serine residue in the P-loop corresponding to G12 in Ras.<h4>Results</h4>We show that the Sec4p residue serine 29 forms a hydrogen bond with the nucleotide. Mutations of this residue have a different impact than equivalent mutations in Ras and can form stable associations with the exchange factor allowing us to elucidate the structure of a complex of Sec4p bound to the exchange factor Sec2p representing an early stage of the exchange reaction.<h4>Conclusions</h4>Our structural investigation of the Sec4p-Sec2p complex reveals the role of the Sec2p coiled-coil domain in facilitating the fast kinetics of the exchange reaction. For Ras-family GTPases, single point mutations that impact the signaling state of the molecule have been well described however less structural information is available for equivalent mutations in the case of Rab proteins. Understanding the structural properties of mutants such as the one described here, provides useful insights into unique aspects of Rab GTPase function.",x-ray diffraction,1.9,1,2,A,69.31216931216932%,33.33333333333333%,1477,344,3,3,"['MG', 'ZN', 'GDP']","GDP, MG, ZN","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ZINC ION",inactive,181,11,10,3,5,12,11,3,15,14,13,15,6,9,1,9,12,2,6,1,2
521P,THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES,H-RAS P21 PROTEIN MUTANT WITH GLY 12 REPLACED BY VAL (G12V) COMPLEX WITH GUANOSINE TRIPHOSPHATE,Homo sapiens,9606,No abstract found,x-ray diffraction,2.6,1,1,A,87.83068783068782%,98.79518072289156%,1360,168,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,0,10,10,4,8,12,13,9,8,11,16,11,11,4,3,5,14,3,11,3,
5A0F,Crystal structure of Yersinia Afp18-modified RhoA,TRANSFORMING PROTEIN RHOA,Homo sapiens,9606,"Yersinia species cause zoonotic infections, including enterocolitis and plague. Here we studied Yersinia ruckeri antifeeding prophage 18 (Afp18), the toxin component of the phage tail-derived protein translocation system Afp, which causes enteric redmouth disease in salmonid fish species. Here we show that microinjection of the glycosyltransferase domain Afp18(G) into zebrafish embryos blocks cytokinesis, actin-dependent motility and cell blebbing, eventually abrogating gastrulation. In zebrafish ZF4 cells, Afp18(G) depolymerizes actin stress fibres by mono-O-GlcNAcylation of RhoA at tyrosine-34; thereby Afp18(G) inhibits RhoA activation by guanine nucleotide exchange factors, and blocks RhoA, but not Rac and Cdc42 downstream signalling. The crystal structure of tyrosine-GlcNAcylated RhoA reveals an open conformation of the effector loop distinct from recently described structures of GDP- or GTP-bound RhoA. Unravelling of the molecular mechanism of the toxin component Afp18 as glycosyltransferase opens new perspectives in studies of phage tail-derived protein translocation systems, which are preserved from archaea to human pathogenic prokaryotes.",x-ray diffraction,2.0,1,1,A,94.17989417989418%,32.38636363636363%,1526,261,3,3,"['SO4', 'NDG', 'GDP']","GDP, SO4, NDG","GUANOSINE-5'-DIPHOSPHATE, SULFATE ION, 2-acetamido-2-deoxy-alpha-D-glucopyranose",inactive,80,10,12,5,6,8,16,5,14,13,16,10,5,6,2,7,15,11,10,5,2
5CJP,The Structural Basis for Cdc42-Induced Dimerization of IQGAPs,"Cell division control protein 42 homolog, Ras GTPase-activating-like protein IQGAP2",Homo sapiens,9606,"In signaling, Rho-family GTPases bind effector proteins and alter their behavior. Here we present the crystal structure of Cdc42GTP bound to the GTPase-activating protein (GAP)-related domain (GRD) of IQGAP2. Four molecules of Cdc42 are bound to two GRD molecules, which bind each other in a parallel dimer. Two Cdc42s bind very similarly to the Ras/RasGAP interaction, while the other two bind primarily to ""extra domain"" sequences from both GRDs, tying the GRDs together. Calorimetry confirms two-site binding of Cdc42GTP for the GRDs of both IQGAP2 and IQGAP1. Mutation of important extra domain residues reduces binding to single-site and abrogates Cdc42 binding to a much larger IQGAP1 fragment. Importantly, Rac1GTP displays only single-site binding to the GRDs, indicating that only Cdc42 promotes IQGAP dimerization. The structure identifies an unexpected role for Cdc42 in protein dimerization, thus expanding the repertoire of interactions of Ras family proteins with their targets.",x-ray diffraction,2.6,1,6,A,93.65079365079364%,32.748538011695906%,1442,209,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,30,9,11,2,9,16,11,7,15,18,18,8,5,5,2,8,11,12,4,5,1
5E95,Crystal Structure of Mb(NS1)/H-Ras Complex,"Mb(NS1), GTPase HRas",Homo sapiens,9606,"RAS GTPases are important mediators of oncogenesis in humans. However, pharmacological inhibition of RAS has proved challenging. Here we describe a functionally critical region, located outside the effector lobe of RAS, that can be targeted for inhibition. We developed NS1, a synthetic binding protein (monobody) that bound with high affinity to both GTP- and GDP-bound states of H-RAS and K-RAS but not N-RAS. NS1 potently inhibited growth factor signaling and oncogenic H-RAS- and K-RAS-mediated signaling and transformation but did not block oncogenic N-RAS, BRAF or MEK1. NS1 bound the 4-6-5 region of RAS, which disrupted RAS dimerization and nanoclustering and led to blocking of CRAF-BRAF heterodimerization and activation. These results establish the importance of the 4-6-5 interface in RAS-mediated signaling and define a previously unrecognized site in RAS for inhibiting RAS function.",x-ray diffraction,1.4,1,2,A,88.88888888888889%,100.0%,1606,414,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,244,12,11,4,9,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
5EZ5,Crystal structure of active Rab11A (S20V) in complex with GTP,Ras-related protein Rab-11A,Homo sapiens,9606,No DOI found,x-ray diffraction,2.4,1,2,A,88.88888888888889%,37.65432098765432%,1349,176,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,6,10,16,1,11,12,12,8,9,16,13,13,4,8,3,7,10,1,12,,2
5FBL,PI4KB in complex with Rab11 and the MI356 Inhibitor,"Phosphatidylinositol 4-kinase beta,Phosphatidylinositol 4-kinase beta (E.C.2.7.1.67,2.7.1.67), Ras-related protein Rab-11A",Homo sapiens,9606,No DOI found,x-ray diffraction,3.37,1,2,B,54.4973544973545%,37.65432098765432%,1247,163,1,1,['GSP'],"5W9, GSP","~{N}-[2-[[6-chloranyl-3-(4-methoxy-3-morpholin-4-ylsulfonyl-phenyl)-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,0,9,15,1,12,12,11,6,9,16,13,13,3,8,3,7,10,1,11,,2
5FBR,PI4KB in complex with Rab11 and the MI359 Inhibitor,"Phosphatidylinositol 4-kinase beta,Phosphatidylinositol 4-kinase beta (E.C.2.7.1.67,2.7.1.67), Ras-related protein Rab-11A",Homo sapiens,9606,No DOI found,x-ray diffraction,3.28,1,2,B,55.55555555555556%,37.03703703703704%,1306,168,1,1,['GSP'],"5W7, GSP","~{N}-[2-[[3-[3-[(4-azanylcyclohexyl)sulfamoyl]-4-methoxy-phenyl]-6-chloranyl-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,0,10,16,1,13,12,11,7,9,16,13,13,4,8,3,7,10,1,11,,2
5HPY,Crystal Structure of RhoA.GDP.MgF3-in complex with human Myosin 9b RhoGAP domain,"Unconventional myosin-IXb, Transforming protein RhoA",Homo sapiens,9606,"The GTP hydrolysis activities of Rho GTPases are stimulated by GTPase-activating proteins (GAPs), which contain a RhoGAP domain equipped with a characteristic arginine finger and an auxiliary asparagine for catalysis. However, the auxiliary asparagine is missing in the RhoGAP domain of Myo9b (Myo9b-RhoGAP), a unique motorized RhoGAP that specifically targets RhoA for controlling cell motility. Here, we determined the structure of Myo9b-RhoGAP in complex with GDP-bound RhoA and magnesium fluoride. Unexpectedly, Myo9b-RhoGAP contains two arginine fingers at its catalytic site. The first arginine finger resembles the one within the canonical RhoGAP domains and inserts into the nucleotide-binding pocket of RhoA, whereas the second arginine finger anchors the Switch I loop of RhoA and interacts with the nucleotide, stabilizing the transition state of GTP hydrolysis and compensating for the lack of the asparagine. Mutating either of the two arginine fingers impaired the catalytic activity of Myo9b-RhoGAP and affected the Myo9b-mediated cell migration. Our data indicate that Myo9b-RhoGAP accelerates RhoA GTP hydrolysis by a previously unknown dual-arginine-finger mechanism, which may be shared by other noncanonical RhoGAP domains lacking the auxiliary asparagine.",x-ray diffraction,2.4,1,4,B,94.17989417989418%,32.38636363636363%,1471,226,3,3,"['MG', 'MGF', 'GDP']","MGF, MG, GDP","TRIFLUOROMAGNESATE, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,45,10,12,5,6,8,16,5,14,13,16,10,5,7,2,6,15,11,10,5,2
5HZK,Crystal structure of photoinhibitable Intersectin1 containing wildtype LOV2 domain in complex with Cdc42,"Cdc42, Intersectin1 containing wildtype LOV2 domain",Homo sapiens,9606,"Optogenetic and chemogenetic control of proteins has revealed otherwise inaccessible facets of signaling dynamics. Here, we use light- or ligand-sensitive domains to modulate the structural disorder of diverse proteins, thereby generating robust allosteric switches. Sensory domains were inserted into nonconserved, surface-exposed loops that were tight and identified computationally as allosterically coupled to active sites. Allosteric switches introduced into motility signaling proteins (kinases, guanosine triphosphatases, and guanine exchange factors) controlled conversion between conformations closely resembling natural active and inactive states, as well as modulated the morphodynamics of living cells. Our results illustrate a broadly applicable approach to design physiological protein switches.",x-ray diffraction,3.3,1,4,A,93.12169312169311%,32.10526315789474%,1401,177,1,1,['GDP'],"GDP, FMN","GUANOSINE-5'-DIPHOSPHATE, FLAVIN MONONUCLEOTIDE",inactive,0,9,11,1,9,16,12,7,14,17,18,8,5,5,2,8,11,12,5,5,1
5IRC,p190A GAP domain complex with RhoA,"Rho GTPase-activating protein 35, Transforming protein RhoA",Rattus norvegicus,10116,"RHO GTPase-activating proteins (RHOGAPs) are one of the major classes of regulators of the RHO-related protein family that are crucial in many cellular processes, motility, contractility, growth, differentiation, and development. Using database searches, we extracted 66 distinct human RHOGAPs, from which 57 have a common catalytic domain capable of terminating RHO protein signaling by stimulating the slow intrinsic GTP hydrolysis (GTPase) reaction. The specificity of the majority of the members of RHOGAP family is largely uncharacterized. Here, we comprehensively investigated the sequence-structure-function relationship between RHOGAPs and RHO proteins by combining our in vitro data with in silico data. The activity of 14 representatives of the RHOGAP family toward 12 RHO family proteins was determined in real time. We identified and structurally verified hot spots in the interface between RHOGAPs and RHO proteins as critical determinants for binding and catalysis. We have found that the RHOGAP domain itself is nonselective and in some cases rather inefficient under cell-free conditions. Thus, we propose that other domains of RHOGAPs confer substrate specificity and fine-tune their catalytic efficiency in cells.",x-ray diffraction,1.72,1,4,D,78.83597883597884%,32.38636363636363%,1548,365,4,4,"['MG', 'GDP', 'MGF', 'CSX']","CL, GDP, MG, MGF","CHLORIDE ION, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, TRIFLUOROMAGNESATE",inactive,191,10,12,5,5,8,15,5,13,13,16,10,4,7,2,5,14,10,10,4,2
5JCP,RhoGAP domain of ARAP3 in complex with RhoA in the transition state,"Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 3,Linker,Transforming protein RhoA",Homo sapiens,9606,"ARAP3 (Arf-GAP with Rho-GAP domain, ANK repeat, and PH domain-containing protein 3) is unique for its dual specificity GAPs (GTPase-activating protein) activity for Arf6 (ADP-ribosylation factor 6) and RhoA (Ras homolog gene family member A) regulated by phosphatidylinositol 3,4,5-trisphosphate and a small GTPase Rap1-GTP and is involved in regulation of cell shape and adhesion. However, the molecular interface between the ARAP3-RhoGAP domain and RhoA is unknown, as is the substrates specificity of the RhoGAP domain. In this study, we solved the crystal structure of RhoA in complex with the RhoGAP domain of ARAP3. The structure of the complex presented a clear interface between the RhoGAP domain and RhoA. By analyzing the crystal structure and in combination with in vitro GTPase activity assays and isothermal titration calorimetry experiments, we identified the crucial residues affecting RhoGAP activity and substrates specificity among RhoA, Rac1 (Ras-related C3 botulinum toxin substrate 1), and Cdc42 (cell division control protein 42 homolog).",x-ray diffraction,2.1,1,2,A,74.07407407407408%,32.38636363636363%,2906,440,3,3,"['MG', 'ALF', 'GDP']","GDP, MG, ALF","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, TETRAFLUOROALUMINATE ION",inactive,76,23,26,7,14,16,27,8,20,37,29,20,16,11,6,12,28,16,33,9,3
5JCZ,Rab11 bound to MyoVa-GTD,"Ras-related protein Rab-11A, Unconventional myosin-Va",Homo sapiens,9606,"There is growing evidence for a coupling of actin assembly and myosin motor activity in cells. However, mechanisms for recruitment of actin nucleators and motors on specific membrane compartments remain unclear. Here we report how Spir actin nucleators and myosin V motors coordinate their specific membrane recruitment. The myosin V globular tail domain (MyoV-GTD) interacts directly with an evolutionarily conserved Spir sequence motif. We determined crystal structures of MyoVa-GTD bound either to the Spir-2 motif or to Rab11 and show that a Spir-2:MyoVa:Rab11 complex can form. The ternary complex architecture explains how Rab11 vesicles support coordinated F-actin nucleation and myosin force generation for vesicle transport and tethering. New insights are also provided into how myosin activation can be coupled with the generation of actin tracks. Since MyoV binds several Rab GTPases, synchronized nucleator and motor targeting could provide a common mechanism to control force generation and motility in different cellular processes.",x-ray diffraction,2.06,1,6,A,91.005291005291%,37.65432098765432%,1630,390,8,8,"['EDO', 'ACT', 'BEF', 'MG', 'GDP', 'GOL']","MG, GDP, BEF, EDO, ACT, GOL","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, BERYLLIUM TRIFLUORIDE ION, 1,2-ETHANEDIOL, ACETATE ION, GLYCEROL",inactive,210,10,16,1,13,12,13,8,9,16,13,13,4,8,3,7,11,1,12,,2
5LEF,Rab6A:Kif20A complex,"Ras-related protein Rab-6A, Kinesin-like protein KIF20A",Homo sapiens,9606,"The actin and microtubule cytoskeletons play important roles in Golgi structure and function, but how they are connected remain poorly known. In this study, we investigated whether RAB6 GTPase, a Golgi-associated RAB involved in the regulation of several transport steps at the Golgi level, and two of its effectors, Myosin IIA and KIF20A participate in the coupling between actin and microtubule cytoskeleton. We have previously shown that RAB6-Myosin IIA interaction is critical for the fission of RAB6-positive transport carriers from Golgi/TGN membranes. Here we show that KIF20A is also involved in the fission process and serves to anchor RAB6 on Golgi/TGN membranes near microtubule nucleating sites. We provide evidence that the fission events occur at a limited number of hotspots sites. Our results suggest that coupling between actin and microtubule cytoskeletons driven by Myosin II and KIF20A ensures the spatial coordination between RAB6-positive vesicles fission from Golgi/TGN membranes and their exit along microtubules.",x-ray diffraction,2.09,1,4,A,87.83068783068782%,31.645569620253166%,2853,322,4,4,"['GTP', 'MG', 'GOL', 'SO4']","GTP, MG, SO4, GOL, IPA","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, SULFATE ION, GLYCEROL, ISOPROPYL ALCOHOL",active,152,9,10,4,11,14,9,6,11,15,15,11,7,6,,9,12,2,13,,2
5LPN,Structure of human Rab10 in complex with the bMERB domain of Mical-1,"Ras-related protein Rab-10, Protein-methionine sulfoxide oxidase MICAL1 (E.C.1.14.13.-)",Homo sapiens,9606,"In their active GTP-bound form, Rab proteins interact with proteins termed effector molecules. In this study, we have thoroughly characterized a Rab effector domain that is present in proteins of the Mical and EHBP families, both known to act in endosomal trafficking. Within our study, we show that these effectors display a preference for Rab8 family proteins (Rab8, 10, 13 and 15) and that some of the effector domains can bind two Rab proteins via separate binding sites. Structural analysis allowed us to explain the specificity towards Rab8 family members and the presence of two similar Rab binding sites that must have evolved via gene duplication. This study is the first to thoroughly characterize a Rab effector protein that contains two separate Rab binding sites within a single domain, allowing Micals and EHBPs to bind two Rabs simultaneously, thus suggesting previously unknown functions of these effector molecules in endosomal trafficking.",x-ray diffraction,2.8,1,3,A,90.47619047619048%,35.80246913580247%,1398,175,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,2,13,9,4,7,14,11,4,16,15,7,17,4,8,3,11,13,2,9,2,2
5M6X,Crystal Structure of human RhoGAP mutated in its arginine finger (R85A) in complex with RhoA.GDP.MgF3- human,"Rho GTPase-activating protein 1, Transforming protein RhoA",Homo sapiens,9606,"We report X-ray crystallographic and <sup>19</sup> FNMR studies of the G-protein RhoA complexed with MgF<sub>3</sub><sup>-</sup> , GDP, and RhoGAP, which has the mutation Arg85'Ala. When combined with DFT calculations, these data permit the identification of changes in transition state (TS) properties. The X-ray data show how Tyr34 maintains solvent exclusion and the core H-bond network in the active site by relocating to replace the missing Arg85' sidechain. The <sup>19</sup> FNMR data show deshielding effects that indicate the main function of Arg85' is electronic polarization of the transferring phosphoryl group, primarily mediated by H-bonding to O<sup>3G</sup> and thence to P<sup>G</sup> . DFT calculations identify electron-density redistribution and pinpoint why the TS for guanosine 5'-triphosphate (GTP) hydrolysis is higher in energy when RhoA is complexed with RhoGAP<sub>Arg85'Ala</sub> relative to wild-type (WT) RhoGAP. This study demonstrates that <sup>19</sup> FNMR measurements, in combination with X-ray crystallography and DFT calculations, can reliably dissect the response of small GTPases to site-specific modifications.",x-ray diffraction,2.4,1,4,B,94.17989417989418%,32.02247191011236%,1482,220,3,3,"['MG', 'MGF', 'GDP']","MG, GDP, MGF","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, TRIFLUOROMAGNESATE",inactive,39,10,12,5,6,8,16,5,14,13,16,10,5,7,2,6,15,11,10,5,2
5MLA,Crystal structure of human RAS in complex with darpin K55,"GTPase KRas, darpin k55",Homo sapiens,9606,No DOI found,x-ray diffraction,2.19,1,2,A,86.77248677248677%,93.37349397590361%,1388,230,3,3,"['MG', 'SO4', 'GSP']","MG, GSP, SO4","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, SULFATE ION",inactive,63,10,9,4,8,12,12,8,9,11,16,11,9,4,3,6,15,4,10,3,
5N6O,Wild type human Rac1-GDP,Ras-related C3 botulinum toxin substrate 1.,Homo sapiens,9606,"Rac small GTPases and their GEFs of the DOCK family are pivotal checkpoints in development, autoimmunity and bone homeostasis, and their abnormal regulation is associated to diverse pathologies. Small molecules that inhibit their activities are therefore needed to investigate their functions. Here, we characterized the mechanism of inhibition of human DOCK5 by C21, a small molecule that inhibits mouse Dock5 in cells and blocks bone degradation in mice models of osteoporosis. We showed that the catalytic DHR2 domain of DOCK5 has a high basal GEF activity in the absence of membranes which is not regulated by a simple feedback loop. C21 blocks this activity in a non-competitive manner and is specific for DOCK5. In contrast, another Dock inhibitor, CPYPP, inhibits both DOCK5 and an unrelated GEF, Trio. To gain insight into structural features of the inhibitory mechanism of C21, we used SAXS analysis of DOCK5<sup>DHR2</sup> and crystallographic analysis of unbound Rac1-GDP. Together, these data suggest that C21 takes advantage of intramolecular dynamics of DOCK5 and Rac1 to remodel the complex into an unproductive conformation. Based on this allosteric mechanism, we propose that diversion of intramolecular dynamics is a potent mechanism for the inhibition of multidomain regulators of small GTPases.",x-ray diffraction,2.59,1,2,A,93.12169312169311%,31.60919540229885%,1439,201,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,23,11,13,2,7,13,9,8,13,18,16,10,5,6,2,6,12,11,7,5,2
5OCO,Discovery of small molecules binding to KRAS via high affinity antibody fragment competition method.,GTPase KRas,Homo sapiens,9606,"Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition. A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site. Here, we explore this strategy using an anti-mutant RAS antibody fragment as a competitor in a small-molecule library screen for identifying RAS-binding compounds. The initial hits are optimized by structure-based design, resulting in potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector interactions and inhibit endogenous RAS-dependent signalling. Our results may aid RAS-dependent cancer drug development and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.",x-ray diffraction,1.66,1,6,A,61.904761904761905%,92.81437125748504%,1569,314,5,5,"['CIT', 'MG', 'CSO', 'GNP']","GNP, 9RK, PEG, MG, CIT","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, ~{N}-[[(3~{R})-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]furan-2-carboxamide, DI(HYDROXYETHYL)ETHER, MAGNESIUM ION, CITRIC ACID",active,138,12,9,4,8,12,13,9,11,11,15,11,9,4,5,7,15,4,10,2,
5SZH,Structure of human Rab1b in complex with the bMERB domain of Mical-cL,"MICAL C-terminal-like protein, Ras-related protein Rab-1B",Homo sapiens,9606,"In their active GTP-bound form, Rab proteins interact with proteins termed effector molecules. In this study, we have thoroughly characterized a Rab effector domain that is present in proteins of the Mical and EHBP families, both known to act in endosomal trafficking. Within our study, we show that these effectors display a preference for Rab8 family proteins (Rab8, 10, 13 and 15) and that some of the effector domains can bind two Rab proteins via separate binding sites. Structural analysis allowed us to explain the specificity towards Rab8 family members and the presence of two similar Rab binding sites that must have evolved via gene duplication. This study is the first to thoroughly characterize a Rab effector protein that contains two separate Rab binding sites within a single domain, allowing Micals and EHBPs to bind two Rabs simultaneously, thus suggesting previously unknown functions of these effector molecules in endosomal trafficking.",x-ray diffraction,2.3,1,2,B,92.5925925925926%,35.02824858757062%,1431,198,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,21,11,12,4,11,16,11,9,14,15,11,13,6,8,2,7,13,2,7,1,2
5SZI,Structure of human Rab8a in complex with the bMERB domain of Mical-cL,"Ras-related protein Rab-8A, MICAL C-terminal-like protein",Homo sapiens,9606,"In their active GTP-bound form, Rab proteins interact with proteins termed effector molecules. In this study, we have thoroughly characterized a Rab effector domain that is present in proteins of the Mical and EHBP families, both known to act in endosomal trafficking. Within our study, we show that these effectors display a preference for Rab8 family proteins (Rab8, 10, 13 and 15) and that some of the effector domains can bind two Rab proteins via separate binding sites. Structural analysis allowed us to explain the specificity towards Rab8 family members and the presence of two similar Rab binding sites that must have evolved via gene duplication. This study is the first to thoroughly characterize a Rab effector protein that contains two separate Rab binding sites within a single domain, allowing Micals and EHBPs to bind two Rabs simultaneously, thus suggesting previously unknown functions of these effector molecules in endosomal trafficking.",x-ray diffraction,2.85,1,2,A,92.06349206349206%,35.91160220994475%,1365,178,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,2,11,12,5,8,12,11,6,18,12,7,18,3,10,1,11,14,,11,2,2
5SZJ,Structure of human Rab10 in complex with the bMERB domain of Mical-cL,"Ras-related protein Rab-10, MICAL C-terminal-like protein",Homo sapiens,9606,"In their active GTP-bound form, Rab proteins interact with proteins termed effector molecules. In this study, we have thoroughly characterized a Rab effector domain that is present in proteins of the Mical and EHBP families, both known to act in endosomal trafficking. Within our study, we show that these effectors display a preference for Rab8 family proteins (Rab8, 10, 13 and 15) and that some of the effector domains can bind two Rab proteins via separate binding sites. Structural analysis allowed us to explain the specificity towards Rab8 family members and the presence of two similar Rab binding sites that must have evolved via gene duplication. This study is the first to thoroughly characterize a Rab effector protein that contains two separate Rab binding sites within a single domain, allowing Micals and EHBPs to bind two Rabs simultaneously, thus suggesting previously unknown functions of these effector molecules in endosomal trafficking.",x-ray diffraction,2.66,1,2,A,92.5925925925926%,34.04255319148936%,1432,200,2,2,"['MG', 'GNP']","GNP, MG, PEG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, DI(HYDROXYETHYL)ETHER",active,23,13,10,5,7,14,11,4,18,15,7,17,4,8,3,11,13,2,9,2,2
5SZK,Structure of human N-terminally engineered Rab1b in complex with the bMERB domain of Mical-cL,"MICAL C-terminal-like protein, Ras-related protein Rab-1B",Homo sapiens,9606,"In their active GTP-bound form, Rab proteins interact with proteins termed effector molecules. In this study, we have thoroughly characterized a Rab effector domain that is present in proteins of the Mical and EHBP families, both known to act in endosomal trafficking. Within our study, we show that these effectors display a preference for Rab8 family proteins (Rab8, 10, 13 and 15) and that some of the effector domains can bind two Rab proteins via separate binding sites. Structural analysis allowed us to explain the specificity towards Rab8 family members and the presence of two similar Rab binding sites that must have evolved via gene duplication. This study is the first to thoroughly characterize a Rab effector protein that contains two separate Rab binding sites within a single domain, allowing Micals and EHBPs to bind two Rabs simultaneously, thus suggesting previously unknown functions of these effector molecules in endosomal trafficking.",x-ray diffraction,2.8,1,2,B,91.53439153439153%,35.02824858757062%,1409,176,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,1,10,13,4,11,17,10,9,15,15,11,13,6,7,1,7,13,1,7,1,2
5TAR,Crystal structure of farnesylated and methylated kras4b in complex with PDE-delta (crystal form II - with ordered hypervariable region),"GTPase KRas, Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta",Homo sapiens,9606,"Farnesylation and carboxymethylation of KRAS4b (Kirsten rat sarcoma isoform 4b) are essential for its interaction with the plasma membrane where KRAS-mediated signaling events occur. Phosphodiesterase- (PDE) binds to KRAS4b and plays an important role in targeting it to cellular membranes. We solved structures of human farnesylated-methylated KRAS4b in complex with PDE in two different crystal forms. In these structures, the interaction is driven by the C-terminal amino acids together with the farnesylated and methylated C185 of KRAS4b that binds tightly in the central hydrophobic pocket present in PDE. In crystal form II, we see the full-length structure of farnesylated-methylated KRAS4b, including the hypervariable region. Crystal form I reveals structural details of farnesylated-methylated KRAS4b binding to PDE, and crystal form II suggests the potential binding mode of geranylgeranylated-methylated KRAS4b to PDE. We identified a 5-aa-long sequence motif (Lys-Ser-Lys-Thr-Lys) in KRAS4b that may enable PDE to bind both forms of prenylated KRAS4b. Structure and sequence analysis of various prenylated proteins that have been previously tested for binding to PDE provides a rationale for why some prenylated proteins, such as KRAS4a, RalA, RalB, and Rac1, do not bind to PDE. Comparison of all four available structures of PDE complexed with various prenylated proteins/peptides shows the presence of additional interactions due to a larger protein-protein interaction interface in KRAS4b-PDE complex. This interface might be exploited for designing an inhibitor with minimal off-target effects.",x-ray diffraction,1.9,1,2,A,97.35449735449735%,93.97590361445783%,1537,211,3,3,"['FAR', 'CMT', 'GDP']","FAR, GDP, EDO","FARNESYL, GUANOSINE-5'-DIPHOSPHATE, 1,2-ETHANEDIOL",inactive,24,13,9,4,10,13,13,8,21,11,15,11,9,4,4,6,16,4,10,3,
5UB8,"Crystal structure of YPT31, a Rab family GTPase from Candida albicans, in complex with GDP and Zn(II)",Likely rab family GTP-binding protein,Candida albicans SC5314,237561,No DOI found,x-ray diffraction,2.35,1,1,A,73.01587301587301%,33.95061728395062%,1562,304,3,3,"['ZN', 'GDP']","GDP, ZN","GUANOSINE-5'-DIPHOSPHATE, ZINC ION",inactive,127,9,15,2,14,8,17,11,11,19,10,12,4,9,4,6,11,1,9,,2
5UFE,Wild-type K-Ras(GNP)/R11.1.6 complex,"GTPase KRas, R11.1.6",Homo sapiens,9606,"Ras is at the hub of signal transduction pathways controlling cell proliferation and survival. Its mutants, present in about 30% of human cancers, are major drivers of oncogenesis and render tumors unresponsive to standard therapies. Here we report the engineering of a protein scaffold for preferential binding to K-Ras G12D. This is the first reported inhibitor to achieve nanomolar affinity while exhibiting specificity for mutant over wild type (WT) K-Ras. Crystal structures of the protein R11.1.6 in complex with K-Ras WT and K-Ras G12D offer insight into the structural basis for specificity, highlighting differences in the switch I conformation as the major defining element in the higher affinity interaction. R11.1.6 directly blocks interaction with Raf and reduces signaling through the Raf/MEK/ERK pathway. Our results support greater consideration of the state of switch I and provide a novel tool to study Ras biology. Most importantly, this work makes an unprecedented contribution to Ras research in inhibitor development strategy by revealing details of a targetable binding surface. Unlike the polar interfaces found for Ras/effector interactions, the K-Ras/R11.1.6 complex reveals an extensive hydrophobic interface that can serve as a template to advance the development of high affinity, non-covalent inhibitors of K-Ras oncogenic mutants.",x-ray diffraction,2.3,1,2,A,87.83068783068782%,93.97590361445783%,1431,259,14,14,"['CA', 'CL', 'MG', 'GNP', 'CO', 'CD']","GNP, CA, CD, CL, MG, CO","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, CALCIUM ION, CADMIUM ION, CHLORIDE ION, MAGNESIUM ION, COBALT (II) ION",active,79,11,9,4,8,12,12,8,10,11,15,11,9,4,4,6,15,4,10,3,
5UFQ,K-RasG12D(GNP)/R11.1.6 complex,"GTPase KRas, R11.1.6",Homo sapiens,9606,"Ras is at the hub of signal transduction pathways controlling cell proliferation and survival. Its mutants, present in about 30% of human cancers, are major drivers of oncogenesis and render tumors unresponsive to standard therapies. Here we report the engineering of a protein scaffold for preferential binding to K-Ras G12D. This is the first reported inhibitor to achieve nanomolar affinity while exhibiting specificity for mutant over wild type (WT) K-Ras. Crystal structures of the protein R11.1.6 in complex with K-Ras WT and K-Ras G12D offer insight into the structural basis for specificity, highlighting differences in the switch I conformation as the major defining element in the higher affinity interaction. R11.1.6 directly blocks interaction with Raf and reduces signaling through the Raf/MEK/ERK pathway. Our results support greater consideration of the state of switch I and provide a novel tool to study Ras biology. Most importantly, this work makes an unprecedented contribution to Ras research in inhibitor development strategy by revealing details of a targetable binding surface. Unlike the polar interfaces found for Ras/effector interactions, the K-Ras/R11.1.6 complex reveals an extensive hydrophobic interface that can serve as a template to advance the development of high affinity, non-covalent inhibitors of K-Ras oncogenic mutants.",x-ray diffraction,2.2,1,4,A,87.83068783068782%,93.37349397590361%,1391,223,6,6,"['CA', 'CL', 'MG', 'GNP', 'CD']","GNP, MG, CL, CA, CD","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, CHLORIDE ION, CALCIUM ION, CADMIUM ION",active,51,10,9,4,8,12,12,8,10,11,15,11,9,4,4,6,16,4,10,3,
5UHV,wild-type NRas bound to GppNHp,GTPase NRas,Homo sapiens,9606,"H-Ras, K-Ras, and N-Ras are small GTPases that are important in the control of cell proliferation, differentiation, and survival, and their mutants occur frequently in human cancers. The G-domain, which catalyzes GTP hydrolysis and mediates downstream signaling, is 95% conserved between the Ras isoforms. Because of their very high sequence identity, biochemical studies done on H-Ras have been considered representative of all three Ras proteins. We show here that this is not a valid assumption. Using enzyme kinetic assays under identical conditions, we observed clear differences between the three isoforms in intrinsic catalysis of GTP by Ras in the absence and presence of the Ras-binding domain (RBD) of the c-Raf kinase protein (Raf-RBD). Given their identical active sites, isoform G-domain differences must be allosteric in origin, due to remote isoform-specific residues that affect conformational states. We present the crystal structure of N-Ras bound to a GTP analogue and interpret the kinetic data in terms of structural features specific for H-, K-, and N-Ras.",x-ray diffraction,1.67,1,1,A,87.83068783068782%,91.56626506024097%,1451,312,3,3,"['MG', 'GNP', 'GOL']","GNP, MG, GOL","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL",active,143,11,10,4,8,12,12,9,10,12,15,11,9,5,2,6,14,4,9,3,
5UQW,Crystal structure of human KRAS G12V mutant in complex with GDP,GTPase KRas (E.C.3.6.5.-),Homo sapiens,9606,"Design of small molecules that disrupt protein-protein interactions, including the interaction of RAS proteins and their effectors, may providechemical probes and therapeutic agents. We describe here the synthesis and testing of potential small-molecule pan-RAS ligands, which were designed to interact with adjacent sites on the surface of oncogenic KRAS. One compound, termed 3144, was found tobind to RAS proteins using microscale thermophoresis, nuclear magnetic resonance spectroscopy, and isothermal titration calorimetry and to exhibit lethality in cells partially dependent on expression of RAS proteins. This compound was metabolically stable in liver microsomes and displayed anti-tumor activity in xenograft mouse cancer models. These findings suggest that pan-RAS inhibition may be an effective therapeutic strategy for some cancers and that structure-based design of small molecules targeting multiple adjacent sites to create multivalent inhibitors may be effective for some proteins.",x-ray diffraction,1.5,1,2,A,88.88888888888889%,93.41317365269461%,1523,327,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,157,10,9,4,8,12,13,8,11,11,16,11,9,4,4,6,15,4,10,3,
5US4,Crystal structure of human KRAS G12D mutant in complex with GDP,GTPase KRas,Homo sapiens,9606,"Design of small molecules that disrupt protein-protein interactions, including the interaction of RAS proteins and their effectors, may providechemical probes and therapeutic agents. We describe here the synthesis and testing of potential small-molecule pan-RAS ligands, which were designed to interact with adjacent sites on the surface of oncogenic KRAS. One compound, termed 3144, was found tobind to RAS proteins using microscale thermophoresis, nuclear magnetic resonance spectroscopy, and isothermal titration calorimetry and to exhibit lethality in cells partially dependent on expression of RAS proteins. This compound was metabolically stable in liver microsomes and displayed anti-tumor activity in xenograft mouse cancer models. These findings suggest that pan-RAS inhibition may be an effective therapeutic strategy for some cancers and that structure-based design of small molecules targeting multiple adjacent sites to create multivalent inhibitors may be effective for some proteins.",x-ray diffraction,1.83,1,2,A,55.55555555555556%,93.41317365269461%,1466,287,3,3,"['MG', 'GOL', 'GDP']","GDP, MG, GOL","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, GLYCEROL",inactive,120,9,9,4,8,12,11,7,12,11,15,11,8,4,4,6,16,4,10,3,
5VBE,Crystal Structure of Small Molecule Disulfide 2C07 Bound to H-Ras M72C GDP,GTPase HRas,Homo sapiens,9606,"Covalent inhibitors of K-Ras(G12C) have been reported that exclusively recognize the GDP state. Here, we utilize disulfide tethering of a non-natural cysteine (K-Ras(M72C)) to identify a new switch-II pocket (S-IIP) binding ligand (2C07) that engages the active GTP state. Co-crystal structures of 2C07 bound to H-Ras(M72C) reveal binding in a cryptic groove we term S-IIG. In the GppNHp state, 2C07 binding to a modified S-IIP pushes switch I away from the nucleotide, breaking the network of polar contacts essential for adopting the canonical GTP state. Biochemical studies show that 2C07 alters nucleotide preference and inhibits SOS binding and catalyzed nucleotide exchange. 2C07 was converted to irreversible covalent analogs, which target both nucleotide states, inhibit PI3K activation invitro, and function as occupancy probes to detect reversible engagement in competition assays. Targeting both nucleotide states opens the possibility of inhibiting oncogenic mutants of Ras, which exist predominantly in the GTP state in cells.",x-ray diffraction,1.57,1,1,A,53.96825396825397%,99.3975903614458%,2705,263,3,3,"['92V', 'MG', 'GDP']","GDP, 92V, MG","GUANOSINE-5'-DIPHOSPHATE, 1-(4-methoxyphenyl)-N-(3-sulfanylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide, MAGNESIUM ION",inactive,97,11,11,3,8,11,11,8,8,11,15,11,11,4,3,5,14,3,11,4,
5VBM,Crystal Structure of Small Molecule Disulfide 2C07 Bound to K-Ras Cys Light M72C GDP,GTPase KRas,Homo sapiens,9606,"Covalent inhibitors of K-Ras(G12C) have been reported that exclusively recognize the GDP state. Here, we utilize disulfide tethering of a non-natural cysteine (K-Ras(M72C)) to identify a new switch-II pocket (S-IIP) binding ligand (2C07) that engages the active GTP state. Co-crystal structures of 2C07 bound to H-Ras(M72C) reveal binding in a cryptic groove we term S-IIG. In the GppNHp state, 2C07 binding to a modified S-IIP pushes switch I away from the nucleotide, breaking the network of polar contacts essential for adopting the canonical GTP state. Biochemical studies show that 2C07 alters nucleotide preference and inhibits SOS binding and catalyzed nucleotide exchange. 2C07 was converted to irreversible covalent analogs, which target both nucleotide states, inhibit PI3K activation invitro, and function as occupancy probes to detect reversible engagement in competition assays. Targeting both nucleotide states opens the possibility of inhibiting oncogenic mutants of Ras, which exist predominantly in the GTP state in cells.",x-ray diffraction,1.49,1,1,A,56.613756613756614%,91.61676646706587%,2826,276,3,3,"['MG', '92V', 'GDP']","MG, GDP, 92V","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1-(4-methoxyphenyl)-N-(3-sulfanylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide",inactive,105,12,9,3,10,12,12,8,12,12,15,11,8,4,4,6,15,4,10,1,
5VCU,Crystal structure of ras-related c3 botulinum toxin substrate 1 isoform x2 from Naegleria fowleri in complex with GDP,Ras-related c3 botulinum toxin substrate 1 isoform x2,Naegleria fowleri,5763,No DOI found,x-ray diffraction,1.85,1,2,A,98.4126984126984%,31.57894736842105%,1699,422,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,234,10,12,5,10,10,15,10,19,15,13,11,4,9,2,5,15,11,3,6,1
5VP7,Crystal structure of human KRAS G12A mutant in complex with GDP,GTPase KRas,Homo sapiens,9606,"K-Ras, a molecular switch that regulates cell growth, apoptosis and metabolism, is activated when it undergoes a conformation change upon binding GTP and is deactivated following the hydrolysis of GTP to GDP. Hydrolysis of GTP in water is accelerated by coordination to K-Ras, where GTP adopts a high-energy conformation approaching the transition state. The G12A mutation reduces intrinsic K-Ras GTP hydrolysis by an unexplained mechanism. Here, crystal structures of G12A K-Ras in complex with GDP, GTP, GTPS and GppNHp, and of Q61A K-Ras in complex with GDP, are reported. In the G12A K-Ras-GTP complex, the switch I region undergoes a significant reorganization such that the Tyr32 side chain points towards the GTP-binding pocket and forms a hydrogen bond to the GTP -phosphate, effectively stabilizing GTP in its precatalytic state, increasing the activation energy required to reach the transition state and contributing to the reduced intrinsic GTPase activity of G12A K-Ras mutants.",x-ray diffraction,1.7,1,2,A,89.94708994708994%,92.81437125748504%,1496,269,4,4,"['MG', 'PGE', 'NA', 'GDP']","GDP, MG, PGE, NA","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, TRIETHYLENE GLYCOL, SODIUM ION",inactive,95,10,10,4,9,12,13,8,12,11,15,11,9,4,5,6,15,4,10,2,
5VQ1,Crystal structure of human KRAS Q61A mutant in complex with GDP,GTPase KRas,Homo sapiens,9606,"K-Ras, a molecular switch that regulates cell growth, apoptosis and metabolism, is activated when it undergoes a conformation change upon binding GTP and is deactivated following the hydrolysis of GTP to GDP. Hydrolysis of GTP in water is accelerated by coordination to K-Ras, where GTP adopts a high-energy conformation approaching the transition state. The G12A mutation reduces intrinsic K-Ras GTP hydrolysis by an unexplained mechanism. Here, crystal structures of G12A K-Ras in complex with GDP, GTP, GTPS and GppNHp, and of Q61A K-Ras in complex with GDP, are reported. In the G12A K-Ras-GTP complex, the switch I region undergoes a significant reorganization such that the Tyr32 side chain points towards the GTP-binding pocket and forms a hydrogen bond to the GTP -phosphate, effectively stabilizing GTP in its precatalytic state, increasing the activation energy required to reach the transition state and contributing to the reduced intrinsic GTPase activity of G12A K-Ras mutants.",x-ray diffraction,1.78,1,2,A,55.55555555555556%,92.81437125748504%,1434,248,2,2,"['MG', 'GDP']","GDP, MG, PG4","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, TETRAETHYLENE GLYCOL",inactive,79,11,10,4,9,12,11,7,12,11,15,11,8,4,5,6,15,4,10,2,
5WDO,H-Ras bound to GMP-PNP at 277K,GTPase HRas (E.C.3.6.5.2),Homo sapiens,9606,"Ras proteins are highly conserved signaling molecules that exhibit regulated, nucleotide-dependent switching between active and inactive states. The high conservation of Ras requires mechanistic explanation, especially given the general mutational tolerance of proteins. Here, we use deep mutational scanning, biochemical analysis and molecular simulations to understand constraints on Ras sequence. Ras exhibits global sensitivity to mutation when regulated by a GTPase activating protein and a nucleotide exchange factor. Removing the regulators shifts the distribution of mutational effects to be largely neutral, and reveals hotspots of activating mutations in residues that restrain Ras dynamics and promote the inactive state. Evolutionary analysis, combined with structural and mutational data, argue that Ras has co-evolved with its regulators in the vertebrate lineage. Overall, our results show that sequence conservation in Ras depends strongly on the biochemical network in which it operates, providing a framework for understanding the origin of global selection pressures on proteins.",x-ray diffraction,1.65,1,1,A,87.83068783068782%,100.0%,2787,300,5,5,"['CA', 'MG', 'GNP', 'NA']","CA, MG, NA, GNP","CALCIUM ION, MAGNESIUM ION, SODIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,129,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
5WDP,H-Ras mutant L120A bound to GMP-PNP at 277K,GTPase HRas (E.C.3.6.5.2),Homo sapiens,9606,"Ras proteins are highly conserved signaling molecules that exhibit regulated, nucleotide-dependent switching between active and inactive states. The high conservation of Ras requires mechanistic explanation, especially given the general mutational tolerance of proteins. Here, we use deep mutational scanning, biochemical analysis and molecular simulations to understand constraints on Ras sequence. Ras exhibits global sensitivity to mutation when regulated by a GTPase activating protein and a nucleotide exchange factor. Removing the regulators shifts the distribution of mutational effects to be largely neutral, and reveals hotspots of activating mutations in residues that restrain Ras dynamics and promote the inactive state. Evolutionary analysis, combined with structural and mutational data, argue that Ras has co-evolved with its regulators in the vertebrate lineage. Overall, our results show that sequence conservation in Ras depends strongly on the biochemical network in which it operates, providing a framework for understanding the origin of global selection pressures on proteins.",x-ray diffraction,1.35,1,1,A,87.83068783068782%,99.3975903614458%,2773,285,5,5,"['CA', 'MG', 'GNP']","CA, GNP, MG","CALCIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,114,11,12,4,8,11,13,9,8,10,15,11,11,4,3,5,14,3,11,3,
5WDQ,H-Ras mutant L120A bound to GMP-PNP at 100K,GTPase HRas (E.C.3.6.5.2),Homo sapiens,9606,"Ras proteins are highly conserved signaling molecules that exhibit regulated, nucleotide-dependent switching between active and inactive states. The high conservation of Ras requires mechanistic explanation, especially given the general mutational tolerance of proteins. Here, we use deep mutational scanning, biochemical analysis and molecular simulations to understand constraints on Ras sequence. Ras exhibits global sensitivity to mutation when regulated by a GTPase activating protein and a nucleotide exchange factor. Removing the regulators shifts the distribution of mutational effects to be largely neutral, and reveals hotspots of activating mutations in residues that restrain Ras dynamics and promote the inactive state. Evolutionary analysis, combined with structural and mutational data, argue that Ras has co-evolved with its regulators in the vertebrate lineage. Overall, our results show that sequence conservation in Ras depends strongly on the biochemical network in which it operates, providing a framework for understanding the origin of global selection pressures on proteins.",x-ray diffraction,1.25,1,1,A,87.83068783068782%,99.3975903614458%,2838,342,10,10,"['CA', 'NA', 'ACT', 'MG', 'GNP']","GNP, CA, MG, NA, ACT","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, CALCIUM ION, MAGNESIUM ION, SODIUM ION, ACETATE ION",active,166,11,12,4,8,11,13,9,8,10,15,11,11,4,3,5,14,3,11,3,
5WDR,Choanoflagellate Salpingoeca rosetta Ras with GMP-PNP,Ras protein,Choanoflagellata,28009,"Ras proteins are highly conserved signaling molecules that exhibit regulated, nucleotide-dependent switching between active and inactive states. The high conservation of Ras requires mechanistic explanation, especially given the general mutational tolerance of proteins. Here, we use deep mutational scanning, biochemical analysis and molecular simulations to understand constraints on Ras sequence. Ras exhibits global sensitivity to mutation when regulated by a GTPase activating protein and a nucleotide exchange factor. Removing the regulators shifts the distribution of mutational effects to be largely neutral, and reveals hotspots of activating mutations in residues that restrain Ras dynamics and promote the inactive state. Evolutionary analysis, combined with structural and mutational data, argue that Ras has co-evolved with its regulators in the vertebrate lineage. Overall, our results show that sequence conservation in Ras depends strongly on the biochemical network in which it operates, providing a framework for understanding the origin of global selection pressures on proteins.",x-ray diffraction,1.6,1,2,A,88.35978835978835%,72.45508982035929%,2797,272,3,3,"['MG', 'GNP', 'NA']","MG, NA, GNP","MAGNESIUM ION, SODIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,102,9,9,5,12,9,17,9,8,12,14,12,11,2,4,5,13,3,10,3,
5WHA,"KRas G12V, bound to GDP and miniprotein 225-11","GTPase KRas, miniprotein 225-11",Homo sapiens,9606,"The Ras proteins are aberrantly activated in a wide range of human cancers, often endowing tumors with aggressive properties and resistance to therapy. Decades of effort to develop direct Ras inhibitors for clinical use have thus far failed, largely because of a lack of adequate small-molecule-binding pockets on the Ras surface. Here, we report the discovery of Ras-binding miniproteins from a nave library and their evolution to afford versions with midpicomolar affinity to Ras. A series of biochemical experiments indicated that these miniproteins bind to the Ras effector domain as dimers, and high-resolution crystal structures revealed that these miniprotein dimers bind Ras in an unprecedented mode in which the Ras effector domain is remodeled to expose an extended pocket that connects two isolated pockets previously found to engage small-molecule ligands. We also report a Ras point mutant that stabilizes the protein in the open conformation trapped by these miniproteins. These findings provide new tools for studying Ras structure and function and present opportunities for the development of both miniprotein and small-molecule inhibitors that directly target the Ras proteins.",x-ray diffraction,2.04,1,12,A,67.72486772486772%,93.37349397590361%,1273,185,4,4,"['CA', 'MG', 'GDP']","MG, GDP, CA","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, CALCIUM ION",inactive,28,10,9,3,8,11,10,7,10,11,15,10,9,4,3,5,12,3,10,3,
5WHD,"Crystal structure of KRas G12V/D38P, bound to GDP",GTPase KRas,Homo sapiens,9606,"The Ras proteins are aberrantly activated in a wide range of human cancers, often endowing tumors with aggressive properties and resistance to therapy. Decades of effort to develop direct Ras inhibitors for clinical use have thus far failed, largely because of a lack of adequate small-molecule-binding pockets on the Ras surface. Here, we report the discovery of Ras-binding miniproteins from a nave library and their evolution to afford versions with midpicomolar affinity to Ras. A series of biochemical experiments indicated that these miniproteins bind to the Ras effector domain as dimers, and high-resolution crystal structures revealed that these miniprotein dimers bind Ras in an unprecedented mode in which the Ras effector domain is remodeled to expose an extended pocket that connects two isolated pockets previously found to engage small-molecule ligands. We also report a Ras point mutant that stabilizes the protein in the open conformation trapped by these miniproteins. These findings provide new tools for studying Ras structure and function and present opportunities for the development of both miniprotein and small-molecule inhibitors that directly target the Ras proteins.",x-ray diffraction,1.64,1,4,A,87.3015873015873%,92.7710843373494%,1444,267,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,101,10,9,4,8,12,12,8,10,11,16,11,9,4,3,6,14,5,10,3,
5WLB,"KRas G12V, bound to GppNHp and miniprotein 225-15a/b","GTPase KRas, 225-15 a, 225-15 b",Homo sapiens,9606,"The Ras proteins are aberrantly activated in a wide range of human cancers, often endowing tumors with aggressive properties and resistance to therapy. Decades of effort to develop direct Ras inhibitors for clinical use have thus far failed, largely because of a lack of adequate small-molecule-binding pockets on the Ras surface. Here, we report the discovery of Ras-binding miniproteins from a nave library and their evolution to afford versions with midpicomolar affinity to Ras. A series of biochemical experiments indicated that these miniproteins bind to the Ras effector domain as dimers, and high-resolution crystal structures revealed that these miniprotein dimers bind Ras in an unprecedented mode in which the Ras effector domain is remodeled to expose an extended pocket that connects two isolated pockets previously found to engage small-molecule ligands. We also report a Ras point mutant that stabilizes the protein in the open conformation trapped by these miniproteins. These findings provide new tools for studying Ras structure and function and present opportunities for the development of both miniprotein and small-molecule inhibitors that directly target the Ras proteins.",x-ray diffraction,1.72,1,6,A,68.25396825396825%,93.37349397590361%,1377,227,3,3,"['MG', 'GNP', 'PG4']","GNP, MG, PG4, SO4","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, TETRAETHYLENE GLYCOL, SULFATE ION",active,65,10,9,4,8,11,10,7,10,11,16,10,9,4,4,6,14,3,10,3,
5WPL,"KRas G12V, bound to GppNHp and miniprotein 225-11","GTPase HRas, Ras-binding peptide",Homo sapiens,9606,"The Ras proteins are aberrantly activated in a wide range of human cancers, often endowing tumors with aggressive properties and resistance to therapy. Decades of effort to develop direct Ras inhibitors for clinical use have thus far failed, largely because of a lack of adequate small-molecule-binding pockets on the Ras surface. Here, we report the discovery of Ras-binding miniproteins from a nave library and their evolution to afford versions with midpicomolar affinity to Ras. A series of biochemical experiments indicated that these miniproteins bind to the Ras effector domain as dimers, and high-resolution crystal structures revealed that these miniprotein dimers bind Ras in an unprecedented mode in which the Ras effector domain is remodeled to expose an extended pocket that connects two isolated pockets previously found to engage small-molecule ligands. We also report a Ras point mutant that stabilizes the protein in the open conformation trapped by these miniproteins. These findings provide new tools for studying Ras structure and function and present opportunities for the development of both miniprotein and small-molecule inhibitors that directly target the Ras proteins.",x-ray diffraction,2.15,1,12,A,87.3015873015873%,97.59036144578313%,1409,222,5,5,"['CA', 'MG', 'GNP']","GNP, MG, CA","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, CALCIUM ION",active,52,10,9,3,9,11,13,9,9,11,16,11,10,4,3,5,14,4,11,3,
5X9S,Crystal structure of fully modified H-Ras-GppNHp,GTPase HRas,Homo sapiens,9606,"Ras undergoes post-translational modifications including farnesylation, proteolysis, and carboxymethylation at the C terminus, which are necessary for membrane recruitment and effector recognition. Full activation of c-Raf-1 requires cooperative interaction of the farnesylated C terminus and the activator region of Ras with its cysteine-rich domain (CRD). However, the molecular basis for this interaction remains unclear because of difficulties in preparing modified Ras in amounts sufficient for structural studies. Here, we use Sortase A-catalyzed protein ligation to prepare modified Ras in sufficient amounts for NMR and X-ray crystallographic analyses. The results show that the farnesylated C terminus establishes an intramolecular interaction with the catalytic domain and brings the farnesyl moiety to the proximity of the activator region, which may be responsible for their cooperative recognition of c-Raf-1-CRD.",x-ray diffraction,2.5,1,1,A,87.83068783068782%,96.23655913978494%,1366,200,5,5,"['CA', 'MG', 'GNP']","MG, CA, GNP","MAGNESIUM ION, CALCIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,29,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
5XCO,Crystal structure of human K-Ras G12D Mutant in complex with GDP and Cyclic Inhibitory Peptide,"B-cell lymphoma 6 protein, F1324 peptide residues 10-13",Homo sapiens,9606,"The Ras proteins play roles in cell differentiation, proliferation, and survival. Aberrant signaling through Ras-mediated pathways in tumor cells occurs as a result of several types of mutational damage, which most frequently affects the amino acids G12, G13, and Q61. Recently, KRpep-2d was identified as a K-Ras(G12D) selective inhibitory peptide against the G12D mutant of K-Ras, which is a key member of the Ras protein family and an attractive cancer therapeutic target. In this study, the crystal structure of the human K-Ras(G12D) mutant was determined in complex with GDP and KRpep-2d at 1.25  resolution. This structure revealed that the peptide binds near Switch II and allosterically blocks protein-protein interactions with the guanine nucleotide exchange factor. This discovery of a unique binding pocket provides valuable information that will facilitate the design of direct Ras inhibitors.",x-ray diffraction,1.25,1,2,A,89.94708994708994%,93.41317365269461%,1513,292,2,2,"['EDO', 'GDP']","GDP, EDO","GUANOSINE-5'-DIPHOSPHATE, 1,2-ETHANEDIOL",inactive,120,10,9,4,9,12,13,8,12,11,15,11,9,4,4,6,16,4,10,3,
5XR4,Crystal structure of RabA1a in complex with GDP,Ras-related protein RABA1a/DNA Complex,Arabidopsis thaliana,3702,No DOI found,x-ray diffraction,2.8,1,2,A,53.43915343915344%,33.532934131736525%,1267,169,3,3,"['SO4', 'MG', 'GDP']","SO4, GDP, MG","SULFATE ION, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,11,8,15,3,7,14,13,6,11,16,14,7,2,8,4,8,7,1,8,1,2
5XR7,Crystal structure of RabA1a (Q72K) in complex with GTP,Ras-related protein RABA1a,Arabidopsis thaliana,3702,No DOI found,x-ray diffraction,2.6,1,2,A,55.026455026455025%,32.93413173652694%,1350,176,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,7,10,17,2,9,15,13,6,13,16,15,9,2,8,4,8,7,1,9,1,2
5Z2M,Structure of Orp1L/Rab7 complex,"Oxysterol-binding protein-related protein 1, Ras-related protein Rab-7a",Mus musculus,10090,"Endosomal transport represents the primary mode for intracellular trafficking and signaling transduction and thus has to be tightly controlled. The molecular processes controlling the endosomal positioning utilize several large protein complexes, one of which contains the small GTPase Rab7, Rab-interacting lysosomal protein (RILP), and oxysterol-binding protein-related protein 1 (ORP1L). Rab7 is known to interact with RILP through a canonical binding site termed the effector-interacting switch region, but it is not clear how Rab7 interacts with ORP1L, limiting our understanding of the overall process. Here, we report structural and biochemical investigation of the Rab7-ORP1L interaction. We found that, contrary to prior studies, the interaction between Rab7 and the N-terminal ankyrin repeat domain (ARD<sub>N</sub>) of ORP1L is independent of Rab7's GTP- or GDP-binding state. Moreover, we show that Rab7 interacts with ORP1L ARD<sub>N</sub> via a unique region consisting of helix3 (3) and 3<sub>10</sub>-helix 2 (2). This architecture leaves the canonical effector-interacting switch regions available for RILP binding and thus allows formation of the ORP1L-Rab7-RILP tripartite complex. Mutational disruption of the interacting interface between ORP1L and Rab7 compromised the ability of ORP1L-Rab7-RILP to regulate the late endosome positioning. Collectively, our results again manifested the versatility in the interaction between GTPase and its effector.",x-ray diffraction,2.14,1,4,A,91.005291005291%,33.12883435582822%,1509,277,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,103,8,15,3,8,11,8,5,14,14,15,9,10,11,,11,11,5,8,3,3
5ZVP,Aspergillus fumigatus Rho1 F25N,Rho GTPase Rho1,Aspergillus fumigatus Af293,330879,No DOI found,x-ray diffraction,1.42,1,1,A,95.76719576719577%,30.409356725146196%,1647,371,3,3,"['MG', 'SO4', 'GDP']","GDP, MG, SO4","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, SULFATE ION",inactive,187,11,12,1,8,10,17,6,13,17,18,11,5,4,5,5,12,9,9,6,2
621P,THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES,"H-RAS P21 PROTEIN MUTANT WITH GLN 61 REPLACED BY HIS (Q61H) COMPLEX WITH GUANOSINE-5'-[B,G-IMIDO] TRIPHOSPHATE",Homo sapiens,9606,No abstract found,x-ray diffraction,2.4,1,1,A,87.83068783068782%,99.3975903614458%,1582,394,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,226,11,11,4,8,11,13,9,8,11,15,11,10,4,4,5,14,3,11,3,
6AMB,Crystal Structure of the Afadin RA1 domain in complex with HRAS,"GTPase HRas, Afadin",Homo sapiens,9606,"Elucidation of activation mechanisms governing protein fusions is essential for therapeutic development. MLL undergoes rearrangement with numerous partners, including a recurrent translocation fusing the epigenetic regulator to a cytoplasmic RAS effector, AF6/afadin. We show here that AF6 employs a non-canonical, evolutionarily conserved -helix to bind RAS, unique to AF6 and the classical RASSF effectors. Further, all patients with MLL-AF6 translocations express fusion proteins missing only this helix from AF6, resulting in exposure of hydrophobic residues that induce dimerization. We provide evidence that oligomerization is the dominant mechanism driving oncogenesis from rare MLL translocation partners and employ our mechanistic understanding of MLL-AF6 to examine how dimers induce leukemia. Proteomic data resolve association of dimerized MLL with gene expression modulators, and inhibiting dimerization disrupts formation of these complexes while completely abrogating leukemogenesis in mice. Oncogenic gene translocations are thus selected under pressure from protein structure/function, underscoring the complex nature of chromosomal rearrangements.",x-ray diffraction,2.5,1,2,A,89.94708994708994%,100.0%,1394,180,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,8,11,11,5,8,11,13,9,9,12,15,11,11,4,4,5,14,3,11,3,
6ASA,KRAS mutant-D33E in GDP-bound,GTPase KRas,Homo sapiens,9606,"KRAS switch loop movements play a crucial role in regulating RAS signaling, and alteration of these sensitive dynamics is a principal mechanism through which disease-associated RAS mutations lead to aberrant RAS activation. Prior studies suggest that despite a high degree of sequence similarity, the switches in KRAS are more dynamic than those in HRAS. We determined X-ray crystal structures of the rare tumorigenic KRAS mutants KRAS<sup>D33E</sup>, in switch 1 (SW1), and KRAS<sup>A59G</sup>, in switch 2 (SW2), bound to GDP and found these adopt nearly identical, open SW1 conformations as well as altered SW2 conformations. KRAS<sup>A59G</sup> bound to a GTP analogue crystallizes in the same conformation. This open conformation is consistent with the inactive ""state 1"" previously observed for HRAS bound to GTP. For KRAS<sup>A59G</sup>, switch rearrangements may be regulated by increased flexibility in the <sup>57</sup>DXXGQ<sup>61</sup> motif at codon 59. However, loss of interactions between side chains at codons 33 and 35 in the SW1 <sup>33</sup>DPT<sup>35</sup> motif drives changes for KRAS<sup>D33E</sup>. The <sup>33</sup>DPT<sup>35</sup> motif is conserved for multiple members of the RAS subfamily but is not found in RAB, RHO, ARF, or G families, suggesting that dynamics mediated by this motif may be important for determining the selectivity of RAS-effector interactions. Biochemically, the consequence of altered switch dynamics is the same, showing impaired interaction with the guanine exchange factor SOS and loss of GAP-dependent GTPase activity. However, interactions with the RBD of RAF are preserved. Overall, these observations add to a body of evidence suggesting that HRAS and KRAS show meaningful differences in functionality stemming from differential protein dynamics independent of the hypervariable region.",x-ray diffraction,2.55,1,1,A,88.88888888888889%,93.41317365269461%,1373,172,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,2,11,9,4,8,12,14,8,11,11,15,11,9,4,4,6,14,4,10,3,
6ASE,KRAS mutant-A59G in GDP-bound,GTPase KRas,Homo sapiens,9606,"KRAS switch loop movements play a crucial role in regulating RAS signaling, and alteration of these sensitive dynamics is a principal mechanism through which disease-associated RAS mutations lead to aberrant RAS activation. Prior studies suggest that despite a high degree of sequence similarity, the switches in KRAS are more dynamic than those in HRAS. We determined X-ray crystal structures of the rare tumorigenic KRAS mutants KRAS<sup>D33E</sup>, in switch 1 (SW1), and KRAS<sup>A59G</sup>, in switch 2 (SW2), bound to GDP and found these adopt nearly identical, open SW1 conformations as well as altered SW2 conformations. KRAS<sup>A59G</sup> bound to a GTP analogue crystallizes in the same conformation. This open conformation is consistent with the inactive ""state 1"" previously observed for HRAS bound to GTP. For KRAS<sup>A59G</sup>, switch rearrangements may be regulated by increased flexibility in the <sup>57</sup>DXXGQ<sup>61</sup> motif at codon 59. However, loss of interactions between side chains at codons 33 and 35 in the SW1 <sup>33</sup>DPT<sup>35</sup> motif drives changes for KRAS<sup>D33E</sup>. The <sup>33</sup>DPT<sup>35</sup> motif is conserved for multiple members of the RAS subfamily but is not found in RAB, RHO, ARF, or G families, suggesting that dynamics mediated by this motif may be important for determining the selectivity of RAS-effector interactions. Biochemically, the consequence of altered switch dynamics is the same, showing impaired interaction with the guanine exchange factor SOS and loss of GAP-dependent GTPase activity. However, interactions with the RBD of RAF are preserved. Overall, these observations add to a body of evidence suggesting that HRAS and KRAS show meaningful differences in functionality stemming from differential protein dynamics independent of the hypervariable region.",x-ray diffraction,1.55,1,1,A,89.41798941798942%,93.41317365269461%,1487,280,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,109,12,8,4,8,12,13,8,12,11,15,11,9,4,4,6,15,4,10,3,
6BC0,A Complex between PH Domain of p190RhoGEF and Activated RhoA Bound to a GTP Analog,"Rho guanine nucleotide exchange factor 28, Transforming protein RhoA",Homo sapiens,9606,"Rho family GTPases regulate a wide range of cellular processes. This includes cellular dynamics where three subfamilies, Rho, Rac, and Cdc42, are known to regulate cell shape and migration though coordinate action. Activation of Rho proteins largely depends on Rho Guanine nucleotide Exchange Factors (RhoGEFs) through a catalytic Dbl homology (DH) domain linked to a pleckstrin homology (PH) domain that subserves various functions. The PH domains from Lbc RhoGEFs, which specifically activate RhoA, have been shown to bind to activated RhoA. Here, p190RhoGEF is shown to also bind Rac1GTP. Crystal structures reveal that activated Rac1 and RhoA use their effector-binding surfaces to associate with the same hydrophobic surface on the PH domain. Both activated RhoA and Rac1 can stimulate exchange of nucleotide on RhoA by localization of p190RhoGEF to its substrate, RhoAGDP, in vitro. The binding of activated RhoA provides a mechanism for positive feedback regulation as previously proposed for the family of Lbc RhoGEFs. In contrast, the novel interaction between activated Rac1 and p190RhoGEF reveals a potential mechanism for cross-talk regulation where Rac can directly effect stimulation of RhoA. The greater capacity of Rac1 to stimulate p190RhoGEF among the Lbc RhoGEFs suggests functional specialization.",x-ray diffraction,2.2,1,2,F,94.70899470899471%,32.38636363636363%,2904,209,2,2,"['MG', 'GSP']","MG, GSP","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,28,10,13,5,6,8,16,5,14,13,16,10,5,6,2,7,15,11,10,5,2
6BC1,A Complex between PH Domain of p190RhoGEF and Activated Rac1 Bound to a GTP Analog,"Ras-related C3 botulinum toxin substrate 1, Rho guanine nucleotide exchange factor 28",Homo sapiens,9606,"Rho family GTPases regulate a wide range of cellular processes. This includes cellular dynamics where three subfamilies, Rho, Rac, and Cdc42, are known to regulate cell shape and migration though coordinate action. Activation of Rho proteins largely depends on Rho Guanine nucleotide Exchange Factors (RhoGEFs) through a catalytic Dbl homology (DH) domain linked to a pleckstrin homology (PH) domain that subserves various functions. The PH domains from Lbc RhoGEFs, which specifically activate RhoA, have been shown to bind to activated RhoA. Here, p190RhoGEF is shown to also bind Rac1GTP. Crystal structures reveal that activated Rac1 and RhoA use their effector-binding surfaces to associate with the same hydrophobic surface on the PH domain. Both activated RhoA and Rac1 can stimulate exchange of nucleotide on RhoA by localization of p190RhoGEF to its substrate, RhoAGDP, in vitro. The binding of activated RhoA provides a mechanism for positive feedback regulation as previously proposed for the family of Lbc RhoGEFs. In contrast, the novel interaction between activated Rac1 and p190RhoGEF reveals a potential mechanism for cross-talk regulation where Rac can directly effect stimulation of RhoA. The greater capacity of Rac1 to stimulate p190RhoGEF among the Lbc RhoGEFs suggests functional specialization.",x-ray diffraction,2.9,1,4,A,93.65079365079364%,31.60919540229885%,2863,213,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,34,11,13,2,7,13,9,8,13,18,16,10,5,6,2,6,12,12,7,5,2
6BOF,Crystal structure of KRAS A146T-GDP demonstrating open switch 1 conformation,GTPase KRas,Homo sapiens,9606,"<i>KRAS</i> is the most frequently mutated oncogene. The incidence of specific <i>KRAS</i> alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRAS<sup>G12D</sup>, a common mutant form, and KRAS<sup>A146T</sup>, a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRAS<sup>A146T</sup> exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor-induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRAS<sup>G12D</sup> and KRAS<sup>A146T</sup> exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the <i>KRAS</i> mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for <i>KRAS</i>, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.<i>See related commentary by Hobbs and Der, p. 696</i>.<i>This article is highlighted in the In This Issue feature, p. 681</i>.",x-ray diffraction,1.4,1,2,A,88.88888888888889%,93.37349397590361%,2874,333,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,164,11,8,3,8,13,13,8,12,11,15,11,9,4,4,6,15,4,10,3,
6BSX,CRYSTAL STRUCTURE OF RHEB IN COMPLEX WITH COMPOUND 1 AT 1.65A RESOLUTION,GTP-binding protein Rheb,Homo sapiens,9606,"The small G-protein Rheb activates the mechanistic target of rapamycin complex 1 (mTORC1) in response to growth factor signals. mTORC1 is a master regulator of cellular growth and metabolism; aberrant mTORC1 signaling is associated with fibrotic, metabolic, and neurodegenerative diseases, cancers, and rare disorders. Point mutations in the Rheb switch II domain impair its ability to activate mTORC1. Here, we report the discovery of a small molecule (NR1) that binds Rheb in the switch II domain and selectively blocks mTORC1 signaling. NR1 potently inhibits mTORC1 driven phosphorylation of ribosomal protein S6 kinase beta-1 (S6K1) but does not inhibit phosphorylation of AKT or ERK. In contrast to rapamycin, NR1 does not cause inhibition of mTORC2 upon prolonged treatment. Furthermore, NR1 potently and selectively inhibits mTORC1 in mouse kidney and muscle in vivo. The data presented herein suggest that pharmacological inhibition of Rheb is an effective approach for selective inhibition of mTORC1 with therapeutic potential.",x-ray diffraction,1.65,1,4,A,89.94708994708994%,36.477987421383645%,1529,335,5,5,"['EDO', 'ACT', 'MG', 'GDP', 'E7S']","MG, ACT, GDP, E7S, EDO","MAGNESIUM ION, ACETATE ION, GUANOSINE-5'-DIPHOSPHATE, (5,6-dimethyl-1H-benzimidazol-2-yl)methanol, 1,2-ETHANEDIOL",inactive,160,10,9,3,15,9,14,8,13,14,15,17,9,6,3,7,8,4,5,,1
6BVI,Ras:SOS:Ras in complex with a small molecule activator,"GTPase HRas, Son of sevenless homolog 1",Homo sapiens,9606,"Deregulated RAS activity, often the result of mutation, is implicated in approximately 30% of all human cancers. Despite this statistic, no clinically successful treatment for RAS-driven tumors has yet been developed. One approach for modulating RAS activity is to target and affect the activity of proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report on structure-activity relationships (SAR) in an indole series of compounds. Using structure-based design, we systematically explored substitution patterns on the indole nucleus, the pendant amino acid moiety, and the linker unit that connects these two fragments. Best-in-class compounds activate the nucleotide exchange process at submicromolar concentrations in vitro, increase levels of active RAS-GTP in HeLa cells, and elicit signaling changes in the mitogen-activated protein kinase-extracellular regulated kinase (MAPK-ERK) pathway, resulting in a decrease in pERK1/2<sup>T202/Y204</sup> protein levels at higher compound concentrations.",x-ray diffraction,1.75,1,3,A,60.84656084656085%,98.79518072289156%,1545,363,3,3,"['MG', 'CSO', 'GNP']","GNP, MG, EC4, FMT, GOL, NA","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, 6-chloro-N-{1-[(5-chloro-1H-indol-3-yl)methyl]piperidin-4-yl}-L-tryptophanamide, FORMIC ACID, GLYCEROL, SODIUM ION",active,195,11,12,4,8,11,13,8,8,11,15,11,11,4,3,5,14,3,11,2,
6BVJ,Ras:SOS:Ras in complex with a small molecule activator,"GTPase HRas, Son of sevenless homolog 1",Homo sapiens,9606,"Deregulated RAS activity, often the result of mutation, is implicated in approximately 30% of all human cancers. Despite this statistic, no clinically successful treatment for RAS-driven tumors has yet been developed. One approach for modulating RAS activity is to target and affect the activity of proteins that interact with RAS, such as the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). Here, we report on structure-activity relationships (SAR) in an indole series of compounds. Using structure-based design, we systematically explored substitution patterns on the indole nucleus, the pendant amino acid moiety, and the linker unit that connects these two fragments. Best-in-class compounds activate the nucleotide exchange process at submicromolar concentrations in vitro, increase levels of active RAS-GTP in HeLa cells, and elicit signaling changes in the mitogen-activated protein kinase-extracellular regulated kinase (MAPK-ERK) pathway, resulting in a decrease in pERK1/2<sup>T202/Y204</sup> protein levels at higher compound concentrations.",x-ray diffraction,1.75,1,3,A,60.84656084656085%,99.3975903614458%,1552,370,3,3,"['MG', 'CSO', 'GNP']","GNP, MG, EAS, FMT, GOL, NA","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, 5-chloro-N-{1-[(5-chloro-1H-indol-3-yl)methyl]piperidin-4-yl}-L-tryptophanamide, FORMIC ACID, GLYCEROL, SODIUM ION",active,202,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,2,
6DZH,HRAS G13D bound to GDP (H13GDP),GTPase HRas,Homo sapiens,9606,"Ras GTPases are mutated at codons 12, 13, and 61, with different frequencies in KRas, HRas, and NRas and in a cancer-specific manner. The G13D mutant appears in 25% of KRas-driven colorectal cancers, while observed only rarely in HRas or NRas. Structures of Ras G13D in the three isoforms show an open active site, with adjustments to the D13 backbone torsion angles and with disconnected switch regions. KRas G13D has unique features that destabilize the nucleotide-binding pocket. In KRas G13D bound to GDP, A59 is placed in the Mg<sup>2+</sup> binding site, as in the HRas-SOS complex. Structure and biochemistry are consistent with an intermediate level of KRas G13D bound to GTP, relative to wild-type and KRas G12D, observed in genetically engineered mouse models. The results explain in part the elevated frequency of the G13D mutant in KRas over the other isoforms of Ras.",x-ray diffraction,1.95,1,3,A,68.78306878306879%,99.3975903614458%,1422,254,3,3,"['MG', 'GOL', 'GDP']","GDP, MG, GOL, CA, DTT","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, GLYCEROL, CALCIUM ION, 2,3-DIHYDROXY-1,4-DITHIOBUTANE",inactive,86,10,11,4,8,11,13,9,8,11,15,10,11,4,3,5,15,3,11,3,
6EKK,Crystal structure of GEF domain of DENND 1A in complex with Rab GTPase Rab35-GDP bound state.,"DENN domain-containing protein 1A, Ras-related protein Rab-35",Homo sapiens,9606,No DOI found,x-ray diffraction,1.82,1,4,C,93.12169312169311%,36.774193548387096%,1550,318,4,4,"['SO4', 'EDO', 'GDP']","SO4, EDO, GDP","SULFATE ION, 1,2-ETHANEDIOL, GUANOSINE-5'-DIPHOSPHATE",inactive,138,12,8,2,9,13,13,6,13,13,17,13,5,11,3,9,13,1,10,3,2
6F76,Antibody derived (Abd-8) small molecule binding to KRAS.,GTPase KRas,Homo sapiens,9606,"The RAS family of proteins is amongst the most highly mutated in human cancers and has so far eluded drug therapy. Currently, much effort is being made to discover mutant RAS inhibitors and in vitro screening for RAS-binding drugs must be followed by cell-based assays. Here, we have developed a robust set of bioluminescence resonance energy transfer (BRET)-based RAS biosensors that enable monitoring of RAS-effector interaction inhibition in living cells. These include KRAS, HRAS and NRAS and a variety of different mutations that mirror those found in human cancers with the major RAS effectors such as CRAF, PI3K and RALGDS. We highlighted the utility of these RAS biosensors by showing a RAS-binding compound is a potent pan-RAS-effector interactions inhibitor in cells. The RAS biosensors represent a useful tool to investigate and characterize the potency of anti-RAS inhibitors in cells and more generally any RAS protein-protein interaction (PPI) in cells.",x-ray diffraction,2.2,1,6,A,91.005291005291%,93.41317365269461%,1443,195,3,3,"['MG', 'GNP', 'CVK']","MG, GNP, CVK","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, 4-(2,3-dihydro-1,4-benzodioxin-5-yl)-~{N}-[3-[(dimethylamino)methyl]phenyl]-2-methoxy-aniline",active,20,12,10,4,8,12,13,8,11,11,15,11,9,4,5,7,15,4,10,3,
6FA1,Antibody derived (Abd-4) small molecule binding to KRAS.,GTPase KRas,Homo sapiens,9606,"Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition. A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site. Here, we explore this strategy using an anti-mutant RAS antibody fragment as a competitor in a small-molecule library screen for identifying RAS-binding compounds. The initial hits are optimized by structure-based design, resulting in potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector interactions and inhibit endogenous RAS-dependent signalling. Our results may aid RAS-dependent cancer drug development and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.",x-ray diffraction,1.97,1,6,A,61.904761904761905%,92.81437125748504%,1538,282,4,4,"['MG', 'D2Z', 'CSO', 'GNP']","MG, GNP, D2Z","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, 2-[4-[[(3~{R})-2,3-dihydro-1,4-benzodioxin-3-yl]methylcarbamoyl]phenoxy]ethyl-dimethyl-azanium",active,107,12,10,4,8,12,13,8,11,11,15,11,9,4,5,7,15,4,10,2,
6FA2,Antibody derived (Abd-5) small molecule binding to KRAS.,GTPase KRas,Homo sapiens,9606,"Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition. A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site. Here, we explore this strategy using an anti-mutant RAS antibody fragment as a competitor in a small-molecule library screen for identifying RAS-binding compounds. The initial hits are optimized by structure-based design, resulting in potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector interactions and inhibit endogenous RAS-dependent signalling. Our results may aid RAS-dependent cancer drug development and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.",x-ray diffraction,2.6,1,6,C,54.4973544973545%,93.41317365269461%,1362,170,3,3,"['MG', 'GNP', 'D2W']","MG, GNP, D2W","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, 4-[2-(dimethylamino)ethoxy]-~{N}-[[(3~{R})-5-(6-methoxypyridin-2-yl)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]benzamide",active,2,12,9,4,8,12,9,8,11,11,15,10,9,4,4,7,15,4,10,3,
6FA3,Antibody derived (Abd-6) small molecule binding to KRAS.,GTPase KRas,Homo sapiens,9606,"Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered unsuitable for PPI inhibition. A potential solution to these problems is to select intracellular antibody fragments to block PPIs, use these antibody fragments for target validation in disease models and finally derive small molecules overlapping the antibody-binding site. Here, we explore this strategy using an anti-mutant RAS antibody fragment as a competitor in a small-molecule library screen for identifying RAS-binding compounds. The initial hits are optimized by structure-based design, resulting in potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector interactions and inhibit endogenous RAS-dependent signalling. Our results may aid RAS-dependent cancer drug development and demonstrate a general concept for developing small compounds to replace intracellular antibody fragments, enabling rational drug development to target validated PPIs.",x-ray diffraction,1.82,1,6,A,90.47619047619048%,93.41317365269461%,1527,270,3,3,"['MG', 'GNP', 'D1Z']","MG, GNP, D1Z, DMS","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, ~{N}-[[(3~{R})-5-[5-[[3-[(dimethylamino)methyl]phenyl]amino]-6-methoxy-pyridin-2-yl]-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]oxane-4-carboxamide, DIMETHYL SULFOXIDE",active,96,12,9,4,8,12,13,8,11,11,15,11,9,4,5,7,15,4,10,3,
6GOD,KRAS full length wild-type GPPNHP,GTPase KRas,Homo sapiens,9606,"The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined crystallization conditions for KRAS169 Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein-protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein-protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules.",x-ray diffraction,1.71,1,1,A,91.005291005291%,93.97590361445783%,1503,273,4,4,"['MG', 'GNP', 'GOL']","MG, GNP, GOL","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, GLYCEROL",active,97,11,9,4,10,12,13,8,13,11,15,11,9,4,4,6,15,4,10,3,
6GOE,KRAS full length G12V GPPNHP,GTPase KRas,Homo sapiens,9606,"The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined crystallization conditions for KRAS169 Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein-protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein-protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules.",x-ray diffraction,1.6,1,1,A,55.55555555555556%,93.37349397590361%,1467,275,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,106,11,8,4,9,12,11,7,12,11,16,11,9,4,4,6,15,4,10,3,
6GOF,KRAS full length G12D GPPNHP,GTPase KRas,Homo sapiens,9606,"The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined crystallization conditions for KRAS169 Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein-protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein-protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules.",x-ray diffraction,1.98,1,1,A,91.005291005291%,93.37349397590361%,1490,256,3,3,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,81,10,9,4,10,12,13,8,13,11,15,11,9,4,4,6,16,4,10,3,
6GOG,KRAS-169 Q61H GPPNHP,GTPase KRas,Homo sapiens,9606,"The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined crystallization conditions for KRAS169 Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein-protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein-protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules.",x-ray diffraction,2.05,1,6,A,89.94708994708994%,93.41317365269461%,1583,341,4,4,"['CIT', 'MG', 'GNP']","GNP, MG, CIT","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, CITRIC ACID",active,167,12,9,4,8,12,12,8,11,11,15,11,9,4,5,7,15,4,10,3,
6GQT,KRAS-169 Q61H GPPNHP + PPIN-2,GTPase KRas,Homo sapiens,9606,"The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined crystallization conditions for KRAS169 Q61H-yielding crystals suitable for soaking with compounds and exploited this to assess new RAS-binding compounds selected by screening a protein-protein interaction-focused compound library using surface plasmon resonance. Two compounds, referred to as PPIN-1 and PPIN-2, with related structures from 30 initial RAS binders showed binding to a pocket where compounds had been previously developed, including RAS effector protein-protein interaction inhibitors selected using an intracellular antibody fragment (called Abd compounds). Unlike the Abd series of RAS binders, PPIN-1 and PPIN-2 compounds were not competed by the inhibitory anti-RAS intracellular antibody fragment and did not show any RAS-effector inhibition properties. By fusing the common, anchoring part from the two new compounds with the inhibitory substituents of the Abd series, we have created a set of compounds that inhibit RAS-effector interactions with increased potency. These fused compounds add to the growing catalog of RAS protein-protein inhibitors and show that building a chemical series by crossing over two chemical series is a strategy to create RAS-binding small molecules.",x-ray diffraction,1.69,1,6,A,90.47619047619048%,93.41317365269461%,1595,353,4,4,"['CIT', 'MG', 'GNP']","GNP, MG, CIT, F8N","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, CITRIC ACID, ~{N}-(3-imidazol-1-ylpropyl)-4-[[3-(3-methoxyphenyl)phenyl]methyl]oxane-4-carboxamide",active,178,12,9,4,8,12,13,8,11,11,15,11,9,4,5,7,15,4,10,3,
6HUF,Coping with strong translational non-crystallographic symmetry and extreme anisotropy in molecular replacement with Phaser: human Rab27a,Ras-related protein Rab-27A,Homo sapiens,9606,"Data pathologies caused by effects such as diffraction anisotropy and translational noncrystallographic symmetry (tNCS) can dramatically complicate the solution of the crystal structures of macromolecules. Such problems were encountered in determining the structure of a mutant form of Rab27a, a member of the Rab GTPases. Mutant Rab27a constructs that crystallize in the free form were designed for use in the discovery of drugs to reduce primary tumour invasiveness and metastasis. One construct, hRab27a<sup>Mut</sup>, crystallized within 24h and diffracted to 2.82 resolution, with a unit cell possessing room for a large number of protein copies. Initial efforts to solve the structure using molecular replacement by Phaser were not successful. Analysis of the data set revealed that the crystals suffered from both extreme anisotropy and strong tNCS. As a result, large numbers of reflections had estimated standard deviations that were much larger than their measured intensities and their expected intensities, revealing problems with the use of such data at the time in Phaser. By eliminating extremely weak reflections with the largest combined effects of anisotropy and tNCS, these problems could be avoided, allowing a molecular-replacement solution to be found. The lessons that were learned in solving this structure have guided improvements in the numerical analysis used in Phaser, particularly in identifying diffraction measurements that convey very little information content. The calculation of information content could also be applied as an alternative to ellipsoidal truncation. The post-mortem analysis also revealed an oversight in accounting for measurement errors in the fast rotation function. While the crystal of mutant Rab27a is not amenable to drug screening, the structure can guide new modifications to obtain more suitable crystal forms.",x-ray diffraction,2.82,1,16,A,90.47619047619048%,30.23255813953488%,1197,178,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,5,10,13,4,11,12,12,7,10,20,7,11,5,9,2,11,11,2,11,1,2
6HXU,Crystal structure of Human RHOB Q63L in complex with GTP,"Rho-related GTP-binding protein RhoB, ANTIBODY",Homo sapiens,9606,"The selective downregulation of activated intracellular proteins is a key challenge in cell biology. RHO small GTPases switch between a guanosine diphosphate (GDP)-bound and a guanosine triphosphate (GTP)-bound state that drives downstream signaling. At present, no tool is available to study endogenous RHO-GTPinduced conformational changes in live cells. Here, we established a cell-based screen to selectively degrade RHOB-GTP using F-box-intracellular single-domain antibody fusion. We identified one intracellular antibody (intrabody) that shows selective targeting of endogenous RHOB-GTP mediated by interactions between the CDR3 loop of the domain antibody and the GTP-binding pocket of RHOB. Our results suggest that, while RHOB is highly regulated at the expression level, only the GTP-bound pool, but not its global expression, mediates RHOB functions in genomic instability and in cell invasion. The F-box/intrabody-targeted protein degradation represents a unique approach to knock down the active form of small GTPases or other proteins with multiple cellular activities.",x-ray diffraction,1.19,1,1,A,96.29629629629629%,32.02247191011236%,3235,478,3,3,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,293,7,15,3,7,9,16,7,13,15,21,8,4,4,2,6,16,10,12,5,2
6IF2,Complex structure of Rab35 and its effector RUSC2,"Ras-related protein Rab-35, Iporin",Homo sapiens,9606,"Rab35, a master regulator of membrane trafficking, regulates diverse cellular processes and is associated with various human diseases. Although a number of effectors have been identified, the molecular basis of Rab35-effector interactions remains unclear. Here, we provide the high-resolution crystal structures of Rab35 in complex with its two specific effectors ACAP2 and RUSC2, respectively. In the Rab35/ACAP2 complex structure, Rab35 binds to the terminal ankyrin repeat and a C-terminal extended  helix of ACAP2, revealing a previously uncharacterized binding mode both for Rabs and ankyrin repeats. In the Rab35/RUSC2 complex structure, Arg1015 of RUSC2 functions as a ""pseudo-arginine finger"" that stabilizes the GTP-bound Rab35, thus facilitating the assembly of Rab35/RUSC2 complex. The structural analysis allows us to design specific Rab35 mutants capable of eliminating Rab35/ACAP2 and Rab35/RUSC2 interactions, but not interfering with other effector bindings. The atomic structures also offer possible explanations to disease-associated mutants identified at the Rab35-effector interfaces.",x-ray diffraction,2.4,1,2,B,94.17989417989418%,36.12903225806451%,1551,298,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,118,12,9,3,9,13,13,6,13,14,17,13,4,11,3,9,13,1,10,3,2
6IY1,Structure of human Ras-related protein Rab11,Ras-related protein Rab-11A,Homo sapiens,9606,No DOI found,x-ray diffraction,2.11,1,6,F,53.96825396825397%,37.65432098765432%,1389,208,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,41,10,16,1,12,12,12,8,9,16,12,12,3,8,3,7,11,1,11,,2
6IYB,Structure of human ORP1 ANK - Rab7 complex,Membrane-anchored lipid-binding protein LAM4,Homo sapiens,9606,"Oxysterol-binding protein (OSBP) and OSBP-related proteins (ORPs) constitute a family of lipid transfer proteins conserved in eukaryotes. ORP1 transports cholesterol at the interface between the late endosomes/lysosomes (LELs) and the endoplasmic reticulum (ER). ORP1 is targeted to the endosomal membranes by forming a tripartite complex with the LE GTPase Rab7 and its effector RILP (Rab7-interacting lysosomal protein). Here, we determined the crystal structure of human ORP1 ANK domain in complex with the GTP-bound form of Rab7. ORP1 ANK binds to the helix 3 of Rab7 located away from the switching regions, which makes the interaction independent of the nucleotide-binding state of Rab7. Thus, the effector-interacting switch regions of Rab7 are accessible for RILP binding, allowing formation of the ORP1-Rab7-RILP complex. ORP1 ANK binds to Rab7 and the Rab7-RILP complex with similar micro-molar affinities, which is consistent with the independence binding of ORP1 and RILP to Rab7. The structural model of the ORP1-Rab7-RILP complex correlates with the recruitment of ORP1 at the LEL-ER interface and the role in lipid transport and regulation.",x-ray diffraction,2.09,1,4,A,90.47619047619048%,33.95061728395062%,1549,326,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,153,8,15,3,8,12,9,5,12,13,15,9,10,11,,11,11,5,8,3,3
6JIK,Aspergillus fumigatus Rho1 GsGTP,Rho GTPase Rho1,Aspergillus fumigatus var. fumigatus,41122,No DOI found,x-ray diffraction,2.35,1,1,A,96.29629629629629%,30.409356725146196%,1606,343,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,159,11,11,,8,11,17,6,14,17,18,11,5,4,6,5,12,9,9,6,2
6KX2,Crystal structure of GDP bound RhoA protein,Transforming protein RhoA (E.C.3.6.5.2),Homo sapiens,9606,"The Rho family GTPases are crucial drivers of tumor growth and metastasis. However, it is difficult to develop GTPases inhibitors due to a lack of well-characterized binding pockets for compounds. Here, through molecular dynamics simulation of the RhoA protein, a groove around cysteine 107 (Cys107) that is relatively well-conserved within the Rho family is discovered. Using a combined strategy, the novel inhibitor DC-Rhoin is discovered, which disrupts interaction of Rho proteins with guanine nucleotide exchange factors (GEFs) and guanine nucleotide dissociation inhibitors (GDIs). Crystallographic studies reveal that the covalent binding of DC-Rhoin to the Cys107 residue stabilizes and captures a novel allosteric pocket. Moreover, the derivative compound DC-Rhoin04 inhibits the migration and invasion of cancer cells, through targeting this allosteric pocket of RhoA. The study reveals a novel allosteric regulatory site within the Rho family, which can be exploited for anti-metastasis drug development, and also provides a novel strategy for inhibitor discovery toward ""undruggable"" protein targets.",x-ray diffraction,1.45,1,1,A,93.65079365079364%,34.090909090909086%,1711,450,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,272,10,11,5,7,9,16,5,14,13,18,10,5,6,2,7,15,11,10,1,2
6KYH,Crystal structure of Shank3 NTD-ANK A42K mutant in complex with HRas,"SH3 and multiple ankyrin repeat domains protein 3, GTPase HRas",Mus musculus,10090,"Shank1/2/3, major scaffold proteins in excitatory synapses, are frequently mutated in patients with psychiatric disorders. Although the Shank N-terminal domain and ankyrin repeats domain tandem (NTD-ANK) is known to bind to Ras and Rap1, the molecular mechanism underlying and functional significance of the bindings in synapses are unknown. Here, we demonstrate that Shank3 NTD-ANK specifically binds to the guanosine triphosphate (GTP)-bound form of HRas and Rap1. In addition to the canonical site mediated by the Ras-association domain and common to both GTPases, Shank3 contains an unconventional Rap1 binding site formed by NTD and ANK together. Binding of Shank3 to the GTP-loaded Rap1 slows down its GTP hydrolysis by SynGAP. We further show that the interactions between Shank3 and HRas/Rap1 at excitatory synapses are promoted by synaptic activation. Thus, Shank3 may be able to modulate signaling of the Ras family proteins via directly binding to and stabilizing the GTP-bound form of the enzymes.",x-ray diffraction,3.3,1,8,E,87.83068783068782%,100.0%,1355,168,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,0,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
6KYK,Crystal structure of Shank3 NTD-ANK mutant in complex with Rap1,"SH3 and multiple ankyrin repeat domains protein 3, Ras-related protein Rap-1b",Mus musculus,10090,"Shank1/2/3, major scaffold proteins in excitatory synapses, are frequently mutated in patients with psychiatric disorders. Although the Shank N-terminal domain and ankyrin repeats domain tandem (NTD-ANK) is known to bind to Ras and Rap1, the molecular mechanism underlying and functional significance of the bindings in synapses are unknown. Here, we demonstrate that Shank3 NTD-ANK specifically binds to the guanosine triphosphate (GTP)-bound form of HRas and Rap1. In addition to the canonical site mediated by the Ras-association domain and common to both GTPases, Shank3 contains an unconventional Rap1 binding site formed by NTD and ANK together. Binding of Shank3 to the GTP-loaded Rap1 slows down its GTP hydrolysis by SynGAP. We further show that the interactions between Shank3 and HRas/Rap1 at excitatory synapses are promoted by synaptic activation. Thus, Shank3 may be able to modulate signaling of the Ras family proteins via directly binding to and stabilizing the GTP-bound form of the enzymes.",x-ray diffraction,2.82,1,6,C,89.41798941798942%,57.48502994011976%,1389,179,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,8,11,9,5,8,8,12,6,10,15,16,9,14,9,1,7,13,3,9,3,1
6M9W,Structure of Mg-free KRAS4b (2-169) bound to GDP with the switch-I in fully open conformation,GTPase KRas,Homo sapiens,9606,"Although post-translational modification of the C-terminus of RAS has been studied extensively, little is known about N-terminal processing. Mass spectrometric characterization of KRAS expressed in mammalian cells showed cleavage of the initiator methionine (iMet) and N-acetylation of the nascent N-terminus. Interestingly, structural studies on GDP- and GMPPNP-bound KRAS lacking the iMet and N-acetylation resulted in Mg<sup>2+</sup>-free structures of KRAS with flexible N-termini. In the Mg<sup>2+</sup>-free KRAS-GDP structure, the flexible N-terminus causes conformational changes in the interswitch region resulting in a fully open conformation of switch I. In the Mg<sup>2+</sup>-free KRAS-GMPPNP structure, the flexible N-terminus causes conformational changes around residue A59 resulting in the loss of Mg<sup>2+</sup> and switch I in the inactive state 1 conformation. Structural studies on N-acetylated KRAS-GDP lacking the iMet revealed the presence of Mg<sup>2+</sup> and a conformation of switch regions also observed in the structure of GDP-bound unprocessed KRAS with the iMet. In the absence of the iMet, the N-acetyl group interacts with the central beta-sheet and stabilizes the N-terminus and the switch regions. These results suggest there is crosstalk between the N-terminus and the Mg<sup>2+</sup> binding site, and that N-acetylation plays an important role by stabilizing the N-terminus of RAS upon excision of the iMet.",x-ray diffraction,1.5,1,1,A,88.88888888888889%,93.97590361445783%,2920,386,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,217,11,9,3,8,12,13,8,12,11,15,11,9,4,4,6,15,4,10,3,
6MBQ,Crystal structure of Mg-free wild-type KRAS (2-166) bound to GMPPNP in the state 1 conformation,GTPase KRas,Homo sapiens,9606,"Although post-translational modification of the C-terminus of RAS has been studied extensively, little is known about N-terminal processing. Mass spectrometric characterization of KRAS expressed in mammalian cells showed cleavage of the initiator methionine (iMet) and N-acetylation of the nascent N-terminus. Interestingly, structural studies on GDP- and GMPPNP-bound KRAS lacking the iMet and N-acetylation resulted in Mg<sup>2+</sup>-free structures of KRAS with flexible N-termini. In the Mg<sup>2+</sup>-free KRAS-GDP structure, the flexible N-terminus causes conformational changes in the interswitch region resulting in a fully open conformation of switch I. In the Mg<sup>2+</sup>-free KRAS-GMPPNP structure, the flexible N-terminus causes conformational changes around residue A59 resulting in the loss of Mg<sup>2+</sup> and switch I in the inactive state 1 conformation. Structural studies on N-acetylated KRAS-GDP lacking the iMet revealed the presence of Mg<sup>2+</sup> and a conformation of switch regions also observed in the structure of GDP-bound unprocessed KRAS with the iMet. In the absence of the iMet, the N-acetyl group interacts with the central beta-sheet and stabilizes the N-terminus and the switch regions. These results suggest there is crosstalk between the N-terminus and the Mg<sup>2+</sup> binding site, and that N-acetylation plays an important role by stabilizing the N-terminus of RAS upon excision of the iMet.",x-ray diffraction,1.35,1,1,A,88.35978835978835%,93.93939393939394%,2835,358,3,3,"['EDO', 'GNP', 'NA']","NA, EDO, GNP","SODIUM ION, 1,2-ETHANEDIOL, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,188,13,9,3,8,12,12,8,10,11,15,11,9,4,4,6,15,4,10,3,
6MNX,Structural basis of impaired hydrolysis in KRAS Q61H mutant,GTPase KRas,Homo sapiens,9606,"Assembly of RAS molecules into complexes at the cell membrane is critical for RAS signaling. We previously showed that oncogenic KRAS codon 61 mutations increase its affinity for RAF, raising the possibility that KRAS<sup>Q61H</sup>, the most common KRAS mutation at codon 61, upregulates RAS signaling through mechanisms at the level of RAS assemblies. We show here that KRAS<sup>Q61H</sup> exhibits preferential binding to RAF relative to PI3K in cells, leading to enhanced MAPK signaling in <i>in vitro</i> models and human NSCLC tumors. X-ray crystallography of KRAS<sup>Q61H</sup>:GTP revealed that a hyperdynamic switch 2 allows for a more stable interaction with switch 1, suggesting that enhanced RAF activity arises from a combination of absent intrinsic GTP hydrolysis activity and increased affinity for RAF. Disruption of KRAS<sup>Q61H</sup> assemblies by the RAS oligomer-disrupting D154Q mutation impaired RAF dimerization and altered MAPK signaling but had little effect on PI3K signaling. However, KRAS<sup>Q61H</sup> oligomers but not KRAS<sup>G12D</sup> oligomers were disrupted by RAF mutations that disrupt RAF-RAF interactions. KRAS<sup>Q61H</sup> cells show enhanced sensitivity to RAF and MEK inhibitors individually, whereas combined treatment elicited synergistic growth inhibition. Furthermore, KRAS<sup>Q61H</sup> tumors in mice exhibited high vulnerability to MEK inhibitor, consistent with cooperativity between KRAS<sup>Q61H</sup> and RAF oligomerization and dependence on MAPK signaling. These findings support the notion that KRAS<sup>Q61H</sup> and functionally similar mutations may serve as predictive biomarkers for targeted therapies against the MAPK pathway. SIGNIFICANCE: These findings show that oncogenic KRAS<sup>Q61H</sup> forms a cooperative RAS-RAF ternary complex, which renders RAS-driven tumors vulnerable to MEKi and RAFi, thus establishing a framework for evaluating RAS biomarker-driven targeted therapies.",x-ray diffraction,2.2,1,6,A,55.026455026455025%,93.41317365269461%,2740,212,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,43,11,9,4,7,12,13,7,12,11,15,11,8,4,5,6,15,4,10,3,
6MQN,Crystal structure of KRAS V14I-GDP demonstrating disorder switch 1 conformation - Form 2,GTPase KRas,Homo sapiens,9606,"RAS regulation and signaling are largely accomplished by direct protein-protein interactions, making RAS protein dynamics a critical determinant of RAS function. Here, we report a crystal structure of GDP-bound KRAS<sup>V14I</sup>, a mutated KRAS variant associated with the developmental RASopathy disorder Noonan syndrome (NS), at 1.5-1.6  resolution. The structure is notable for revealing a marked extension of switch 1 away from the G-domain and nucleotide-binding site of the KRAS protein. We found that this extension is associated with a loss of the magnesium ion and a tilt in the position of the guanine base because of the additional carbon introduced by the isoleucine substitution. Hydrogen-deuterium exchange MS analysis confirmed that this conformation occurs in solution, but also disclosed a difference in kinetics when compared with KRAS<sup>A146T</sup>, another RAS mutant that displays a nearly identical conformation in previously reported crystal structures. This conformational change contributed to a high rate of guanine nucleotide-exchange factor (GEF)-dependent and -independent nucleotide exchange and to an increase in affinity for SOS Ras/Rac GEF 1 (SOS1), which appears to be the major mode of activation for this RAS variant. These results highlight a mechanistic connection between KRAS<sup>A146T</sup> and KRAS<sup>V14I</sup> that may have implications for the regulation of these variants and for the development of therapeutic strategies to manage KRAS variant-associated disorders.",x-ray diffraction,1.6,1,3,A,69.84126984126983%,93.41317365269461%,2709,270,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,108,11,9,4,8,11,12,7,11,11,14,11,9,4,4,6,13,3,10,3,
6MQT,HRAS G12S in complex with GDP,GTPase KRas,Homo sapiens,9606,No DOI found,x-ray diffraction,1.5,1,8,A,88.35978835978835%,99.3975903614458%,2836,331,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,162,10,12,4,9,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
6MS9,GDP-bound KRAS P34R mutant,GTPase KRas,Homo sapiens,9606,"RAS proteins are commonly mutated in cancerous tumors, but germline RAS mutations are also found in RASopathy syndromes such as Noonan syndrome (NS) and cardiofaciocutaneous (CFC) syndrome. Activating RAS mutations can be subclassified based on their activating mechanisms. Understanding the structural basis for these mechanisms may provide clues for how to manage associated health conditions. We determined high-resolution X-ray structures of the RASopathy mutant KRAS<sup>P34R</sup> seen in NS and CFCS. GTP and GDP-bound KRAS<sup>P34R</sup> crystallized in multiple forms, with each lattice consisting of multiple protein conformations. In all GTP-bound conformations, the switch regions are not compatible with GAP binding, suggesting a structural mechanism for the GAP insensitivity of this RAS mutant. However, GTP-bound conformations are compatible with intrinsic nucleotide hydrolysis, including one that places R34 in a position analogous to the GAP arginine finger or intrinsic arginine finger found in heterotrimeric G proteins, which may support intrinsic GTP hydrolysis. We also note that the affinity between KRAS<sup>P34R</sup> and RAF-RBD is decreased, suggesting another possible mechanism for dampening of RAS signaling. These results may provide a foothold for development of new mutation-specific strategies to address KRAS<sup>P34R</sup> -driven diseases.",x-ray diffraction,1.49,1,3,A,69.31216931216932%,94.01197604790418%,2707,300,1,1,['GDP'],"GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,140,11,9,4,8,11,11,7,11,11,14,10,9,4,4,6,13,3,10,3,
6MTA,KRAS P34R mutant structure in complex with GTP analogue,GTPase KRas,Homo sapiens,9606,"RAS proteins are commonly mutated in cancerous tumors, but germline RAS mutations are also found in RASopathy syndromes such as Noonan syndrome (NS) and cardiofaciocutaneous (CFC) syndrome. Activating RAS mutations can be subclassified based on their activating mechanisms. Understanding the structural basis for these mechanisms may provide clues for how to manage associated health conditions. We determined high-resolution X-ray structures of the RASopathy mutant KRAS<sup>P34R</sup> seen in NS and CFCS. GTP and GDP-bound KRAS<sup>P34R</sup> crystallized in multiple forms, with each lattice consisting of multiple protein conformations. In all GTP-bound conformations, the switch regions are not compatible with GAP binding, suggesting a structural mechanism for the GAP insensitivity of this RAS mutant. However, GTP-bound conformations are compatible with intrinsic nucleotide hydrolysis, including one that places R34 in a position analogous to the GAP arginine finger or intrinsic arginine finger found in heterotrimeric G proteins, which may support intrinsic GTP hydrolysis. We also note that the affinity between KRAS<sup>P34R</sup> and RAF-RBD is decreased, suggesting another possible mechanism for dampening of RAS signaling. These results may provide a foothold for development of new mutation-specific strategies to address KRAS<sup>P34R</sup> -driven diseases.",x-ray diffraction,2.15,1,3,A,53.43915343915344%,93.41317365269461%,1370,213,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,50,11,8,3,7,12,11,7,11,11,15,11,8,4,4,6,15,3,11,3,
6NTC,Crystal Structure of G12V HRas-GppNHp bound in complex with the engineered RBD variant 1 of CRAF Kinase protein,"GTPase HRas, RAF proto-oncogene serine/threonine-protein kinase (E.C.2.7.11.1)",Homo sapiens,9606,"The small GTPases H, K, and NRAS are molecular switches indispensable for proper regulation of cellular proliferation and growth. Several mutations in the genes encoding members of this protein family are associated with cancer and result in aberrant activation of signaling processes caused by a deregulated recruitment of downstream effector proteins. In this study, we engineered variants of the Ras-binding domain (RBD) of the C-Raf proto-oncogene, Ser/Thr kinase (CRAF). These variants bound with high affinity with the effector-binding site of Ras in an active conformation. Structural characterization disclosed how the newly identified RBD mutations cooperate and thereby enhance affinity with the effector-binding site in Ras compared with WT RBD. The engineered RBD variants closely mimicked the interaction mode of naturally occurring Ras effectors and acted as dominant-negative affinity reagents that block Ras signal transduction. Experiments with cancer cells showed that expression of these RBD variants inhibits Ras signaling, reducing cell growth and inducing apoptosis. Using these optimized RBD variants, we stratified patient-derived colorectal cancer organoids with known Ras mutational status according to their response to Ras inhibition. These results revealed that the presence of Ras mutations was insufficient to predict sensitivity to Ras inhibition, suggesting that not all of these tumors required Ras signaling for proliferation. In summary, by engineering the Ras/Raf interface of the CRAF-RBD, we identified potent and selective inhibitors of Ras in its active conformation that outcompete binding of Ras-signaling effectors.",x-ray diffraction,2.9,1,2,A,88.88888888888889%,99.3975903614458%,1270,176,3,3,"['MG', 'GNP', 'GOL']","GNP, GOL, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, GLYCEROL, MAGNESIUM ION",active,5,10,11,4,8,11,13,9,8,11,16,11,11,4,3,5,15,4,11,3,
6O36,Crystal structure of human KRAS P34R mutant in complex with GNP,GTPase KRas,Homo sapiens,9606,"RAS proteins are commonly mutated in cancerous tumors, but germline RAS mutations are also found in RASopathy syndromes such as Noonan syndrome (NS) and cardiofaciocutaneous (CFC) syndrome. Activating RAS mutations can be subclassified based on their activating mechanisms. Understanding the structural basis for these mechanisms may provide clues for how to manage associated health conditions. We determined high-resolution X-ray structures of the RASopathy mutant KRAS<sup>P34R</sup> seen in NS and CFCS. GTP and GDP-bound KRAS<sup>P34R</sup> crystallized in multiple forms, with each lattice consisting of multiple protein conformations. In all GTP-bound conformations, the switch regions are not compatible with GAP binding, suggesting a structural mechanism for the GAP insensitivity of this RAS mutant. However, GTP-bound conformations are compatible with intrinsic nucleotide hydrolysis, including one that places R34 in a position analogous to the GAP arginine finger or intrinsic arginine finger found in heterotrimeric G proteins, which may support intrinsic GTP hydrolysis. We also note that the affinity between KRAS<sup>P34R</sup> and RAF-RBD is decreased, suggesting another possible mechanism for dampening of RAS signaling. These results may provide a foothold for development of new mutation-specific strategies to address KRAS<sup>P34R</sup> -driven diseases.",x-ray diffraction,2.0,1,3,A,88.88888888888889%,93.41317365269461%,1458,246,3,3,"['MG', 'GNP', 'PO4']","MG, PO4, GNP","MAGNESIUM ION, PHOSPHATE ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,75,11,9,4,8,12,13,8,11,11,15,11,9,4,4,6,15,3,11,3,
6O46,Crystal structure of human KRAS P34R mutant in complex with GNP and Phosphate,GTPase KRas,Homo sapiens,9606,"RAS proteins are commonly mutated in cancerous tumors, but germline RAS mutations are also found in RASopathy syndromes such as Noonan syndrome (NS) and cardiofaciocutaneous (CFC) syndrome. Activating RAS mutations can be subclassified based on their activating mechanisms. Understanding the structural basis for these mechanisms may provide clues for how to manage associated health conditions. We determined high-resolution X-ray structures of the RASopathy mutant KRAS<sup>P34R</sup> seen in NS and CFCS. GTP and GDP-bound KRAS<sup>P34R</sup> crystallized in multiple forms, with each lattice consisting of multiple protein conformations. In all GTP-bound conformations, the switch regions are not compatible with GAP binding, suggesting a structural mechanism for the GAP insensitivity of this RAS mutant. However, GTP-bound conformations are compatible with intrinsic nucleotide hydrolysis, including one that places R34 in a position analogous to the GAP arginine finger or intrinsic arginine finger found in heterotrimeric G proteins, which may support intrinsic GTP hydrolysis. We also note that the affinity between KRAS<sup>P34R</sup> and RAF-RBD is decreased, suggesting another possible mechanism for dampening of RAS signaling. These results may provide a foothold for development of new mutation-specific strategies to address KRAS<sup>P34R</sup> -driven diseases.",x-ray diffraction,1.9,1,3,A,89.41798941798942%,93.41317365269461%,1551,336,3,3,"['MG', 'GNP', 'PO4']","GNP, MG, PO4","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, PHOSPHATE ION",active,164,12,9,4,8,12,13,8,11,11,15,11,9,4,4,6,15,3,11,3,
6O62,"Crystal structure of Sec4p, a Rab family GTPase from Candida albicans",Ras-related protein SEC4,Candida albicans SC5314,237561,No DOI found,x-ray diffraction,1.88,1,1,A,72.4867724867725%,31.28834355828221%,1554,337,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,167,10,11,3,10,8,15,5,12,13,14,13,9,10,2,9,11,1,9,2,2
6OB3,Crystal structure of G13D-KRAS (GMPPNP-bound) in complex with GAP-related domain (GRD) of neurofibromin (NF1),"GTPase KRas, Neurofibromin",Homo sapiens,9606,"KRAS mutations occur in 35% of colorectal cancers and promote tumor growth by constitutively activating the mitogen-activated protein kinase (MAPK) pathway. KRAS mutations at codons 12, 13, or 61 are thought to prevent GAP protein-stimulated GTP hydrolysis and render KRAS-mutated colorectal cancers unresponsive to epidermal growth factor receptor (EGFR) inhibitors. We report here that KRAS G13-mutated cancer cells are frequently comutated with NF1 GAP but NF1 is rarely mutated in cancers with KRAS codon 12 or 61 mutations. Neurofibromin protein (encoded by the NF1 gene) hydrolyzes GTP directly in complex with KRAS G13D, and KRAS G13D-mutated cells can respond to EGFR inhibitors in a neurofibromin-dependent manner. Structures of the wild type and G13D mutant of KRAS in complex with neurofibromin (RasGAP domain) provide the structural basis for neurofibromin-mediated GTP hydrolysis. These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of KRAS G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.",x-ray diffraction,2.1,1,4,A,89.94708994708994%,93.41317365269461%,1469,253,2,2,"['MG', 'GNP']","GNP, MG, CL, MES","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, CHLORIDE ION, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID",active,81,11,9,4,8,12,13,8,12,11,15,11,9,4,4,6,16,4,10,3,
6P0I,Crystal structure of GDP-bound human RalA in a covalent complex with aryl sulfonyl fluoride compounds.,Ras-related protein Ral-A,Homo sapiens,9606,"Ral (Ras-like) GTPases are directly activated by oncogenic Ras GTPases. Mutant K-Ras (G12C) has enabled the development of covalent K-Ras inhibitors currently in clinical trials. However, Ral, and the overwhelming majority of mutant oncogenic K-Ras, are devoid of a druggable pocket and lack an accessible cysteine for the development of a covalent inhibitor. Here, we report that covalent bond formation by an aryl sulfonyl fluoride electrophile at a tyrosine residue (Tyr-82) inhibits guanine exchange factor Rgl2-mediated nucleotide exchange of Ral GTPase. A high-resolution 1.18- X-ray cocrystal structure shows that the compound binds to a well-defined binding site in RalA as a result of a switch II loop conformational change. The structure, along with additional high-resolution crystal structures of several analogs in complex with RalA, confirm the importance of key hydrogen bond anchors between compound sulfone oxygen atoms and Ral backbone nitrogen atoms. Our discovery of a pocket with features found on known druggable sites and covalent modification of a bystander tyrosine residue present in Ral and Ras GTPases provide a strategy that could lead to therapeutic agent targeting oncogenic Ras mutants that are devoid of a cysteine nucleophile.",x-ray diffraction,1.18,1,1,B,89.41798941798942%,54.93827160493827%,2975,373,10,10,"['CA', 'CL', 'EDO', 'ACT', 'NA', 'GOL', 'GDP', 'NL7']","GDP, EDO, ACT, GOL, NL7, CA, CL, NA","GUANOSINE-5'-DIPHOSPHATE, 1,2-ETHANEDIOL, ACETATE ION, GLYCEROL, 4-[(5-methoxypyridin-3-yl)sulfamoyl]benzene-1-sulfonic acid, CALCIUM ION, CHLORIDE ION, SODIUM ION",inactive,194,9,14,4,10,7,18,6,11,13,17,7,6,7,1,10,14,2,11,1,1
6P0Z,Crystal structure of N-acetylated KRAS (2-169) bound to GDP and Mg,GTPase KRas,Homo sapiens,9606,"Although post-translational modification of the C-terminus of RAS has been studied extensively, little is known about N-terminal processing. Mass spectrometric characterization of KRAS expressed in mammalian cells showed cleavage of the initiator methionine (iMet) and N-acetylation of the nascent N-terminus. Interestingly, structural studies on GDP- and GMPPNP-bound KRAS lacking the iMet and N-acetylation resulted in Mg<sup>2+</sup>-free structures of KRAS with flexible N-termini. In the Mg<sup>2+</sup>-free KRAS-GDP structure, the flexible N-terminus causes conformational changes in the interswitch region resulting in a fully open conformation of switch I. In the Mg<sup>2+</sup>-free KRAS-GMPPNP structure, the flexible N-terminus causes conformational changes around residue A59 resulting in the loss of Mg<sup>2+</sup> and switch I in the inactive state 1 conformation. Structural studies on N-acetylated KRAS-GDP lacking the iMet revealed the presence of Mg<sup>2+</sup> and a conformation of switch regions also observed in the structure of GDP-bound unprocessed KRAS with the iMet. In the absence of the iMet, the N-acetyl group interacts with the central beta-sheet and stabilizes the N-terminus and the switch regions. These results suggest there is crosstalk between the N-terminus and the Mg<sup>2+</sup> binding site, and that N-acetylation plays an important role by stabilizing the N-terminus of RAS upon excision of the iMet.",x-ray diffraction,1.01,1,2,A,88.35978835978835%,93.97590361445783%,2913,411,3,3,"['MG', 'ACE', 'GDP']","MG, GDP, ACE, PEG","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, ACETYL GROUP, DI(HYDROXYETHYL)ETHER",inactive,241,11,9,3,8,12,13,8,11,11,15,11,9,4,4,6,15,4,10,3,
6R3V,Crystal Structure of RhoA-GDP-Pi in Complex with RhoGAP,"Rho GTPase-activating protein 1, Transforming protein RhoA",Homo sapiens,9606,"Cell signaling by small G proteins uses an ON to OFF signal based on conformational changes following the hydrolysis of GTP to GDP and release of dihydrogen phosphate (P<sub>i</sub> ). The catalytic mechanism of GTP hydrolysis by RhoA is strongly accelerated by a GAP protein and is now well defined, but timing of inorganic phosphate release and signal change remains unresolved. We have generated a quaternary complex for RhoA-GAP-GDP-P<sub>i</sub> . Its 1.75 crystal structure shows geometry for ionic and hydrogen bond coordination of GDP and P<sub>i</sub> in an intermediate state. It enables the selection of a QM core for DFT exploration of a 20H-bonded network. This identifies serial locations of the two mobile protons from the original nucleophilic water molecule, showing how they move in three rational steps to form a stable quaternary complex. It also suggests how two additional proton transfer steps can facilitate P<sub>i</sub> release.",x-ray diffraction,1.75,1,2,B,78.83597883597884%,32.02247191011236%,1523,299,5,5,"['DTT', 'MG', 'MES', 'GDP', 'PO4']","PO4, MES, GDP, MG, DTT","PHOSPHATE ION, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 2,3-DIHYDROXY-1,4-DITHIOBUTANE",inactive,122,10,14,5,5,8,15,5,13,13,15,10,4,6,2,5,14,10,11,5,2
6RIR,Crystal structure of phosphorylated Rab8a in complex with the Rab-binding domain of RILPL2,"Ras-related protein Rab-8A, RILP-like protein 2",Homo sapiens,9606,"Rab8a is associated with the dynamic regulation of membrane protrusions in polarized cells. Rab8a is one of several Rab GTPases that are substrates of leucine-rich repeat kinase 2 (LRRK2), a serine/threonine kinase that is linked to Parkinson's disease. Rab8a is phosphorylated at T72 (pT72) in its switch 2 helix and recruits the phospho-specific effector RILPL2, which subsequently regulates ciliogenesis. Here, we report the crystal structure of phospho-Rab8a (pRab8a) in complex with the RH2 (RILP homology) domain of RILPL2. The complex is a heterotetramer with RILPL2 forming a central -helical dimer that bridges two pRab8a molecules. The N termini ofthe  helices cross over, forming an X-shaped cap (X-cap) that orients Arg residues from RILPL2 toward pT72. X-cap residues critical for pRab8a binding are conserved in JIP3 and JIP4, which also interact with LRRK2-phosphorylated Rab10. We propose a general mode of recognition for phosphorylated Rab GTPases by this family of phospho-specific effectors.",x-ray diffraction,1.77,1,4,A,55.026455026455025%,35.294117647058826%,1605,339,4,4,"['GTP', 'MG', 'TPO', 'GOL']","GTP, MG, GOL","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, GLYCEROL",active,163,11,12,5,8,11,11,6,17,13,7,18,2,10,1,11,14,,11,2,2
6S5F,Structure of the human RAB39B in complex with GMPPNP,Ras-related protein Rab-39B,Homo sapiens,9606,No DOI found,x-ray diffraction,1.7,1,1,A,100.0%,38.55421686746988%,1691,299,4,4,"['GLY', 'MG', 'EDO', 'GNP']","GLY, GNP, EDO, MG","GLYCINE, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, 1,2-ETHANEDIOL, MAGNESIUM ION",active,107,13,10,1,9,13,15,7,10,14,17,15,10,4,4,10,10,3,17,2,4
6SQ2,Structure of a phosphomimetic switch 2 variant of Rab8a in complex with the phospho-Rab binding domain of RILPL2,"Ras-related protein Rab-8A, RILP-like protein 2",Homo sapiens,9606,No DOI found,x-ray diffraction,1.68,1,4,A,93.12169312169311%,35.294117647058826%,1678,400,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,222,11,13,5,8,11,12,6,18,14,7,18,2,10,1,11,14,,11,2,2
6SUR,The Rab33B-Atg16L1 crystal structure,"Ras-related protein Rab-33B, Autophagy-related protein 16-1",Mus musculus,10090,The Atg12-Atg5/Atg16L1 complex is recruited by WIPI2b to the site of autophagosome formation. Atg16L1 is an effector of the Golgi resident GTPase Rab33B. Here we identified a minimal stable complex of murine Rab33B(30-202) Q92L and Atg16L1(153-210). Atg16L1(153-210) comprises the C-terminal part of the Atg16L1 coiled-coil domain. We have determined the crystal structure of the Rab33B Q92L/Atg16L1(153-210) effector complex at 3.47 resolution. This structure reveals that two Rab33B molecules bind to the diverging -helices of the dimeric Atg16L1 coiled-coil domain. We mutated Atg16L1 and Rab33B interface residues and found that they disrupt complex formation in pull-down assays and cellular co-localization studies. The Rab33B binding site of Atg16L1 comprises 20 residues and immediately precedes the WIPI2b binding site. Rab33B mutations that abolish Atg16L binding also abrogate Rab33B association with the Golgi stacks. Atg16L1 mutants that are defective in Rab33B binding still co-localize with WIPI2b in vivo. The close proximity of the Rab33B and WIPI2b binding sites might facilitate the recruitment of Rab33B containing vesicles to provide a source of lipids during autophagosome biogenesis.,x-ray diffraction,3.47,1,12,A,90.47619047619048%,34.9112426035503%,1388,173,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,0,7,14,5,9,10,8,4,10,12,12,13,5,8,7,10,13,6,12,4,2
6T5B,KRasG12C ligand complex,GTPase KRas,Homo sapiens,9606,"Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an ""Achilles heel"" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.",x-ray diffraction,1.37,1,1,A,89.94708994708994%,91.01796407185628%,1670,416,4,4,"['MG', 'SO4', 'O7K', 'GDP']","MG, GDP, O7K, SO4","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, pyrazinoquinolinone, SULFATE ION",inactive,242,11,9,4,10,12,13,8,12,12,14,12,9,4,4,6,15,4,10,1,
6T5U,KRasG12C ligand complex,"GTPase KRas isoform X2, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, isoform CRA_b",Homo sapiens,9606,"Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an ""Achilles heel"" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.",x-ray diffraction,1.72,1,2,B,88.35978835978835%,91.56626506024097%,1455,232,3,3,"['MG', 'MKW', 'GDP']","MG, GDP, MKW","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1-[(7R)-16-chloro-15-(5-methyl-1H-indazol-4-yl)-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",inactive,62,11,9,4,10,12,12,8,10,12,15,11,9,4,4,6,15,4,10,1,
6T5V,KRasG12C ligand complex,GTPase KRas,Homo sapiens,9606,"Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an ""Achilles heel"" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.",x-ray diffraction,1.31,1,1,A,89.41798941798942%,91.61676646706587%,1608,354,3,3,"['MG', 'MKZ', 'GDP']","MG, GDP, MKZ","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1-[4-[6-chloranyl-7-(5-methyl-1~{H}-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]propan-1-one",inactive,182,10,9,4,10,12,13,8,12,12,15,11,9,4,4,6,15,4,10,1,
6UKA,Crystal structure of RHOG and ELMO complex,"Rho-related GTP-binding protein RhoG, Engulfment and cell motility protein 2",Homo sapiens,9606,"DOCK (dedicator of cytokinesis) proteins are multidomain guanine nucleotide exchange factors (GEFs) for RHO GTPases that regulate intracellular actin dynamics. DOCK proteins share catalytic (DOCK<sup>DHR2</sup>) and membrane-associated (DOCK<sup>DHR1</sup>) domains. The structurally-related DOCK1 and DOCK2 GEFs are specific for RAC, and require ELMO (engulfment and cell motility) proteins for function. The N-terminal RAS-binding domain (RBD) of ELMO (ELMO<sup>RBD</sup>) interacts with RHOG to modulate DOCK1/2 activity. Here, we determine the cryo-EM structures of DOCK2-ELMO1 alone, and as a ternary complex with RAC1, together with the crystal structure of a RHOG-ELMO2<sup>RBD</sup> complex. The binary DOCK2-ELMO1 complex adopts a closed, auto-inhibited conformation. Relief of auto-inhibition to an active, open state, due to a conformational change of the ELMO1 subunit, exposes binding sites for RAC1 on DOCK2<sup>DHR2</sup>, and RHOG and BAI GPCRs on ELMO1. Our structure explains how up-stream effectors, including DOCK2 and ELMO1 phosphorylation, destabilise the auto-inhibited state to promote an active GEF.",x-ray diffraction,2.4,1,2,A,93.65079365079364%,34.84848484848485%,1515,275,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,96,9,15,1,8,11,9,7,9,15,18,8,13,6,5,5,9,11,9,7,2
6V6M,Crystal structure of an inactive state of GMPPNP-bound RhoA,Transforming protein RhoA (E.C.3.6.5.2),Homo sapiens,9606,"By using <sup>31</sup>P NMR, we present evidence that the Rho family GTPase RhoA, similar to Ras GTPases, exists in an equilibrium of conformations when bound to GTP. High-resolution crystal structures of RhoA bound to the GTP analog GMPPNP and to GDP show that they display a similar overall inactive conformation. In contrast to the previously reported crystal structures of GTP analog-bound forms of two RhoA dominantly active mutants (G14V and Q63L), GMPPNP-bound RhoA assumes an open conformation in the Switch I loop with a previously unseen interaction between the -phosphate and Pro36, instead of the canonical Thr37. Molecular dynamics simulations found that the oncogenic RhoA<sup>G14V</sup> mutant displays a reduced flexibility in the Switch regions, consistent with a crystal structure of GDP-bound RhoA<sup>G14V</sup>. Thus, GDP- and GTP-bound RhoA can present similar inactive conformations, and the molecular dynamics in the Switch regions are likely to have a role in RhoA activation.",x-ray diffraction,1.39,1,1,A,94.70899470899471%,32.38636363636363%,1709,432,4,4,"['MG', 'GNP', 'DIO']","GNP, MG, DIO","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, 1,4-DIETHYLENE DIOXIDE",active,249,10,13,5,6,8,16,5,14,13,16,10,5,7,2,6,15,11,10,5,2
6V6V,Crystal structure of oncogenic RhoA mutant G14V complexed with GDP,Transforming protein RhoA (E.C.3.6.5.2),Homo sapiens,9606,"By using <sup>31</sup>P NMR, we present evidence that the Rho family GTPase RhoA, similar to Ras GTPases, exists in an equilibrium of conformations when bound to GTP. High-resolution crystal structures of RhoA bound to the GTP analog GMPPNP and to GDP show that they display a similar overall inactive conformation. In contrast to the previously reported crystal structures of GTP analog-bound forms of two RhoA dominantly active mutants (G14V and Q63L), GMPPNP-bound RhoA assumes an open conformation in the Switch I loop with a previously unseen interaction between the -phosphate and Pro36, instead of the canonical Thr37. Molecular dynamics simulations found that the oncogenic RhoA<sup>G14V</sup> mutant displays a reduced flexibility in the Switch regions, consistent with a crystal structure of GDP-bound RhoA<sup>G14V</sup>. Thus, GDP- and GTP-bound RhoA can present similar inactive conformations, and the molecular dynamics in the Switch regions are likely to have a role in RhoA activation.",x-ray diffraction,1.4,1,1,A,94.70899470899471%,31.818181818181817%,1637,361,4,4,"['MG', 'DIO', 'GDP']","GDP, MG, DIO","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 1,4-DIETHYLENE DIOXIDE",inactive,178,9,13,5,6,8,16,5,14,13,17,10,5,7,2,6,15,11,10,5,2
6WCW,Structure of human Rubicon RH domain in complex with GTP-bound Rab7,"Ras-related protein Rab-7a, Run domain Beclin-1-interacting and cysteine-rich domain-containing protein",Homo sapiens,9606,"Rubicon is a potent negative regulator of autophagy and a potential target for autophagy-inducing therapeutics. Rubicon-mediated inhibition of autophagy requires the interaction of the C-terminal Rubicon homology (RH) domain of Rubicon with Rab7-GTP. Here we report the 2.8- crystal structure of the Rubicon RH domain in complex with Rab7-GTP. Our structure reveals a fold for the RH domain built around four zinc clusters. The switch regions of Rab7 insert into pockets on the surface of the RH domain in a mode that is distinct from those of other Rab-effector complexes. Rubicon residues at the dimer interface are required for Rubicon and Rab7 to colocalize in living cells. Mutation of Rubicon RH residues in the Rab7-binding site restores efficient autophagic flux in the presence of overexpressed Rubicon, validating the Rubicon RH domain as a promising therapeutic target.",x-ray diffraction,2.8,1,2,B,93.12169312169311%,33.33333333333333%,1438,178,2,2,"['GTP', 'MG']","GTP, MG, ZN","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, ZINC ION",active,0,8,15,3,8,12,11,5,12,15,16,9,10,11,,11,11,5,8,3,3
6WGH,Crystal structure of GDP-bound NRAS with ten residues long internal tandem duplication in the switch II region,GTPase KRas,Homo sapiens,9606,"The oncogene RAS is one of the most widely studied proteins in cancer biology, and mutant active RAS is a driver in many types of solid tumors and hematological malignancies. Yet the biological effects of different <i>RAS</i> mutations and the tissue-specific clinical implications are complex and nuanced. Here, we identified an internal tandem duplication (ITD) in the switch II domain of NRAS from a patient with extremely aggressive colorectal carcinoma. Results of whole-exome DNA sequencing of primary and metastatic tumors indicated that this mutation was present in all analyzed metastases and excluded the presence of any other clear oncogenic driver mutations. Biochemical analysis revealed increased interaction of the RAS ITD with Raf proto-oncogene Ser/Thr kinase (RAF), leading to increased phosphorylation of downstream MAPK/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK). The ITD prevented interaction with neurofibromin 1 (NF1)-GTPase-activating protein (GAP), providing a mechanism for sustained activity of the RAS ITD protein. We present the first crystal structures of NRAS and KRAS ITD at 1.65-1.75  resolution, respectively, providing insight into the physical interactions of this class of RAS variants with its regulatory and effector proteins. Our in-depth bedside-to-bench analysis uncovers the molecular mechanism underlying a case of highly aggressive colorectal cancer and illustrates the importance of robust biochemical and biophysical approaches in the implementation of individualized medicine.",x-ray diffraction,1.65,1,2,A,55.55555555555556%,85.0%,1426,245,5,5,"['MG', 'GOL', 'FLC', 'GDP']","MG, GDP, FLC, GOL","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, CITRATE ANION, GLYCEROL",inactive,74,12,10,5,8,12,10,8,11,12,15,11,8,5,2,6,14,4,10,3,
6WGN,Crystal structure of K-Ras(G12D) GppNHp bound to cyclic peptide ligand KD2,"GTPase KRas, Cyclic Peptide KD2",Homo sapiens,9606,"We report the identification of three cyclic peptide ligands of K-Ras(G12D) using an integrated <i>in vitro</i> translation-mRNA display selection platform. These cyclic peptides show preferential binding to the GTP-bound state of K-Ras(G12D) over the GDP-bound state and block Ras-Raf interaction. A co-crystal structure of peptide KD2 with K-Ras(G12D)GppNHp reveals that this peptide binds in the Switch II groove region with concomitant opening of the Switch II loop and a 40 rotation of the 2 helix, and that a threonine residue (Thr10) on KD2 has direct access to the mutant aspartate (Asp12) on K-Ras. Replacing this threonine with non-natural amino acids afforded peptides with improved potency at inhibiting the interaction between Raf1-RBD and K-Ras(G12D) but not wildtype K-Ras. The union of G12D over wildtype selectivity and GTP state/GDP state selectivity is particularly desirable, considering that oncogenic K-Ras(G12D) exists predominantly in the GTP state in cancer cells, and wildtype K-Ras signaling is important for the maintenance of healthy cells.",x-ray diffraction,1.6,1,6,A,69.84126984126983%,91.61676646706587%,1536,339,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,171,10,9,4,10,11,12,8,12,12,15,10,9,4,4,6,16,4,10,,
6WS2,"Crystal structure of KRAS-K104Q mutant, GDP-bound",,Homo sapiens,9606,No DOI found,x-ray diffraction,1.59,1,4,A,89.94708994708994%,93.41317365269461%,1509,301,6,6,"['MG', 'SO4', 'GDP']","GDP, MG, SO4, CL","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, SULFATE ION, CHLORIDE ION",inactive,125,12,9,4,8,12,13,8,11,11,15,11,10,4,4,6,15,4,10,3,
6WS4,"Crystal structure of KRAS-G12D/K104Q mutant, GDP-bound",,Homo sapiens,9606,No DOI found,x-ray diffraction,1.84,1,4,A,89.41798941798942%,92.81437125748504%,1426,234,2,2,"['MG', 'GDP']","GDP, MG, TCE","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 3,3',3''-phosphanetriyltripropanoic acid",inactive,63,11,9,4,8,12,13,8,10,11,15,11,10,4,4,6,16,4,10,3,
6XGU,Crystal Structure of KRAS-Q61R (GMPPNP-bound) in complex with RAS-binding domain (RBD) and cysteine-rich domain (CRD) of RAF1/CRAF,,Homo sapiens,9606,"The first step of RAF activation involves binding to active RAS, resulting in the recruitment of RAF to the plasma membrane. To understand the molecular details of RAS-RAF interaction, we present crystal structures of wild-type and oncogenic mutants of KRAS complexed with the RAS-binding domain (RBD) and the membrane-interacting cysteine-rich domain (CRD) from the N-terminal regulatory region of RAF1. Our structures reveal that RBD and CRD interact with each other to form one structural entity in which both RBD and CRD interact extensively with KRAS. Mutations at the KRAS-CRD interface result in a significant reduction in RAF1 activation despite only a modest decrease in binding affinity. Combining our structures and published data, we provide a model of RAS-RAF complexation at the membrane, and molecular insights into RAS-RAF interaction during the process of RAS-mediated RAF activation.",x-ray diffraction,2.7,1,2,A,88.88888888888889%,93.41317365269461%,1377,178,3,3,"['MG', 'GNP', 'ZN']","GNP, MG, ZN, GOL","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, ZINC ION, GLYCEROL",active,7,11,9,4,8,12,13,8,11,11,15,11,8,4,4,6,15,4,11,3,
6Y09,Crystal structure of Atg16L in complex with GTP-bound Rab33B (Q92L),,Homo sapiens,9606,"Autophagosome formation is a fundamental process in macroautophagy/autophagy, a conserved self-eating mechanism in all eukaryotes, which requires the conjugating ATG (autophagy related) protein complex, ATG12-ATG5-ATG16L1 and lipidated MAP1LC3/LC3 (microtubule associated protein 1 light chain 3). How the ATG12-ATG5-ATG16L1 complex is recruited to membranes is not fully understood. Here, we demonstrated that RAB33B plays a key role in recruiting the ATG16L1 complex to phagophores during starvation-induced autophagy. Crystal structures of RAB33B bound to the coiled-coil domain (CCD) of ATG16L1 revealed the recognition mechanism between RAB33B and ATG16L1. ATG16L1 is a novel RAB-binding protein (RBP) that can induce RAB proteins to adopt active conformation without nucleotide exchange. RAB33B and ATG16L1 mutually determined the localization of each other on phagophores. RAB33B-ATG16L1 interaction was required for LC3 lipidation and autophagosome formation. Upon starvation, a fraction of RAB33B translocated from the Golgi to phagophores and recruited the ATG16L1 complex. In this work, we reported a new mechanism for the recruitment of the ATG12-ATG5-ATG16L1 complex to phagophores by RAB33B, which is required for autophagosome formation.<b>Abbreviations</b>: ATG: autophagy-related; C: alpha carbon; CCD: coiled-coil domain; CLEM: correlative light and electron microscopy; DTE: dithioerythritol; EBSS: Earle's balanced salt solution; EDTA: ethylenediaminetetraacetic acid; EGFP: enhanced green fluorescent protein; FBS: fetal bovine serum; FLIM: fluorescence lifetime imaging microscopy; FRET: Frster resonance energy transfer; GDP: guanosine diphosphate; GOLGA2/GM130: golgin A2; GppNHp: guanosine 5'-[,-imido]triphosphate; GST: glutathione S-transferase; GTP: guanosine triphosphate; GTPS: guanosine 5'-O-[gamma-thio]triphosphate; HA (tag): hemagglutinin (tag); HEK: human embryonic kidney; HeLa: Henrietta Lacks; HEPES: (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); IgG: immunoglobulin G; K<sub>d</sub>: dissociation constant; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MCF7: Michigan cancer foundation-7; MEF: mouse embryonic fibroblast; MEM: minimum essential medium Eagle; MST: microscale thermophoresis; NEAA: non-essential amino acids; PBS: phosphate-buffered saline; PE: phosphatidylethanolamine; PtdIns3P: phosphatidylinositol-3-phosphate; RAB: RAS-associated binding; RB1CC1/FIP200: RB1 inducible coiled-coil protein 1; RBP: RAB-binding protein; SD: standard deviation; SDS: sodium dodecyl sulfate; SQSTM1/p62: sequestosome 1; TBS-T: tris-buffered saline-tween 20; WD (repeat): tryptophan-aspartic acid (repeat); WIPI2B: WD repeat domain phosphoinositide interacting 2B; WT: wild type.",x-ray diffraction,2.4,1,4,A,93.12169312169311%,34.806629834254146%,1579,280,6,6,"['GTP', 'MG', 'PEG', 'PO4']","MG, GTP, PO4, PEG, EDO","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE, PHOSPHATE ION, DI(HYDROXYETHYL)ETHER, 1,2-ETHANEDIOL",active,98,7,13,5,10,10,9,4,11,13,12,13,5,8,8,10,12,7,13,4,2
6YR8,Affimer K6 - KRAS protein complex,,Homo sapiens,9606,"RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that reveals a conformer of wild-type RAS with a large, druggable SII/3 pocket. Competitive NanoBRET between the RAS-binding Affimers and known RAS binding small-molecules demonstrates the potential to use Affimers as tools to identify pharmacophores. This work highlights the potential of using biologics with small interface surfaces to select unseen, druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins.",x-ray diffraction,1.9,1,2,A,53.96825396825397%,93.97590361445783%,1361,234,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,68,11,9,4,9,12,10,7,10,11,15,11,8,4,5,6,15,4,10,3,
6YX5,Structure of DrrA from Legionella pneumophilia in complex with human Rab8a,"Ras-related protein Rab-8A, Multifunctional virulence effector protein DrrA",Homo sapiens,9606,"Legionella pneumophila infects eukaryotic cells by forming a replicative organelle - the Legionella containing vacuole. During this process, the bacterial protein DrrA/SidM is secreted and manipulates the activity and post-translational modification (PTM) states of the vesicular trafficking regulator Rab1. As a result, Rab1 is modified with an adenosine monophosphate (AMP), and this process is referred to as AMPylation. Here, we use a chemical approach to stabilise low-affinity Rab:DrrA complexes in a site-specific manner to gain insight into the molecular basis of the interaction between the Rab protein and the AMPylation domain of DrrA. The crystal structure of the Rab:DrrA complex reveals a previously unknown non-conventional Rab-binding site (NC-RBS). Biochemical characterisation demonstrates allosteric stimulation of the AMPylation activity of DrrA via Rab binding to the NC-RBS. We speculate that allosteric control of DrrA could in principle prevent random and potentially cytotoxic AMPylation in the host, thereby perhaps ensuring efficient infection by Legionella.",x-ray diffraction,2.14,1,2,A,91.53439153439153%,36.19631901840491%,1500,206,6,6,"['MG', 'SO4', 'GNP', 'LJN', 'GLC']","MG, GNP, GLC, LJN, SO4","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, alpha-D-glucopyranose, [(2~{R},3~{S},4~{R},5~{R})-5-[4-(acetamidomethyl)-1,2,3-triazol-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl dihydrogen phosphate, SULFATE ION",active,27,11,12,6,9,11,11,5,16,12,7,18,3,10,2,11,14,,11,2,2
6YXW,Affimer K3 - KRAS protein complex,,Homo sapiens,9606,"RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that reveals a conformer of wild-type RAS with a large, druggable SII/3 pocket. Competitive NanoBRET between the RAS-binding Affimers and known RAS binding small-molecules demonstrates the potential to use Affimers as tools to identify pharmacophores. This work highlights the potential of using biologics with small interface surfaces to select unseen, druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins.",x-ray diffraction,2.06,1,4,A,87.83068783068782%,94.01197604790418%,1378,197,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,29,11,9,3,8,12,12,8,11,11,15,11,9,4,4,6,15,4,10,3,
6ZAY,Crystal structure of Atg16L in complex with GDP-bound Rab33B,,Homo sapiens,9606,"Autophagosome formation is a fundamental process in macroautophagy/autophagy, a conserved self-eating mechanism in all eukaryotes, which requires the conjugating ATG (autophagy related) protein complex, ATG12-ATG5-ATG16L1 and lipidated MAP1LC3/LC3 (microtubule associated protein 1 light chain 3). How the ATG12-ATG5-ATG16L1 complex is recruited to membranes is not fully understood. Here, we demonstrated that RAB33B plays a key role in recruiting the ATG16L1 complex to phagophores during starvation-induced autophagy. Crystal structures of RAB33B bound to the coiled-coil domain (CCD) of ATG16L1 revealed the recognition mechanism between RAB33B and ATG16L1. ATG16L1 is a novel RAB-binding protein (RBP) that can induce RAB proteins to adopt active conformation without nucleotide exchange. RAB33B and ATG16L1 mutually determined the localization of each other on phagophores. RAB33B-ATG16L1 interaction was required for LC3 lipidation and autophagosome formation. Upon starvation, a fraction of RAB33B translocated from the Golgi to phagophores and recruited the ATG16L1 complex. In this work, we reported a new mechanism for the recruitment of the ATG12-ATG5-ATG16L1 complex to phagophores by RAB33B, which is required for autophagosome formation.<b>Abbreviations</b>: ATG: autophagy-related; C: alpha carbon; CCD: coiled-coil domain; CLEM: correlative light and electron microscopy; DTE: dithioerythritol; EBSS: Earle's balanced salt solution; EDTA: ethylenediaminetetraacetic acid; EGFP: enhanced green fluorescent protein; FBS: fetal bovine serum; FLIM: fluorescence lifetime imaging microscopy; FRET: Frster resonance energy transfer; GDP: guanosine diphosphate; GOLGA2/GM130: golgin A2; GppNHp: guanosine 5'-[,-imido]triphosphate; GST: glutathione S-transferase; GTP: guanosine triphosphate; GTPS: guanosine 5'-O-[gamma-thio]triphosphate; HA (tag): hemagglutinin (tag); HEK: human embryonic kidney; HeLa: Henrietta Lacks; HEPES: (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); IgG: immunoglobulin G; K<sub>d</sub>: dissociation constant; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MCF7: Michigan cancer foundation-7; MEF: mouse embryonic fibroblast; MEM: minimum essential medium Eagle; MST: microscale thermophoresis; NEAA: non-essential amino acids; PBS: phosphate-buffered saline; PE: phosphatidylethanolamine; PtdIns3P: phosphatidylinositol-3-phosphate; RAB: RAS-associated binding; RB1CC1/FIP200: RB1 inducible coiled-coil protein 1; RBP: RAB-binding protein; SD: standard deviation; SDS: sodium dodecyl sulfate; SQSTM1/p62: sequestosome 1; TBS-T: tris-buffered saline-tween 20; WD (repeat): tryptophan-aspartic acid (repeat); WIPI2B: WD repeat domain phosphoinositide interacting 2B; WT: wild type.",x-ray diffraction,2.4,1,4,A,92.5925925925926%,35.35911602209944%,1555,265,7,7,"['EDO', 'MG', 'PEG', 'GDP', 'PO4']","PO4, PEG, EDO, MG, GDP","PHOSPHATE ION, DI(HYDROXYETHYL)ETHER, 1,2-ETHANEDIOL, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,83,7,13,5,10,10,9,4,11,11,12,13,6,8,8,10,12,7,13,4,2
6ZIO,CRYSTAL STRUCTURE OF NRAS (C118S) IN COMPLEX WITH GDP,GTPase NRas,Homo sapiens,9606,"Activating mutations in the three human RAS genes, <i>KRAS</i>, <i>NRAS</i> and <i>HRAS</i>, are among the most common oncogenic drivers in human cancers. Covalent KRAS<sup>G12C</sup> inhibitors, which bind to the switch II pocket in the 'off state'of KRAS, represent the first direct KRAS drugs that entered human clinical trials. However, the remaining 85% of non-KRAS<sup>G12C</sup>-driven cancers remain undrugged as do NRAS and HRAS and no drugs targeting the 'on state'have been discovered so far. The switch I/II pocket is a second pocket for which the nanomolar inhibitor BI-2852 has been discovered. Here, we elucidate inhibitor binding modes in KRAS, NRAS and HRAS on and off and discuss future strategies to drug all RAS isoforms with this one pocket.",x-ray diffraction,1.55,1,2,A,90.47619047619048%,89.53488372093024%,1496,311,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,138,12,10,5,9,12,12,9,12,12,15,11,9,5,2,6,14,4,10,2,
6ZIZ,CRYSTAL STRUCTURE OF NRAS Q61R IN COMPLEX WITH GTP AND COMPOUND 18,GTPase NRas,Homo sapiens,9606,"Activating mutations in the three human RAS genes, <i>KRAS</i>, <i>NRAS</i> and <i>HRAS</i>, are among the most common oncogenic drivers in human cancers. Covalent KRAS<sup>G12C</sup> inhibitors, which bind to the switch II pocket in the 'off state'of KRAS, represent the first direct KRAS drugs that entered human clinical trials. However, the remaining 85% of non-KRAS<sup>G12C</sup>-driven cancers remain undrugged as do NRAS and HRAS and no drugs targeting the 'on state'have been discovered so far. The switch I/II pocket is a second pocket for which the nanomolar inhibitor BI-2852 has been discovered. Here, we elucidate inhibitor binding modes in KRAS, NRAS and HRAS on and off and discuss future strategies to drug all RAS isoforms with this one pocket.",x-ray diffraction,1.79,1,2,A,89.94708994708994%,88.95348837209302%,2946,338,3,3,"['GTP', 'MG', 'EZZ']","GTP, MG, EZZ","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, (3~{S})-3-[2-[(dimethylamino)methyl]-1~{H}-indol-3-yl]-5-oxidanyl-2,3-dihydroisoindol-1-one",active,165,11,10,5,9,12,12,9,12,12,15,11,8,5,2,6,14,4,11,2,
6ZQT,Crystal structure of the RLIP76 Ral binding domain mutant (E427H/Q433L/K440R) in complex with RalB-GMPPNP,,Homo sapiens,9606,"Ral GTPases have been implicated as critical drivers of cell growth and metastasis in numerous Ras-driven cancers. We have previously reported stapled peptides, based on the Ral effector RLIP76, that can disrupt Ral signaling. Stapled peptides are short peptides that are locked into their bioactive form using a synthetic brace. Here, using an affinity maturation of the RLIP76 Ral-binding domain, we identified several sequence substitutions that together improve binding to Ral proteins by more than 20-fold. Hits from the selection were rigorously analyzed to determine the contributions of individual residues and two 1.5  cocrystal structures of the tightest-binding mutants in complex with RalB revealed key interactions. Insights gained from this maturation were used to design second-generation stapled peptides based on RLIP76 that exhibited vastly improved selectivity for Ral GTPases when compared with the first-generation lead peptide. The binding of second-generation peptides to Ral proteins was quantified and the binding site of the lead peptide on RalB was determined by NMR. Stapled peptides successfully competed with multiple Ral-effector interactions in cellular lysates. Our findings demonstrate how manipulation of a native binding partner can assist in the rational design of stapled peptide inhibitors targeting a protein-protein interaction.",x-ray diffraction,1.51,1,4,A,91.53439153439153%,52.69461077844312%,1558,312,2,2,"['MG', 'GNP']","GNP, MG, GOL","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL",active,137,10,13,4,11,9,22,6,13,14,17,8,5,3,2,9,12,3,11,,1
6ZSI,The mechanism of activation of the actin binding protein EHBP1 by Rab8 family members.,"Ras-related protein Rab-8A, EH domain-binding protein 1",Homo sapiens,9606,"EHBP1 is an adaptor protein that regulates vesicular trafficking by recruiting Rab8 family members and Eps15-homology domain-containing proteins 1/2 (EHD1/2). It also links endosomes to the actin cytoskeleton. However, the underlying molecular mechanism of activation of EHBP1 actin-binding activity is unclear. Here, we show that both termini of EHBP1 have membrane targeting potential. EHBP1 associates with PI(3)P, PI(5)P, and phosphatidylserine via its N-terminal C2 domain. We show that in the absence of Rab8 family members, the C-terminal bivalent Mical/EHBP Rab binding (bMERB) domain forms an intramolecular complex with its central calponin homology (CH) domain and auto-inhibits actin binding. Rab8 binding to the bMERB domain relieves this inhibition. We have analyzed the CH:bMERB auto-inhibited complex and the active bMERB:Rab8 complex biochemically and structurally. Together with structure-based mutational studies, this explains how binding of Rab8 frees the CH domain and allows it to interact with the actin cytoskeleton, leading to membrane tubulation.",x-ray diffraction,1.91,1,4,A,90.47619047619048%,36.19631901840491%,1440,192,3,3,"['MG', 'PEG', 'GNP']","GNP, PEG, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, DI(HYDROXYETHYL)ETHER, MAGNESIUM ION",active,18,11,12,5,8,12,11,6,15,12,7,18,3,10,1,11,14,,11,2,2
7BTA,Crystal structure of Rheb D60K mutant bound to GDP,GTP-binding protein Rheb,Homo sapiens,9606,,x-ray diffraction,2.6,1,2,A,70.8994708994709%,35.84905660377358%,1322,174,2,2,"['PO4', 'GDP']","GDP, PO4","GUANOSINE-5'-DIPHOSPHATE, PHOSPHATE ION",inactive,7,10,9,3,15,9,13,7,14,14,15,17,8,6,3,7,6,3,5,,1
7BTC,Crystal structure of Rheb Y35N mutant bound to GDP,GTP-binding protein Rheb,Homo sapiens,9606,,x-ray diffraction,2.1,1,4,A,88.88888888888889%,35.84905660377358%,1413,238,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,69,10,9,3,15,9,13,7,13,14,15,17,9,7,3,7,8,3,5,,1
7BWT,SopD-Rab8 complex structure,"SPI-1 type III secretion system effector SopD, Ras-related protein Rab-8A",Salmonella enterica subsp. enterica serovar Typhimurium,90371,"The food-borne bacterial pathogen Salmonella Typhimurium uses a type III protein secretion system to deliver multiple proteins into host cells. These secreted effectors modulate the functions of host cells and activate specific signalling cascades that result in the production of pro-inflammatory cytokines and intestinal inflammation. Some of the Salmonella-encoded effectors counteract this inflammatory response and help to preserve host homeostasis. Here, we demonstrate that the Salmonella effector protein SopD, which is required for pathogenesis, functions to both activate and inhibit the inflammatory response by targeting the Rab8 GTPase, which is a negative regulator of inflammation. We show that SopD has GTPase-activating protein activity for Rab8 and, therefore, inhibits this GTPase and stimulates inflammation. We also show that SopD activates Rab8 by displacing it from its cognate guanosine dissociation inhibitor, resulting in the stimulation of a signalling cascade that suppresses inflammation. We solved the crystal structure of SopD in association with Rab8 to a resolution of 2.3, which reveals a unique contact interface that underlies these complex interactions. These findings show the remarkable evolution of a bacterial effector protein to exert both agonistic and antagonistic activities towards the same host cellular target to modulate the inflammatory response.",x-ray diffraction,2.3,1,2,B,94.17989417989418%,36.0%,1527,220,6,6,"['MG', 'GOL', 'GDP']","PEG, GOL, GDP, MG","DI(HYDROXYETHYL)ETHER, GLYCEROL, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,36,12,12,5,8,12,12,6,18,13,7,18,3,11,1,11,14,,11,2,2
7C40,MgGDP bound KRAS G12V,GTPase KRas,Homo sapiens,9606,"Kirsten-RAS (KRAS) has been the target of drugs because it is the most mutated gene in human cancers. Because of the low affinity of drugs for KRAS mutations, it was difficult to target these tumor genes directly. We found a direct interaction between KRAS G12V and tumor suppressor novel H-REV107 peptide with high binding affinity. We report the first crystal structure of an oncogenic mutant, KRAS G12V-H-REV107. This peptide was shown to interact with KRAS G12V in the guanosine diphosphate (GDP)-bound inactive state and to form a stable complex, blocking the activation function of KRAS. We showed that the peptide acted as an inhibitor of mutant KRAS targets by [-32P] guanosine triphosphate (GTP) binding assay. The H-REV107 peptide inhibited pancreatic cancer and colon cancer cell lines in cell proliferation assay. Specially, the H-REV107 peptide can suppress pancreatic tumor growth by reduction of tumor volume and weight in xenotransplantation mouse models. Overall, the results presented herein will facilitate development of novel drugs for inhibition of KRAS mutations in cancer patients.",x-ray diffraction,2.52,1,1,A,88.88888888888889%,93.90243902439023%,1380,184,2,2,"['MG', 'GDP']","MG, GDP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,14,10,9,4,8,12,13,8,11,11,16,11,9,4,4,6,15,4,10,3,
7C7I,"Crystal structure of SHANK3 SPN domain in complex with GTP-bound Rap1b(E30D,K31E)","Ras-related protein Rap-1b, SH3 and multiple ankyrin repeat domains protein 3",Homo sapiens,9606,No abstract found,x-ray diffraction,2.28,1,4,A,55.55555555555556%,58.68263473053892%,1417,231,3,3,"['GTP', 'CA', 'MG']","GTP, CA, MG","GUANOSINE-5'-TRIPHOSPHATE, CALCIUM ION, MAGNESIUM ION",active,62,11,9,5,8,8,11,6,9,15,16,9,14,9,,7,14,2,9,3,1
7C7J,"Crystal structure of SHANK3 SPN domain in complex with GTP-bound Rap1b(G12V,Q63E)","Ras-related protein Rap-1b, SH3 and multiple ankyrin repeat domains protein 3",Homo sapiens,9606,No abstract found,x-ray diffraction,2.39,1,4,A,88.35978835978835%,57.48502994011976%,1398,200,3,3,"['GTP', 'CA', 'MG']","GTP, CA, MG","GUANOSINE-5'-TRIPHOSPHATE, CALCIUM ION, MAGNESIUM ION",active,30,10,9,5,8,8,13,6,10,15,17,9,13,9,,7,13,2,9,3,1
7E1T,Crystal structure of Rab9A-GTP-Nde1,,Homo sapiens,9606,"Rab9 is mainly located on late endosomes and required for their intracellular transport to trans-Golgi network (TGN). The cytoplasmic dynein motor, together with its regulatory proteins Nde1/Ndel1 and Lis1, controls intracellular retrograde transport of membranous organelles along the microtubule network. How late endosomes are tethered to the microtubule-based motor dynein for their retrograde transport remains unclear. Here, we demonstrate that the guanosine triphosphate (GTP)-bound Rab9A/B specifically uses Nde1/Ndel1 as an effector to interact with the dynein motor complex. We determined the crystal structure of Rab9A-GTP in complex with the Rab9-binding region of Nde1. The functional roles of key residues involved in the Rab9A-Nde1 interaction are verified using biochemical and cell biology assays. Rab9A mutants unable to bind to Nde1 also failed to associate with dynein, Lis1, and dynactin. Therefore, Nde1 is a Rab9 effector that tethers Rab9-associated late endosomes to the dynein motor for their retrograde transport to the TGN.",x-ray diffraction,2.45,1,4,A,89.94708994708994%,32.72727272727273%,1482,258,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,86,10,11,2,13,11,12,6,9,14,13,7,6,8,2,14,13,4,9,3,3
7EQ2,Crystal structure of GDP-bound Rab1a-T75D,,Homo sapiens,9606,No DOI found,x-ray diffraction,1.55,1,2,A,91.005291005291%,36.52694610778443%,1599,345,5,5,"['MG', 'MPD', 'NCO', 'GDP']","GDP, MG, NCO, MPD, CAC","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, COBALT HEXAMMINE(III), (4S)-2-METHYL-2,4-PENTANEDIOL, CACODYLATE ION",inactive,168,10,10,3,11,15,12,9,14,16,11,13,6,7,1,8,14,1,7,2,2
7EYX,Crystal structure of Mg-free KRAS-G12D bound to GDP,Isoform 2B of GTPase KRas (E.C.3.6.5.2),Homo sapiens,9606,No DOI found,x-ray diffraction,1.82,1,1,A,68.78306878306879%,93.37349397590361%,2525,224,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,59,10,9,3,9,11,11,8,11,11,15,10,9,4,4,6,16,4,10,3,
7EZB,Thorarchaeota Rab bound to GDP,,Candidatus Thorarchaeota archaeon SMTZ1-45,1706444,No DOI found,x-ray diffraction,1.5,1,2,A,58.201058201058196%,32.71604938271605%,1638,380,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,204,10,13,6,9,13,16,8,10,13,14,10,5,9,1,8,11,2,13,1,2
7F68,Crystal structure of N-ras S89D,,Homo sapiens,9606,No DOI found,x-ray diffraction,1.24,1,1,A,89.41798941798942%,88.75739644970415%,1614,398,3,3,"['GTP', 'MG', 'SO4']","GTP, MG, SO4","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, SULFATE ION",active,226,11,10,5,7,12,12,9,11,12,15,11,8,5,2,6,15,4,11,3,
7F6J,Crystal structure of the PDZD8 coiled-coil domain - Rab7 complex,,Homo sapiens,9606,"The membrane contact sites (MCSs) between the ER and late endosomes (LEs) are essential for the regulation of endosomal protein sorting, dynamics, and motility. PDZD8 is an ER transmembrane protein containing a Synaptotagmin-like Mitochondrial lipid-binding Proteins (SMP) domain. PDZD8 tethers the ER to late endosomes and lysosomes by associating its C-terminal coiled-coil (CC) with the LE Rab7. To identify the structural determinants for the PDZD8-Rab7 interaction, we determined the crystal structure of the human PDZD8 CC domain in complex with the GTP-bound form of Rab7. The PDZD8 CC contains one short helix and the two helices forming an antiparallel coiled-coil. Two Rab7 molecules bind to the opposite sides of the PDZD8 CC in a 2:1 ratio. The switch I/II and interswitch regions of the GTP-loaded Rab7 form the binding interfaces, which correlates with the GTP-dependent interaction of PDZD8 and Rab7. Analysis of the protein interaction by isothermal titration calorimetry confirms that two Rab7 molecules bind the PDZD8 CC in a GTP-dependent manner. The structural model of the PDZD8 CC-Rab7 complex correlates with the recruitment of PDZD8 at the LE-ER interface and its role in lipid transport and regulation.",x-ray diffraction,2.1,1,3,A,90.47619047619048%,33.33333333333333%,1460,236,2,2,"['GTP', 'MG']","MG, GTP","MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,63,8,15,3,8,11,9,5,12,14,15,9,10,11,,11,11,5,8,3,3
7JHP,Crystal structure of HRas in complex with the Ras-binding and cysteine-rich domains of CRaf-kinase,,Homo sapiens,9606,"Ras and Raf-kinase interact through the Ras-binding (RBD) and cysteine-rich domains (CRD) of Raf to signal through the mitogen-activated protein kinase pathway, yet the molecular mechanism leading to Raf activation has remained elusive. We present the 2.8  crystal structure of the HRas-CRaf-RBD_CRD complex showing the Ras-Raf interface as a continuous surface on Ras, as seen in the KRas-CRaf-RBD_CRD structure. In molecular dynamics simulations of a Ras dimer model formed through the 4-5 interface, the CRD is dynamic and located between the two Ras protomers, poised for direct or allosteric modulation of functionally relevant regions of Ras and Raf. We propose a molecular model in which Ras binding is involved in the release of Raf autoinhibition while the Ras-Raf complex dimerizes to promote a platform for signal amplification, with Raf-CRD centrally located to impact regulation and function.",x-ray diffraction,2.77,1,2,A,87.83068783068782%,99.3975903614458%,1357,200,2,2,"['MG', 'GNP']","GNP, MG, ZN","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, ZINC ION",active,32,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,10,4,
7JIF,HRAS A59T GppNHp,,Homo sapiens,9606,"A unifying feature of the RAS superfamily is a conserved GTPase cycle by which these proteins transition between active and inactive states. We demonstrate that autophosphorylation of some GTPases is an intrinsic regulatory mechanism that reduces nucleotide hydrolysis and enhances nucleotide exchange, altering the on/off switch that forms the basis for their signaling functions. Using X-ray crystallography, nuclear magnetic resonance spectroscopy, binding assays, and molecular dynamics on autophosphorylated mutants of H-RAS and K-RAS, we show that phosphoryl transfer from GTP requires dynamic movement of the switch II region and that autophosphorylation promotes nucleotide exchange by opening the active site and extracting the stabilizing Mg<sup>2+</sup>. Finally, we demonstrate that autophosphorylated K-RAS exhibits altered effector interactions, including a reduced affinity for RAF proteins in mammalian cells. Thus, autophosphorylation leads to altered active site dynamics and effector interaction properties, creating a pool of GTPases that are functionally distinct from their non-phosphorylated counterparts.",x-ray diffraction,1.76,1,1,A,87.83068783068782%,99.3975903614458%,1509,324,3,3,"['MG', 'GNP', 'GOL']","GNP, MG, GOL","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL",active,155,11,10,4,8,12,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
7JIH,HRAS A59E GppNHp,,Homo sapiens,9606,"A unifying feature of the RAS superfamily is a conserved GTPase cycle by which these proteins transition between active and inactive states. We demonstrate that autophosphorylation of some GTPases is an intrinsic regulatory mechanism that reduces nucleotide hydrolysis and enhances nucleotide exchange, altering the on/off switch that forms the basis for their signaling functions. Using X-ray crystallography, nuclear magnetic resonance spectroscopy, binding assays, and molecular dynamics on autophosphorylated mutants of H-RAS and K-RAS, we show that phosphoryl transfer from GTP requires dynamic movement of the switch II region and that autophosphorylation promotes nucleotide exchange by opening the active site and extracting the stabilizing Mg<sup>2+</sup>. Finally, we demonstrate that autophosphorylated K-RAS exhibits altered effector interactions, including a reduced affinity for RAF proteins in mammalian cells. Thus, autophosphorylation leads to altered active site dynamics and effector interaction properties, creating a pool of GTPases that are functionally distinct from their non-phosphorylated counterparts.",x-ray diffraction,1.99,1,2,A,68.25396825396825%,99.3975903614458%,1304,217,3,3,"['MG', 'GNP', 'GOL']","GNP, MG, GOL","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL",active,55,11,10,4,8,10,12,8,8,11,15,10,11,4,3,5,13,2,11,3,
7KMR,Crystal structure analysis of human KRAS mutant,,Homo sapiens,9606,"A unifying feature of the RAS superfamily is a conserved GTPase cycle by which these proteins transition between active and inactive states. We demonstrate that autophosphorylation of some GTPases is an intrinsic regulatory mechanism that reduces nucleotide hydrolysis and enhances nucleotide exchange, altering the on/off switch that forms the basis for their signaling functions. Using X-ray crystallography, nuclear magnetic resonance spectroscopy, binding assays, and molecular dynamics on autophosphorylated mutants of H-RAS and K-RAS, we show that phosphoryl transfer from GTP requires dynamic movement of the switch II region and that autophosphorylation promotes nucleotide exchange by opening the active site and extracting the stabilizing Mg<sup>2+</sup>. Finally, we demonstrate that autophosphorylated K-RAS exhibits altered effector interactions, including a reduced affinity for RAF proteins in mammalian cells. Thus, autophosphorylation leads to altered active site dynamics and effector interaction properties, creating a pool of GTPases that are functionally distinct from their non-phosphorylated counterparts.",x-ray diffraction,1.51,1,1,A,90.47619047619048%,93.41317365269461%,1521,308,1,1,['GDP'],GDP,GUANOSINE-5'-DIPHOSPHATE,inactive,136,11,8,4,9,12,14,8,13,11,15,11,9,4,4,6,15,4,10,3,
7L0F,Monobody 12VC3 Bound to HRAS(WT),"GTPase HRas (E.C.3.6.5.2), Monobody 12VC3",Homo sapiens,9606,"Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times more tightly than wild-type KRAS. The crystal structures reveal that 12VC1 recognizes the mutations through a shallow pocket, and 12VC1 competes against RAS-effector interaction. When expressed intracellularly, 12VC1 potently inhibits ERK activation and the proliferation of RAS-driven cancer cell lines in vitro and in mouse xenograft models. 12VC1 fused to VHL selectively degrades the KRAS mutants and provides more extended suppression of mutant RAS activity than inhibition by 12VC1 alone. These results demonstrate the feasibility of selective targeting and degradation of KRAS mutants in the active state with noncovalent reagents and provide a starting point for designing noncovalent therapeutics against oncogenic RAS mutants.",x-ray diffraction,1.98,1,8,A,87.83068783068782%,100.0%,1452,265,2,2,"['MG', 'GSP']","MG, GSP","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,97,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
7L0G,Monobody 12VC1 Bound to HRAS(G12C),"GTPase HRas (E.C.3.6.5.2), Monobody 12VC1",Homo sapiens,9606,"Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times more tightly than wild-type KRAS. The crystal structures reveal that 12VC1 recognizes the mutations through a shallow pocket, and 12VC1 competes against RAS-effector interaction. When expressed intracellularly, 12VC1 potently inhibits ERK activation and the proliferation of RAS-driven cancer cell lines in vitro and in mouse xenograft models. 12VC1 fused to VHL selectively degrades the KRAS mutants and provides more extended suppression of mutant RAS activity than inhibition by 12VC1 alone. These results demonstrate the feasibility of selective targeting and degradation of KRAS mutants in the active state with noncovalent reagents and provide a starting point for designing noncovalent therapeutics against oncogenic RAS mutants.",x-ray diffraction,2.54,1,8,A,87.83068783068782%,99.3975903614458%,1367,178,2,2,"['MG', 'GSP']","GSP, MG","5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, MAGNESIUM ION",inactive,10,10,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,4,
7LC1,Crystal Structure of KRAS4b (GMPPNP-bound) in complex with the RBD-PH domains of SIN1,,Homo sapiens,9606,"RAS proteins are molecular switches that interact with effector proteins when bound to guanosine triphosphate, stimulating downstream signaling in response to multiple stimuli. Although several canonical downstream effectors have been extensively studied and tested as potential targets for RAS-driven cancers, many of these remain poorly characterized. In this study, we undertook a biochemical and structural approach to further study the role of Sin1 as a RAS effector. Sin1 interacted predominantly with KRAS isoform 4A in cells through an atypical RAS-binding domain that we have characterized by X-ray crystallography. Despite the essential role of Sin1 in the assembly and activity of mTORC2, we find that the interaction with RAS is not required for these functions. Cells and mice expressing a mutant of Sin1 that is unable to bind RAS are proficient for activation and assembly of mTORC2. Our results suggest that Sin1 is a bona fide RAS effector that regulates downstream signaling in an mTORC2-independent manner.",x-ray diffraction,2.35,1,4,A,88.35978835978835%,93.41317365269461%,1358,186,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,17,11,10,4,8,12,12,8,11,11,15,11,8,4,4,6,15,4,10,3,
7MDP,KRas G12C in complex with G-2897,,Homo sapiens,9606,"Small molecules that stabilize inactive protein conformations are an underutilized strategy for drugging dynamic or otherwise intractable proteins. To facilitate the discovery and characterization of such inhibitors, we created a screening platform to identify conformation-locking antibodies for molecular probes (CLAMPs) that distinguish and induce rare protein conformational states. Applying the approach to KRAS, we discovered CLAMPs that recognize the open conformation of KRAS<sup>G12C</sup> stabilized by covalent inhibitors. One CLAMP enables the visualization of KRAS<sup>G12C</sup> covalent modification in vivo and can be used to investigate response heterogeneity to KRAS<sup>G12C</sup> inhibitors in patient tumors. A second CLAMP enhances the affinity of weak ligands binding to the KRAS<sup>G12C</sup> switchII region (SWII) by stabilizing a specific conformation of KRAS<sup>G12C</sup>, thereby enabling the discovery of such ligands that could serve as leads for the development of drugs in a high-throughput screen. We show that combining the complementary properties of antibodies and small molecules facilitates the study and drugging of dynamic proteins.",x-ray diffraction,1.96,1,3,A,88.35978835978835%,93.41317365269461%,1388,178,4,4,"['MG', 'Z07', 'ACT', 'GDP']","Z07, GDP, MG, ACT, CAD, P15, EDO, DMS","4-(trifluoromethyl)-1,3-benzothiazol-2-amine, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, ACETATE ION, CACODYLIC ACID, 2,5,8,11,14,17-HEXAOXANONADECAN-19-OL, 1,2-ETHANEDIOL, DIMETHYL SULFOXIDE",inactive,7,10,9,4,8,12,12,8,11,11,15,11,9,4,4,6,15,4,10,4,
7OGD,GTPase HRAS mutant D33K under ambient pressure,,Homo sapiens,9606,"In this work, we experimentally investigate the allosteric transitions between conformational states on the Ras oncogene protein using high pressure crystallography. Ras protein is a small GTPase involved in central regulatory processes occurring in multiple conformational states. Ras acts as a molecular switch between active GTP-bound, and inactive GDP-bound states, controlling essential signal transduction pathways. An allosteric network of interactions between the effector binding regions and the membrane interacting regions is involved in Ras cycling. The conformational states which coexist simultaneously in solution possess higher Gibbs free energy than the ground state. Equilibria between these states can be shifted by applying pressure favouring conformations with lower partial molar volume, and has been previously analyzed by high-pressure NMR spectroscopy. High-pressure macromolecular crystallography (HPMX) is a powerful tool perfectly complementary to high-pressure NMR, allowing characterization at the molecular level with a high resolution the different allosteric states involved in the Ras cycling. We observe a transition above 300 MPa in the crystal leading to more stable conformers. Thus, we compare the crystallographic structures of Ras(wt)Mg<sup>2+</sup>GppNHp and Ras(D33K)Mg<sup>2+</sup>GppNHp at various high hydrostatic pressures. This gives insight into per-residue descriptions of the structural plasticity involved in allosteric equilibria between conformers. We have mapped out at atomic resolution the different segments of Ras protein which remain in the ground-state conformation or undergo structural changes, adopting excited-energy conformations corresponding to transient intermediate states. Such <i>in crystallo</i> phase transitions induced by pressure open the possibility to finely explore the structural determinants related to switching between Ras allosteric sub-states without any mutations nor exogenous partners.",x-ray diffraction,1.95,1,1,A,87.83068783068782%,99.3975903614458%,1448,251,3,3,"['MG', 'PGE', 'GNP']","GNP, MG, PGE","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, TRIETHYLENE GLYCOL",active,82,11,11,4,8,11,13,9,9,11,15,11,11,4,3,5,13,3,11,3,
7OO7,KRasG12C ligand complex,,Homo sapiens,9606,"KRAS is an archetypal high-value intractable oncology drug target. The glycine to cysteine mutation at codon 12 represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based drug design approach that led to the identification of <b>21</b>, AZD4625, a clinical development candidate for the treatment of KRAS<sup>G12C</sup> positive tumors. Highlights include a quinazoline tethering strategy to lock out a bio-relevant binding conformation and an optimization strategy focused on the reduction of extrahepatic clearance mechanisms seen in preclinical species. Crystallographic analysis was also key in helping to rationalize unusual structure-activity relationship in terms of ring size and enantio-preference. AZD4625 is a highly potent and selective inhibitor of KRAS<sup>G12C</sup> with an anticipated low clearance and high oral bioavailability profile in humans.",x-ray diffraction,1.48,1,2,A,88.88888888888889%,91.61676646706587%,1469,237,3,3,"['MG', 'VLE', 'GDP']","MG, GDP, VLE, CA","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1-[(6aS)-3-chloro-2-(5-methyl-1H-indazol-4-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1',2':5,6][1,5]oxazocino[4,3,2-de]quinazolin-8-yl]-2-propen-1-one, CALCIUM ION",inactive,66,11,9,4,10,12,12,8,11,12,15,11,9,4,4,6,15,4,10,1,
7OPP,Crystal structure of the Rab27a fusion with Slp2a-RBDa1 effector for SF4 pocket drug targeting,,Homo sapiens,9606,"Rab27A is a small GTPase, which mediates transport and docking of secretory vesicles at the plasma membrane <i>via</i> protein-protein interactions (PPIs) with effector proteins. Rab27A promotes the growth and invasion of multiple cancer types such as breast, lung and pancreatic, by enhancing secretion of chemokines, metalloproteases and exosomes. The significant role of Rab27A in multiple cancer types and the minor role in adults suggest that Rab27A may be a suitable target to disrupt cancer metastasis. Similar to many GTPases, the flat topology of the Rab27A-effector PPI interface and the high affinity for GTP make it a challenging target for inhibition by small molecules. Reported co-crystal structures show that several effectors of Rab27A interact with the Rab27A SF4 pocket ('WF-binding pocket') <i>via</i> a conserved tryptophan-phenylalanine (WF) dipeptide motif. To obtain structural insight into the ligandability of this pocket, a novel construct was designed fusing Rab27A to part of an effector protein (fRab27A), allowing crystallisation of Rab27A in high throughput. The paradigm of KRas covalent inhibitor development highlights the challenge presented by GTPase proteins as targets. However, taking advantage of two cysteine residues, C123 and C188, that flank the WF pocket and are unique to Rab27A and Rab27B among the >60 Rab family proteins, we used the quantitative Irreversible Tethering (qIT) assay to identify the first covalent ligands for native Rab27A. The binding modes of two hits were elucidated by co-crystallisation with fRab27A, exemplifying a platform for identifying suitable lead fragments for future development of competitive inhibitors of the Rab27A-effector interaction interface, corroborating the use of covalent libraries to tackle challenging targets.",x-ray diffraction,2.32,1,2,A,65.60846560846561%,31.547619047619047%,1897,407,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,195,12,16,7,13,11,19,8,11,23,10,12,10,8,3,12,15,3,14,1,2
7OPQ,Rab27a fusion with Slp2a-RBDa1 effector covalent adduct with CA1 in C188,,Homo sapiens,9606,"Rab27A is a small GTPase, which mediates transport and docking of secretory vesicles at the plasma membrane <i>via</i> protein-protein interactions (PPIs) with effector proteins. Rab27A promotes the growth and invasion of multiple cancer types such as breast, lung and pancreatic, by enhancing secretion of chemokines, metalloproteases and exosomes. The significant role of Rab27A in multiple cancer types and the minor role in adults suggest that Rab27A may be a suitable target to disrupt cancer metastasis. Similar to many GTPases, the flat topology of the Rab27A-effector PPI interface and the high affinity for GTP make it a challenging target for inhibition by small molecules. Reported co-crystal structures show that several effectors of Rab27A interact with the Rab27A SF4 pocket ('WF-binding pocket') <i>via</i> a conserved tryptophan-phenylalanine (WF) dipeptide motif. To obtain structural insight into the ligandability of this pocket, a novel construct was designed fusing Rab27A to part of an effector protein (fRab27A), allowing crystallisation of Rab27A in high throughput. The paradigm of KRas covalent inhibitor development highlights the challenge presented by GTPase proteins as targets. However, taking advantage of two cysteine residues, C123 and C188, that flank the WF pocket and are unique to Rab27A and Rab27B among the >60 Rab family proteins, we used the quantitative Irreversible Tethering (qIT) assay to identify the first covalent ligands for native Rab27A. The binding modes of two hits were elucidated by co-crystallisation with fRab27A, exemplifying a platform for identifying suitable lead fragments for future development of competitive inhibitors of the Rab27A-effector interaction interface, corroborating the use of covalent libraries to tackle challenging targets.",x-ray diffraction,2.23,1,2,A,97.35449735449735%,31.547619047619047%,1852,320,9,9,"['06D', 'MG', 'GNP', 'GOL']","06D, GNP, MG, GOL","1-[(2~{S})-2-(4-methoxyphenyl)pyrrolidin-1-yl]propan-1-one, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL",active,99,14,17,7,12,12,18,8,11,23,10,12,10,8,3,12,14,3,14,2,2
7OPR,Rab27a fusion with Slp2a-RBDa1 effector covalent adduct with CB1 in C123,,Homo sapiens,9606,"Rab27A is a small GTPase, which mediates transport and docking of secretory vesicles at the plasma membrane <i>via</i> protein-protein interactions (PPIs) with effector proteins. Rab27A promotes the growth and invasion of multiple cancer types such as breast, lung and pancreatic, by enhancing secretion of chemokines, metalloproteases and exosomes. The significant role of Rab27A in multiple cancer types and the minor role in adults suggest that Rab27A may be a suitable target to disrupt cancer metastasis. Similar to many GTPases, the flat topology of the Rab27A-effector PPI interface and the high affinity for GTP make it a challenging target for inhibition by small molecules. Reported co-crystal structures show that several effectors of Rab27A interact with the Rab27A SF4 pocket ('WF-binding pocket') <i>via</i> a conserved tryptophan-phenylalanine (WF) dipeptide motif. To obtain structural insight into the ligandability of this pocket, a novel construct was designed fusing Rab27A to part of an effector protein (fRab27A), allowing crystallisation of Rab27A in high throughput. The paradigm of KRas covalent inhibitor development highlights the challenge presented by GTPase proteins as targets. However, taking advantage of two cysteine residues, C123 and C188, that flank the WF pocket and are unique to Rab27A and Rab27B among the >60 Rab family proteins, we used the quantitative Irreversible Tethering (qIT) assay to identify the first covalent ligands for native Rab27A. The binding modes of two hits were elucidated by co-crystallisation with fRab27A, exemplifying a platform for identifying suitable lead fragments for future development of competitive inhibitors of the Rab27A-effector interaction interface, corroborating the use of covalent libraries to tackle challenging targets.",x-ray diffraction,2.32,1,2,A,98.4126984126984%,30.952380952380953%,1972,375,10,10,"['MG', 'GNP', '05Y', 'GOL']","GNP, MG, GOL, 05Y","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL, ~{N}-[1-(2-pyridin-2-ylethyl)benzimidazol-2-yl]propanamide",active,147,16,17,7,13,12,19,8,11,23,10,12,10,8,3,12,15,3,15,2,2
7QSC,GTPase IN COMPLEX WITH GDP.MGF3-,,Homo sapiens,9606,No DOI found,x-ray diffraction,1.91,1,4,B,77.24867724867724%,31.46067415730337%,1514,253,4,4,"['MG', 'FY3', 'MGF', 'GDP']","GDP, MGF, MG","GUANOSINE-5'-DIPHOSPHATE, TRIFLUOROMAGNESATE, MAGNESIUM ION",inactive,73,10,11,5,6,8,16,4,14,13,16,10,5,7,2,6,15,11,10,5,2
7RP3,Crystal structure of GNE-1952 alkylated KRAS G12C in complex with 2H11 CLAMP,,Homo sapiens,9606,"Small molecules that stabilize inactive protein conformations are an underutilized strategy for drugging dynamic or otherwise intractable proteins. To facilitate the discovery and characterization of such inhibitors, we created a screening platform to identify conformation-locking antibodies for molecular probes (CLAMPs) that distinguish and induce rare protein conformational states. Applying the approach to KRAS, we discovered CLAMPs that recognize the open conformation of KRAS<sup>G12C</sup> stabilized by covalent inhibitors. One CLAMP enables the visualization of KRAS<sup>G12C</sup> covalent modification in vivo and can be used to investigate response heterogeneity to KRAS<sup>G12C</sup> inhibitors in patient tumors. A second CLAMP enhances the affinity of weak ligands binding to the KRAS<sup>G12C</sup> switchII region (SWII) by stabilizing a specific conformation of KRAS<sup>G12C</sup>, thereby enabling the discovery of such ligands that could serve as leads for the development of drugs in a high-throughput screen. We show that combining the complementary properties of antibodies and small molecules facilitates the study and drugging of dynamic proteins.",x-ray diffraction,2.0,1,3,A,88.35978835978835%,93.37349397590361%,1482,245,6,6,"['MG', 'GOL', 'MKZ', 'GDP']","MKZ, GDP, MG, GOL, EDO, SO4","1-[4-[6-chloranyl-7-(5-methyl-1~{H}-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]propan-1-one, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, GLYCEROL, 1,2-ETHANEDIOL, SULFATE ION",inactive,72,10,9,3,9,12,12,8,11,11,15,11,9,4,4,6,15,4,10,4,
7RP4,Crystal structure of KRAS G12C in complex with GNE-1952,,Homo sapiens,9606,"Small molecules that stabilize inactive protein conformations are an underutilized strategy for drugging dynamic or otherwise intractable proteins. To facilitate the discovery and characterization of such inhibitors, we created a screening platform to identify conformation-locking antibodies for molecular probes (CLAMPs) that distinguish and induce rare protein conformational states. Applying the approach to KRAS, we discovered CLAMPs that recognize the open conformation of KRAS<sup>G12C</sup> stabilized by covalent inhibitors. One CLAMP enables the visualization of KRAS<sup>G12C</sup> covalent modification in vivo and can be used to investigate response heterogeneity to KRAS<sup>G12C</sup> inhibitors in patient tumors. A second CLAMP enhances the affinity of weak ligands binding to the KRAS<sup>G12C</sup> switchII region (SWII) by stabilizing a specific conformation of KRAS<sup>G12C</sup>, thereby enabling the discovery of such ligands that could serve as leads for the development of drugs in a high-throughput screen. We show that combining the complementary properties of antibodies and small molecules facilitates the study and drugging of dynamic proteins.",x-ray diffraction,2.15,1,2,A,89.41798941798942%,91.56626506024097%,1488,248,3,3,"['MG', 'MKZ', 'GDP']","MKZ, GDP, MG, GOL","1-[4-[6-chloranyl-7-(5-methyl-1~{H}-indazol-4-yl)quinazolin-4-yl]piperazin-1-yl]propan-1-one, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, GLYCEROL",inactive,76,10,9,3,11,12,13,8,12,12,15,11,9,4,4,6,15,4,10,1,
7RPZ,KRAS G12D in complex with MRTX-1133,,Homo sapiens,9606,"KRAS<sup>G12D</sup>, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS<sup>G12C</sup>, selective inhibition of KRAS<sup>G12D</sup> presents a significant challenge due to the requirement of inhibitors to bind KRAS<sup>G12D</sup> with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS<sup>G12D</sup> inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS<sup>G12D</sup> mutant xenograft mouse tumor model.",x-ray diffraction,1.3,1,1,A,88.88888888888889%,91.61676646706587%,1690,446,3,3,"['6IC', 'MG', 'GDP']","GDP, 6IC, MG","GUANOSINE-5'-DIPHOSPHATE, 4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2R,4R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol, MAGNESIUM ION",inactive,275,10,9,3,10,12,13,8,12,12,15,11,9,4,4,6,16,4,10,,
7S0Y,Structures of TcdB in complex with Cdc42,,Clostridioides difficile,1496,"Toxin B (TcdB) is a primary cause of <i>Clostridioides difficile</i> infection (CDI). This toxin acts by glucosylating small GTPases in the Rho/Ras families, but the structural basis for TcdB recognition and selectivity of specific GTPase substrates remain unsolved. Here, we report the cocrystal structures of the glucosyltransferase domain (GTD) of two distinct TcdB variants in complex with human Cdc42 and R-Ras, respectively. These structures reveal a common structural mechanism by which TcdB recognizes Rho and R-Ras. Furthermore, we find selective clustering of adaptive residue changes in GTDs that determine their substrate preferences, which helps partition all known TcdB variants into two groups that display distinct specificities toward Rho or R-Ras. Mutations that selectively disrupt GTPases binding reduce the glucosyltransferase activity of the GTD and the toxicity of TcdB holotoxin. These findings establish the structural basis for TcdB recognition of small GTPases and reveal strategies for therapeutic interventions for CDI.",x-ray diffraction,2.79,1,2,B,95.23809523809523%,32.93413173652694%,1428,191,4,4,"['MG', 'SO4', 'GDP']","MN, UDP, SO4, GDP, MG","MANGANESE (II) ION, URIDINE-5'-DIPHOSPHATE, SULFATE ION, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,7,10,11,1,10,14,12,7,16,18,18,8,5,6,2,8,11,13,4,5,1
7S0Z,Structures of TcdB in complex with R-Ras,,Clostridioides difficile,1496,"Toxin B (TcdB) is a primary cause of <i>Clostridioides difficile</i> infection (CDI). This toxin acts by glucosylating small GTPases in the Rho/Ras families, but the structural basis for TcdB recognition and selectivity of specific GTPase substrates remain unsolved. Here, we report the cocrystal structures of the glucosyltransferase domain (GTD) of two distinct TcdB variants in complex with human Cdc42 and R-Ras, respectively. These structures reveal a common structural mechanism by which TcdB recognizes Rho and R-Ras. Furthermore, we find selective clustering of adaptive residue changes in GTDs that determine their substrate preferences, which helps partition all known TcdB variants into two groups that display distinct specificities toward Rho or R-Ras. Mutations that selectively disrupt GTPases binding reduce the glucosyltransferase activity of the GTD and the toxicity of TcdB holotoxin. These findings establish the structural basis for TcdB recognition of small GTPases and reveal strategies for therapeutic interventions for CDI.",x-ray diffraction,2.34,1,4,C,94.70899470899471%,56.72514619883041%,1510,247,5,5,"['NH4', 'EDO', 'ACT', 'GDP']","UDP, NH4, EDO, ACT, PEG, MN, GLC, MG, GDP","URIDINE-5'-DIPHOSPHATE, AMMONIUM ION, 1,2-ETHANEDIOL, ACETATE ION, DI(HYDROXYETHYL)ETHER, MANGANESE (II) ION, alpha-D-glucopyranose, MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE",inactive,63,13,15,2,13,5,13,6,8,14,17,8,11,5,4,11,13,9,11,1,
7SCW,KRAS full length wild-type in complex with RGL1 Ras association domain,,Homo sapiens,9606,"Ral Guanine Nucleotide Dissociation Stimulator Like 1 (RGL1) is a RAS effector protein that activates Ral GTPase by stimulating nucleotide exchange. Most structures of RAS-effector complexes are for the HRAS isoform; relatively few KRAS-effector structures have been solved, even though KRAS mutations are more frequent in human cancers. We determined crystal structures of KRAS/RGL1-RAS-association (RA) domain complexes and characterized the interaction in solution using nuclear magnetic resonance spectroscopy, size-exclusion chromatography combined with multi-angle light scattering and biolayer interferometry. We report structures of wild-type KRAS and the oncogenic G12V mutant in complex with the RA domain of RGL1 at<2 resolution. KRAS<sup>WT</sup>/RGL1-RA crystallized as a 1:1 heterodimer, whilst KRAS<sup>G12V</sup>/RGL1-RA crystallized as a heterotetrameric structure in which RGL1-RA dimerized via domain-swapping the C-terminal beta-strand. Solution data indicated that KRAS<sup>WT</sup> and KRAS<sup>G12V</sup> in complex with RGL1-RA both exist predominantly as 1:1 dimers, while tetramerization occurs through very slow association. Through detailed structural analyses, the distance and angle between RAS 1 helix and RBD/RA 1 helix were found to differ significantly among RAS and RBD/RA complexes. The KRAS/RGL1-RA structures possess some of the largest 1<sup>RAS</sup>/1<sup>Effector</sup> distances (21.7-22.2), whereas the corresponding distances in previously reported RAS/RAF complexes are significantly shorter (15.2-17.7). Contact map analysis identified unique structural signatures involving contacts between the 1-2 loop of RA and the 1 helix of RAS, clearly distinguishing the KRAS/RGL1-RA (and other RAS/RA complexes) from RAS/RBD complexes. These results demonstrate that RAS effectors employ an assortment of finely-tuned docking surfaces to achieve optimal interactions with RAS.",x-ray diffraction,1.98,1,2,A,90.47619047619048%,93.41317365269461%,2882,323,2,2,"['MG', 'GSP']","MG, GSP","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,150,12,9,4,10,12,13,8,12,11,15,11,9,4,4,6,15,4,10,2,
7SCX,KRAS full-length G12V in complex with RGL1 Ras association domain,,Homo sapiens,9606,"Ral Guanine Nucleotide Dissociation Stimulator Like 1 (RGL1) is a RAS effector protein that activates Ral GTPase by stimulating nucleotide exchange. Most structures of RAS-effector complexes are for the HRAS isoform; relatively few KRAS-effector structures have been solved, even though KRAS mutations are more frequent in human cancers. We determined crystal structures of KRAS/RGL1-RAS-association (RA) domain complexes and characterized the interaction in solution using nuclear magnetic resonance spectroscopy, size-exclusion chromatography combined with multi-angle light scattering and biolayer interferometry. We report structures of wild-type KRAS and the oncogenic G12V mutant in complex with the RA domain of RGL1 at<2 resolution. KRAS<sup>WT</sup>/RGL1-RA crystallized as a 1:1 heterodimer, whilst KRAS<sup>G12V</sup>/RGL1-RA crystallized as a heterotetrameric structure in which RGL1-RA dimerized via domain-swapping the C-terminal beta-strand. Solution data indicated that KRAS<sup>WT</sup> and KRAS<sup>G12V</sup> in complex with RGL1-RA both exist predominantly as 1:1 dimers, while tetramerization occurs through very slow association. Through detailed structural analyses, the distance and angle between RAS 1 helix and RBD/RA 1 helix were found to differ significantly among RAS and RBD/RA complexes. The KRAS/RGL1-RA structures possess some of the largest 1<sup>RAS</sup>/1<sup>Effector</sup> distances (21.7-22.2), whereas the corresponding distances in previously reported RAS/RAF complexes are significantly shorter (15.2-17.7). Contact map analysis identified unique structural signatures involving contacts between the 1-2 loop of RA and the 1 helix of RAS, clearly distinguishing the KRAS/RGL1-RA (and other RAS/RA complexes) from RAS/RBD complexes. These results demonstrate that RAS effectors employ an assortment of finely-tuned docking surfaces to achieve optimal interactions with RAS.",x-ray diffraction,1.96,1,2,A,89.41798941798942%,92.81437125748504%,2780,266,3,3,"['MG', 'PO4', 'GSP']","MG, GSP, PO4","MAGNESIUM ION, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE, PHOSPHATE ION",inactive,94,10,9,4,9,12,13,8,12,11,16,11,9,4,4,6,15,4,10,2,
7T1F,Crystal structure of GDP-bound T50I mutant of human KRAS4B,,Homo sapiens,9606,No DOI found,x-ray diffraction,2.2,1,3,A,89.41798941798942%,93.41317365269461%,1450,240,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,69,11,9,4,8,11,13,8,12,11,15,12,9,4,4,6,15,4,10,3,
7T47,KRAS G12D (GppCp) with MRTX-1133,,Homo sapiens,9606,"The ability to effectively target mutated KRAS has remained elusive despite decades of research. The recent identification of KRASG12C inhibitors has provided an effective treatment option for patients harboring this particular mutation and has also provided insight toward targeting other KRAS mutants, including KRASG12D. MRTX1133 was identified via a structure-based drug design (SBDD) strategy as a potent, selective, and non-covalent KRASG12D inhibitor directed at the switch II binding pocket. MRTX1133 demonstrated a high-affinity interaction with KRASG12D with KD or IC50 values each determined at ~0.2 pM or <2 nM using SPR direct binding or HTRF competition assays, respectively. MRTX1133 also demonstrated ~700-fold selectivity for KRASG12D vs KRASWT binding utilizing SPR. Interestingly, MRTX1133 demonstrated potent inhibition of active KRASG12D using an HTRF effector interaction assay with a IC50 value of 9 nM. Insight toward the structural basis of binding of MRTX1133 to both the inactive GDP-bound and active GMPPCP-bound conformations of KRASG12D is also provided by co-crystal structures. MRTX1133 demonstrated potent inhibition of ERK1/2 phosphorylation and cell viability in KRASG12D-mutant cell lines with median IC50 values of ~5 nM. Consistent with binding affinity determination in cell-free systems, MRTX1133 demonstrated >1000-fold selectivity for inhibition of ERK1/2 phosphorylation in KRASG12D-mutant cell lines compared with KRASWT cell lines. Dose-dependent inhibition of KRAS-mediated signal transduction was also observed in multiple KRASG12D-mutant tumor models in vivo. MRTX1133 demonstrated marked tumor regression (>30%) in a subset of KRASG12D-mutant cell line- and patient-derived xenograft (PDX) models, including 8 out of 11 (73%) pancreatic ductal adenocarcinoma (PDAC) models evaluated. Pharmacological studies and CRISPR-based screens demonstrated co-targeting KRASG12D in concert with putative feedback or bypass pathways including EGFR and PI3K led to enhanced anti-tumor activity relative to targeting each individual protein. Together, these data indicate the feasibility of utilizing SBDD approaches to selectively target alternative KRAS mutant variants with non-covalent, high-affinity small molecules targeting either the active or inactive state of KRAS. In addition, these data illustrate the therapeutic susceptibility and broad dependence of KRASG12D mutation-positive tumors, including PDAC, on KRAS for tumor cell growth and survival.",x-ray diffraction,1.27,1,1,A,89.41798941798942%,91.61676646706587%,1699,407,6,6,"['ACT', '6IC', 'MG', 'GOL', 'GDP', 'GCP']","6IC, GCP, GDP, GOL, ACT, MG","4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2R,4R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol, PHOSPHOMETHYLPHOSPHONIC ACID GUANYLATE ESTER, GUANOSINE-5'-DIPHOSPHATE, GLYCEROL, ACETATE ION, MAGNESIUM ION",inactive,232,10,9,4,10,12,13,8,12,12,15,11,9,4,4,6,16,4,10,,
7TLE,Crystal Structure of small molecule beta-lactone 1 covalently bound to K-Ras(G12S),,Homo sapiens,9606,"Drugs that directly impede the function of driver oncogenes offer exceptional efficacy and a therapeutic window. The recently approved mutant selective small-molecule cysteine-reactive covalent inhibitor of the G12C mutant of K-Ras, sotorasib, provides a case in point. KRAS is the most frequently mutated proto-oncogene in human cancer, yet despite success targeting the G12C allele, targeted therapy for other hotspot mutants of KRAS has not been described. Here we report the discovery of small molecules that covalently target a G12S somatic mutation in K-Ras and suppress its oncogenic signaling. We show that these molecules are active in cells expressing K-Ras(G12S) but spare the wild-type protein. Our results provide a path to targeting a second somatic mutation in the oncogene KRAS by overcoming the weak nucleophilicity of an acquired serine residue. The chemistry we describe may serve as a basis for the selective targeting of other unactivated serines.",x-ray diffraction,1.99,1,1,A,89.41798941798942%,91.61676646706587%,1515,262,4,4,"['MG', 'SO4', 'I6T', 'GDP']","MG, I6T, GDP, SO4","MAGNESIUM ION, (3R,4R)-1-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-3-hydroxypiperidine-4-carbaldehyde, GUANOSINE-5'-DIPHOSPHATE, SULFATE ION",inactive,89,10,9,4,11,12,13,8,12,12,15,11,9,4,4,6,15,4,10,,
7TLG,Crystal Structure of small molecule beta-lactone 5 covalently bound to K-Ras(G12S),,Homo sapiens,9606,"Drugs that directly impede the function of driver oncogenes offer exceptional efficacy and a therapeutic window. The recently approved mutant selective small-molecule cysteine-reactive covalent inhibitor of the G12C mutant of K-Ras, sotorasib, provides a case in point. KRAS is the most frequently mutated proto-oncogene in human cancer, yet despite success targeting the G12C allele, targeted therapy for other hotspot mutants of KRAS has not been described. Here we report the discovery of small molecules that covalently target a G12S somatic mutation in K-Ras and suppress its oncogenic signaling. We show that these molecules are active in cells expressing K-Ras(G12S) but spare the wild-type protein. Our results provide a path to targeting a second somatic mutation in the oncogene KRAS by overcoming the weak nucleophilicity of an acquired serine residue. The chemistry we describe may serve as a basis for the selective targeting of other unactivated serines.",x-ray diffraction,1.8,1,2,A,89.94708994708994%,91.61676646706587%,1646,362,3,3,"['MG', 'I7H', 'GDP']","GDP, I7H, MG","GUANOSINE-5'-DIPHOSPHATE, (3R,4R)-1-[7-(8-chloronaphthalen-1-yl)-8-fluoro-2-{[(4S,7as)-tetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-4-yl]-3-hydroxypiperidine-4-carbaldehyde, MAGNESIUM ION",inactive,189,11,9,4,11,12,13,8,12,12,15,11,9,4,4,6,15,4,10,,
7TLK,Crystal Structure of K-Ras(G12S),,Homo sapiens,9606,"Drugs that directly impede the function of driver oncogenes offer exceptional efficacy and a therapeutic window. The recently approved mutant selective small-molecule cysteine-reactive covalent inhibitor of the G12C mutant of K-Ras, sotorasib, provides a case in point. KRAS is the most frequently mutated proto-oncogene in human cancer, yet despite success targeting the G12C allele, targeted therapy for other hotspot mutants of KRAS has not been described. Here we report the discovery of small molecules that covalently target a G12S somatic mutation in K-Ras and suppress its oncogenic signaling. We show that these molecules are active in cells expressing K-Ras(G12S) but spare the wild-type protein. Our results provide a path to targeting a second somatic mutation in the oncogene KRAS by overcoming the weak nucleophilicity of an acquired serine residue. The chemistry we describe may serve as a basis for the selective targeting of other unactivated serines.",x-ray diffraction,1.71,1,2,A,88.35978835978835%,93.41317365269461%,1611,417,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,248,10,9,4,9,12,12,8,11,11,15,11,9,4,4,6,15,4,10,3,
7TVF,Crystal structure of the SHOC2-MRAS-PP1CA (SMP) complex to a resolution of 2.17 Angstrom,,Homo sapiens,9606,"SHOC2 acts as a strong synthetic lethal interactor with MEK inhibitors in multiple KRAS cancer cell lines. SHOC2 forms a heterotrimeric complex with MRAS and PP1C that is essential for regulating RAF and MAPK-pathway activation by dephosphorylating a specific phosphoserine on RAF kinases. Here we present the high-resolution crystal structure of the SHOC2-MRAS-PP1C (SMP) complex and apo-SHOC2. Our structures reveal that SHOC2, MRAS, and PP1C form a stable ternary complex in which all three proteins synergistically interact with each other. Our results show that dephosphorylation of RAF substrates by PP1C is enhanced upon interacting with SHOC2 and MRAS. The SMP complex forms only when MRAS is in an active state and is dependent on SHOC2 functioning as a scaffolding protein in the complex by bringing PP1C and MRAS together. Our results provide structural insights into the role of the SMP complex in RAF activation and how mutations found in Noonan syndrome enhance complex formation, and reveal new avenues for therapeutic interventions.",x-ray diffraction,2.17,1,6,B,92.5925925925926%,55.688622754491014%,1633,355,4,4,"['SO4', 'MG', 'GNP', 'GOL']","GOL, SO4, MN, NA, PO4, CL, GNP, MG","GLYCEROL, SULFATE ION, MANGANESE (II) ION, SODIUM ION, PHOSPHATE ION, CHLORIDE ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,176,8,10,5,9,10,10,6,12,15,16,12,8,5,6,9,16,8,9,,1
7TXH,Human MRas Q71R in complex with human Shoc2 LRR domain M173I and human PP1Ca,,Homo sapiens,9606,"RAS-MAPK signalling is fundamental for cell proliferation and is altered in most human cancers<sup>1-3</sup>. However, our mechanistic understanding of how RAS signals through RAF is still incomplete. Although studies revealed snapshots for autoinhibited and active RAF-MEK1-14-3-3 complexes<sup>4</sup>, the intermediate steps that lead to RAF activation remain unclear. The MRAS-SHOC2-PP1C holophosphatase dephosphorylates RAF at serine 259, resulting in the partial displacement of 14-3-3 and RAF-RAS association<sup>3,5,6</sup>. MRAS, SHOC2 and PP1C are mutated in rasopathies-developmental syndromes caused by aberrant MAPK pathway activation<sup>6-14</sup>-and SHOC2 itself has emerged as potential target in receptor tyrosine kinase (RTK)-RAS-driven tumours<sup>15-18</sup>. Despite its importance, structural understanding of the SHOC2 holophosphatase is lacking. Here we determine, using X-ray crystallography, the structure of the MRAS-SHOC2-PP1C complex. SHOC2 bridges PP1C and MRAS through its concave surface and enables reciprocal interactions between all three subunits. Biophysical characterization indicates a cooperative assembly driven by the MRAS GTP-bound active state, an observation that is extendible to other RAS isoforms. Our findings support the concept of a RAS-driven and multi-molecular model for RAF activation in which individual RAS-GTP molecules recruit RAF-14-3-3 and SHOC2-PP1C to produce downstream pathway activation. Importantly, we find that rasopathy and cancer mutations reside at protein-protein interfaces within the holophosphatase, resulting in enhanced affinities and function. Collectively, our findings shed light on a fundamental mechanism of RAS biology and on mechanisms of clinically observed enhanced RAS-MAPK signalling, therefore providing the structural basis for therapeutic interventions.",x-ray diffraction,1.95,1,6,A,91.53439153439153%,55.688622754491014%,1593,325,3,3,"['MG', 'GNP', 'GOL']","GNP, MG, GOL, MN, PO4","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GLYCEROL, MANGANESE (II) ION, PHOSPHATE ION",active,149,8,9,5,8,10,10,6,12,14,16,12,8,5,6,9,16,8,10,,1
7U2P,Structure of TcdA GTD in complex with RhoA,,Clostridioides difficile,1496,"Clostridioides difficile is one of the most common causes of antibiotic-associated diarrhea in developed countries. As key virulence factors of C. difficile, toxin A (TcdA) and toxin B (TcdB) act by glucosylating and inactivating Rho and Ras family small GTPases in host cells, which leads to actin cytoskeleton disruption, cell rounding, and ultimately cell death. Here we present the co-crystal structure of the glucosyltransferase domain (GTD) of TcdA in complex with its substrate human RhoA at 2.60-angstrom resolution. This structure reveals that TcdA GTD grips RhoA mainly through its switch I and switch II regions, which is complemented by interactions involving RhoA's pre-switch I region. Comprehensive structural comparisons between the TcdA GTD-RhoA complex and the structures of TcdB GTD in complex with Cdc42 and R-Ras reveal both the conserved and divergent features of these two toxins in terms of substrate recognition. Taken together, these findings establish the structural basis for TcdA recognition of small GTPases and advance our understanding of the substrates selectivity of large clostridial toxins.",x-ray diffraction,2.6,1,2,B,94.70899470899471%,31.818181818181817%,1450,191,2,2,"['MG', 'GDP']","UPG, MN, SO4, GDP, MG","URIDINE-5'-DIPHOSPHATE-GLUCOSE, MANGANESE (II) ION, SULFATE ION, GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,10,10,13,5,6,7,16,5,14,13,16,10,5,7,2,7,15,11,10,5,2
7UPI,Cryo-EM structure of SHOC2-PP1c-MRAS holophosphatase complex,,Homo sapiens,9606,"Receptor tyrosine kinase (RTK)-RAS signalling through the downstream mitogen-activated protein kinase (MAPK) cascade regulates cell proliferation and survival. The SHOC2-MRAS-PP1C holophosphatase complex functions as a key regulator of RTK-RAS signalling by removing an inhibitory phosphorylation event on the RAF family of proteins to potentiate MAPK signalling<sup>1</sup>. SHOC2 forms a ternary complex with MRAS and PP1C, and human germline gain-of-function mutations in this complex result in congenital RASopathy syndromes<sup>2-5</sup>. However, the structure and assembly of this complex are poorly understood. Here we use cryo-electron microscopy to resolve the structure of the SHOC2-MRAS-PP1C complex. We define the biophysical principles of holoenzyme interactions, elucidate the assembly order of the complex, and systematically interrogate the functional consequence of nearly all of the possible missense variants of SHOC2 through deep mutational scanning. We show that SHOC2 binds PP1C and MRAS through the concave surface of the leucine-richrepeat regionand further engages PP1C through the N-terminal disordered region that contains a cryptic RVXF motif. Complex formationis initiallymediated by interactions between SHOC2 and PP1C and is stabilized by the binding of GTP-loaded MRAS. These observations explain how mutant versions of SHOC2 in RASopathies and cancer stabilize the interactions of complex members to enhance holophosphatase activity. Together, this integrative structure-function model comprehensively defines key binding interactions within the SHOC2-MRAS-PP1C holophosphatase complex and will inform therapeutic development .",electron microscopy,2.89,1,3,A,92.06349206349206%,55.688622754491014%,1439,176,2,2,"['GTP', 'MG']","GTP, MG, MN, CL","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, MANGANESE (II) ION, CHLORIDE ION",active,0,8,10,5,8,10,10,6,12,15,16,12,8,5,6,9,16,8,9,,1
7USD,Cryo-EM structure of D-site Rac1-bound WAVE Regulatory Complex,,Homo sapiens,9606,"TheRho-family GTPase Rac1 activates the WAVE regulatory complex (WRC) to drive Arp2/3 complex-mediated actin polymerization in many essential processes. Rac1 binds to WRC at two distinct sites-the A and D sites. Precisely how Rac1 binds and how the binding triggers WRC activation remain unknown. Here we report WRC structures by itself, and when bound to single or double Rac1 molecules, at ~3 resolutions by cryogenic-electron microscopy. The structures reveal that Rac1 binds to the two sites by distinct mechanisms, and binding to the A site, but not the D site, drives WRC activation. Activation involves a series of unique conformational changes leading to the release of sequestered WCA (WH2-central-acidic) polypeptide, which stimulates the Arp2/3 complex to polymerize actin. Together with biochemical and cellular analyses, the structures provide a novel mechanistic understanding of how the Rac1-WRC-Arp2/3-actin signaling axis is regulated in diverse biological processes and diseases.",electron microscopy,3.0,1,6,F,93.65079365079364%,32.02247191011236%,1412,179,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,0,11,13,2,8,13,9,8,13,19,16,10,4,6,2,6,12,10,7,6,2
7USE,Cryo-EM structure of WAVE regulatory complex with Rac1 bound on both A and D site,,Homo sapiens,9606,"TheRho-family GTPase Rac1 activates the WAVE regulatory complex (WRC) to drive Arp2/3 complex-mediated actin polymerization in many essential processes. Rac1 binds to WRC at two distinct sites-the A and D sites. Precisely how Rac1 binds and how the binding triggers WRC activation remain unknown. Here we report WRC structures by itself, and when bound to single or double Rac1 molecules, at ~3 resolutions by cryogenic-electron microscopy. The structures reveal that Rac1 binds to the two sites by distinct mechanisms, and binding to the A site, but not the D site, drives WRC activation. Activation involves a series of unique conformational changes leading to the release of sequestered WCA (WH2-central-acidic) polypeptide, which stimulates the Arp2/3 complex to polymerize actin. Together with biochemical and cellular analyses, the structures provide a novel mechanistic understanding of how the Rac1-WRC-Arp2/3-actin signaling axis is regulated in diverse biological processes and diseases.",electron microscopy,3.0,1,7,F,93.12169312169311%,32.58426966292135%,1407,178,2,2,"['MG', 'GNP']","GNP, MG, GTP","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION, GUANOSINE-5'-TRIPHOSPHATE",active,0,11,13,2,8,13,9,8,13,18,16,10,5,6,2,6,12,10,7,5,2
7VV8,Crystal Structure of HRasQ61L(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1,,Homo sapiens,9606,"Over the years it has been established that SIN1, a key component of mTORC2, could interact with Ras family small GTPases through its Ras-binding domain (RBD). The physical association of Ras and SIN1/mTORC2 could potentially affect both mTORC2 and Ras-ERK pathways. To decipher the precise molecular mechanism of this interaction, we determined the high-resolution structures of HRas/KRas-SIN1 RBD complexes, showing the detailed interaction interface. Mutation of critical interface residues abolished Ras-SIN1 interaction and in SIN1 knockout cells we demonstrated that Ras-SIN1 association promotes SGK1 activity but inhibits insulin-induced ERK activation. With structural comparison and competition fluorescence resonance energy transfer (FRET) assays we showed that HRas-SIN1 RBD association is much weaker than HRas-Raf1 RBD but is slightly stronger than HRas-PI3K RBD interaction, providing a possible explanation for the different outcome of insulin or EGF stimulation. We also found that SIN1 isoform lacking the PH domain binds stronger to Ras than other longer isoforms and the PH domain appears to have an inhibitory effect on Ras-SIN1 binding. In addition, we uncovered a Ras dimerization interface that could be critical for Ras oligomerization. Our results advance our understanding of Ras-SIN1 association and crosstalk between growth factor-stimulated pathways.",x-ray diffraction,1.7,1,2,A,88.35978835978835%,99.3975903614458%,1538,347,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,178,11,11,4,9,11,13,9,8,12,15,11,10,4,3,5,14,3,11,3,
7VV9,Crystal Structure of HRas(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1,,Homo sapiens,9606,"Over the years it has been established that SIN1, a key component of mTORC2, could interact with Ras family small GTPases through its Ras-binding domain (RBD). The physical association of Ras and SIN1/mTORC2 could potentially affect both mTORC2 and Ras-ERK pathways. To decipher the precise molecular mechanism of this interaction, we determined the high-resolution structures of HRas/KRas-SIN1 RBD complexes, showing the detailed interaction interface. Mutation of critical interface residues abolished Ras-SIN1 interaction and in SIN1 knockout cells we demonstrated that Ras-SIN1 association promotes SGK1 activity but inhibits insulin-induced ERK activation. With structural comparison and competition fluorescence resonance energy transfer (FRET) assays we showed that HRas-SIN1 RBD association is much weaker than HRas-Raf1 RBD but is slightly stronger than HRas-PI3K RBD interaction, providing a possible explanation for the different outcome of insulin or EGF stimulation. We also found that SIN1 isoform lacking the PH domain binds stronger to Ras than other longer isoforms and the PH domain appears to have an inhibitory effect on Ras-SIN1 binding. In addition, we uncovered a Ras dimerization interface that could be critical for Ras oligomerization. Our results advance our understanding of Ras-SIN1 association and crosstalk between growth factor-stimulated pathways.",x-ray diffraction,1.6,1,2,A,87.83068783068782%,100.0%,1561,374,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,206,11,11,4,8,11,13,9,8,11,15,11,11,4,3,5,14,3,11,3,
7VVB,Crystal Structure of KRas4A(GMPPNP-bound) in complex with the Ras-binding domain(RBD) of SIN1,,Homo sapiens,9606,"Over the years it has been established that SIN1, a key component of mTORC2, could interact with Ras family small GTPases through its Ras-binding domain (RBD). The physical association of Ras and SIN1/mTORC2 could potentially affect both mTORC2 and Ras-ERK pathways. To decipher the precise molecular mechanism of this interaction, we determined the high-resolution structures of HRas/KRas-SIN1 RBD complexes, showing the detailed interaction interface. Mutation of critical interface residues abolished Ras-SIN1 interaction and in SIN1 knockout cells we demonstrated that Ras-SIN1 association promotes SGK1 activity but inhibits insulin-induced ERK activation. With structural comparison and competition fluorescence resonance energy transfer (FRET) assays we showed that HRas-SIN1 RBD association is much weaker than HRas-Raf1 RBD but is slightly stronger than HRas-PI3K RBD interaction, providing a possible explanation for the different outcome of insulin or EGF stimulation. We also found that SIN1 isoform lacking the PH domain binds stronger to Ras than other longer isoforms and the PH domain appears to have an inhibitory effect on Ras-SIN1 binding. In addition, we uncovered a Ras dimerization interface that could be critical for Ras oligomerization. Our results advance our understanding of Ras-SIN1 association and crosstalk between growth factor-stimulated pathways.",x-ray diffraction,1.7,1,2,A,88.35978835978835%,86.77248677248677%,1553,352,2,2,"['MG', 'GNP']","MG, GNP","MAGNESIUM ION, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,183,11,9,4,8,12,13,9,9,11,15,11,10,4,3,6,14,4,11,3,
7WZA,An open conformation Form 1 of switch II for RhoA,,Homo sapiens,9606,No DOI found,x-ray diffraction,1.5,1,1,A,97.35449735449735%,34.090909090909086%,1698,397,2,2,"['MG', 'GDP']","GDP, MG","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION",inactive,211,11,13,6,7,9,16,6,14,13,18,10,6,6,2,8,15,11,10,1,2
7XKJ,Kras-G12D-GDP-MRXT1133 by FIB-MicroED,,Homo sapiens,9606,No DOI found,electron crystallography,3.0,1,1,A,88.88888888888889%,92.81437125748504%,1406,177,3,3,"['6IC', 'MG', 'GDP']","GDP, 6IC, MG","GUANOSINE-5'-DIPHOSPHATE, 4-(4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-{[(2R,4R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol, MAGNESIUM ION",inactive,6,10,9,3,9,12,13,8,12,11,15,11,9,4,4,6,16,4,10,2,
7Y4A,Crystal structure of human ELMO1 RBD-RhoG complex,,Homo sapiens,9606,"The control of cell movement through manipulation of cytoskeletal structure has therapeutic prospects notably in the development of novel anti-metastatic drugs. In this study, we determine the structure of Ras-binding domain (RBD) of ELMO1, a protein involved in cytoskeletal regulation, both alone and in complex with the activator RhoG and verify its targetability through computational nanobody design. Using our dock-and-design approach optimized with native-like initial pose selection, we obtain Nb01, a detectable binder from scratch in the first-round design. An affinity maturation step guided by structure-activity relationship at the interface generates 23 Nb01 sequence variants and 17 of them show enhanced binding to ELMO1-RBD and are modeled to form major spatial overlaps with RhoG. The best binder, Nb29, inhibited ELMO1-RBD/RhoG interaction. Molecular dynamics simulation of the flexibility of CDR2 and CDR3 of Nb29 reveal the design of stabilizing mutations at the CDR-framework junctions potentially confers the affinity enhancement.",x-ray diffraction,1.6,1,8,A,95.76719576719577%,35.1063829787234%,1741,474,3,3,"['MG', 'GDP', 'PO4']","MG, PO4, GDP","MAGNESIUM ION, PHOSPHATE ION, GUANOSINE-5'-DIPHOSPHATE",inactive,290,9,15,1,8,12,9,7,9,15,18,8,13,7,5,5,9,13,9,7,2
7YCC,KRas G12C in complex with Compound 5c,,Homo sapiens,9606,"RAS protein plays a key role in cellular proliferation and differentiation. RAS gene mutation is a known driver of oncogenic alternation in human cancer. RAS inhibition is an effective therapeutic treatment for solid tumors, but RAS protein has been classified as an undruggable target. Recent reports have demonstrated that a covalent binder to KRAS protein at a mutated cysteine residue (G12C) is effective for the treatment of solid tumors. Here, we report a series of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as potent covalent inhibitors against KRAS G12C identified throughout structural optimization of an acryloyl amine moiety to improve in vitro inhibitory activity. From an X-ray complex structural analysis, the 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one moiety binds in the switch-II pocket of KRAS G12C. Further optimization of the lead compound (5c) led to the successful identification of 1-[7-[6-chloro-8-fluoro-7-(5-methyl-1H-indazol-4-yl)-2-[(1-methylpiperidin-4-yl)amino]quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one (7b), a potent compound with high metabolic stabilities in human and mouse liver microsomes. Compound 7b showed a dose-dependent antitumor effect on subcutaneous administration in an NCI-H1373 xenograft mouse model.",x-ray diffraction,1.79,1,3,A,54.4973544973545%,92.81437125748504%,1458,234,3,3,"['IQC', 'MG', 'GDP']","GDP, MG, IQC","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 1-[7-[6-chloranyl-8-fluoranyl-7-(5-methyl-1~{H}-indazol-4-yl)-2-[(1-methylpiperidin-4-yl)amino]quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]propan-1-one",inactive,66,10,8,4,8,12,12,7,12,11,15,11,9,4,4,6,15,4,10,3,
7YUZ,Human K-Ras G12D (GDP-bound) in complex with cyclic peptide inhibitor AP8784,,Homo sapiens,9606,No DOI found,x-ray diffraction,1.88,1,2,A,89.94708994708994%,93.37349397590361%,1374,203,3,3,"['IOD', 'MG', 'GDP']","GDP, MG, IOD","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, IODIDE ION",inactive,30,10,9,4,9,12,13,8,12,11,15,11,9,4,4,6,16,4,10,3,
8A4B,Structure of human Rep15:Rab3B_Q81L complex.,,Homo sapiens,9606,"In their GTP-bound (active) form, Rab proteins interact with effector proteins that control downstream signaling. One such Rab15 effector is Rep15, which is known to have a role in receptor recycling from the endocytic recycling compartment but otherwise remains poorly characterized. Here, we report the characterization of the Rep15:Rab15 interaction and identification of Rab3 paralogs and Rab34 as Rep15 interacting partners from a yeast two-hybrid assay. Biochemical validation of the interactions is presented and crystal structures of the Rep15:Rab3B and Rep15:Rab3C complexes provide additional mechanistic insight. We find that Rep15 adopts a globular structure that is distinct from other reported Rab15, Rab3 and Rab34 effectors. Structure-based mutagenesis experiments explain the Rep15:Rab interaction specificity. Rep15 depletion in U138MG glioblastoma cells impairs cell proliferation, cell migration and receptor recycling, underscoring the need for further clarification of the role of Rep15 in cancer.",x-ray diffraction,2.8,1,4,B,89.94708994708994%,32.71604938271605%,1428,182,2,2,"['GTP', 'MG']","GTP, MG","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION",active,10,9,13,5,8,13,12,8,11,11,13,11,7,7,1,13,12,2,9,2,3
8A4C,Structure of human Rep15:Rab3B complex.,,Homo sapiens,9606,"In their GTP-bound (active) form, Rab proteins interact with effector proteins that control downstream signaling. One such Rab15 effector is Rep15, which is known to have a role in receptor recycling from the endocytic recycling compartment but otherwise remains poorly characterized. Here, we report the characterization of the Rep15:Rab15 interaction and identification of Rab3 paralogs and Rab34 as Rep15 interacting partners from a yeast two-hybrid assay. Biochemical validation of the interactions is presented and crystal structures of the Rep15:Rab3B and Rep15:Rab3C complexes provide additional mechanistic insight. We find that Rep15 adopts a globular structure that is distinct from other reported Rab15, Rab3 and Rab34 effectors. Structure-based mutagenesis experiments explain the Rep15:Rab interaction specificity. Rep15 depletion in U138MG glioblastoma cells impairs cell proliferation, cell migration and receptor recycling, underscoring the need for further clarification of the role of Rep15 in cancer.",x-ray diffraction,2.75,1,4,B,89.94708994708994%,33.33333333333333%,1429,182,2,2,"['MG', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,10,9,13,5,8,13,12,8,11,10,13,11,8,7,1,13,12,2,9,2,3
8AFC,CRYSTAL STRUCTURE OF KRAS-G12C IN COMPLEX WITH COMPOUND 12,,Homo sapiens,9606,"Activating mutations in KRAS are the most frequent oncogenic alterations in cancer. The oncogenic hotspot position 12, located at the lip of the switch II pocket, offers a covalent attachment point for KRAS<sup>G12C</sup> inhibitors. To date, KRAS<sup>G12C</sup> inhibitors have been discovered by first covalently binding to the cysteine at position 12 and then optimizing pocket binding. We report on the discovery of the in vivo active KRAS<sup>G12C</sup> inhibitor BI-0474 using a different approach, in which small molecules that bind reversibly to the switch II pocket were identified and then optimized for non-covalent binding using structure-based design. Finally, the Michael acceptor containing warhead was attached. Our approach offers not only an alternative approach to discovering KRAS<sup>G12C</sup> inhibitors but also provides a starting point for the discovery of inhibitors against other oncogenic KRAS mutants.",x-ray diffraction,2.41,1,2,A,89.41798941798942%,92.81437125748504%,1427,199,4,4,"['MG', 'LXK', 'SO4', 'GDP']","GDP, MG, LXK, SO4","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 2-azanyl-4,4-dimethyl-6,7-dihydro-5~{H}-1-benzothiophene-3-carbonitrile, SULFATE ION",inactive,26,10,9,4,9,12,13,8,12,11,15,11,9,4,4,6,15,4,10,3,
8B00,KRAS-G13D in complex with BI-2865,,Homo sapiens,9606,"KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients<sup>1-7</sup>. Whether inactive-state selective inhibition can be used to therapeutically target non-G12C KRAS mutants remains under investigation. Here we report the discovery and characterization of a non-covalent inhibitor that binds preferentially and with high affinity to the inactive state of KRAS while sparing NRAS and HRAS. Although limited to only a few amino acids, the evolutionary divergence in the GTPase domain of RAS isoforms was sufficient to impart orthosteric and allosteric constraints for KRAS selectivity. The inhibitor blocked nucleotide exchange to prevent the activation of wild-type KRASand a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight. Our study suggests that most KRAS oncoproteins cycle between an active stateand aninactive state in cancer cells and are dependent on nucleotide exchange for activation. Pan-KRAS inhibitors, such as the one described here, have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.",x-ray diffraction,1.04,1,1,A,88.88888888888889%,92.81437125748504%,3034,421,6,6,"['OFU', 'MG', 'EDO', 'GDP']","GDP, MG, EDO, OFU","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, 1,2-ETHANEDIOL, (4S)-2-azanyl-4-methyl-4-[3-[4-[(1S)-1-[(2S)-1-methylpyrrolidin-1-ium-2-yl]ethoxy]pyrimidin-2-yl]-1,2,4-oxadiazol-5-yl]-6,7-dihydro-5H-1-benzothiophene-3-carbonitrile",inactive,247,11,9,4,9,12,12,8,11,11,15,11,9,4,4,6,16,4,10,2,
8B78,KRasG12C ligand complex,,Homo sapiens,9606,"The glycine to cysteine mutation at codon 12 of Kirsten rat sarcoma (KRAS) represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based drug design approach that led to the identification of <b>14</b>, AZD4747, a clinical development candidate for the treatment of KRAS<sup>G12C</sup>-positive tumors, including the treatment of central nervous system (CNS) metastases. Building on our earlier discovery of C5-tethered quinazoline AZD4625, excision of a usually critical pyrimidine ring yielded a weak but brain-penetrant start point which was optimized for potency and DMPK. Key design principles and measured parameters that give high confidence in CNS exposure are discussed. During optimization, divergence between rodent and non-rodent species was observed in CNS exposure, with primate PET studies ultimately giving high confidence in the expected translation to patients. AZD4747 is a highly potent and selective inhibitor of KRAS<sup>G12C</sup> with an anticipated low clearance and high oral bioavailability profile in humans.",x-ray diffraction,1.11,1,1,A,88.88888888888889%,91.01796407185628%,1524,295,3,3,"['MG', 'PUO', 'GDP']","MG, GDP, PUO","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1-[(4~{a}~{R})-8-(2-chloranyl-6-oxidanyl-phenyl)-7-fluoranyl-9-prop-1-ynyl-1,2,4,4~{a},5,11-hexahydropyrazino[2,1-c][1,4]benzoxazepin-3-yl]propan-1-one",inactive,124,10,9,4,10,12,12,8,11,12,15,11,9,4,4,6,15,4,11,1,
8CX5,"Crystal Structure of small molecule alpha,beta-ketoamide 4 covalently bound to K-Ras(G12R)",,Homo sapiens,9606,"<i>KRAS</i> mutations are one of the most common oncogenic drivers in human cancer. While small molecule inhibitors for the G12C mutant have been successfully developed, allele-specific inhibition for other <i>KRAS</i> hotspot mutants remains challenging. Here we report the discovery of covalent chemical ligands for the common oncogenic mutant K-Ras(G12R). These ligands bind in the Switch II pocket and irreversibly react with the mutant arginine residue. An X-ray crystal structure reveals an imidazolium condensation product formed between the ,-diketoamide ligand and the - and -nitrogens of arginine 12. Our results show that arginine residues can be selectively targeted with small molecule electrophiles despite their weak nucleophilicity and provide the basis for the development of mutant-specific therapies for K-Ras(G12R)-driven cancer.",x-ray diffraction,1.72,1,2,A,89.94708994708994%,91.61676646706587%,1531,269,3,3,"['MG', 'P7U', 'GDP']","MG, P7U, GDP, PO4, NA","MAGNESIUM ION, {(2S)-4-[(7P)-7-(8-chloronaphthalen-1-yl)-8-fluoro-2-{[(4R,7as)-tetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidin-4-yl]-1-[(3S)-2,2,3-trihydroxybutanoyl]piperazin-2-yl}acetonitrile, GUANOSINE-5'-DIPHOSPHATE, PHOSPHATE ION, SODIUM ION",inactive,96,11,9,4,10,12,13,8,12,12,15,11,9,4,4,6,15,4,11,,
8DGS,Cryo-EM structure of a RAS/RAF complex (state 1),,Homo sapiens,9606,"RAF-family kinases are activated by recruitment to the plasma membrane by GTP-bound RAS, whereupon they initiate signaling through the MAP kinase cascade. Prior structural studies of KRAS with RAF have focused on the isolated RAS-binding and cysteine-rich domains of RAF (RBD and CRD, respectively), which interact directly with RAS. Here we describe cryo-EM structures of a KRAS bound to intact BRAF in an autoinhibited state with MEK1 and a 14-3-3 dimer. Analysis of this KRAS/BRAF/MEK1/14-3-3 complex reveals KRAS bound to the RAS-binding domain of BRAF, captured in two orientations. Core autoinhibitory interactions in the complex are unperturbed by binding of KRAS and in vitro activation studies confirm that KRAS binding is insufficient to activate BRAF, absent membrane recruitment. These structures illustrate the separability of binding and activation of BRAF by RAS and suggest stabilization of this pre-activation intermediate as an alternative therapeutic strategy to blocking binding of KRAS.",electron microscopy,4.3,1,5,E,88.35978835978835%,94.01197604790418%,1357,169,2,2,"['MG', 'GNP']","AGS, ZN, MG, LCJ, GNP","PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER, ZINC ION, MAGNESIUM ION, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide, PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER",active,0,11,9,4,8,12,12,8,11,11,15,11,9,4,4,6,15,4,10,3,
8DNJ,Crystal structure of human KRAS G12C covalently bound with AstraZeneca WO2020/178282A1 compound 76,,Homo sapiens,9606,"KRAS has long been referred to as an 'undruggable' target due to its high affinity for its cognate ligands (GDP and GTP) and its lack of readily exploited allosteric binding pockets. Recent progress in the development of covalent inhibitors of KRAS<sup>G12C</sup> has revealed that occupancy of an allosteric binding site located between the 3-helix and switch-II loop of KRAS<sup>G12C</sup>-sometimes referred to as the 'switch-II pocket'-holds great potential in the design of direct inhibitors of KRAS<sup>G12C</sup>. In studying diverse switch-II pocket binders during the development of sotorasib (AMG 510), the first FDA-approved inhibitor of KRAS<sup>G12C</sup>, we found the dramatic conformational flexibility of the switch-II pocket posing significant challenges toward the structure-based design of inhibitors. Here, we present our computational approaches for dealing with receptor flexibility in the prediction of ligand binding pose and binding affinity. For binding pose prediction, we modified the covalent docking program CovDock to allow for protein conformational mobility. This new docking approach, termed as FlexCovDock, improves success rates from 55 to 89% for binding pose prediction on a dataset of 10 cross-docking cases and has been prospectively validated across diverse ligand chemotypes. For binding affinity prediction, we found standard free energy perturbation (FEP) methods could not adequately handle the significant conformational change of the switch-II loop. We developed a new computational strategy to accelerate conformational transitions through the use of targeted protein mutations. Using this methodology, the mean unsigned error (MUE) of binding affinity prediction were reduced from 1.44 to 0.89kcal/mol on a set of 14 compounds. These approaches were of significant use in facilitating the structure-based design of KRAS<sup>G12C</sup> inhibitors and are anticipated to be of further use in the design of covalent (and noncovalent) inhibitors of other conformationally labile protein targets.",x-ray diffraction,1.81,1,3,A,89.94708994708994%,91.61676646706587%,1484,243,3,3,"['MG', 'U4U', 'GDP']","MG, GDP, U4U","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, 1-[(5S,9P,12aR)-9-(2-chloro-6-hydroxyphenyl)-8-ethynyl-10-fluoro-3,4,12,12a-tetrahydro-6H-pyrazino[2,1-c][1,4]benzoxazepin-2(1H)-yl]propan-1-one",inactive,70,11,9,4,11,12,13,8,11,12,15,11,9,4,4,6,15,4,10,1,
8EBZ,Crystal Structure of GMPPNP-bound KRAS-G13D mutant at 1.2 Ang resolution,,Homo sapiens,9606,"Localized dynamics of RAS, including regions distal to the nucleotide-binding site, is of high interest for elucidating the mechanisms by which RAS proteins interact with effectors and regulators and for designing inhibitors. Among several oncogenic mutants, methyl relaxation dispersion experiments reveal highly synchronized conformational dynamics in the active (GMPPNP-bound) KRAS<sup>G13D</sup>, which suggests an exchange between two conformational states in solution. Methyl and <sup>31</sup>P NMR spectra of active KRAS<sup>G13D</sup> in solution confirm a two-state ensemble interconverting on the millisecond timescale, with a major P<sup></sup> atom peak corresponding to the dominant State 1 conformation and a secondary peak indicating an intermediate state different from the known State 2 conformation recognized by RAS effectors. High-resolution crystal structures of active KRAS<sup>G13D</sup> and KRAS<sup>G13D</sup>-RAF1 RBD complex provide snapshots of the State 1 and 2 conformations, respectively. We use residual dipolar couplings to solve and cross-validate the structure of the intermediate state of active KRAS<sup>G13D</sup>, showing a conformation distinct from those of States 1 and 2 outside the known flexible switch regions. The dynamic coupling between the conformational exchange in the effector lobe and the breathing motion in the allosteric lobe is further validated by a secondary mutation in the allosteric lobe, which affects the conformational population equilibrium.",x-ray diffraction,1.2,1,1,A,62.43386243386243%,92.81437125748504%,1568,361,6,6,"['MG', 'CSO', 'GNP']","GNP, MG","PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER, MAGNESIUM ION",active,186,11,9,4,8,12,13,8,12,11,15,11,9,4,4,6,16,4,10,2,
8EZG,Monobody 12D1 bound to KRAS(G12D),,Homo sapiens,9606,"The G12D mutation is among the most common KRAS mutations associated with cancer, in particular, pancreatic cancer. Here, we have developed monobodies, small synthetic binding proteins, that are selective to KRAS(G12D) over KRAS(wild type) and other oncogenic KRAS mutations, as well as over the G12D mutation in HRAS and NRAS. Crystallographic studies revealed that, similar to other KRAS mutant-selective inhibitors, the initial monobody bound to the S-II pocket, the groove between switch II and 3 helix, and captured this pocket in the most widely open form reported to date. Unlike other G12D-selective polypeptides reported to date, the monobody used its backbone NH group to directly recognize the side chain of KRAS Asp12, a feature that closely resembles that of a small-molecule inhibitor, MTRX1133. The monobody also directly interacted with H95, a residue not conserved in RAS isoforms. These features rationalize the high selectivity toward the G12D mutant and the KRAS isoform. Structure-guided affinity maturation resulted in monobodies with low nM <i>K</i><sub>D</sub> values. Deep mutational scanning of a monobody generated hundreds of functional and nonfunctional single-point mutants, which identified crucial residues for binding and those that contributed to the selectivity toward the GTP- and GDP-bound states. When expressed in cells as genetically encoded reagents, these monobodies engaged selectively with KRAS(G12D) and inhibited KRAS(G12D)-mediated signaling and tumorigenesis. These results further illustrate the plasticity of the S-II pocket, which may be exploited for the design of next-generation KRAS(G12D)-selective inhibitors.",x-ray diffraction,2.52,1,2,A,88.88888888888889%,91.61676646706587%,1439,233,2,2,"['MG', 'GDP']","GDP, MG, NA","GUANOSINE-5'-DIPHOSPHATE, MAGNESIUM ION, SODIUM ION",inactive,63,10,9,4,10,12,13,8,11,12,15,11,9,4,4,6,16,4,10,,
8F0M,Monobody 12D5 bound to KRAS(G12D),,Homo sapiens,9606,"The G12D mutation is among the most common KRAS mutations associated with cancer, in particular, pancreatic cancer. Here, we have developed monobodies, small synthetic binding proteins, that are selective to KRAS(G12D) over KRAS(wild type) and other oncogenic KRAS mutations, as well as over the G12D mutation in HRAS and NRAS. Crystallographic studies revealed that, similar to other KRAS mutant-selective inhibitors, the initial monobody bound to the S-II pocket, the groove between switch II and 3 helix, and captured this pocket in the most widely open form reported to date. Unlike other G12D-selective polypeptides reported to date, the monobody used its backbone NH group to directly recognize the side chain of KRAS Asp12, a feature that closely resembles that of a small-molecule inhibitor, MTRX1133. The monobody also directly interacted with H95, a residue not conserved in RAS isoforms. These features rationalize the high selectivity toward the G12D mutant and the KRAS isoform. Structure-guided affinity maturation resulted in monobodies with low nM <i>K</i><sub>D</sub> values. Deep mutational scanning of a monobody generated hundreds of functional and nonfunctional single-point mutants, which identified crucial residues for binding and those that contributed to the selectivity toward the GTP- and GDP-bound states. When expressed in cells as genetically encoded reagents, these monobodies engaged selectively with KRAS(G12D) and inhibited KRAS(G12D)-mediated signaling and tumorigenesis. These results further illustrate the plasticity of the S-II pocket, which may be exploited for the design of next-generation KRAS(G12D)-selective inhibitors.",x-ray diffraction,2.44,1,4,A,69.84126984126983%,91.61676646706587%,1371,198,3,3,"['MG', 'GLC', 'GDP']","MG, GDP, GLC, GSP","MAGNESIUM ION, GUANOSINE-5'-DIPHOSPHATE, alpha-D-glucopyranose, 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE",inactive,32,11,9,4,11,11,12,7,11,12,15,10,9,4,4,6,14,3,10,,
8IJ9,Crystal structure of the ELKS1/Rab6B complex,,Mus musculus,10090,"ELKS proteins play a key role in organizing intracellular vesicle trafficking and targeting in both neurons and non-neuronal cells. While it is known that ELKS interacts with the vesicular traffic regulator, the Rab6 GTPase, the molecular basis governing ELKS-mediated trafficking of Rab6-coated vesicles, has remained unclear. In this study, we solved the Rab6B structure in complex with the Rab6-binding domain of ELKS1, revealing that a C-terminal segment of ELKS1 forms a helical hairpin to recognize Rab6B through a unique binding mode. We further showed that liquid-liquid phase separation (LLPS) of ELKS1 allows it to compete with other Rab6 effectors for binding to Rab6B and accumulate Rab6B-coated liposomes to the protein condensate formed by ELKS1. We also found that the ELKS1 condensate recruits Rab6B-coated vesicles to vesicle-releasing sites and promotes vesicle exocytosis. Together, our structural, biochemical, and cellular analyses suggest that ELKS1, via the LLPS-enhanced interaction with Rab6, captures Rab6-coated vesicles from the cargo transport machine for efficient vesicle release at exocytotic sites. These findings shed new light on the understanding of spatiotemporal regulation of vesicle trafficking through the interplay between membranous structures and membraneless condensates.",x-ray diffraction,2.04,1,4,A,88.88888888888889%,31.645569620253166%,1480,261,2,2,"['GTP', 'MG']","GTP, MG, PGE","GUANOSINE-5'-TRIPHOSPHATE, MAGNESIUM ION, TRIETHYLENE GLYCOL",active,91,9,8,4,13,15,9,6,10,16,13,12,8,6,,9,12,3,13,,2
